[ { "aliases": [ "guides", "research guides", "cannabinoid guides", "cbd vs cbg", "cbd vs cbn", "sleep research", "inflammation research" ], "claims": 5561, "evidence_rows": 5561, "search_boost": 12, "search_terms": [ "guides", "research guides", "cannabinoid guides", "cbd vs cbg", "cbd vs cbn", "sleep research", "inflammation research" ], "search_text": "CBD vs CBG CBD vs CBN cannabinoids and sleep research cannabinoids and inflammation research evidence guides reader routes PubMed for Dummies source-backed pages.", "sources": 4535, "status": "education-first growth layer", "subtitle": "Plain-English routes for common cannabinoid questions that point readers into source-backed evidence pages.", "title": "Cannabinoid Research Guides", "type": "reader guide", "url": "/guides/" }, { "aliases": [ "newsletter", "email list", "research digest", "updates", "quality literacy", "expert review" ], "claims": 5561, "evidence_rows": 5561, "search_boost": 14, "search_terms": [ "newsletter", "email list", "research digest", "updates", "quality literacy", "expert review" ], "search_text": "Research digest newsletter email list source-backed updates expert review calls quality literacy CBD CBG CBN THC safety formulation COA cannabinoid education.", "sources": 4535, "status": "audience engine", "subtitle": "Join the education-first digest for research updates, new guides, safety notes, expert-review calls, and quality-literacy notes.", "title": "Cannabinoid Research Digest", "type": "research digest", "url": "/digest/" }, { "aliases": [ "standards", "quality standards", "research standards", "organic cbd", "organic cbg", "coa", "certificate of analysis", "full spectrum", "quality transparency" ], "claims": 5561, "evidence_rows": 5561, "search_boost": 13, "search_terms": [ "standards", "quality standards", "research standards", "organic cbd", "organic cbg", "coa", "certificate of analysis", "full spectrum", "quality transparency" ], "search_text": "Quality standards organic CBD organic CBG certificate of analysis COA lab testing batch testing full-spectrum formulation transparency roadmap cannabinoid quality literacy evidence-first education.", "sources": 4535, "status": "quality literacy layer", "subtitle": "Education-first standards for cannabinoid sourcing language, testing and COAs, formulation context, and transparent evidence limits.", "title": "Quality Standards", "type": "quality standards", "url": "/standards/" }, { "aliases": [ "coa", "coas", "certificate of analysis", "batch testing", "lab report literacy", "lot number", "lab report", "potency test", "contaminant panel", "quality proof" ], "claims": 0, "evidence_rows": 0, "result_label": "0 batch records / 0 published COAs", "search_boost": 15, "search_terms": [ "coa", "coas", "certificate of analysis", "batch testing", "lab report literacy", "lot number", "lab report", "potency test", "contaminant panel", "quality proof" ], "search_text": "COA certificate of analysis lab report literacy lot number lab reports potency cannabinoid profile pesticides heavy metals residual solvents microbials mycotoxins quality proof batch JSON machine readable transparency.", "sources": 0, "status": "lab-report literacy layer", "subtitle": "Public COA literacy library for lot IDs, lab reports, potency panels, contaminant screens, and machine-readable example records.", "title": "COA Literacy Library", "type": "coa library", "url": "/coas/" }, { "aliases": [ "how to read a coa", "read lab test", "certificate of analysis guide", "batch test guide", "potency panel", "contaminant panel" ], "claims": 0, "evidence_rows": 0, "search_boost": 12, "search_terms": [ "how to read a coa", "read lab test", "certificate of analysis guide", "batch test guide", "potency panel", "contaminant panel" ], "search_text": "How to read a COA certificate of analysis batch ID lot number potency contaminants pesticides heavy metals residual solvents microbials mycotoxins test date lab report quality context not medical proof.", "sources": 0, "status": "coa literacy", "subtitle": "Plain-English guide to reading cannabinoid certificates of analysis, batch IDs, potency panels, contaminant screens, and product-quality limits.", "title": "How to Read a COA", "type": "coa guide", "url": "/coas/how-to-read-a-coa/" }, { "aliases": [ "CBD vs CBG Research Guide", "Compound Comparison", "cbd or cbg", "cbg vs cbd", "cannabidiol vs cannabigerol" ], "claims": 5561, "evidence_rows": 5561, "result_label": "4 evidence routes / 3 overread warnings", "search_boost": 11, "search_terms": [ "CBD vs CBG Research Guide", "Compound Comparison", "cbd or cbg", "cbg vs cbd", "cannabidiol vs cannabigerol" ], "search_text": "CBD vs CBG Research Guide Compound Comparison A plain-English route through CBD and CBG evidence pages, safety context, and the research pages that separate studied outcomes from product hype. Use this guide when someone asks whether CBD or CBG is the better starting point. The honest answer is to compare the evidence lanes: human studies, preclinical work, target biology, safety signals, and what each page still cannot say. cbd or cbg cbg vs cbd cannabidiol vs cannabigerol CBD CBG CBD and drug interactions CBG target pharmacology The strongest current compound page for human-oriented evidence, safety context, and source density. A growing minor-cannabinoid page with target, inflammation, appetite, skin, pain, and safety routes. A safety-first map for readers comparing cannabinoids alongside medication context. The biology lane for receptor and target discussion before outcome interpretation. Do not turn CBG mechanism pages into human-health promises. Do not treat CBD evidence in one formulation, dose, or population as universal. Do not compare cannabinoids without separating isolated compounds from full-spectrum products.", "sources": 4535, "status": "Compound Comparison", "subtitle": "A plain-English route through CBD and CBG evidence pages, safety context, and the research pages that separate studied outcomes from product hype. ", "title": "CBD vs CBG Research Guide", "type": "reader guide", "url": "/guides/cbd-vs-cbg/" }, { "aliases": [ "CBD vs CBN Research Guide", "Sleep Research Comparison", "cbn vs cbd", "cbd or cbn", "cannabinoids sleep", "cbd sleep", "cbn sleep" ], "claims": 5561, "evidence_rows": 5561, "result_label": "4 evidence routes / 3 overread warnings", "search_boost": 11, "search_terms": [ "CBD vs CBN Research Guide", "Sleep Research Comparison", "cbn vs cbd", "cbd or cbn", "cannabinoids sleep", "cbd sleep", "cbn sleep" ], "search_text": "CBD vs CBN Research Guide Sleep Research Comparison A sleep-focused guide to CBD and CBN pages, evidence limits, sedation context, and why sleep claims need careful wording. Use this guide when the question sounds simple: CBD or CBN for sleep? The useful answer is a map of sleep endpoints, sedation signals, human evidence, and the places where the literature is still too thin for strong consumer conclusions. cbn vs cbd cbd or cbn cannabinoids sleep cbd sleep cbn sleep CBD CBN CBD sleep review CBN sleep pilot The broad CBD hub for sleep, anxiety-related, pain-related, seizure, and safety-linked evidence routes. The CBN hub built from the original sleep pilot and expanded target/safety maps. A source-backed page for CBD and sleep-related endpoints. The first controlled pilot topic for the workbench and encyclopedia workflow. Do not write sleep pages as bedtime instructions. Do not collapse sedation into improved sleep quality. Do not ignore next-day impairment, drug interactions, or product formulation.", "sources": 4535, "status": "Sleep Research Comparison", "subtitle": "A sleep-focused guide to CBD and CBN pages, evidence limits, sedation context, and why sleep claims need careful wording.", "title": "CBD vs CBN Research Guide", "type": "reader guide", "url": "/guides/cbd-vs-cbn/" }, { "aliases": [ "Cannabinoids and Sleep Research Guide", "Outcome Guide", "sleep cannabinoids", "cannabinoids for sleep", "sleep latency", "sleep quality" ], "claims": 5561, "evidence_rows": 5561, "result_label": "4 evidence routes / 3 overread warnings", "search_boost": 11, "search_terms": [ "Cannabinoids and Sleep Research Guide", "Outcome Guide", "sleep cannabinoids", "cannabinoids for sleep", "sleep latency", "sleep quality" ], "search_text": "Cannabinoids and Sleep Research Guide Outcome Guide A reader route for sleep-related cannabinoid research, from simple endpoint vocabulary to source-backed CBD, CBN, THC, and safety pages. Sleep is not one outcome. This guide helps readers split sleep questions into latency, awakenings, total sleep time, subjective quality, REM/NREM findings, daytime sleepiness, and safety context. sleep cannabinoids cannabinoids for sleep sleep latency sleep quality Sleep outcome hub CBD sleep review THC sleep review CBN sleep pilot The main outcome doorway for sleep-related endpoints and related pages. A source-backed route for CBD and sleep-related outcomes. A source-backed route for THC and sleep-related outcomes. The original pilot route for CBN and sleep-related evidence. Do not infer improved sleep from a sedating adverse-event signal. Do not generalize one sleep endpoint to all sleep outcomes. Do not ignore THC impairment and psychiatric-risk context.", "sources": 4535, "status": "Outcome Guide", "subtitle": "A reader route for sleep-related cannabinoid research, from simple endpoint vocabulary to source-backed CBD, CBN, THC, and safety pages.", "title": "Cannabinoids and Sleep Research Guide", "type": "reader guide", "url": "/guides/cannabinoids-and-sleep-research/" }, { "aliases": [ "Cannabinoids and Inflammation Research Guide", "Outcome And Mechanism Guide", "cannabinoids inflammation", "cbd inflammation", "cbg inflammation", "anti inflammatory cannabinoids" ], "claims": 5561, "evidence_rows": 5561, "result_label": "4 evidence routes / 3 overread warnings", "search_boost": 11, "search_terms": [ "Cannabinoids and Inflammation Research Guide", "Outcome And Mechanism Guide", "cannabinoids inflammation", "cbd inflammation", "cbg inflammation", "anti inflammatory cannabinoids" ], "search_text": "Cannabinoids and Inflammation Research Guide Outcome And Mechanism Guide A plain-English route through inflammation-related cannabinoid pages, immune modulation, skin research, targets, and the limits of preclinical evidence. Inflammation questions often mix cell studies, animal models, skin research, immune markers, pain, and product claims. This guide keeps those lanes separate so the evidence stays useful. cannabinoids inflammation cbd inflammation cbg inflammation anti inflammatory cannabinoids Inflammation-related outcomes Immune modulation CBG inflammation and immune outcomes CBC inflammation-related outcomes The outcome doorway for inflammation-related endpoints and related maps. Use this page when the question is about immune signaling rather than symptoms. A source-backed route for CBG and inflammation or immune-related evidence. A source-backed route for CBC and inflammation-related evidence. Do not equate anti-inflammatory mechanisms with proven clinical benefit. Do not merge skin and systemic inflammation without source support. Do not ignore contaminants, formulation, and route of administration.", "sources": 4535, "status": "Outcome And Mechanism Guide", "subtitle": "A plain-English route through inflammation-related cannabinoid pages, immune modulation, skin research, targets, and the limits of preclinical evidence.", "title": "Cannabinoids and Inflammation Research Guide", "type": "reader guide", "url": "/guides/cannabinoids-and-inflammation-research/" }, { "aliases": [ "Cannabinoid Sourcing Literacy Standard", "Quality Literacy", "organic cbd", "organic cbg", "hemp sourcing", "clean cannabinoid quality" ], "claims": 5561, "evidence_rows": 5561, "result_label": "3 principles / 3 proof routes", "search_boost": 10, "search_terms": [ "Cannabinoid Sourcing Literacy Standard", "Quality Literacy", "organic cbd", "organic cbg", "hemp sourcing", "clean cannabinoid quality" ], "search_text": "Cannabinoid Sourcing Literacy Standard Quality Literacy How readers can evaluate organic sourcing language, hemp quality, ingredient traceability, and what sourcing documents can and cannot prove. Use this standard when a reader wants to know what organic, clean, or premium should mean in cannabinoid education. The answer should be traceable sourcing, clear limits, and plain language that separates agricultural quality from health claims. organic cbd organic cbg hemp sourcing clean cannabinoid quality Product contamination risk Certificate of analysis Full-spectrum The safety page that keeps contaminants, formulation, and quality-control questions visible. The dictionary term that explains why third-party testing matters to readers. The vocabulary route for readers comparing whole-extract language with isolate or broad-spectrum language. Do not imply organic sourcing treats, prevents, or cures a condition. Do not use clean-label language as a substitute for batch testing. Do not blur hemp sourcing, extraction method, cannabinoid profile, and clinical evidence into one claim.", "sources": 4535, "status": "Quality Literacy", "subtitle": "How readers can evaluate organic sourcing language, hemp quality, ingredient traceability, and what sourcing documents can and cannot prove.", "title": "Cannabinoid Sourcing Literacy Standard", "type": "quality standard", "url": "/standards/organic-cannabinoid-sourcing/" }, { "aliases": [ "Testing and COA Standard", "Lab Report Literacy", "coa", "certificate of analysis", "lab test", "third party testing", "batch testing" ], "claims": 5561, "evidence_rows": 5561, "result_label": "3 principles / 3 proof routes", "search_boost": 10, "search_terms": [ "Testing and COA Standard", "Lab Report Literacy", "coa", "certificate of analysis", "lab test", "third party testing", "batch testing" ], "search_text": "Testing and COA Standard Lab Report Literacy An educational standard for reading certificates of analysis, batch testing, cannabinoid potency, contaminants, and public traceability language. Use this standard when someone asks how to judge a cannabinoid COA. The answer should not be a vague badge. It should be an understandable certificate of analysis, a lot number, potency context, contaminant screens, and a clear explanation of what testing can and cannot prove. coa certificate of analysis lab test third party testing batch testing Certificate of analysis Dose Product contamination risk The simplest doorway for readers who need COA vocabulary before reading a lab report. The term route for separating labeled amount, serving size, and study dose context. The safety route for contaminants, formulation concerns, and quality-control gaps. Do not call a product proven because the COA is clean. Do not publish a COA without making the product lot and test date obvious. Do not hide failed, missing, stale, or superseded testing behind marketing copy.", "sources": 4535, "status": "Lab Report Literacy", "subtitle": "An educational standard for reading certificates of analysis, batch testing, cannabinoid potency, contaminants, and public traceability language.", "title": "Testing and COA Standard", "type": "quality standard", "url": "/standards/testing-and-coas/" }, { "aliases": [ "Full-Spectrum Formulation Standard", "Formulation Literacy", "full spectrum cbd", "broad spectrum", "isolate", "entourage effect", "minor cannabinoids" ], "claims": 5561, "evidence_rows": 5561, "result_label": "3 principles / 3 proof routes", "search_boost": 10, "search_terms": [ "Full-Spectrum Formulation Standard", "Formulation Literacy", "full spectrum cbd", "broad spectrum", "isolate", "entourage effect", "minor cannabinoids" ], "search_text": "Full-Spectrum Formulation Standard Formulation Literacy How to explain full-spectrum, broad-spectrum, isolate, minor cannabinoids, terpenes, route, and dose without pretending that product composition automatically proves outcomes. Use this standard when a reader wants to compare CBD, CBG, CBN, THC, full-spectrum, broad-spectrum, and isolate preparations. The answer should be composition first, evidence second, and product choice only after safety and context are understood. full spectrum cbd broad spectrum isolate entourage effect minor cannabinoids Full-spectrum Isolate Route of administration The dictionary route for what full-spectrum usually means and why details matter. The route for separating isolated-compound evidence from whole-extract language. The route for understanding why oral, topical, inhaled, and other delivery paths cannot be swapped casually. Do not use entourage-effect language as a blanket proof of benefit. Do not treat isolated-compound findings as proof for every full-spectrum product. Do not ignore THC, impairment, drug-interaction, or product-quality context when discussing full-spectrum products.", "sources": 4535, "status": "Formulation Literacy", "subtitle": "How to explain full-spectrum, broad-spectrum, isolate, minor cannabinoids, terpenes, route, and dose without pretending that product composition automatically proves outcomes.", "title": "Full-Spectrum Formulation Standard", "type": "quality standard", "url": "/standards/full-spectrum-formulation/" }, { "aliases": [ "Research Transparency Roadmap", "Build In Public", "research roadmap", "cannabinoid transparency", "quality standards", "evidence transparency" ], "claims": 5561, "evidence_rows": 5561, "result_label": "3 principles / 3 proof routes", "search_boost": 10, "search_terms": [ "Research Transparency Roadmap", "Build In Public", "research roadmap", "cannabinoid transparency", "quality standards", "evidence transparency" ], "search_text": "Research Transparency Roadmap Build In Public The roadmap for turning Cannabinoid Encyclopedia into a public education system with traceable sources, correction pathways, and transparent uncertainty. Use this page as the public operating standard for the site. The encyclopedia should teach first, show sources, invite correction, publish quality context, and keep education separate from sales pressure. research roadmap cannabinoid transparency quality standards evidence transparency Methodology Contribute evidence Research digest The operating method for evidence lanes, uncertainty, and source-backed public pages. The route for readers and experts to suggest sources and corrections. The audience bridge for updates, review calls, and source-backed education releases. Do not make the encyclopedia read like promotional copy. Do not let any CTA outrank safety or evidence context. Do not present educational pages as individualized medical advice.", "sources": 4535, "status": "Build In Public", "subtitle": "The roadmap for turning Cannabinoid Encyclopedia into a public education system with traceable sources, correction pathways, and transparent uncertainty.", "title": "Research Transparency Roadmap", "type": "quality standard", "url": "/standards/product-transparency-roadmap/" }, { "aliases": [ "adverse event", "agonist", "allosteric modulator", "antagonist", "bioavailability", "broad spectrum", "certificate of analysis", "dictionary", "dose", "drug interaction", "entourage effect", "formulation", "full spectrum", "glossary", "human evidence", "insufficient evidence", "isolate", "lookup", "mechanistic evidence", "observational study", "partial agonist", "pharmacodynamics", "pharmacokinetics", "preclinical evidence", "product terms", "rct", "receptor binding", "research terms", "route of administration", "terminology" ], "claims": 0, "evidence_rows": 0, "search_boost": 8, "search_terms": [ "adverse event", "agonist", "allosteric modulator", "antagonist", "bioavailability", "broad spectrum", "certificate of analysis", "dictionary", "dose", "drug interaction", "entourage effect", "formulation", "full spectrum", "glossary", "human evidence", "insufficient evidence", "isolate", "lookup", "mechanistic evidence", "observational study", "partial agonist", "pharmacodynamics", "pharmacokinetics", "preclinical evidence", "product terms", "rct", "receptor binding", "research terms", "route of administration", "terminology" ], "search_text": "Dictionary glossary lookup terminology research vocabulary definitions aliases source-backed pages evidence terms.", "sources": 0, "status": "IA foundation", "subtitle": "Lookup hub for cannabinoids, receptors, outcomes, safety concepts, product-language terms, and research vocabulary.", "title": "Cannabinoid Dictionary", "type": "dictionary", "url": "/dictionary/" }, { "aliases": [ "adverse event", "adverse events", "side effect", "side effects", "tolerability" ], "claims": 780, "evidence_rows": 780, "result_label": "Safety / 369 exact evidence rows / 8 related pages", "search_boost": 6, "search_terms": [ "Adverse event", "adverse event", "adverse events", "Safety", "side effect", "side effects", "tolerability" ], "search_text": "Adverse event A safety observation reported in a source, with context about population and product. Safety adverse event adverse events side effect side effects tolerability", "sources": 304, "status": "Safety", "subtitle": "A safety observation reported in a source, with context about population and product.", "title": "Adverse event", "type": "term definition", "url": "/dictionary/adverse-event/" }, { "aliases": [ "agonist" ], "claims": 0, "evidence_rows": 0, "result_label": "Mechanism concept / 0 exact evidence rows / 0 related pages", "search_boost": 3, "search_terms": [ "Agonist", "agonist", "Mechanism concept" ], "search_text": "Agonist Receptor-language term for activating a target in a defined model. Mechanism concept agonist", "sources": 0, "status": "Mechanism concept", "subtitle": "Receptor-language term for activating a target in a defined model.", "title": "Agonist", "type": "term definition", "url": "/dictionary/agonist/" }, { "aliases": [ "allosteric modulator" ], "claims": 0, "evidence_rows": 0, "result_label": "Mechanism concept / 0 exact evidence rows / 0 related pages", "search_boost": 3, "search_terms": [ "Allosteric modulator", "allosteric modulator", "Mechanism concept" ], "search_text": "Allosteric modulator Mechanism term for changing signaling through a site other than the main binding site. Mechanism concept allosteric modulator", "sources": 0, "status": "Mechanism concept", "subtitle": "Mechanism term for changing signaling through a site other than the main binding site.", "title": "Allosteric modulator", "type": "term definition", "url": "/dictionary/allosteric-modulator/" }, { "aliases": [ "antagonist" ], "claims": 0, "evidence_rows": 0, "result_label": "Mechanism concept / 0 exact evidence rows / 0 related pages", "search_boost": 3, "search_terms": [ "Antagonist", "antagonist", "Mechanism concept" ], "search_text": "Antagonist Receptor-language term for blocking or reducing activation in a defined model. Mechanism concept antagonist", "sources": 0, "status": "Mechanism concept", "subtitle": "Receptor-language term for blocking or reducing activation in a defined model.", "title": "Antagonist", "type": "term definition", "url": "/dictionary/antagonist/" }, { "aliases": [ "bioavailability" ], "claims": 0, "evidence_rows": 0, "result_label": "Pharmacology / 0 exact evidence rows / 0 related pages", "search_boost": 3, "search_terms": [ "Bioavailability", "bioavailability", "Pharmacology" ], "search_text": "Bioavailability How much of a compound reaches circulation or a target tissue after a given route. Pharmacology bioavailability", "sources": 0, "status": "Pharmacology", "subtitle": "How much of a compound reaches circulation or a target tissue after a given route.", "title": "Bioavailability", "type": "term definition", "url": "/dictionary/bioavailability/" }, { "aliases": [ "broad spectrum", "broad-spectrum", "extract", "thc-free" ], "claims": 25, "evidence_rows": 25, "result_label": "Product identity / 1 exact evidence row / 2 related pages", "search_boost": 6, "search_terms": [ "Broad spectrum", "broad spectrum", "broad-spectrum", "extract", "Product identity", "thc free", "thc-free" ], "search_text": "Broad spectrum Product-language term that needs formulation, testing, and THC-context links. Product identity broad spectrum broad-spectrum extract thc-free", "sources": 24, "status": "Product identity", "subtitle": "Product-language term that needs formulation, testing, and THC-context links.", "title": "Broad spectrum", "type": "term definition", "url": "/dictionary/broad-spectrum/" }, { "aliases": [ "certificate of analysis", "coa", "lab test", "third-party test" ], "claims": 24, "evidence_rows": 24, "result_label": "Product identity / 0 exact evidence rows / 2 related pages", "search_boost": 3, "search_terms": [ "Certificate of analysis", "certificate of analysis", "coa", "lab test", "Product identity", "third party test", "third-party test" ], "search_text": "Certificate of analysis Product-testing record that belongs near quality, contaminant, and labeling evidence. Product identity certificate of analysis coa lab test third-party test", "sources": 24, "status": "Product identity", "subtitle": "Product-testing record that belongs near quality, contaminant, and labeling evidence.", "title": "Certificate of analysis", "type": "term definition", "url": "/dictionary/certificate-of-analysis/" }, { "aliases": [ "dose" ], "claims": 40, "evidence_rows": 40, "result_label": "Study context / 40 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "Dose", "dose", "Study context" ], "search_text": "Dose Amount, timing, frequency, and formulation context behind a source-backed row. Study context dose", "sources": 0, "status": "Study context", "subtitle": "Amount, timing, frequency, and formulation context behind a source-backed row.", "title": "Dose", "type": "term definition", "url": "/dictionary/dose/" }, { "aliases": [ "cyp enzymes", "cyp interaction", "drug interaction", "drug interactions", "medicine interaction" ], "claims": 116, "evidence_rows": 116, "result_label": "Safety / 11 exact evidence rows / 6 related pages", "search_boost": 6, "search_terms": [ "cyp enzymes", "cyp interaction", "Drug interaction", "drug interaction", "drug interactions", "medicine interaction", "Safety" ], "search_text": "Drug interaction A safety topic connecting cannabinoids with medicines, enzymes, or clinical monitoring. Safety cyp enzymes cyp interaction drug interaction drug interactions medicine interaction", "sources": 90, "status": "Safety", "subtitle": "A safety topic connecting cannabinoids with medicines, enzymes, or clinical monitoring.", "title": "Drug interaction", "type": "term definition", "url": "/dictionary/drug-interaction/" }, { "aliases": [ "entourage", "entourage effect", "synergy", "whole plant" ], "claims": 20, "evidence_rows": 20, "result_label": "Mechanism concept / 0 exact evidence rows / 2 related pages", "search_boost": 3, "search_terms": [ "entourage", "Entourage effect", "entourage effect", "Mechanism concept", "synergy", "whole plant" ], "search_text": "Entourage effect Common cannabinoid concept that needs careful source-linked explanation. Mechanism concept entourage entourage effect synergy whole plant", "sources": 20, "status": "Mechanism concept", "subtitle": "Common cannabinoid concept that needs careful source-linked explanation.", "title": "Entourage effect", "type": "term definition", "url": "/dictionary/entourage-effect/" }, { "aliases": [ "formulation" ], "claims": 340, "evidence_rows": 340, "result_label": "Study context / 201 exact evidence rows / 7 related pages", "search_boost": 6, "search_terms": [ "Formulation", "formulation", "Study context" ], "search_text": "Formulation Product form, carrier, purity, and mixture details that affect evidence scope. Study context formulation", "sources": 139, "status": "Study context", "subtitle": "Product form, carrier, purity, and mixture details that affect evidence scope.", "title": "Formulation", "type": "term definition", "url": "/dictionary/formulation/" }, { "aliases": [ "extract", "full spectrum", "full-spectrum", "whole plant" ], "claims": 24, "evidence_rows": 24, "result_label": "Product identity / 0 exact evidence rows / 2 related pages", "search_boost": 3, "search_terms": [ "extract", "Full spectrum", "full spectrum", "full-spectrum", "Product identity", "whole plant" ], "search_text": "Full spectrum Product-language term that needs clear separation from isolated-compound evidence. Product identity extract full spectrum full-spectrum whole plant", "sources": 24, "status": "Product identity", "subtitle": "Product-language term that needs clear separation from isolated-compound evidence.", "title": "Full spectrum", "type": "term definition", "url": "/dictionary/full-spectrum/" }, { "aliases": [ "clinical evidence", "human evidence", "human studies", "human study" ], "claims": 114, "evidence_rows": 114, "result_label": "Evidence method / 114 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "clinical evidence", "Evidence method", "Human evidence", "human evidence", "human studies", "human study" ], "search_text": "Human evidence Evidence from studies involving human participants, kept separate from preclinical and mechanistic evidence. Evidence method clinical evidence human evidence human studies human study", "sources": 0, "status": "Evidence method", "subtitle": "Evidence from studies involving human participants, kept separate from preclinical and mechanistic evidence.", "title": "Human evidence", "type": "term definition", "url": "/dictionary/human-evidence/" }, { "aliases": [ "insufficient evidence", "limited evidence", "not enough evidence", "unclear evidence" ], "claims": 635, "evidence_rows": 635, "result_label": "Evidence method / 635 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "Evidence method", "Insufficient evidence", "insufficient evidence", "limited evidence", "not enough evidence", "unclear evidence" ], "search_text": "Insufficient evidence A valid conclusion when sources are absent, too narrow, inconsistent, or indirect. Evidence method insufficient evidence limited evidence not enough evidence unclear evidence", "sources": 0, "status": "Evidence method", "subtitle": "A valid conclusion when sources are absent, too narrow, inconsistent, or indirect.", "title": "Insufficient evidence", "type": "term definition", "url": "/dictionary/insufficient-evidence/" }, { "aliases": [ "isolate", "isolated compound", "purified cbd", "purified compound" ], "claims": 313, "evidence_rows": 313, "result_label": "Product identity / 16 exact evidence rows / 6 related pages", "search_boost": 6, "search_terms": [ "Isolate", "isolate", "isolated compound", "Product identity", "purified cbd", "purified compound" ], "search_text": "Isolate Single-compound product language that should not be mixed with extract evidence. Product identity isolate isolated compound purified cbd purified compound", "sources": 266, "status": "Product identity", "subtitle": "Single-compound product language that should not be mixed with extract evidence.", "title": "Isolate", "type": "term definition", "url": "/dictionary/isolate/" }, { "aliases": [ "biochemical", "mechanism", "mechanistic", "mechanistic evidence", "pharmacological" ], "claims": 1434, "evidence_rows": 1434, "result_label": "Evidence method / 382 exact evidence rows / 8 related pages", "search_boost": 6, "search_terms": [ "biochemical", "Evidence method", "mechanism", "mechanistic", "Mechanistic evidence", "mechanistic evidence", "pharmacological" ], "search_text": "Mechanistic evidence Evidence about plausible biological pathways, not proof of consumer benefit. Evidence method biochemical mechanism mechanistic mechanistic evidence pharmacological", "sources": 739, "status": "Evidence method", "subtitle": "Evidence about plausible biological pathways, not proof of consumer benefit.", "title": "Mechanistic evidence", "type": "term definition", "url": "/dictionary/mechanistic-evidence/" }, { "aliases": [ "observational study" ], "claims": 10, "evidence_rows": 10, "result_label": "Evidence method / 10 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "Evidence method", "Observational study", "observational study" ], "search_text": "Observational study Human research design that observes associations without randomized assignment. Evidence method observational study", "sources": 0, "status": "Evidence method", "subtitle": "Human research design that observes associations without randomized assignment.", "title": "Observational study", "type": "term definition", "url": "/dictionary/observational-study/" }, { "aliases": [ "partial agonist" ], "claims": 0, "evidence_rows": 0, "result_label": "Mechanism concept / 0 exact evidence rows / 0 related pages", "search_boost": 3, "search_terms": [ "Mechanism concept", "Partial agonist", "partial agonist" ], "search_text": "Partial agonist Receptor-language term that needs context about model, target, and comparator. Mechanism concept partial agonist", "sources": 0, "status": "Mechanism concept", "subtitle": "Receptor-language term that needs context about model, target, and comparator.", "title": "Partial agonist", "type": "term definition", "url": "/dictionary/partial-agonist/" }, { "aliases": [ "pharmacodynamics" ], "claims": 3, "evidence_rows": 3, "result_label": "Pharmacology / 3 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "Pharmacodynamics", "pharmacodynamics", "Pharmacology" ], "search_text": "Pharmacodynamics What a compound does at receptors, enzymes, channels, pathways, or tissues. Pharmacology pharmacodynamics", "sources": 0, "status": "Pharmacology", "subtitle": "What a compound does at receptors, enzymes, channels, pathways, or tissues.", "title": "Pharmacodynamics", "type": "term definition", "url": "/dictionary/pharmacodynamics/" }, { "aliases": [ "pharmacokinetics" ], "claims": 21, "evidence_rows": 21, "result_label": "Pharmacology / 21 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "Pharmacokinetics", "pharmacokinetics", "Pharmacology" ], "search_text": "Pharmacokinetics How a compound is absorbed, distributed, metabolized, and eliminated. Pharmacology pharmacokinetics", "sources": 0, "status": "Pharmacology", "subtitle": "How a compound is absorbed, distributed, metabolized, and eliminated.", "title": "Pharmacokinetics", "type": "term definition", "url": "/dictionary/pharmacokinetics/" }, { "aliases": [ "animal evidence", "animal study", "cell study", "cellular evidence", "preclinical evidence" ], "claims": 1123, "evidence_rows": 1123, "result_label": "Evidence method / 71 exact evidence rows / 8 related pages", "search_boost": 6, "search_terms": [ "animal evidence", "animal study", "cell study", "cellular evidence", "Evidence method", "Preclinical evidence", "preclinical evidence" ], "search_text": "Preclinical evidence Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes. Evidence method animal evidence animal study cell study cellular evidence preclinical evidence", "sources": 739, "status": "Evidence method", "subtitle": "Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes.", "title": "Preclinical evidence", "type": "term definition", "url": "/dictionary/preclinical-evidence/" }, { "aliases": [ "controlled trial", "randomised controlled trial", "randomized controlled trial", "rct" ], "claims": 73, "evidence_rows": 73, "result_label": "Evidence method / 73 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "controlled trial", "Evidence method", "randomised controlled trial", "randomized controlled trial", "RCT", "rct" ], "search_text": "RCT Randomized controlled trial; one study-design term used in evidence summaries. Evidence method controlled trial randomised controlled trial randomized controlled trial rct", "sources": 0, "status": "Evidence method", "subtitle": "Randomized controlled trial; one study-design term used in evidence summaries.", "title": "RCT", "type": "term definition", "url": "/dictionary/rct/" }, { "aliases": [ "receptor binding" ], "claims": 9, "evidence_rows": 9, "result_label": "Mechanism concept / 9 exact evidence rows / 0 related pages", "search_boost": 6, "search_terms": [ "Mechanism concept", "Receptor binding", "receptor binding" ], "search_text": "Receptor binding Evidence language for interaction with a target, not automatic clinical effect. Mechanism concept receptor binding", "sources": 0, "status": "Mechanism concept", "subtitle": "Evidence language for interaction with a target, not automatic clinical effect.", "title": "Receptor binding", "type": "term definition", "url": "/dictionary/receptor-binding/" }, { "aliases": [ "inhaled", "oral", "route", "route of administration", "sublingual", "topical" ], "claims": 174, "evidence_rows": 174, "result_label": "Study context / 70 exact evidence rows / 7 related pages", "search_boost": 6, "search_terms": [ "inhaled", "oral", "route", "Route of administration", "route of administration", "Study context", "sublingual", "topical" ], "search_text": "Route of administration How oral, inhaled, topical, sublingual, and other routes change interpretation. Study context inhaled oral route route of administration sublingual topical", "sources": 104, "status": "Study context", "subtitle": "How oral, inhaled, topical, sublingual, and other routes change interpretation.", "title": "Route of administration", "type": "term definition", "url": "/dictionary/route-of-administration/" }, { "aliases": [ "2", "2 AG", "2 ag", "2 arachidonoylglycerol", "2-AG", "2-arachidonoylglycerol", "ag", "arachidonoylglycerol", "Compound", "compound", "compound endocannabinoid", "compound / endocannabinoid", "compounds", "compounds 2 ag", "source backed draft", "source-backed draft" ], "claims": 15, "evidence_rows": 15, "search_boost": 8, "search_terms": [ "2", "2 AG", "2 ag", "2 arachidonoylglycerol", "2-AG", "2-arachidonoylglycerol", "ag", "arachidonoylglycerol", "Compound", "compound", "compound endocannabinoid", "compound / endocannabinoid", "compounds", "compounds 2 ag", "source backed draft", "source-backed draft" ], "search_text": "2-AG Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary 2-AG has 15 source-backed evidence row s from 15 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: 2-ag - Type: compound - Subtype: endocannabinoid - Description: Not recorded Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 8 , mechanistic or pharmacological 6 , preclinical 1 - Draft sections: mechanistic evidence 6 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic and preclinical research summary: insufficient 8 , mechanistic or pharmacological 5 , preclinical 1 14 14 rows 1078-1091 2-AG modulates CB2 Mechanistic research summary: mechanistic or pharmacological 1 1 920 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 920 2-AG modulates CB2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. PMID 16086683; DOI 10.1111/j.1471-4159.2005.03380.x 1078 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The Endocannabinoid System and its Modulation by Phytocannabinoids. PMID 26271952; DOI 10.1007/s13311-015-0374-6 1079 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. PMID 21418147; DOI 10.1111/j.1748-1716.2011.02280.x 1080 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Cannabinergic ligands. PMID 12505686; DOI 10.1016/s0009-3084 02 00143-3 1081 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. PMID 16678907; DOI 10.1016/j.plipres.2006.03.003 1082 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoid overload. PMID 20952498; DOI 10.1124/mol.110.069427 1083 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoid hydrolases. PMID 12432941; DOI 10.1016/s0090-6980 02 00053-9 1084 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study desi...", "sources": 15, "status": "source-backed draft", "subtitle": "compound / endocannabinoid", "title": "2-AG", "type": "compound", "url": "/compounds/2-ag/" }, { "aliases": [ "aea", "Anandamide", "anandamide", "Compound", "compound", "compound endocannabinoid", "compound / endocannabinoid", "compounds", "compounds anandamide", "n arachidonoylethanolamine", "n-arachidonoylethanolamine", "source backed draft", "source-backed draft" ], "claims": 20, "evidence_rows": 20, "search_boost": 8, "search_terms": [ "aea", "Anandamide", "anandamide", "Compound", "compound", "compound endocannabinoid", "compound / endocannabinoid", "compounds", "compounds anandamide", "n arachidonoylethanolamine", "n-arachidonoylethanolamine", "source backed draft", "source-backed draft" ], "search_text": "Anandamide Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Anandamide has 20 source-backed evidence row s from 20 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: anandamide - Type: compound - Subtype: endocannabinoid - Description: Not recorded Evidence Snapshot - Evidence rows: 20 - Sources: 20 - Evidence classes: insufficient 16 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 16 Key Draft Sections - Uncertainty and gaps: 16 evidence row s . - Mechanistic evidence: 4 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 11 , mechanistic or pharmacological 4 15 15 rows 1063-1077 Anandamide modulates CB2 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 890-894 Anandamide modulates GPR119 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 964-965 Anandamide modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 979 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 890 Anandamide modulates CB2; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. PMID 16678907; DOI 10.1016/j.plipres.2006.03.003 894 Anandamide modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Structural requirements for cannabinoid receptor probes. PMID 16596776; DOI 10.1007/3-540-26573-2 7 964 Anandamide modulates GPR119; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . N-acylethanolamines, anandamide and food intake. PMID 19413995; DOI 10.1016/j.bcp.2009.04.024 965 Anandamide modulates GPR119; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PMID 20353771; DOI 10.1016/j.expneurol.2010.03.022 979 Anandamide modulates TRPV1; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. PMID 26411767; DOI 10.2174/1570159x13666150216222543 1063 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. PMID 36150527; DOI 10.1016/j.plipres.2022.101194 1064 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Metabolism of endocannabinoids. PMID 27516570; DOI 10.5604/17322693.1213898 1065 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide uptake explained? PMID 22297258; DOI 10.1016/j.tips.2012.01.001 1066 Anandamide studied...", "sources": 20, "status": "source-backed draft", "subtitle": "compound / endocannabinoid", "title": "Anandamide", "type": "compound", "url": "/compounds/anandamide/" }, { "aliases": [ "cannabichromene", "CBC", "cbc", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbc", "source backed draft", "source-backed draft" ], "claims": 112, "evidence_rows": 112, "search_boost": 12, "search_terms": [ "cannabichromene", "CBC", "cbc", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbc", "source backed draft", "source-backed draft" ], "search_text": "CBC Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBC has 112 source-backed evidence row s from 83 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbc - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 112 - Sources: 83 - Evidence classes: insufficient 53 , mechanistic or pharmacological 39 , preclinical 14 , preliminary human 6 - Draft sections: human evidence 3 , mechanistic evidence 35 , preclinical evidence 10 , safety 24 , uncertainty 40 Key Draft Sections - Human evidence: 3 evidence row s . - Safety and tolerability: 24 evidence row s . - Uncertainty and gaps: 40 evidence row s . - Preclinical evidence: 10 evidence row s . - Mechanistic evidence: 35 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Developed but mixed human research summary: insufficient 2 , mechanistic or pharmacological 4 , preclinical 2 , preliminary human 1 9 9 rows 34-76 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mechanistic and preclinical research summary: insufficient 5 , mechanistic or pharmacological 6 , preclinical 1 12 12 rows 721-732 CBC studied for Pain-related outcomes Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 9 , preclinical 4 , preliminary human 1 17 17 rows 683-699 CBC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 251 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 283-284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 16 , mechanistic or pharmacological 10 26 26 rows 657-682 CBC studied for safety, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 1 , preclinical 1 , preliminary human 1 3 3 rows 169-173 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Developed but mixed human research summary: insufficient 12 , mechanistic or pharmacological 4 , preclinical 3 , preliminary human 2 21 21 rows 636-656 CBC studied for Skin and inflammatory dermatology Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 6 , preclinical 3 , preliminary human 1 21 21 rows 700-720 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 34 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 35 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 36 CBC studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. PMID 37332213; DOI 10.1097/sap.0000000000003547 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 72 CBC studied for Inflammation-related outcomes; evidence class: preliminary human outcome measure: inflammatio...", "sources": 83, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBC", "type": "compound", "url": "/compounds/cbc/" }, { "aliases": [ "cannabichromenic acid", "CBCA", "cbca", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbca", "source backed draft", "source-backed draft" ], "claims": 23, "evidence_rows": 23, "search_boost": 8, "search_terms": [ "cannabichromenic acid", "CBCA", "cbca", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbca", "source backed draft", "source-backed draft" ], "search_text": "CBCA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBCA has 23 source-backed evidence row s from 17 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbca - Type: compound - Subtype: phytocannabinoid acid - Description: Not recorded Evidence Snapshot - Evidence rows: 23 - Sources: 17 - Evidence classes: insufficient 16 , mechanistic or pharmacological 5 , preclinical 1 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 4 , preclinical evidence 1 , safety 1 , uncertainty 16 Key Draft Sections - Human evidence: 1 evidence row s . - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 16 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 4 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 71 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 722-723 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 283-284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 1 4 4 rows 661-677 CBC studied for Skin and inflammatory dermatology Early human research summary: preliminary human 1 1 717 CBCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 282 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 1 3 3 rows 279-281 CBDA studied for nausea-related or inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 125 CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 165 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 70 THC studied for receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 201-287 THCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 286 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 70 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 125 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 165 CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. PMID 41822224; DOI 10.3389/fvets.2026.1779760 201 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target,...", "sources": 17, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "CBCA", "type": "compound", "url": "/compounds/cbca/" }, { "aliases": [ "cannabichromevarin", "CBCV", "cbcv", "Compound", "compound", "compound phytocannabinoid varin", "compound / phytocannabinoid varin", "compounds", "compounds cbcv", "source backed draft", "source-backed draft" ], "claims": 10, "evidence_rows": 10, "search_boost": 8, "search_terms": [ "cannabichromevarin", "CBCV", "cbcv", "Compound", "compound", "compound phytocannabinoid varin", "compound / phytocannabinoid varin", "compounds", "compounds cbcv", "source backed draft", "source-backed draft" ], "search_text": "CBCV Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBCV has 10 source-backed evidence row s from 9 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbcv - Type: compound - Subtype: phytocannabinoid varin - Description: Not recorded Evidence Snapshot - Evidence rows: 10 - Sources: 9 - Evidence classes: insufficient 9 , mechanistic or pharmacological 1 - Draft sections: mechanistic evidence 1 , safety 1 , uncertainty 8 Key Draft Sections - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 8 evidence row s . - Mechanistic evidence: 1 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 696 CBC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 251 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 673 CBD studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 246 CBG studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 248 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 THC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 3 3 3 rows 249-252 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 325 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 246 CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 248 CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids research topics . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 249 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics . Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PMID 35648593; DOI 10.1021/acs.jnatprod.2c00155 250 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. PMID 36770831; DOI 10.3390/molecules28031164 251 CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. PMID 34078070; DOI 10.1021/acs.joc.1c00451 252 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5 325 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natu...", "sources": 9, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid varin", "title": "CBCV", "type": "compound", "url": "/compounds/cbcv/" }, { "aliases": [ "cannabidiol", "CBD", "cbd", "cbd oil", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbd", "hemp extract", "source backed draft", "source-backed draft" ], "claims": 166, "evidence_rows": 166, "search_boost": 14, "search_terms": [ "cannabidiol", "CBD", "cbd", "cbd oil", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbd", "hemp extract", "source backed draft", "source-backed draft" ], "search_text": "CBD Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBD has 166 source-backed evidence row s from 139 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbd - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for evidence review; claims require sourced support. Evidence Snapshot - Evidence rows: 166 - Sources: 139 - Evidence classes: insufficient 84 , mechanistic or pharmacological 43 , preclinical 3 , preliminary human 36 - Draft sections: human evidence 32 , mechanistic evidence 42 , preclinical evidence 3 , safety 27 , uncertainty 62 Key Draft Sections - Human evidence: 32 evidence row s . - Safety and tolerability: 27 evidence row s . - Uncertainty and gaps: 62 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 42 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Anxiety-related outcomes Developed but mixed human research summary: insufficient 3 , preliminary human 7 10 10 rows 28-63 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes Mechanistic research summary: insufficient 8 , mechanistic or pharmacological 1 9 9 rows 22-52 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 5 , preliminary human 3 12 12 rows 224-373 CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics Mechanistic research summary: mechanistic or pharmacological 1 1 292 CBD modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 5 5 5 rows 955-962 CBD modulates GPR55 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 3 5 5 rows 935-943 CBD studied for Pain-related outcomes Developed but mixed human research summary: insufficient 7 , mechanistic or pharmacological 1 , preliminary human 7 15 15 rows 392-433 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 7 , preclinical 1 , preliminary human 1 9 9 rows 98-194 CBD studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 246 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3 , mechanistic or pharmacological 2 , preclinical 1 6 6 rows 253-261 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 1 3 3 rows 279-281 CBD studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 5 5 5 rows 196-200 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 9 , preliminary human 4 12 13 rows 217-342 CBD studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 18 , mechanistic or pharmacological 2 , preliminary human 7 27 27 rows 380-429 CBD studied for Sleep Developed but mixed human research summary: insufficient 5 , preliminary human 7 12 12 rows 403-414 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPA1 Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 3 6 6 rows 1031-1047 CBD modulates TRPM8 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1048-1058 CBD modulates TRPV1 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 978-983 CBD modulates TRPV2 Mechanistic research summary: mechanistic or pharmacological 9 9 9 rows 991-1003 CBD modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 4 5 5 rows 1005-1013 CBD modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 3 5 5 rows 1017-1029 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 22 CBD interacts with drug or class drug-interaction me...", "sources": 139, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBD", "type": "compound", "url": "/compounds/cbd/" }, { "aliases": [ "cannabidiolic acid", "CBDA", "cbda", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbda", "source backed draft", "source-backed draft" ], "claims": 26, "evidence_rows": 26, "search_boost": 9, "search_terms": [ "cannabidiolic acid", "CBDA", "cbda", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbda", "source backed draft", "source-backed draft" ], "search_text": "CBDA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBDA has 26 source-backed evidence row s from 26 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbda - Type: compound - Subtype: phytocannabinoid acid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 26 - Sources: 26 - Evidence classes: insufficient 12 , mechanistic or pharmacological 10 , preclinical 4 - Draft sections: mechanistic evidence 9 , preclinical evidence 4 , safety 1 , uncertainty 12 Key Draft Sections - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 12 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 9 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBDA studied for nausea-related or inflammation-related outcomes Mechanistic and preclinical research summary: insufficient 12 , mechanistic or pharmacological 9 , preclinical 4 25 25 rows 43-148 CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 165 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 43 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. PMID 30627539; DOI 10.1155/2018/1691428 125 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 126 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. PMID 34115951; DOI 10.1089/can.2021.0041 127 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. PMID 29057454; DOI 10.1111/bph.14073 128 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Evaluation of Sex Differences in the Potential of \u03949-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats. PMID 35984924; DOI 10.1089/can.2022.0158 129 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Evaluation of repeated or acute treatment with cannabidiol CBD , cannabidiolic acid CBDA or CBDA methyl ester HU-580 on nausea and/or vomiting in rats and shrews. PMID 32488349; DOI 10.1007/s00213-020-05559-z 130 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Effect of combined doses of \u03949-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and canna...", "sources": 26, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "CBDA", "type": "compound", "url": "/compounds/cbda/" }, { "aliases": [ "cannabidivarin", "CBDV", "cbdv", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbdv", "source backed draft", "source-backed draft" ], "claims": 22, "evidence_rows": 22, "search_boost": 8, "search_terms": [ "cannabidivarin", "CBDV", "cbdv", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbdv", "source backed draft", "source-backed draft" ], "search_text": "CBDV Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBDV has 22 source-backed evidence row s from 22 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbdv - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 22 - Sources: 22 - Evidence classes: insufficient 11 , mechanistic or pharmacological 3 , preclinical 6 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 3 , preclinical evidence 6 , uncertainty 11 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 11 evidence row s . - Preclinical evidence: 6 evidence row s . - Mechanistic evidence: 3 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 CBDV studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 3 , preclinical 5 , preliminary human 2 21 21 rows 40-124 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 40 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. PMID 33895189; DOI 10.1016/j.pharmthera.2021.107878 41 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabis sativa: Much more beyond \u03949-tetrahydrocannabinol. PMID 32335286; DOI 10.1016/j.phrs.2020.104822 42 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. PMID 32825313; DOI 10.3390/brainsci10090572 84 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. PMID 42339654; DOI 10.1177/10445463261462382 85 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? PMID 33613289; DOI 10.3389/fphar.2020.635763 109 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Investigational cannabinoids in seizure disorders, what have we learned thus far? PMID 29842819; DOI 10.1080/13543784.2018.1482275 110 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes . Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. PMID 35364618; DOI 10.1111/epi.17247 111 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Phytocannabinoi...", "sources": 22, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBDV", "type": "compound", "url": "/compounds/cbdv/" }, { "aliases": [ "a", "cannabidivarinic", "cannabidivarinic acid", "cbdv", "CBDV A", "cbdv a", "CBDV-A", "cbdv-a", "cbdva", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbdv a", "source backed draft", "source-backed draft" ], "claims": 44, "evidence_rows": 44, "search_boost": 9, "search_terms": [ "a", "cannabidivarinic", "cannabidivarinic acid", "cbdv", "CBDV A", "cbdv a", "CBDV-A", "cbdv-a", "cbdva", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbdv a", "source backed draft", "source-backed draft" ], "search_text": "CBDV-A Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBDV-A has 44 source-backed evidence row s from 40 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbdv-a - Type: compound - Subtype: phytocannabinoid acid - Description: Not recorded Evidence Snapshot - Evidence rows: 44 - Sources: 40 - Evidence classes: insufficient 19 , mechanistic or pharmacological 17 , preclinical 6 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 16 , preclinical evidence 6 , safety 1 , uncertainty 19 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 19 evidence row s . - Preclinical evidence: 6 evidence row s . - Mechanistic evidence: 16 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 283-284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 668 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 707 CBCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 282 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 1 3 3 rows 279-281 CBDV studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 3 , preclinical 5 , preliminary human 2 21 21 rows 40-124 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 580 CBG studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 619 THC studied for receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 201-287 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 364 THC modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1050 THCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 286 THCV studied for Appetite and metabolic outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 81 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 765-782 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 752 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 40 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. PMID 33895189; DOI 10.1016/j.pharmthera.2021.107878 41 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabis sativa: Much more beyond \u03949-tetrahydrocannabinol. PMID 32335286; DOI 10.1016/j.phrs.2020.104822 42 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. PMID 32825313; DOI 10.3390/brainsci10090572 81 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or ph...", "sources": 40, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "CBDV-A", "type": "compound", "url": "/compounds/cbdv-a/" }, { "aliases": [ "cannabigerol", "CBG", "cbg", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbg", "source backed draft", "source-backed draft" ], "claims": 123, "evidence_rows": 123, "search_boost": 12, "search_terms": [ "cannabigerol", "CBG", "cbg", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbg", "source backed draft", "source-backed draft" ], "search_text": "CBG Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBG has 123 source-backed evidence row s from 96 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbg - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 123 - Sources: 96 - Evidence classes: insufficient 53 , mechanistic or pharmacological 45 , preclinical 17 , preliminary human 8 - Draft sections: human evidence 3 , mechanistic evidence 34 , preclinical evidence 15 , safety 35 , uncertainty 36 Key Draft Sections - Human evidence: 3 evidence row s . - Safety and tolerability: 35 evidence row s . - Uncertainty and gaps: 36 evidence row s . - Preclinical evidence: 15 evidence row s . - Mechanistic evidence: 34 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBG studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 5 , mechanistic or pharmacological 5 , preclinical 4 , preliminary human 2 16 16 rows 620-635 CBG studied for Inflammation-related outcomes Mechanistic and preclinical research summary: insufficient 7 , mechanistic or pharmacological 8 , preclinical 7 22 22 rows 584-605 CBG studied for Pain-related outcomes Mechanistic and preclinical research summary: insufficient 7 , mechanistic or pharmacological 1 , preclinical 3 11 11 rows 31-540 CBG studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 248 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 13 , mechanistic or pharmacological 8 21 21 rows 563-583 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 1 , preliminary human 3 13 13 rows 157-174 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 8 , preclinical 1 , preliminary human 2 22 22 rows 541-562 CBG studied for Skin and inflammatory dermatology Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 9 , preclinical 1 , preliminary human 1 14 14 rows 606-619 CBG modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 1051-1062 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 31 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabigerol CBG : A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PMID 39598860; DOI 10.3390/molecules29225471 32 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 33 CBG studied for Pain-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Orally administered Cannabigerol CBG in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. PMID 39322049; DOI 10.1016/j.pbb.2024.173883 64 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes . The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PMID 33998900; DOI 10.1089/can.2020.0105 65 CBG studied for Pain-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. PMID 35994012...", "sources": 96, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBG", "type": "compound", "url": "/compounds/cbg/" }, { "aliases": [ "cannabigerolic", "cannabigerolic acid", "CBGA", "cbga", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbga", "source backed draft", "source-backed draft" ], "claims": 45, "evidence_rows": 45, "search_boost": 9, "search_terms": [ "cannabigerolic", "cannabigerolic acid", "CBGA", "cbga", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbga", "source backed draft", "source-backed draft" ], "search_text": "CBGA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBGA has 45 source-backed evidence row s from 33 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbga - Type: compound - Subtype: phytocannabinoid acid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 45 - Sources: 33 - Evidence classes: insufficient 21 , mechanistic or pharmacological 19 , preclinical 2 , preliminary human 3 - Draft sections: human evidence 2 , mechanistic evidence 16 , preclinical evidence 2 , safety 7 , uncertainty 18 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 7 evidence row s . - Uncertainty and gaps: 18 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 16 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 71 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 283-284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 661-682 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 640-655 CBC studied for Skin and inflammatory dermatology Developed but mixed human research summary: insufficient 1 , mechanistic or pharmacological 2 , preliminary human 1 4 4 rows 702-717 CBCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 282 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 1 3 3 rows 279-281 CBD modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1047 CBD modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1058 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 125-140 CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 165 CBG studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 1 , preclinical 1 , preliminary human 1 3 3 rows 627-635 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 68-70 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 575 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 168 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 562 CBG modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1062 THC studied for receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 201-287 THC studied for safety, risk, adverse-event, or formulation-specific concerns Early human research summary: preliminary human 1 1 334 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 364 THC modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1050 THC modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 1 1 1008 THC modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1019 THCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 286 THCA studied for THCA-specific safety, effect, or mechanism claims Mapped evidence with interpretation limits: insufficient 1 1 92 TH...", "sources": 33, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "CBGA", "type": "compound", "url": "/compounds/cbga/" }, { "aliases": [ "cannabigerovarin", "CBGV", "cbgv", "Compound", "compound", "compound phytocannabinoid varin", "compound / phytocannabinoid varin", "compounds", "compounds cbgv", "source backed draft", "source-backed draft" ], "claims": 22, "evidence_rows": 22, "search_boost": 8, "search_terms": [ "cannabigerovarin", "CBGV", "cbgv", "Compound", "compound", "compound phytocannabinoid varin", "compound / phytocannabinoid varin", "compounds", "compounds cbgv", "source backed draft", "source-backed draft" ], "search_text": "CBGV Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBGV has 22 source-backed evidence row s from 14 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbgv - Type: compound - Subtype: phytocannabinoid varin - Description: Not recorded Evidence Snapshot - Evidence rows: 22 - Sources: 14 - Evidence classes: insufficient 9 , mechanistic or pharmacological 12 , preclinical 1 - Draft sections: mechanistic evidence 10 , preclinical evidence 1 , safety 3 , uncertainty 8 Key Draft Sections - Safety and tolerability: 3 evidence row s . - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 10 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 697 CBC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 251 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 636 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 700-707 CBD studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 246 CBD studied for receptor, target, or pharmacology mechanisms Preclinical research summary: preclinical 1 1 280 CBG studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 248 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 161 CBG studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 619 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 THC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 3 3 3 rows 249-252 THC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 287 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 325 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 364 THC modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1050 THC modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 1 1 1008 THC modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1019 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 765-780 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 161 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PMID 42163693; DOI 10.2174/0109298673390667251201115054 246 CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 248 CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids re...", "sources": 14, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid varin", "title": "CBGV", "type": "compound", "url": "/compounds/cbgv/" }, { "aliases": [ "cannabicyclol", "CBL", "cbl", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbl", "source backed draft", "source-backed draft" ], "claims": 15, "evidence_rows": 15, "search_boost": 8, "search_terms": [ "cannabicyclol", "CBL", "cbl", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbl", "source backed draft", "source-backed draft" ], "search_text": "CBL Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBL has 15 source-backed evidence row s from 10 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbl - Type: compound - Subtype: phytocannabinoid - Description: Not recorded Evidence Snapshot - Evidence rows: 15 - Sources: 10 - Evidence classes: insufficient 11 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 11 Key Draft Sections - Uncertainty and gaps: 11 evidence row s . - Mechanistic evidence: 4 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 35 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 721 CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 684 CBC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 251 CBC studied for Skin and inflammatory dermatology Mapped evidence with interpretation limits: insufficient 1 1 705 CBD studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 246 CBG studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 248 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 566 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 525 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 THC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 3 3 3 rows 249-252 THC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 201-285 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 35 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 201 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. PMID 36257598; DOI 10.1055/a-1962-8165 246 CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 248 CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids research topics . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 249 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics . Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PMID 35648593; DOI 10.1021/acs.jnatprod.2c00155 250 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phase...", "sources": 10, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBL", "type": "compound", "url": "/compounds/cbl/" }, { "aliases": [ "cannabicyclolic", "cannabicyclolic acid", "CBLA", "cbla", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbla", "source backed draft", "source-backed draft" ], "claims": 9, "evidence_rows": 9, "search_boost": 8, "search_terms": [ "cannabicyclolic", "cannabicyclolic acid", "CBLA", "cbla", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbla", "source backed draft", "source-backed draft" ], "search_text": "CBLA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBLA has 9 source-backed evidence row s from 9 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbla - Type: compound - Subtype: phytocannabinoid acid - Description: Not recorded Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 9 - Draft sections: uncertainty 9 Key Draft Sections - Uncertainty and gaps: 9 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 251 CBD studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 246 CBG studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 248 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 THC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 3 3 3 rows 249-252 THC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 201-285 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 201 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. PMID 36257598; DOI 10.1055/a-1962-8165 246 CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 248 CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids research topics . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 249 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics . Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PMID 35648593; DOI 10.1021/acs.jnatprod.2c00155 250 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. PMID 36770831; DOI 10.3390/molecules28031164 251 CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. PMID 34078070; DOI 10.1021/acs.joc.1c00451 252 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5 285 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid. PMID 37708768; DOI 10.1016/j.talanta.2023.125161 Related Pages - CBC - CBD - CBG - H...", "sources": 9, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "CBLA", "type": "compound", "url": "/compounds/cbla/" }, { "aliases": [ "cannabinol", "CBN", "cbn", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbn", "source backed draft", "source-backed draft" ], "claims": 56, "evidence_rows": 56, "search_boost": 10, "search_terms": [ "cannabinol", "CBN", "cbn", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbn", "source backed draft", "source-backed draft" ], "search_text": "CBN Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBN has 56 source-backed evidence row s from 35 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbn - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for evidence review; claims require sourced support. Evidence Snapshot - Evidence rows: 56 - Sources: 35 - Evidence classes: insufficient 19 , mechanistic or pharmacological 13 , preclinical 3 , preliminary human 21 - Draft sections: human evidence 14 , mechanistic evidence 12 , preclinical evidence 3 , safety 12 , uncertainty 15 Key Draft Sections - Human evidence: 14 evidence row s . - Safety and tolerability: 12 evidence row s . - Uncertainty and gaps: 15 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 12 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 2 2 2 rows 4-14 CBN studied for Pain-related outcomes Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 1 6 6 rows 534-539 CBN modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 3 8 8 rows 517-524 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 4 9 9 rows 508-516 CBN no detected effect on Side effect frequency Early human research summary: preliminary human 1 1 5 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 7 9 9 rows 525-533 CBN studied for Sleep Developed but mixed human research summary: insufficient 3 , preliminary human 2 5 5 rows 19-108 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats Mechanistic research summary: mechanistic or pharmacological 1 1 13 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN associated with sleep-promoting claims in the pre-2021 evidence base Mapped evidence with interpretation limits: insufficient 1 1 1 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN increases Total sleep time Preclinical research summary: preclinical 1 1 10 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 2 2 2 rows 6-17 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1 CBN associated with sleep-promoting claims in the pre-2021 evidence base; evidence class: insufficient study design: narrative review . Cannabinol and Sleep: Separating Fact from Fiction PMID 34468204; DOI 10.1089/can.2021.0006 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or dayti...", "sources": 35, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBN", "type": "compound", "url": "/compounds/cbn/" }, { "aliases": [ "a", "cannabinolic", "cannabinolic acid", "cbn", "CBN A", "cbn a", "CBN-A", "cbn-a", "cbna", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbn a", "source backed draft", "source-backed draft" ], "claims": 110, "evidence_rows": 110, "search_boost": 12, "search_terms": [ "a", "cannabinolic", "cannabinolic acid", "cbn", "CBN A", "cbn a", "CBN-A", "cbn-a", "cbna", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds cbn a", "source backed draft", "source-backed draft" ], "search_text": "CBN-A Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBN-A has 110 source-backed evidence row s from 76 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbn-a - Type: compound - Subtype: phytocannabinoid acid - Description: Not recorded Evidence Snapshot - Evidence rows: 110 - Sources: 76 - Evidence classes: insufficient 44 , mechanistic or pharmacological 33 , preclinical 8 , preliminary human 25 - Draft sections: human evidence 16 , mechanistic evidence 30 , preclinical evidence 7 , safety 20 , uncertainty 37 Key Draft Sections - Human evidence: 16 evidence row s . - Safety and tolerability: 20 evidence row s . - Uncertainty and gaps: 37 evidence row s . - Preclinical evidence: 7 evidence row s . - Mechanistic evidence: 30 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 71-76 CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 689-696 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 283-284 CBC studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 169 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: preliminary human 1 1 641 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 712 CBCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 282 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 369 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 1 3 3 rows 279-281 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 2 7 7 rows 125-144 CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 165 CBDV studied for Seizure and neurodevelopmental outcomes Mapped evidence with interpretation limits: insufficient 1 1 109 CBG studied for Appetite and metabolic outcomes Mechanistic and preclinical research summary: mechanistic or pharmacological 1 , preclinical 1 2 2 rows 621-635 CBG studied for Pain-related outcomes Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 70-540 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 2 2 2 rows 4-14 CBN studied for Pain-related outcomes Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 1 6 6 rows 534-539 CBN modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 3 8 8 rows 517-524 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 4 9 9 rows 508-516 CBN no detected effect on Side effect frequency Early human research summary: preliminary human 1 1 5 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 7 9 9 rows 525-533 CBN studied for Sleep Develop...", "sources": 76, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "CBN-A", "type": "compound", "url": "/compounds/cbn-a/" }, { "aliases": [ "cannabicitran", "CBT", "cbt", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbt", "source backed draft", "source-backed draft" ], "claims": 11, "evidence_rows": 11, "search_boost": 8, "search_terms": [ "cannabicitran", "CBT", "cbt", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds cbt", "source backed draft", "source-backed draft" ], "search_text": "CBT Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CBT has 11 source-backed evidence row s from 9 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: cbt - Type: compound - Subtype: phytocannabinoid - Description: Not recorded Evidence Snapshot - Evidence rows: 11 - Sources: 9 - Evidence classes: insufficient 10 , mechanistic or pharmacological 1 - Draft sections: mechanistic evidence 1 , uncertainty 10 Key Draft Sections - Uncertainty and gaps: 10 evidence row s . - Mechanistic evidence: 1 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 696 CBC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 251 CBC studied for Skin and inflammatory dermatology Mapped evidence with interpretation limits: insufficient 1 1 705 CBD studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 246 CBG studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 248 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 566 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 THC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 3 3 3 rows 249-252 THC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 201 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 201 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. PMID 36257598; DOI 10.1055/a-1962-8165 246 CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 248 CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids research topics . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 249 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics . Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PMID 35648593; DOI 10.1021/acs.jnatprod.2c00155 250 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. PMID 36770831; DOI 10.3390/molecules28031164 251 CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. PMID 34078070; DOI 10.1021/acs.joc.1c00451 252 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5 566 CBG modulates receptor, target,...", "sources": 9, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "CBT", "type": "compound", "url": "/compounds/cbt/" }, { "aliases": [ "10", "Compound", "compound", "compound commercial or semi synthetic cannabinoid", "compound / commercial or semi synthetic cannabinoid", "compounds", "compounds delta 10 thc", "d10 thc", "delta", "Delta 10", "delta 10 tetrahydrocannabinol", "Delta 10 THC", "delta 10 thc", "Delta-10", "delta-10 tetrahydrocannabinol", "Delta-10 THC", "delta-10 thc", "delta-10-thc", "source backed draft", "source-backed draft", "THC", "thc" ], "claims": 12, "evidence_rows": 12, "search_boost": 8, "search_terms": [ "10", "Compound", "compound", "compound commercial or semi synthetic cannabinoid", "compound / commercial or semi synthetic cannabinoid", "compounds", "compounds delta 10 thc", "d10 thc", "delta", "Delta 10", "delta 10 tetrahydrocannabinol", "Delta 10 THC", "delta 10 thc", "Delta-10", "delta-10 tetrahydrocannabinol", "Delta-10 THC", "delta-10 thc", "delta-10-thc", "source backed draft", "source-backed draft", "THC", "thc" ], "search_text": "Delta-10 THC Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Delta-10 THC has 12 source-backed evidence row s from 12 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: delta-10-thc - Type: compound - Subtype: commercial or semi synthetic cannabinoid - Description: Not recorded Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 6 , mechanistic or pharmacological 1 , preclinical 2 , preliminary human 3 - Draft sections: safety 12 Key Draft Sections - Safety and tolerability: 12 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 244 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 3 , preliminary human 1 4 4 rows 348-352 HHC studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 2 , preliminary human 1 5 5 rows 243-356 THC studied for safety, risk, adverse-event, or formulation-specific concerns Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 245-351 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 243 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. PMID 42106886; DOI 10.1186/s42238-026-00435-7 244 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Not all drugs are the same . PMID 23974649; DOI 10.1007/s00063-013-0219-1 245 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. PMID 41324909; DOI 10.1080/10826084.2025.2592227 348 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System FAERS Database. PMID 36742440; DOI 10.2147/dhps.s391857 349 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. PMID 38686923; DOI 10.1080/15563650.2024.2340115 350 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. PMID 38127427; DOI 10.2196/49469 351 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Derivation of a health-based guidance value for \u03948-tetrahydrocannabinol \u03948-THC and its occurrence in food. PMID 41262681; DOI 10.2903/j.efsa.2025...", "sources": 12, "status": "source-backed draft", "subtitle": "compound / commercial or semi synthetic cannabinoid", "title": "Delta-10 THC", "type": "compound", "url": "/compounds/delta-10-thc/" }, { "aliases": [ "8", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds delta 8 thc", "d8 thc", "delta", "Delta 8", "delta 8 tetrahydrocannabinol", "Delta 8 THC", "delta 8 thc", "Delta-8", "delta-8 tetrahydrocannabinol", "Delta-8 THC", "source backed draft", "source-backed draft", "THC", "thc" ], "claims": 12, "evidence_rows": 12, "search_boost": 8, "search_terms": [ "8", "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds delta 8 thc", "d8 thc", "delta", "Delta 8", "delta 8 tetrahydrocannabinol", "Delta 8 THC", "delta 8 thc", "Delta-8", "delta-8 tetrahydrocannabinol", "Delta-8 THC", "source backed draft", "source-backed draft", "THC", "thc" ], "search_text": "Delta-8 THC Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Delta-8 THC has 12 source-backed evidence row s from 11 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: delta-8-thc - Type: compound - Subtype: phytocannabinoid - Description: Tracked separately so source review can keep isomers and formulations distinct. Evidence Snapshot - Evidence rows: 12 - Sources: 11 - Evidence classes: insufficient 8 , preclinical 1 , preliminary human 3 - Draft sections: safety 12 Key Draft Sections - Safety and tolerability: 12 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 4 , preclinical 1 , preliminary human 2 7 7 rows 150-172 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 4 , preliminary human 1 5 5 rows 335-352 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 150 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Self-reported adverse events associated with \u22068-Tetrahydrocannabinol Delta-8-THC Use. PMID 37217977; DOI 10.1186/s42238-023-00191-y 151 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. PMID 38868665; DOI 10.3389/fphar.2024.1282831 152 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. PMID 39805119; DOI 10.1097/wnf.0000000000000619 154 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System FAERS Database. PMID 36742440; DOI 10.2147/dhps.s391857 155 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report. PMID 36941718; DOI 10.1186/s42238-023-00176-x 156 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection. PMID 38696245; DOI 10.2196/52499 172 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PMID 37721989; DOI 10.1089/can.2023.0049 335 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient popula...", "sources": 11, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "Delta-8 THC", "type": "compound", "url": "/compounds/delta-8-thc/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds dhea synaptamide", "DHEA", "dhea", "DHEA synaptamide", "DHEA / synaptamide", "source backed draft", "source-backed draft", "synaptamide" ], "claims": 5, "evidence_rows": 5, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds dhea synaptamide", "DHEA", "dhea", "DHEA synaptamide", "DHEA / synaptamide", "source backed draft", "source-backed draft", "synaptamide" ], "search_text": "DHEA / synaptamide Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary DHEA / synaptamide has 5 source-backed evidence row s from 5 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: dhea-synaptamide - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 2 , mechanistic or pharmacological 3 - Draft sections: mechanistic evidence 3 , uncertainty 2 Key Draft Sections - Uncertainty and gaps: 2 evidence row s . - Mechanistic evidence: 3 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 3 5 5 rows 1167-1171 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1167 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. PMID 22959887; DOI 10.1016/j.plefa.2012.08.002 1168 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. PMID 27809877; DOI 10.1186/s12974-016-0751-z 1169 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. PMID 23570577; DOI 10.1111/jnc.12255 1170 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . Orphan GPR110 ADGRF1 targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. PMID 27759003; DOI 10.1038/ncomms13123 1171 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. PMID 21810478; DOI 10.1016/j.prostaglandins.2011.07.002 Related Pages - No related source-backed entities yet. References - Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. PMID 22959887; DOI 10.1016/j.plefa.2012.08.002 - N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. PMID 27809877; DOI 10.1186/s12974-016-0751-z - N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. PMID 23570577; DOI 10.1111/jnc.12255 - Orphan GPR110 ADGRF1 targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. PMID 27759003; DOI 10...", "sources": 5, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "DHEA / synaptamide", "type": "compound", "url": "/compounds/dhea-synaptamide/" }, { "aliases": [ "Compound", "compound", "compound commercial or semi synthetic cannabinoid", "compound / commercial or semi synthetic cannabinoid", "compounds", "compounds hhc", "hexahydrocannabinol", "HHC", "hhc", "source backed draft", "source-backed draft" ], "claims": 8, "evidence_rows": 8, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound commercial or semi synthetic cannabinoid", "compound / commercial or semi synthetic cannabinoid", "compounds", "compounds hhc", "hexahydrocannabinol", "HHC", "hhc", "source backed draft", "source-backed draft" ], "search_text": "HHC Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary HHC has 8 source-backed evidence row s from 8 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: hhc - Type: compound - Subtype: commercial or semi synthetic cannabinoid - Description: Not recorded Evidence Snapshot - Evidence rows: 8 - Sources: 8 - Evidence classes: insufficient 2 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 - Draft sections: mechanistic evidence 2 , safety 5 , uncertainty 1 Key Draft Sections - Safety and tolerability: 5 evidence row s . - Uncertainty and gaps: 1 evidence row s . - Mechanistic evidence: 2 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- HHC modulates CB1 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 809-830 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 HHC studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 2 , preliminary human 1 5 5 rows 243-356 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 243 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. PMID 42106886; DOI 10.1186/s42238-026-00435-7 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 353 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. PMID 40643195; DOI 10.1093/ijnp/pyaf041 354 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Not Available . PMID 39323250; DOI 10.61409/v04240241 355 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects. PMID 37934167; DOI 10.1089/can.2023.0143 356 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. PMID 40176500; DOI 10.1177/02698811251330739 809 HHC modulates CB1; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Crystal structures of agonist-bound human cannabinoid receptor CB1. PMID 40866700; DOI 10.1038/s41586-025-09454-5 830 HHC modulates CB1; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Crystal structures of agonist-bound human cannabinoid receptor CB1. PMID 28678776; DOI 10.1038/nature23272 Related Pages - CB1 References - Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic...", "sources": 8, "status": "source-backed draft", "subtitle": "compound / commercial or semi synthetic cannabinoid", "title": "HHC", "type": "compound", "url": "/compounds/hhc/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds lea", "LEA", "lea", "source backed draft", "source-backed draft" ], "claims": 14, "evidence_rows": 14, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds lea", "LEA", "lea", "source backed draft", "source-backed draft" ], "search_text": "LEA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary LEA has 14 source-backed evidence row s from 14 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: lea - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 4 , mechanistic or pharmacological 5 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 5 , preclinical evidence 3 , uncertainty 4 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 5 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 5 , preclinical 3 , preliminary human 2 14 14 rows 1172-1185 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1172 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Classical endocannabinoid-like compounds and their regulation by nutrients. PMID 24677570; DOI 10.1002/biof.1158 1173 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males. PMID 29778785; DOI 10.1016/j.prostaglandins.2018.05.009 1174 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. PMID 24681513; DOI 10.1016/j.phrs.2014.03.006 1175 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder. PMID 37298321; DOI 10.3390/ijms24119371 1176 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide. PMID 36733808; DOI 10.3389/fendo.2022.1056116 1177 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. PMID 35203453; DOI 10.3390/biomedicines10020243 1178 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. PMID 18316044; DOI 10.1016/j.bbalip.2008.01.006 1179 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharm...", "sources": 14, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "LEA", "type": "compound", "url": "/compounds/lea/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds nada", "NADA", "nada", "source backed draft", "source-backed draft" ], "claims": 13, "evidence_rows": 13, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds nada", "NADA", "nada", "source backed draft", "source-backed draft" ], "search_text": "NADA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary NADA has 13 source-backed evidence row s from 13 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: nada - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 1 , mechanistic or pharmacological 12 - Draft sections: mechanistic evidence 12 , uncertainty 1 Key Draft Sections - Uncertainty and gaps: 1 evidence row s . - Mechanistic evidence: 12 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 12 13 13 rows 1131-1143 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1131 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. PMID 29082315; DOI 10.1089/can.2017.0015 1132 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . TRPV1 and CB 1 receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. PMID 15245490; DOI 10.1111/j.1460-9568.2004.03481.x 1133 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . Arvanil, anandamide and N-arachidonoyl-dopamine NADA inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. PMID 17459108; DOI 10.1111/j.1460-9568.2007.05521.x 1134 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . The endocannabinoid/endovanilloid N-arachidonoyl dopamine NADA and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. PMID 24644287; DOI 10.1074/jbc.m113.536953 1135 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endovanilloids are potential activators of the trigeminovascular nocisensor complex. PMID 27189587; DOI 10.1186/s10194-016-0644-7 1136 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid s...", "sources": 13, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "NADA", "type": "compound", "url": "/compounds/nada/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds noladin ether", "ether", "Noladin", "noladin", "Noladin ether", "source backed draft", "source-backed draft" ], "claims": 12, "evidence_rows": 12, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds noladin ether", "ether", "Noladin", "noladin", "Noladin ether", "source backed draft", "source-backed draft" ], "search_text": "Noladin ether Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Noladin ether has 12 source-backed evidence row s from 12 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: noladin-ether - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 2 , mechanistic or pharmacological 9 , preclinical 1 - Draft sections: mechanistic evidence 9 , preclinical evidence 1 , uncertainty 2 Key Draft Sections - Uncertainty and gaps: 2 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 9 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic and preclinical research summary: insufficient 2 , mechanistic or pharmacological 9 , preclinical 1 12 12 rows 1144-1155 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1144 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and Their Pharmacological Actions. PMID 26408156; DOI 10.1007/978-3-319-20825-1 1 1145 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. PMID 11259648; DOI 10.1073/pnas.061029898 1146 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The cannabinoid receptors. PMID 12432948; DOI 10.1016/s0090-6980 02 00060-6 1147 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. PMID 17698254; DOI 10.1016/j.neuint.2007.06.033 1148 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Noladin ether acts on trabecular meshwork cannabinoid CB1 receptors to enhance aqueous humor outflow facility. PMID 16639008; DOI 10.1167/iovs.05-0729 1149 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Ether-linked analogue of 2-arachidonoylglycerol noladin ether was not detected in the brains of various mammalian species. PMID 12787057; DOI 10.1046/j.1471-4159.2003.01804.x 1150 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design:...", "sources": 12, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "Noladin ether", "type": "compound", "url": "/compounds/noladin-ether/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds oea", "OEA", "oea", "source backed draft", "source-backed draft" ], "claims": 15, "evidence_rows": 15, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds oea", "OEA", "oea", "source backed draft", "source-backed draft" ], "search_text": "OEA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary OEA has 15 source-backed evidence row s from 15 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: oea - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 11 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 11 Key Draft Sections - Uncertainty and gaps: 11 evidence row s . - Mechanistic evidence: 4 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 10 , mechanistic or pharmacological 4 14 14 rows 1092-1105 OEA modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 977 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 977 OEA modulates TRPV1; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Novel cannabinoid receptors. PMID 17906678; DOI 10.1038/sj.bjp.0707481 1092 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and nutrition. PMID 18426507; DOI 10.1111/j.1365-2826.2008.01687.x 1093 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . N-acylethanolamines, anandamide and food intake. PMID 19413995; DOI 10.1016/j.bcp.2009.04.024 1094 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PMID 19285259; DOI 10.1016/j.beem.2008.10.003 1095 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. PMID 30537148; DOI 10.1002/jcp.27913 1096 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . A fatty gut feeling. PMID 23567058; DOI 10.1016/j.tem.2013.03.001 1097 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Analgesic properties of oleoylethanolamide OEA in visceral and inflammatory pain. PMID 17449181; DOI 10.1016/j.pain.2007.03.008 1098 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Regulation of food intake by oleoylethanolamide. PMID 15770421; DOI 10.1...", "sources": 15, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "OEA", "type": "compound", "url": "/compounds/oea/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds oleamide", "Oleamide", "oleamide", "source backed draft", "source-backed draft" ], "claims": 13, "evidence_rows": 13, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds oleamide", "Oleamide", "oleamide", "source backed draft", "source-backed draft" ], "search_text": "Oleamide Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Oleamide has 13 source-backed evidence row s from 13 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: oleamide - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 9 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 9 Key Draft Sections - Uncertainty and gaps: 9 evidence row s . - Mechanistic evidence: 4 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms Mechanistic research summary: insufficient 9 , mechanistic or pharmacological 4 13 13 rows 1119-1202 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1119 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Endocannabinoid hydrolases. PMID 12432941; DOI 10.1016/s0090-6980 02 00053-9 1120 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. PMID 11945157; DOI 10.2174/1381612023395655 1121 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Oleamide: a member of the endocannabinoid family? PMID 14691053; DOI 10.1038/sj.bjp.0705608 1122 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? PMID 17445087; DOI 10.1111/j.1527-3466.2007.00004.x 1123 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? PMID 10469890 1124 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . The role of the CB1 receptor in the regulation of sleep. PMID 18514375; DOI 10.1016/j.pnpbp.2008.04.008 1125 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. PMID 9344854; DOI 10.1006/b...", "sources": 13, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "Oleamide", "type": "compound", "url": "/compounds/oleamide/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds pea", "PEA", "pea", "source backed draft", "source-backed draft" ], "claims": 14, "evidence_rows": 14, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds pea", "PEA", "pea", "source backed draft", "source-backed draft" ], "search_text": "PEA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary PEA has 14 source-backed evidence row s from 13 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: pea - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 14 - Sources: 13 - Evidence classes: insufficient 7 , mechanistic or pharmacological 7 - Draft sections: mechanistic evidence 7 , uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . - Mechanistic evidence: 7 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- PEA studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 270 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms Mechanistic research summary: insufficient 7 , mechanistic or pharmacological 6 13 13 rows 1106-1118 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 270 PEA studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PMID 35176443; DOI 10.1016/j.bbi.2022.02.008 1106 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PMID 35176443; DOI 10.1016/j.bbi.2022.02.008 1107 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Mechanisms and clinical applications of palmitoylethanolamide PEA in the treatment of neuropathic pain. PMID 39714723; DOI 10.1007/s10787-024-01623-8 1108 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . The search for the palmitoylethanolamide receptor. PMID 15963531; DOI 10.1016/j.lfs.2005.05.012 1109 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. PMID 40563990; DOI 10.3390/biomedicines13061271 1110 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Probiotics and palmitoylethanolamide PEA for osteoarthritic pain: individual effects in a multiple baseline design study. PMID 41709243; DOI 10.1186/s12906-025-05187-0 1111 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class:...", "sources": 13, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "PEA", "type": "compound", "url": "/compounds/pea/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds sea", "SEA", "sea", "source backed draft", "source-backed draft" ], "claims": 16, "evidence_rows": 16, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds sea", "SEA", "sea", "source backed draft", "source-backed draft" ], "search_text": "SEA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary SEA has 16 source-backed evidence row s from 16 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: sea - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 16 - Sources: 16 - Evidence classes: insufficient 4 , mechanistic or pharmacological 5 , preclinical 6 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 5 , preclinical evidence 6 , uncertainty 4 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Preclinical evidence: 6 evidence row s . - Mechanistic evidence: 5 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 5 , preclinical 6 , preliminary human 1 16 16 rows 1186-1201 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1186 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PMID 20353771; DOI 10.1016/j.expneurol.2010.03.022 1187 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. PMID 31881191; DOI 10.1016/j.bcp.2019.113783 1188 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Roles of fatty acid ethanolamides FAE in traumatic and ischemic brain injury. PMID 24874648; DOI 10.1016/j.phrs.2014.05.009 1189 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. PMID 12010121; DOI 10.1042/bj20020438 1190 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PMID 22125609; DOI 10.1371/journal.pone.0027257 1191 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. PMID 23707281; DOI 10.1016/j.pain.2013.05.002 1192 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Serum levels of endocannabinoids and related lipids in painful vs painless diabetic neuropathy: results from the Pain in Neuropathy Study. PMID 37578507; DOI 10.1097/j.pain.0000000000003015 1193 SEA studied for SEA biology, metabolis...", "sources": 16, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "SEA", "type": "compound", "url": "/compounds/sea/" }, { "aliases": [ "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds thc", "d9 thc", "delta 9 thc", "delta-9 thc", "source backed draft", "source-backed draft", "tetrahydrocannabinol", "THC", "thc" ], "claims": 192, "evidence_rows": 192, "search_boost": 15, "search_terms": [ "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds thc", "d9 thc", "delta 9 thc", "delta-9 thc", "source backed draft", "source-backed draft", "tetrahydrocannabinol", "THC", "thc" ], "search_text": "THC Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary THC has 192 source-backed evidence row s from 156 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: thc - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for evidence review; claims require sourced support. Evidence Snapshot - Evidence rows: 192 - Sources: 156 - Evidence classes: insufficient 143 , mechanistic or pharmacological 28 , preclinical 2 , preliminary human 19 - Draft sections: human evidence 16 , mechanistic evidence 27 , preclinical evidence 2 , safety 18 , uncertainty 129 Key Draft Sections - Human evidence: 16 evidence row s . - Safety and tolerability: 18 evidence row s . - Uncertainty and gaps: 129 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 27 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- THC studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 8 , preliminary human 2 10 10 rows 488-497 THC studied for Cannabinoids and immune modulation research outcomes Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 269-273 THC studied for Cannabinoids and nausea/vomiting research outcomes Developed but mixed human research summary: insufficient 3 , preliminary human 1 4 4 rows 233-379 THC studied for Cardiovascular risk Developed but mixed human research summary: insufficient 7 , preliminary human 2 9 9 rows 443-451 THC modulates CB1 Mechanistic research summary: insufficient 6 , mechanistic or pharmacological 4 10 10 rows 808-858 THC modulates CB2 Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 7 11 11 rows 863-922 THC studied for Cognition and memory Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 1 , preliminary human 3 10 10 rows 461-470 THC studied for Dependence and withdrawal Mapped evidence with interpretation limits: insufficient 9 9 9 rows 452-460 THC associated with driving impairment or safety-relevant performance outcomes Mapped evidence with interpretation limits: insufficient 7 7 7 rows 25-56 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics Mapped evidence with interpretation limits: insufficient 4 4 4 rows 288-294 THC modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 946-957 THC modulates GPR55 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 927-939 THC studied for Nausea and vomiting Developed but mixed human research summary: insufficient 7 , preliminary human 1 8 8 rows 480-487 THC studied for Pain-related outcomes Developed but mixed human research summary: insufficient 8 , preliminary human 1 9 9 rows 471-479 THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 1 , preliminary human 1 8 8 rows 99-183 THC studied for Psychiatric risk Mapped evidence with interpretation limits: insufficient 9 9 9 rows 434-442 THC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 3 3 3 rows 249-252 THC studied for receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 201-287 THC modulates receptor, target, or pharmacology mechanisms Preclinical research summary: insufficient 2 , preclinical 1 3 3 rows 204-213 THC studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 14 , mechanistic or pharmacological 1 , preliminary human 3 18 18 rows 218-375 THC studied for Sleep Developed but mixed human research summary: insufficient 6 , preliminary human 4 10 10 rows 498-507 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 214-364 THC modulates TRPA1 Mechanistic research summary: insufficient 4 , mechanistic or ph...", "sources": 156, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "THC", "type": "compound", "url": "/compounds/thc/" }, { "aliases": [ "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds thca", "source backed draft", "source-backed draft", "tetrahydrocannabinolic acid", "THCA", "thca" ], "claims": 11, "evidence_rows": 11, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds thca", "source backed draft", "source-backed draft", "tetrahydrocannabinolic acid", "THCA", "thca" ], "search_text": "THCA Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary THCA has 11 source-backed evidence row s from 11 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: thca - Type: compound - Subtype: phytocannabinoid acid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 11 - Sources: 11 - Evidence classes: insufficient 6 , mechanistic or pharmacological 2 , preclinical 1 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 2 , preclinical evidence 1 , uncertainty 6 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 6 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 2 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- THCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 286 THCA studied for THCA-specific safety, effect, or mechanism claims Developed but mixed human research summary: insufficient 5 , mechanistic or pharmacological 2 , preclinical 1 , preliminary human 2 10 10 rows 44-92 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 44 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological outcome measure: safety, effect, or mechanism claims . Cannabis Therapeutics and the Future of Neurology. PMID 30405366; DOI 10.3389/fnint.2018.00051 45 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, effect, or mechanism claims . Investigational cannabinoids in seizure disorders, what have we learned thus far? PMID 29842819; DOI 10.1080/13543784.2018.1482275 46 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, effect, or mechanism claims . Cannabinoid Content in Cannabis Flowers and Homemade Cannabis-Based Products Used for Therapeutic Purposes in Argentina. PMID 33998894; DOI 10.1089/can.2020.0117 86 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preliminary human study design: Human clinical study; outcome measure: safety, effect, or mechanism claims . Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows. PMID 37641272; DOI 10.3168/jds.2023-23222 87 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient outcome measure: safety, effect, or mechanism claims . Semiquantitative Screening of THC Analogues by Silica Gel TLC with an Ag I Retention Zone and Chromogenic Smartphone Detection. PMID 36178203; DOI 10.1021/acs.analchem.2c01627 88 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological study design: Human clinical study; outcome measure: safety, effect, or mechanism claims . Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle. PMID 41358942; DOI 10.1093/jas/skaf418 89 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preclinical population or model: Human participants or patients mentioned; outcome measure: safety, effect, or mechanism claims . Determination of Cannabinoids in Meat Products and Animal Feeds in Singapore Using Liquid Chromatography-Tandem Mass Spectrometry. PMID 39200508; DOI 10.3390/foods13162581 90 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient population or model: Human participants or patients mentioned; outcome measure: safety, effect, or mechanism claims . Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation-Eemission Matrix Fluorescence Coupled with Parallel Factor Analysis. PMID 37810707; DOI 10.1021/acsomega.3c04913 91 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient outcome measure: safety, effect, or mechanism claims . Ultrafast, Selective, and Highl...", "sources": 11, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "THCA", "type": "compound", "url": "/compounds/thca/" }, { "aliases": [ "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds thcv", "source backed draft", "source-backed draft", "tetrahydrocannabivarin", "THCV", "thcv" ], "claims": 86, "evidence_rows": 86, "search_boost": 11, "search_terms": [ "Compound", "compound", "compound phytocannabinoid", "compound / phytocannabinoid", "compounds", "compounds thcv", "source backed draft", "source-backed draft", "tetrahydrocannabivarin", "THCV", "thcv" ], "search_text": "THCV Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary THCV has 86 source-backed evidence row s from 63 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: thcv - Type: compound - Subtype: phytocannabinoid - Description: Controlled compound entry for future source discovery and claim review. Evidence Snapshot - Evidence rows: 86 - Sources: 63 - Evidence classes: insufficient 30 , mechanistic or pharmacological 48 , preclinical 3 , preliminary human 5 - Draft sections: human evidence 4 , mechanistic evidence 42 , preclinical evidence 1 , safety 24 , uncertainty 15 Key Draft Sections - Human evidence: 4 evidence row s . - Safety and tolerability: 24 evidence row s . - Uncertainty and gaps: 15 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 42 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- THCV studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 8 , preliminary human 2 13 13 rows 37-735 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 783-786 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 4 , preliminary human 1 9 9 rows 787-795 THCV studied for Pain-related outcomes Developed but mixed human research summary: insufficient 2 , mechanistic or pharmacological 6 , preclinical 1 , preliminary human 1 10 10 rows 796-805 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 6 , mechanistic or pharmacological 17 23 23 rows 760-782 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Developed but mixed human research summary: insufficient 15 , mechanistic or pharmacological 6 , preclinical 2 , preliminary human 1 24 24 rows 736-759 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 1006-1007 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 37 THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . \u03949-Tetrahydrocannabivarin THCV : a commentary on potential therapeutic benefit for the management of obesity and diabetes. PMID 33526143; DOI 10.1186/s42238-020-0016-7 38 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . The role of tetrahydrocannabivarin THCV in metabolic disorders: A promising cannabinoid for diabetes and weight management. PMID 40270953; DOI 10.3934/neuroscience.2025003 39 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 77 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PMID 27573936; DOI 10.2337/dc16-0650 78 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . CB\u2081-independent...", "sources": 63, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid", "title": "THCV", "type": "compound", "url": "/compounds/thcv/" }, { "aliases": [ "a", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds thcv a", "source backed draft", "source-backed draft", "tetrahydrocannabivarinic", "tetrahydrocannabivarinic acid", "thcv", "THCV A", "thcv a", "THCV-A", "thcv-a", "thcva" ], "claims": 108, "evidence_rows": 108, "search_boost": 12, "search_terms": [ "a", "Compound", "compound", "compound phytocannabinoid acid", "compound / phytocannabinoid acid", "compounds", "compounds thcv a", "source backed draft", "source-backed draft", "tetrahydrocannabivarinic", "tetrahydrocannabivarinic acid", "thcv", "THCV A", "thcv a", "THCV-A", "thcv-a", "thcva" ], "search_text": "THCV-A Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary THCV-A has 108 source-backed evidence row s from 78 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: thcv-a - Type: compound - Subtype: phytocannabinoid acid - Description: Not recorded Evidence Snapshot - Evidence rows: 108 - Sources: 78 - Evidence classes: insufficient 45 , mechanistic or pharmacological 54 , preclinical 4 , preliminary human 5 - Draft sections: human evidence 4 , mechanistic evidence 48 , preclinical evidence 2 , safety 26 , uncertainty 28 Key Draft Sections - Human evidence: 4 evidence row s . - Safety and tolerability: 26 evidence row s . - Uncertainty and gaps: 28 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 48 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 74 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 283-284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 658-660 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 639 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 711-713 CBCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 282 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 1 , preclinical 1 3 3 rows 279-281 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 167 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 526 HHC studied for Rare phytocannabinoids research topics Mapped evidence with interpretation limits: insufficient 1 1 247 THC modulates CB2 Mapped evidence with interpretation limits: insufficient 1 1 863 THC studied for receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 201-287 THC modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 204 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 364 THC modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1050 THCA studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 286 THCV studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 8 , preliminary human 2 13 13 rows 37-735 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 783-786 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 4 , preliminary human 1 9 9 rows 787-795 THCV studied for Pain-related outcomes Developed but mixed human research summary: insufficient 2 , mechanistic or pharmacological 6 , preclinical 1 , preliminary human 1 10 10 rows 796-805 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 6 , mechanistic or pharmacological 17 23 23 rows 760-782 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Developed but mixed human research summary: insufficient 15 , mechanistic or pharmacological 6 , preclinical 2 , preliminary human 1 24 24 rows 736-759 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 37 THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human popula...", "sources": 78, "status": "source-backed draft", "subtitle": "compound / phytocannabinoid acid", "title": "THCV-A", "type": "compound", "url": "/compounds/thcv-a/" }, { "aliases": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds virodhamine", "source backed draft", "source-backed draft", "Virodhamine", "virodhamine" ], "claims": 11, "evidence_rows": 11, "search_boost": 8, "search_terms": [ "Compound", "compound", "compound endocannabinoid like lipid", "compound / endocannabinoid like lipid", "compounds", "compounds virodhamine", "source backed draft", "source-backed draft", "Virodhamine", "virodhamine" ], "search_text": "Virodhamine Page type: compound Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Virodhamine has 11 source-backed evidence row s from 11 source s . The current page should separate outcomes, mechanisms, formulation context, and safety signals. Identity - Canonical name: virodhamine - Type: compound - Subtype: endocannabinoid like lipid - Description: Not recorded Evidence Snapshot - Evidence rows: 11 - Sources: 11 - Evidence classes: insufficient 3 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 3 Key Draft Sections - Uncertainty and gaps: 3 evidence row s . - Mechanistic evidence: 8 evidence row s . Studied Outcomes And Mechanisms Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 8 11 11 rows 1156-1166 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 1156 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and Their Pharmacological Actions. PMID 26408156; DOI 10.1007/978-3-319-20825-1 1 1157 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . GPR55: a new member of the cannabinoid receptor clan? PMID 17876300; DOI 10.1038/sj.bjp.0707464 1158 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The role of the CB1 receptor in the regulation of sleep. PMID 18514375; DOI 10.1016/j.pnpbp.2008.04.008 1159 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. PMID 18806815; DOI 10.1038/bjp.2008.371 1160 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. PMID 12023533; DOI 10.1124/jpet.301.3.1020 1161 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. PMID 22454039; DOI 10.1007/s11481-012-9351-6 1162 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Virodh...", "sources": 11, "status": "source-backed draft", "subtitle": "compound / endocannabinoid like lipid", "title": "Virodhamine", "type": "compound", "url": "/compounds/virodhamine/" }, { "aliases": [ "Cannabinoids", "cannabinoids", "Other", "other", "other compound class", "other / compound class", "other cannabinoids", "source backed draft", "source-backed draft" ], "claims": 143, "evidence_rows": 143, "search_boost": 8, "search_terms": [ "Cannabinoids", "cannabinoids", "Other", "other", "other compound class", "other / compound class", "other cannabinoids", "source backed draft", "source-backed draft" ], "search_text": "Cannabinoids Page type: other Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This page has 143 source-backed evidence row s from 127 source s . Identity - Canonical name: cannabinoids - Type: other - Subtype: compound class - Description: Broad cannabinoid class entry for cross-compound safety and population evidence. Evidence Snapshot - Evidence rows: 143 - Sources: 127 - Evidence classes: insufficient 87 , mechanistic or pharmacological 50 , preclinical 2 , preliminary human 4 - Draft sections: human evidence 2 , mechanistic evidence 50 , preclinical evidence 1 , safety 20 , uncertainty 70 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 20 evidence row s . - Uncertainty and gaps: 70 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 50 evidence row s . Evidence Relationships Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 274-276 Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes Mapped evidence with interpretation limits: insufficient 3 3 3 rows 234-236 Cannabinoids modulates CB1 Mechanistic research summary: insufficient 13 , mechanistic or pharmacological 16 28 29 rows 806-860 Cannabinoids modulates CB2 Mechanistic research summary: insufficient 13 , mechanistic or pharmacological 24 37 37 rows 864-925 Cannabinoids modulates GPR18 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 944-951 Cannabinoids modulates GPR55 Mapped evidence with interpretation limits: insufficient 5 5 5 rows 926-934 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 11 , preliminary human 2 13 13 rows 100-195 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 7 , mechanistic or pharmacological 3 10 10 rows 206-267 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 5 , preliminary human 1 6 6 rows 93-153 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 12 , preclinical 1 , preliminary human 1 14 14 rows 219-376 Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPA1 Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 3 6 6 rows 1034-1042 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1054-1060 Cannabinoids modulates TRPV1 Preclinical research summary: insufficient 2 , preclinical 1 3 3 rows 974-981 Cannabinoids modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 997 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1011-1014 Cannabinoids modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 1020-1026 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 93 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Pharmacologic treatment of fibromyalgia: an update. PMID 41142233; DOI 10.3389/fphar.2025.1651181 94 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . The safety of studies with intravenous \u0394\u2079-tetrahydrocannabinol in humans, with case histories. PMID 21845389; DOI 10.1007/s00213-011-2417-y 95 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or mod...", "sources": 127, "status": "source-backed draft", "subtitle": "other / compound class", "title": "Cannabinoids", "type": "other", "url": "/other/cannabinoids/" }, { "aliases": [ "Endocannabinoids", "endocannabinoids", "Other", "other", "other lipid class", "other / lipid class", "other endocannabinoids", "source backed draft", "source-backed draft" ], "claims": 96, "evidence_rows": 96, "search_boost": 6, "search_terms": [ "Endocannabinoids", "endocannabinoids", "Other", "other", "other lipid class", "other / lipid class", "other endocannabinoids", "source backed draft", "source-backed draft" ], "search_text": "Endocannabinoids Page type: other Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This page has 96 source-backed evidence row s from 95 source s . Identity - Canonical name: endocannabinoids - Type: other - Subtype: lipid class - Description: Not recorded Evidence Snapshot - Evidence rows: 96 - Sources: 95 - Evidence classes: insufficient 59 , mechanistic or pharmacological 31 , preclinical 2 , preliminary human 4 - Draft sections: human evidence 3 , mechanistic evidence 30 , preclinical evidence 2 , safety 12 , uncertainty 49 Key Draft Sections - Human evidence: 3 evidence row s . - Safety and tolerability: 12 evidence row s . - Uncertainty and gaps: 49 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 30 evidence row s . Evidence Relationships Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Endocannabinoids studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 268-272 Endocannabinoids modulates CB1 Mechanistic research summary: insufficient 11 , mechanistic or pharmacological 5 16 16 rows 814-862 Endocannabinoids modulates CB2 Mechanistic research summary: insufficient 6 , mechanistic or pharmacological 6 12 12 rows 868-917 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 1 , preliminary human 1 8 8 rows 202-299 Endocannabinoids modulates GPR119 Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 1 6 6 rows 963-970 Endocannabinoids modulates GPR18 Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 2 7 7 rows 947-961 Endocannabinoids modulates GPR55 Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 1 5 5 rows 929-941 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 2 6 6 rows 209-265 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 10 , mechanistic or pharmacological 1 , preliminary human 1 12 12 rows 222-347 Endocannabinoids modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1041 Endocannabinoids modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 1059-1061 Endocannabinoids modulates TRPV1 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 980-987 Endocannabinoids modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 1023-1027 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 202 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPAR\u03b1. PMID 31325449; DOI 10.1016/j.bcp.2019.07.017 209 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. PMID 31146657; DOI 10.2174/1570159x17666190118143014 210 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. PMID 30670965; DOI 10.33...", "sources": 95, "status": "source-backed draft", "subtitle": "other / lipid class", "title": "Endocannabinoids", "type": "other", "url": "/other/endocannabinoids/" }, { "aliases": [ "Adverse", "adverse", "Adverse events", "events", "Outcome", "outcome", "outcomes", "outcomes adverse events", "source backed draft", "source-backed draft" ], "claims": 109, "evidence_rows": 109, "search_boost": 10, "search_terms": [ "Adverse", "adverse", "Adverse events", "events", "Outcome", "outcome", "outcomes", "outcomes adverse events", "source backed draft", "source-backed draft" ], "search_text": "Adverse events Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Adverse events. The current ledger contributes 109 evidence row s from 74 source s . Identity - Canonical name: adverse-events - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 109 - Sources: 74 - Evidence classes: insufficient 61 , mechanistic or pharmacological 6 , preclinical 1 , preliminary human 41 - Draft sections: human evidence 27 , mechanistic evidence 1 , preclinical evidence 1 , safety 39 , uncertainty 41 Key Draft Sections - Human evidence: 27 evidence row s . - Safety and tolerability: 39 evidence row s . - Uncertainty and gaps: 41 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes Mapped evidence with interpretation limits: insufficient 1 1 236 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 4 , preliminary human 1 5 5 rows 93-153 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 651 CBD studied for Anxiety-related outcomes Developed but mixed human research summary: insufficient 1 , preliminary human 3 4 4 rows 28-63 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 1 4 4 rows 22-49 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 365-373 CBD studied for Pain-related outcomes Developed but mixed human research summary: insufficient 4 , preliminary human 4 8 8 rows 392-433 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 3 , preliminary human 1 4 4 rows 98-188 CBD studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 5 5 5 rows 196-200 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 2 , preliminary human 4 5 6 rows 217-324 CBD studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 8 , mechanistic or pharmacological 1 , preliminary human 7 16 16 rows 380-427 CBD studied for Sleep Developed but mixed human research summary: insufficient 2 , preliminary human 2 4 4 rows 404-413 CBD modulates TRPA1 Mapped evidence with interpretation limits: insufficient 1 1 1045 CBD modulates TRPM8 Mapped evidence with interpretation limits: insufficient 1 1 1057 CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 165 CBDV studied for Seizure and neurodevelopmental outcomes Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 84-110 CBG studied for Appetite and metabolic outcomes Early human research summary: preliminary human 1 1 629 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 162 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: mechanistic or pharmacological 1 , preliminary human 1 2 2 rows 546-562 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 2 2 2 rows 509-510 CBN studied for Sleep Early human research summary: preliminary human 1 1 108 CBN decreases Sleep onset latency Earl...", "sources": 74, "status": "source-backed draft", "subtitle": "outcome", "title": "Adverse events", "type": "outcome", "url": "/outcomes/adverse-events/" }, { "aliases": [ "anxiety", "Anxiety related", "Anxiety related outcomes", "Anxiety-related", "Anxiety-related outcomes", "Outcome", "outcome", "outcomes", "outcomes anxiety related outcomes", "related", "source backed draft", "source-backed draft" ], "claims": 10, "evidence_rows": 10, "search_boost": 6, "search_terms": [ "anxiety", "Anxiety related", "Anxiety related outcomes", "Anxiety-related", "Anxiety-related outcomes", "Outcome", "outcome", "outcomes", "outcomes anxiety related outcomes", "related", "source backed draft", "source-backed draft" ], "search_text": "Anxiety-related outcomes Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Anxiety-related outcomes. The current ledger contributes 10 evidence row s from 10 source s . Identity - Canonical name: anxiety-related-outcomes - Type: outcome - Subtype: Not recorded - Description: Outcome area for auditable evidence review. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 3 , preliminary human 7 - Draft sections: human evidence 7 , uncertainty 3 Key Draft Sections - Human evidence: 7 evidence row s . - Uncertainty and gaps: 3 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Anxiety-related outcomes Developed but mixed human research summary: insufficient 3 , preliminary human 7 10 10 rows 28-63 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 28 CBD studied for Anxiety-related outcomes; evidence class: preliminary human study design: Human clinical study; outcome measure: anxiety-related outcomes . Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution 150 mg/mL versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PMID 38797087; DOI 10.1016/j.ajp.2024.104073 29 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. PMID 35617670; DOI 10.47626/2237-6089-2021-0396 30 CBD studied for Anxiety-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes . Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. PMID 33424664; DOI 10.3389/fpsyt.2020.595584 57 CBD studied for Anxiety-related outcomes; evidence class: preliminary human study design: Human clinical study; outcome measure: anxiety-related outcomes . Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PMID 38174873; DOI 10.5664/jcsm.10998 58 CBD studied for Anxiety-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes . Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 59 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. PMID 39680411; DOI 10.1001/jamanetworkopen.2024.50391 60 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. PMID 39505200; DOI 10.1016/j.joen.2024.10.010 61 CBD studied for Anxiety-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: anxiety-related outcomes . Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PMID 35982439; DOI 10.1186/s12916-022-02459-1 62 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, P...", "sources": 10, "status": "source-backed draft", "subtitle": "outcome", "title": "Anxiety-related outcomes", "type": "outcome", "url": "/outcomes/anxiety-related-outcomes/" }, { "aliases": [ "and", "Appetite", "appetite", "Appetite and metabolic outcomes", "metabolic", "Outcome", "outcome", "outcomes", "outcomes appetite and metabolic outcomes", "source backed draft", "source-backed draft" ], "claims": 39, "evidence_rows": 39, "search_boost": 7, "search_terms": [ "and", "Appetite", "appetite", "Appetite and metabolic outcomes", "metabolic", "Outcome", "outcome", "outcomes", "outcomes appetite and metabolic outcomes", "source backed draft", "source-backed draft" ], "search_text": "Appetite and metabolic outcomes Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Appetite and metabolic outcomes. The current ledger contributes 39 evidence row s from 37 source s . Identity - Canonical name: appetite-metabolic-outcomes - Type: outcome - Subtype: Not recorded - Description: Outcome area for auditable evidence review. Evidence Snapshot - Evidence rows: 39 - Sources: 37 - Evidence classes: insufficient 16 , mechanistic or pharmacological 13 , preclinical 4 , preliminary human 6 - Draft sections: human evidence 6 , mechanistic evidence 13 , preclinical evidence 4 , uncertainty 16 Key Draft Sections - Human evidence: 6 evidence row s . - Uncertainty and gaps: 16 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 13 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBG studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 5 , mechanistic or pharmacological 5 , preclinical 4 , preliminary human 2 16 16 rows 620-635 THC studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 8 , preliminary human 2 10 10 rows 488-497 THCV studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 8 , preliminary human 2 13 13 rows 37-735 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 37 THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . \u03949-Tetrahydrocannabivarin THCV : a commentary on potential therapeutic benefit for the management of obesity and diabetes. PMID 33526143; DOI 10.1186/s42238-020-0016-7 38 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . The role of tetrahydrocannabivarin THCV in metabolic disorders: A promising cannabinoid for diabetes and weight management. PMID 40270953; DOI 10.3934/neuroscience.2025003 39 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 77 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PMID 27573936; DOI 10.2337/dc16-0650 78 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . CB\u2081-independent mechanisms of \u0394\u2079-THCV, AM251 and SR141716 rimonabant . PMID 21740450; DOI 10.1111/j.1365-2710.2011.01284.x 79 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes . SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r G894C Zebrafish Model of Obesity. PMID 42196303; DOI 10.3390/ijms27104321 80 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes . In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannab...", "sources": 37, "status": "source-backed draft", "subtitle": "outcome", "title": "Appetite and metabolic outcomes", "type": "outcome", "url": "/outcomes/appetite-and-metabolic-outcomes/" }, { "aliases": [ "and", "Cognition", "cognition", "Cognition and memory", "memory", "Outcome", "outcome", "outcomes", "outcomes cognition and memory", "source backed draft", "source-backed draft" ], "claims": 14, "evidence_rows": 14, "search_boost": 6, "search_terms": [ "and", "Cognition", "cognition", "Cognition and memory", "memory", "Outcome", "outcome", "outcomes", "outcomes cognition and memory", "source backed draft", "source-backed draft" ], "search_text": "Cognition and memory Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Cognition and memory. The current ledger contributes 14 evidence row s from 14 source s . Identity - Canonical name: cognition-memory - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 6 , mechanistic or pharmacological 5 , preliminary human 3 - Draft sections: human evidence 3 , mechanistic evidence 5 , uncertainty 6 Key Draft Sections - Human evidence: 3 evidence row s . - Uncertainty and gaps: 6 evidence row s . - Mechanistic evidence: 5 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates CB1 Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 851-854 Endocannabinoids modulates CB1 Mechanistic research summary: mechanistic or pharmacological 1 1 861 THC studied for Cognition and memory Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 1 , preliminary human 3 10 10 rows 461-470 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 461 THC studied for Cognition and memory; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes . Cannabinoids: Medical implications. PMID 26912385; DOI 10.3109/07853890.2016.1145794 462 THC studied for Cognition and memory; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: cognition or memory outcomes . \u03949-Tetrahydrocannabinol THC impairs visual working memory performance: a randomized crossover trial. PMID 32386395; DOI 10.1038/s41386-020-0690-3 463 THC studied for Cognition and memory; evidence class: insufficient study design: Human clinical study; outcome measure: cognition or memory outcomes . Developing a phone-based measure of impairment after acute oral \u22069-tetrahydrocannabinol. PMID 31407943; DOI 10.1177/0269881119862533 464 THC studied for Cognition and memory; evidence class: insufficient outcome measure: cognition or memory outcomes . Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study. PMID 33526107; DOI 10.1186/s42238-020-00034-0 465 THC studied for Cognition and memory; evidence class: mechanistic or pharmacological outcome measure: cognition or memory outcomes . Acute administration of THC impairs spatial but not associative memory function in zebrafish. PMID 24639045; DOI 10.1007/s00213-014-3522-5 466 THC studied for Cognition and memory; evidence class: insufficient study design: Systematic review; outcome measure: cognition or memory outcomes . Effects of different methods of cannabis use on cognition and blood THC: A systematic review. PMID 40368229; DOI 10.1016/j.pnpbp.2025.111399 467 THC studied for Cognition and memory; evidence class: insufficient study design: Narrative or expert review; outcome measure: cognition or memory outcomes . Cannabis: Similarities and differences with tobacco . PMID 32381378; DOI 10.1016/j.rmr.2020.04.002 468 THC studied for Cognition and memory; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: cognition or memory outcomes . The Individual and Interactive Effects of Alpha-Pinene and Delta-9-Tetrahydrocannabinol in Healthy Adults. PMID 40734690; DOI 10.1159/000547014 469 THC studied for Cognition and memory; evidence class: preliminary human study design: Human clinical study; outcome measure: cognition or memory outcomes . Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol THC in infrequent cannabis users. PMID 12373420; DOI 10.1007/s00213-002-1169-0 470 THC studied for Cognition and memory; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes . The acute effects of cannabis on human executive function. PMID 30199388; DOI 10.1097/fbp.0000000000000426 851 Cannabinoids modulates CB1; evidence class: mechanistic or pharmacologi...", "sources": 14, "status": "source-backed draft", "subtitle": "outcome", "title": "Cognition and memory", "type": "outcome", "url": "/outcomes/cognition-and-memory/" }, { "aliases": [ "Daytime", "daytime", "Daytime fatigue", "fatigue", "Outcome", "outcome", "outcomes", "outcomes daytime fatigue", "source backed draft", "source-backed draft" ], "claims": 10, "evidence_rows": 10, "search_boost": 6, "search_terms": [ "Daytime", "daytime", "Daytime fatigue", "fatigue", "Outcome", "outcome", "outcomes", "outcomes daytime fatigue", "source backed draft", "source-backed draft" ], "search_text": "Daytime fatigue Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Daytime fatigue. The current ledger contributes 10 evidence row s from 2 source s . Identity - Canonical name: daytime-fatigue - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 10 - Sources: 2 - Evidence classes: preliminary human 10 - Draft sections: human evidence 8 , safety 2 Key Draft Sections - Human evidence: 8 evidence row s . - Safety and tolerability: 2 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Sleep Early human research summary: preliminary human 1 1 404 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 1 1 14 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 2 2 2 rows 508-510 CBN studied for Sleep Early human research summary: preliminary human 1 1 108 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 1 1 17 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 14 CBN decreases Overall sleep disturbance; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 16 CBN no detected effect on Sleep onset latency; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 17 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 18 CBN no detected effect on Daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Daytime fatigue . A double-blind, randomized, placebo-controlled study of...", "sources": 2, "status": "source-backed draft", "subtitle": "outcome", "title": "Daytime fatigue", "type": "outcome", "url": "/outcomes/daytime-fatigue/" }, { "aliases": [ "cytokine", "Immune", "immune", "immune cell", "Immune modulation", "immune modulation", "immune system", "immune-cell", "immune-system", "modulation", "Outcome", "outcome", "outcomes", "outcomes immune modulation", "source backed draft", "source-backed draft" ], "claims": 131, "evidence_rows": 131, "search_boost": 11, "search_terms": [ "cytokine", "Immune", "immune", "immune cell", "Immune modulation", "immune modulation", "immune system", "immune-cell", "immune-system", "modulation", "Outcome", "outcome", "outcomes", "outcomes immune modulation", "source backed draft", "source-backed draft" ], "search_text": "Immune modulation Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Immune modulation. The current ledger contributes 131 evidence row s from 106 source s . Identity - Canonical name: immune-modulation - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 131 - Sources: 106 - Evidence classes: insufficient 54 , mechanistic or pharmacological 69 , preclinical 6 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 67 , preclinical evidence 6 , safety 10 , uncertainty 46 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 10 evidence row s . - Uncertainty and gaps: 46 evidence row s . - Preclinical evidence: 6 evidence row s . - Mechanistic evidence: 67 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 274-276 Cannabinoids modulates CB1 Mapped evidence with interpretation limits: insufficient 1 1 817 Cannabinoids modulates CB2 Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 14 19 19 rows 869-925 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 1 1 1014 Cannabinoids modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1026 CBC studied for Inflammation-related outcomes Developed but mixed human research summary: mechanistic or pharmacological 1 , preclinical 1 , preliminary human 1 3 3 rows 35-72 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 721-727 CBC studied for Pain-related outcomes Developed but mixed human research summary: mechanistic or pharmacological 1 , preclinical 1 , preliminary human 1 3 3 rows 684-687 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 670-681 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 707-716 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 369-372 CBD modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 942 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 4 4 4 rows 327-342 CBD modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1046 CBD modulates TRPV1 Mechanistic research summary: mechanistic or pharmacological 1 1 978 CBD modulates TRPV2 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 991-1001 CBD modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 1009-1010 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 137-143 CBG studied for Appetite and metabolic outcomes Mapped evidence with interpretation limits: insufficient 1 1 622 CBG studied for Inflammation-related outcomes Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 587-597 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 64-68 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 565-571 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 157 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 542 CBG studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 606-619 CBN modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1...", "sources": 106, "status": "source-backed draft", "subtitle": "outcome", "title": "Immune modulation", "type": "outcome", "url": "/outcomes/immune-modulation/" }, { "aliases": [ "inflammation", "Inflammation related", "Inflammation related outcomes", "Inflammation-related", "Inflammation-related outcomes", "Outcome", "outcome", "outcomes", "outcomes inflammation related outcomes", "related", "source backed draft", "source-backed draft" ], "claims": 60, "evidence_rows": 60, "search_boost": 8, "search_terms": [ "inflammation", "Inflammation related", "Inflammation related outcomes", "Inflammation-related", "Inflammation-related outcomes", "Outcome", "outcome", "outcomes", "outcomes inflammation related outcomes", "related", "source backed draft", "source-backed draft" ], "search_text": "Inflammation-related outcomes Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Inflammation-related outcomes. The current ledger contributes 60 evidence row s from 56 source s . Identity - Canonical name: inflammation-related-outcomes - Type: outcome - Subtype: Not recorded - Description: Outcome area for auditable evidence review. Evidence Snapshot - Evidence rows: 60 - Sources: 56 - Evidence classes: insufficient 21 , mechanistic or pharmacological 25 , preclinical 13 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 25 , preclinical evidence 13 , uncertainty 21 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 21 evidence row s . - Preclinical evidence: 13 evidence row s . - Mechanistic evidence: 25 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Developed but mixed human research summary: insufficient 2 , mechanistic or pharmacological 4 , preclinical 2 , preliminary human 1 9 9 rows 34-76 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic and preclinical research summary: insufficient 12 , mechanistic or pharmacological 9 , preclinical 4 25 25 rows 43-148 CBG studied for Inflammation-related outcomes Mechanistic and preclinical research summary: insufficient 7 , mechanistic or pharmacological 8 , preclinical 7 22 22 rows 584-605 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 783-786 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 34 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 35 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 36 CBC studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. PMID 37332213; DOI 10.1097/sap.0000000000003547 43 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. PMID 30627539; DOI 10.1155/2018/1691428 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 72 CBC studied for Inflammation-related outcomes; evidence class: preliminary human outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. PMID 41213439; DOI 10.1016/j.jep.2025.120856 73 CBC studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PMID 39921943; DOI 10.1016/j.jpet.2025.103389...", "sources": 56, "status": "source-backed draft", "subtitle": "outcome", "title": "Inflammation-related outcomes", "type": "outcome", "url": "/outcomes/inflammation-related-outcomes/" }, { "aliases": [ "and", "Nausea", "nausea", "Nausea and vomiting", "Outcome", "outcome", "outcomes", "outcomes nausea and vomiting", "source backed draft", "source-backed draft", "vomiting" ], "claims": 39, "evidence_rows": 39, "search_boost": 7, "search_terms": [ "and", "Nausea", "nausea", "Nausea and vomiting", "Outcome", "outcome", "outcomes", "outcomes nausea and vomiting", "source backed draft", "source-backed draft", "vomiting" ], "search_text": "Nausea and vomiting Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Nausea and vomiting. The current ledger contributes 39 evidence row s from 27 source s . Identity - Canonical name: nausea-vomiting - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 39 - Sources: 27 - Evidence classes: insufficient 30 , mechanistic or pharmacological 3 , preliminary human 6 - Draft sections: human evidence 6 , mechanistic evidence 3 , uncertainty 30 Key Draft Sections - Human evidence: 6 evidence row s . - Uncertainty and gaps: 30 evidence row s . - Mechanistic evidence: 3 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 235-236 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Mapped evidence with interpretation limits: insufficient 1 1 195 CBC studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 686 CBD studied for Anxiety-related outcomes Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 58-62 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Mapped evidence with interpretation limits: insufficient 1 1 176 CBD studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 412 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 43-131 CBG studied for Appetite and metabolic outcomes Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 620-632 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 576 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1133 THC studied for Appetite and metabolic outcomes Mapped evidence with interpretation limits: insufficient 1 1 489 THC studied for Cannabinoids and nausea/vomiting research outcomes Developed but mixed human research summary: insufficient 3 , preliminary human 1 4 4 rows 233-379 THC studied for Nausea and vomiting Developed but mixed human research summary: insufficient 7 , preliminary human 1 8 8 rows 480-487 THC studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 471 THC studied for Psychiatric risk Mapped evidence with interpretation limits: insufficient 2 2 2 rows 434-437 THC modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 205 THC studied for receptor, target, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 278 THC studied for Sleep Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 501-505 THCV studied for Appetite and metabolic outcomes Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 39-83 THCV studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 796 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 760 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 39 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 43 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. PMID 3062...", "sources": 27, "status": "source-backed draft", "subtitle": "outcome", "title": "Nausea and vomiting", "type": "outcome", "url": "/outcomes/nausea-and-vomiting/" }, { "aliases": [ "awakenings", "Nighttime", "nighttime", "Nighttime awakenings", "Outcome", "outcome", "outcomes", "outcomes nighttime awakenings", "source backed draft", "source-backed draft" ], "claims": 7, "evidence_rows": 7, "search_boost": 6, "search_terms": [ "awakenings", "Nighttime", "nighttime", "Nighttime awakenings", "Outcome", "outcome", "outcomes", "outcomes nighttime awakenings", "source backed draft", "source-backed draft" ], "search_text": "Nighttime awakenings Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Nighttime awakenings. The current ledger contributes 7 evidence row s from 1 source s . Identity - Canonical name: nighttime-awakenings - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 7 - Sources: 1 - Evidence classes: preliminary human 7 - Draft sections: human evidence 6 , safety 1 Key Draft Sections - Human evidence: 6 evidence row s . - Safety and tolerability: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 1 1 14 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 508 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 1 1 17 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 14 CBN decreases Overall sleep disturbance; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 16 CBN no detected effect on Sleep onset latency; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 17 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 18 CBN no detected effect on Daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 508 CBN studied for safety, tolerability, sedatio...", "sources": 1, "status": "source-backed draft", "subtitle": "outcome", "title": "Nighttime awakenings", "type": "outcome", "url": "/outcomes/nighttime-awakenings/" }, { "aliases": [ "non rapid eye movement", "non-rapid eye movement", "nonrapid eye movement", "NREM", "nrem", "NREM sleep", "nrem sleep", "Outcome", "outcome", "outcomes", "outcomes nrem sleep", "sleep", "source backed draft", "source-backed draft" ], "claims": 14, "evidence_rows": 14, "search_boost": 6, "search_terms": [ "non rapid eye movement", "non-rapid eye movement", "nonrapid eye movement", "NREM", "nrem", "NREM sleep", "nrem sleep", "Outcome", "outcome", "outcomes", "outcomes nrem sleep", "sleep", "source backed draft", "source-backed draft" ], "search_text": "NREM sleep Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to NREM sleep. The current ledger contributes 14 evidence row s from 5 source s . Identity - Canonical name: nrem-sleep - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 14 - Sources: 5 - Evidence classes: insufficient 2 , mechanistic or pharmacological 2 , preclinical 3 , preliminary human 7 - Draft sections: human evidence 4 , mechanistic evidence 1 , preclinical evidence 3 , safety 4 , uncertainty 2 Key Draft Sections - Human evidence: 4 evidence row s . - Safety and tolerability: 4 evidence row s . - Uncertainty and gaps: 2 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 165 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 509 CBN studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 20 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats Mechanistic research summary: mechanistic or pharmacological 1 1 13 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN increases Total sleep time Preclinical research summary: preclinical 1 1 10 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 1 1 6 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1202 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 6 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 7 CBN decreases Sleep onset latency; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 8 CBN increases Subjective sleep quality; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: Subjective sleep quality . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 9 CBN increases NREM-2 sleep; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: polysomnography NREM-2 sleep . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 10 CBN increases Total sleep time; evidence class: preclinical population or model: rats; study design: rat poly...", "sources": 5, "status": "source-backed draft", "subtitle": "outcome", "title": "NREM sleep", "type": "outcome", "url": "/outcomes/nrem-sleep/" }, { "aliases": [ "2", "n2 sleep", "nrem", "NREM 2", "NREM 2 sleep", "nrem 2 sleep", "nrem stage 2", "NREM-2", "NREM-2 sleep", "nrem-2 sleep", "Outcome", "outcome", "outcomes", "outcomes nrem 2 sleep", "sleep", "source backed draft", "source-backed draft", "stage n2" ], "claims": 3, "evidence_rows": 3, "search_boost": 6, "search_terms": [ "2", "n2 sleep", "nrem", "NREM 2", "NREM 2 sleep", "nrem 2 sleep", "nrem stage 2", "NREM-2", "NREM-2 sleep", "nrem-2 sleep", "Outcome", "outcome", "outcomes", "outcomes nrem 2 sleep", "sleep", "source backed draft", "source-backed draft", "stage n2" ], "search_text": "NREM-2 sleep Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to NREM-2 sleep. The current ledger contributes 3 evidence row s from 2 source s . Identity - Canonical name: nrem-2-sleep - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 3 - Sources: 2 - Evidence classes: preliminary human 3 - Draft sections: human evidence 3 Key Draft Sections - Human evidence: 3 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Sleep Early human research summary: preliminary human 1 1 409 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 THC studied for Sleep Early human research summary: preliminary human 1 1 500 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 9 CBN increases NREM-2 sleep; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: polysomnography NREM-2 sleep . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 409 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 500 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 Related Pages - CBD - CBN - Sleep - THC References - Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 - Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124", "sources": 2, "status": "source-backed draft", "subtitle": "outcome", "title": "NREM-2 sleep", "type": "outcome", "url": "/outcomes/nrem-2-sleep/" }, { "aliases": [ "disturbance", "Outcome", "outcome", "outcomes", "outcomes overall sleep disturbance", "Overall", "overall", "Overall sleep disturbance", "sleep", "source backed draft", "source-backed draft" ], "claims": 8, "evidence_rows": 8, "search_boost": 6, "search_terms": [ "disturbance", "Outcome", "outcome", "outcomes", "outcomes overall sleep disturbance", "Overall", "overall", "Overall sleep disturbance", "sleep", "source backed draft", "source-backed draft" ], "search_text": "Overall sleep disturbance Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Overall sleep disturbance. The current ledger contributes 8 evidence row s from 2 source s . Identity - Canonical name: overall-sleep-disturbance - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 8 - Sources: 2 - Evidence classes: preliminary human 8 - Draft sections: human evidence 7 , safety 1 Key Draft Sections - Human evidence: 7 evidence row s . - Safety and tolerability: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 2 2 2 rows 4-14 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 508 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 1 1 17 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 4 CBN decreases Overall sleep disturbance; evidence class: preliminary human population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose: 25 mg, 50 mg, or 100 mg oral CBN formulation; outcome measure: PROMIS Sleep Disturbance 8A . A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PMID 39204082; DOI 10.3390/ph17080977 14 CBN decreases Overall sleep disturbance; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 16 CBN no detected effect on Sleep onset latency; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 17 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with an...", "sources": 2, "status": "source-backed draft", "subtitle": "outcome", "title": "Overall sleep disturbance", "type": "outcome", "url": "/outcomes/overall-sleep-disturbance/" }, { "aliases": [ "analgesia", "nociception", "Outcome", "outcome", "outcomes", "outcomes pain related outcomes", "pain", "Pain related", "Pain related outcomes", "Pain-related", "Pain-related outcomes", "related", "source backed draft", "source-backed draft" ], "claims": 77, "evidence_rows": 77, "search_boost": 9, "search_terms": [ "analgesia", "nociception", "Outcome", "outcome", "outcomes", "outcomes pain related outcomes", "pain", "Pain related", "Pain related outcomes", "Pain-related", "Pain-related outcomes", "related", "source backed draft", "source-backed draft" ], "search_text": "Pain-related outcomes Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Pain-related outcomes. The current ledger contributes 77 evidence row s from 60 source s . Identity - Canonical name: pain-related-outcomes - Type: outcome - Subtype: Not recorded - Description: Outcome area for auditable evidence review. Evidence Snapshot - Evidence rows: 77 - Sources: 60 - Evidence classes: insufficient 33 , mechanistic or pharmacological 22 , preclinical 10 , preliminary human 12 - Draft sections: human evidence 12 , mechanistic evidence 22 , preclinical evidence 10 , uncertainty 33 Key Draft Sections - Human evidence: 12 evidence row s . - Uncertainty and gaps: 33 evidence row s . - Preclinical evidence: 10 evidence row s . - Mechanistic evidence: 22 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Developed but mixed human research summary: insufficient 2 , mechanistic or pharmacological 4 , preclinical 2 , preliminary human 1 9 9 rows 34-76 CBC studied for Pain-related outcomes Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 9 , preclinical 4 , preliminary human 1 17 17 rows 683-699 CBD studied for Pain-related outcomes Developed but mixed human research summary: insufficient 7 , mechanistic or pharmacological 1 , preliminary human 7 15 15 rows 392-433 CBG studied for Pain-related outcomes Mechanistic and preclinical research summary: insufficient 7 , mechanistic or pharmacological 1 , preclinical 3 11 11 rows 31-540 CBN studied for Pain-related outcomes Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 1 6 6 rows 534-539 THC studied for Pain-related outcomes Developed but mixed human research summary: insufficient 8 , preliminary human 1 9 9 rows 471-479 THCV studied for Pain-related outcomes Developed but mixed human research summary: insufficient 2 , mechanistic or pharmacological 6 , preclinical 1 , preliminary human 1 10 10 rows 796-805 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 31 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabigerol CBG : A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PMID 39598860; DOI 10.3390/molecules29225471 32 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 33 CBG studied for Pain-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Orally administered Cannabigerol CBG in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. PMID 39322049; DOI 10.1016/j.pbb.2024.173883 34 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 35 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 36 CBC studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Re...", "sources": 60, "status": "source-backed draft", "subtitle": "outcome", "title": "Pain-related outcomes", "type": "outcome", "url": "/outcomes/pain-related-outcomes/" }, { "aliases": [ "Outcome", "outcome", "outcomes", "outcomes rem sleep", "REM", "rem", "REM sleep", "sleep", "source backed draft", "source-backed draft" ], "claims": 10, "evidence_rows": 10, "search_boost": 6, "search_terms": [ "Outcome", "outcome", "outcomes", "outcomes rem sleep", "REM", "rem", "REM sleep", "sleep", "source backed draft", "source-backed draft" ], "search_text": "REM sleep Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to REM sleep. The current ledger contributes 10 evidence row s from 6 source s . Identity - Canonical name: rem-sleep - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 10 - Sources: 6 - Evidence classes: insufficient 3 , mechanistic or pharmacological 1 , preclinical 3 , preliminary human 3 - Draft sections: human evidence 3 , mechanistic evidence 1 , preclinical evidence 3 , uncertainty 3 Key Draft Sections - Human evidence: 3 evidence row s . - Uncertainty and gaps: 3 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Sleep Early human research summary: preliminary human 2 2 2 rows 406-409 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 20 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats Mechanistic research summary: mechanistic or pharmacological 1 1 13 CBN increases Total sleep time Preclinical research summary: preclinical 1 1 10 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1127-1202 THC studied for Sleep Early human research summary: preliminary human 1 1 500 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 10 CBN increases Total sleep time; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: total sleep time . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 11 CBN increases NREM sleep; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: NREM sleep . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 12 CBN increases REM sleep; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 13 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological population or model: rats; study design: rat and pharmacological study . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 20 CBN studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabinol CBN; 30 and 300 mg effects on sleep and next-day function in insomnia disorder 'CUPID' study : protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. PMID 37612115; DOI 10.1136/bmjopen-2022-071148 406 CBD studied for Sleep; evidence class: preliminary human study design: Human clinical study; outcome measure: sleep-related outcomes . Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PMID 39167421; DOI 10.5664/jcsm.11324 409 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 500 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids...", "sources": 6, "status": "source-backed draft", "subtitle": "outcome", "title": "REM sleep", "type": "outcome", "url": "/outcomes/rem-sleep/" }, { "aliases": [ "and", "neurodevelopmental", "Outcome", "outcome", "outcomes", "outcomes seizure and neurodevelopmental outcomes", "Seizure", "seizure", "Seizure and neurodevelopmental outcomes", "source backed draft", "source-backed draft" ], "claims": 48, "evidence_rows": 48, "search_boost": 7, "search_terms": [ "and", "neurodevelopmental", "Outcome", "outcome", "outcomes", "outcomes seizure and neurodevelopmental outcomes", "Seizure", "seizure", "Seizure and neurodevelopmental outcomes", "source backed draft", "source-backed draft" ], "search_text": "Seizure and neurodevelopmental outcomes Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Seizure and neurodevelopmental outcomes. The current ledger contributes 48 evidence row s from 48 source s . Identity - Canonical name: seizure-neurodevelopmental-outcomes - Type: outcome - Subtype: Not recorded - Description: Outcome area for auditable evidence review. Evidence Snapshot - Evidence rows: 48 - Sources: 48 - Evidence classes: insufficient 29 , mechanistic or pharmacological 5 , preclinical 5 , preliminary human 9 - Draft sections: human evidence 9 , mechanistic evidence 5 , preclinical evidence 5 , uncertainty 29 Key Draft Sections - Human evidence: 9 evidence row s . - Uncertainty and gaps: 29 evidence row s . - Preclinical evidence: 5 evidence row s . - Mechanistic evidence: 5 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 18 , mechanistic or pharmacological 2 , preliminary human 7 27 27 rows 380-429 CBDV studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 3 , preclinical 5 , preliminary human 2 21 21 rows 40-124 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 40 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. PMID 33895189; DOI 10.1016/j.pharmthera.2021.107878 41 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabis sativa: Much more beyond \u03949-tetrahydrocannabinol. PMID 32335286; DOI 10.1016/j.phrs.2020.104822 42 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. PMID 32825313; DOI 10.3390/brainsci10090572 84 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. PMID 42339654; DOI 10.1177/10445463261462382 85 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? PMID 33613289; DOI 10.3389/fphar.2020.635763 109 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Investigational cannabinoids in seizure disorders, what have we learned thus far? PMID 29842819; DOI 10.1080/13543784.2018.1482275 110 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes . Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. PMID 35364618; DOI 10.1111/epi.17247 111 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients men...", "sources": 48, "status": "source-backed draft", "subtitle": "outcome", "title": "Seizure and neurodevelopmental outcomes", "type": "outcome", "url": "/outcomes/seizure-and-neurodevelopmental-outcomes/" }, { "aliases": [ "adverse event frequency", "adverse event rate", "adverse-event frequency", "adverse-event rate", "effect", "frequency", "frequency of adverse", "Outcome", "outcome", "outcomes", "outcomes side effect frequency", "Side", "side", "Side effect frequency", "side effect frequency", "side effect rate", "side-effect frequency", "side-effect rate", "source backed draft", "source-backed draft" ], "claims": 7, "evidence_rows": 7, "search_boost": 6, "search_terms": [ "adverse event frequency", "adverse event rate", "adverse-event frequency", "adverse-event rate", "effect", "frequency", "frequency of adverse", "Outcome", "outcome", "outcomes", "outcomes side effect frequency", "Side", "side", "Side effect frequency", "side effect frequency", "side effect rate", "side-effect frequency", "side-effect rate", "source backed draft", "source-backed draft" ], "search_text": "Side effect frequency Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Side effect frequency. The current ledger contributes 7 evidence row s from 4 source s . Identity - Canonical name: side-effect-frequency - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 7 - Sources: 4 - Evidence classes: insufficient 5 , preliminary human 2 - Draft sections: human evidence 1 , safety 4 , uncertainty 2 Key Draft Sections - Human evidence: 1 evidence row s . - Safety and tolerability: 4 evidence row s . - Uncertainty and gaps: 2 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Pain-related outcomes Early human research summary: preliminary human 1 1 433 CBN no detected effect on Side effect frequency Early human research summary: preliminary human 1 1 5 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 154 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 348 THC studied for Dependence and withdrawal Mapped evidence with interpretation limits: insufficient 1 1 452 THC associated with driving impairment or safety-relevant performance outcomes Mapped evidence with interpretation limits: insufficient 1 1 53 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 228 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 5 CBN no detected effect on Side effect frequency; evidence class: preliminary human population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose: 25 mg, 50 mg, or 100 mg oral CBN formulation; outcome measure: Side effect frequency . A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PMID 39204082; DOI 10.3390/ph17080977 53 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: driving impairment or performance outcomes . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 154 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System FAERS Database. PMID 36742440; DOI 10.2147/dhps.s391857 228 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 348 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System FAERS Database. PMID 36742440; DOI 10.2147/dhps.s391857 433 CBD studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes . Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. PMID 42261989; DOI 10.1177/2578512525...", "sources": 4, "status": "source-backed draft", "subtitle": "outcome", "title": "Side effect frequency", "type": "outcome", "url": "/outcomes/side-effect-frequency/" }, { "aliases": [ "and", "dermatology", "inflammatory", "Outcome", "outcome", "outcomes", "outcomes skin and inflammatory dermatology", "Skin", "skin", "Skin and inflammatory dermatology", "source backed draft", "source-backed draft" ], "claims": 44, "evidence_rows": 44, "search_boost": 7, "search_terms": [ "and", "dermatology", "inflammatory", "Outcome", "outcome", "outcomes", "outcomes skin and inflammatory dermatology", "Skin", "skin", "Skin and inflammatory dermatology", "source backed draft", "source-backed draft" ], "search_text": "Skin and inflammatory dermatology Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Skin and inflammatory dermatology. The current ledger contributes 44 evidence row s from 41 source s . Identity - Canonical name: skin-dermatology - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 44 - Sources: 41 - Evidence classes: insufficient 16 , mechanistic or pharmacological 22 , preclinical 4 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 22 , preclinical evidence 4 , uncertainty 16 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 16 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 22 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Skin and inflammatory dermatology Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 6 , preclinical 3 , preliminary human 1 21 21 rows 700-720 CBG studied for Skin and inflammatory dermatology Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 9 , preclinical 1 , preliminary human 1 14 14 rows 606-619 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 7 9 9 rows 525-533 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 525 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 526 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 527 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. PMID 39275884; DOI 10.1002/biof.2122 528 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. PMID 36228902; DOI 10.1016/j.fct.2022.113458 529 CBN studied for Skin and inflammatory dermatology; evidence class: insufficient study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. PMID 38673788; DOI 10.3390/ijms25084204 530 CBN studied for Skin and inflammatory dermatology; evidence class: insufficient study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Cannabinoids, inflammation, and fibrosis. PMID 27435265; DOI 10.1096/fj.201600646r 531 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices. PMID 41478536; DOI 10.1016/j.jep.2025.121134 532 CBN studied for Skin and inflammatory derm...", "sources": 41, "status": "source-backed draft", "subtitle": "outcome", "title": "Skin and inflammatory dermatology", "type": "outcome", "url": "/outcomes/skin-and-inflammatory-dermatology/" }, { "aliases": [ "insomnia", "Outcome", "outcome", "outcomes", "outcomes sleep", "Sleep", "sleep", "sleep latency", "sleep quality", "sleeping", "source backed draft", "source-backed draft" ], "claims": 110, "evidence_rows": 110, "search_boost": 10, "search_terms": [ "insomnia", "Outcome", "outcome", "outcomes", "outcomes sleep", "Sleep", "sleep", "sleep latency", "sleep quality", "sleeping", "source backed draft", "source-backed draft" ], "search_text": "Sleep Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Sleep. The current ledger contributes 110 evidence row s from 69 source s . Identity - Canonical name: sleep - Type: outcome - Subtype: Not recorded - Description: Outcome area for auditable evidence review. Evidence Snapshot - Evidence rows: 110 - Sources: 69 - Evidence classes: insufficient 58 , mechanistic or pharmacological 6 , preclinical 3 , preliminary human 43 - Draft sections: human evidence 27 , mechanistic evidence 5 , preclinical evidence 3 , safety 24 , uncertainty 51 Key Draft Sections - Human evidence: 27 evidence row s . - Safety and tolerability: 24 evidence row s . - Uncertainty and gaps: 51 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 5 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1083 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 259-264 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 93 CBC studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 686 CBC studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 169 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: preliminary human 1 1 641 CBD studied for Anxiety-related outcomes Developed but mixed human research summary: insufficient 1 , preliminary human 2 3 3 rows 28-61 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes Mapped evidence with interpretation limits: insufficient 1 1 51 CBD studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 393-430 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Mapped evidence with interpretation limits: insufficient 1 1 98 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 2 , preliminary human 4 5 6 rows 217-324 CBD studied for Seizure and neurodevelopmental outcomes Mapped evidence with interpretation limits: insufficient 3 3 3 rows 386-429 CBD studied for Sleep Developed but mixed human research summary: insufficient 5 , preliminary human 7 12 12 rows 403-414 CBDA studied for nausea-related or inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 145 CBDV studied for Seizure and neurodevelopmental outcomes Mapped evidence with interpretation limits: insufficient 1 1 42 CBG studied for Appetite and metabolic outcomes Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 620-629 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 571 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 159 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: preliminary human 1 1 544 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 2 2 2 rows 4-14 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied...", "sources": 69, "status": "source-backed draft", "subtitle": "outcome", "title": "Sleep", "type": "outcome", "url": "/outcomes/sleep/" }, { "aliases": [ "duration", "Outcome", "outcome", "outcomes", "outcomes sleep duration", "Sleep", "sleep", "Sleep duration", "sleep duration", "sleep time", "source backed draft", "source-backed draft", "total sleep time" ], "claims": 11, "evidence_rows": 11, "search_boost": 6, "search_terms": [ "duration", "Outcome", "outcome", "outcomes", "outcomes sleep duration", "Sleep", "sleep", "Sleep duration", "sleep duration", "sleep time", "source backed draft", "source-backed draft", "total sleep time" ], "search_text": "Sleep duration Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Sleep duration. The current ledger contributes 11 evidence row s from 7 source s . Identity - Canonical name: sleep-duration - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 11 - Sources: 7 - Evidence classes: insufficient 1 , mechanistic or pharmacological 1 , preclinical 3 , preliminary human 6 - Draft sections: human evidence 5 , mechanistic evidence 1 , preclinical evidence 3 , safety 1 , uncertainty 1 Key Draft Sections - Human evidence: 5 evidence row s . - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 1 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for safety, risk, adverse-event, or formulation-specific concerns Early human research summary: preliminary human 1 1 227 CBD studied for Sleep Developed but mixed human research summary: insufficient 1 , preliminary human 2 3 3 rows 406-411 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for Sleep Early human research summary: preliminary human 1 1 107 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats Mechanistic research summary: mechanistic or pharmacological 1 1 13 CBN increases Total sleep time Preclinical research summary: preclinical 1 1 10 THC studied for Sleep Early human research summary: preliminary human 2 2 2 rows 500-503 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 10 CBN increases Total sleep time; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: total sleep time . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 11 CBN increases NREM sleep; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: NREM sleep . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 12 CBN increases REM sleep; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 13 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological population or model: rats; study design: rat and pharmacological study . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 107 CBN studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes . Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. PMID 42207928; DOI 10.1097/jxx.0000000000001289 227 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PMID 42204954; DOI 10.1177/10445463261452514 406 CBD studied for Sleep; evidence class: preliminary human study design: Human clinical study; outcome measure: sleep-related outcomes . Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PMID 39167421; DOI 10.5664/jcsm.11324 409 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcome...", "sources": 7, "status": "source-backed draft", "subtitle": "outcome", "title": "Sleep duration", "type": "outcome", "url": "/outcomes/sleep-duration/" }, { "aliases": [ "latency", "Outcome", "outcome", "outcomes", "outcomes sleep latency", "Sleep", "sleep", "Sleep latency", "sleep latency", "sleep onset latency", "sleep-onset latency", "source backed draft", "source-backed draft" ], "claims": 19, "evidence_rows": 19, "search_boost": 6, "search_terms": [ "latency", "Outcome", "outcome", "outcomes", "outcomes sleep latency", "Sleep", "sleep", "Sleep latency", "sleep latency", "sleep onset latency", "sleep-onset latency", "source backed draft", "source-backed draft" ], "search_text": "Sleep latency Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Sleep latency. The current ledger contributes 19 evidence row s from 6 source s . Identity - Canonical name: sleep-latency - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 19 - Sources: 6 - Evidence classes: insufficient 2 , mechanistic or pharmacological 1 , preliminary human 16 - Draft sections: human evidence 12 , mechanistic evidence 1 , safety 4 , uncertainty 2 Key Draft Sections - Human evidence: 12 evidence row s . - Safety and tolerability: 4 evidence row s . - Uncertainty and gaps: 2 evidence row s . - Mechanistic evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Anxiety-related outcomes Early human research summary: preliminary human 1 1 57 CBD studied for Sleep Early human research summary: preliminary human 1 1 403 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 1 1 14 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 2 2 2 rows 508-509 CBN studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 20 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 2 2 2 rows 6-17 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1130 THC studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 504 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 6 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 7 CBN decreases Sleep onset latency; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomize...", "sources": 6, "status": "source-backed draft", "subtitle": "outcome", "title": "Sleep latency", "type": "outcome", "url": "/outcomes/sleep-latency/" }, { "aliases": [ "latency", "onset", "Outcome", "outcome", "outcomes", "outcomes sleep onset latency", "Sleep", "sleep", "Sleep onset latency", "source backed draft", "source-backed draft" ], "claims": 14, "evidence_rows": 14, "search_boost": 6, "search_terms": [ "latency", "onset", "Outcome", "outcome", "outcomes", "outcomes sleep onset latency", "Sleep", "sleep", "Sleep onset latency", "source backed draft", "source-backed draft" ], "search_text": "Sleep onset latency Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Sleep onset latency. The current ledger contributes 14 evidence row s from 2 source s . Identity - Canonical name: sleep-onset-latency - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 14 - Sources: 2 - Evidence classes: preliminary human 14 - Draft sections: human evidence 10 , safety 4 Key Draft Sections - Human evidence: 10 evidence row s . - Safety and tolerability: 4 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 1 1 14 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 2 2 2 rows 508-509 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 2 2 2 rows 6-17 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 6 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 7 CBN decreases Sleep onset latency; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 8 CBN increases Subjective sleep quality; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: Subjective sleep quality . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 9 CBN increases NREM-2 sleep; evi...", "sources": 2, "status": "source-backed draft", "subtitle": "outcome", "title": "Sleep onset latency", "type": "outcome", "url": "/outcomes/sleep-onset-latency/" }, { "aliases": [ "insomnia", "Outcome", "outcome", "outcomes", "outcomes sleep quality", "quality", "Sleep", "sleep", "Sleep quality", "sleep quality", "source backed draft", "source-backed draft", "subjective sleep quality" ], "claims": 64, "evidence_rows": 64, "search_boost": 8, "search_terms": [ "insomnia", "Outcome", "outcome", "outcomes", "outcomes sleep quality", "quality", "Sleep", "sleep", "Sleep quality", "sleep quality", "source backed draft", "source-backed draft", "subjective sleep quality" ], "search_text": "Sleep quality Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Sleep quality. The current ledger contributes 64 evidence row s from 35 source s . Identity - Canonical name: sleep-quality - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 64 - Sources: 35 - Evidence classes: insufficient 24 , preclinical 1 , preliminary human 39 - Draft sections: human evidence 28 , preclinical evidence 1 , safety 13 , uncertainty 22 Key Draft Sections - Human evidence: 28 evidence row s . - Safety and tolerability: 13 evidence row s . - Uncertainty and gaps: 22 evidence row s . - Preclinical evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 169 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: preliminary human 1 1 641 CBD studied for Anxiety-related outcomes Developed but mixed human research summary: insufficient 1 , preliminary human 3 4 4 rows 28-58 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 176-191 CBD studied for Seizure and neurodevelopmental outcomes Mapped evidence with interpretation limits: insufficient 1 1 386 CBD studied for Sleep Developed but mixed human research summary: insufficient 4 , preliminary human 7 11 11 rows 403-414 CBG studied for Appetite and metabolic outcomes Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 622-629 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 571 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 159 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: preliminary human 1 1 544 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 2 2 2 rows 4-14 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: preliminary human 4 4 4 rows 508-512 CBN no detected effect on Side effect frequency Early human research summary: preliminary human 1 1 5 CBN studied for Sleep Developed but mixed human research summary: insufficient 3 , preliminary human 2 5 5 rows 19-108 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 2 2 2 rows 6-17 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1202 THC studied for Dependence and withdrawal Mapped evidence with interpretation limits: insufficient 1 1 455 THC studied for Nausea and vomiting Mapped evidence with interpretation limits: insufficient 1 1 480 THC studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 471 THC studied for Psychiatric risk Mapped evidence with interpretation limits: insufficient 1 1 434...", "sources": 35, "status": "source-backed draft", "subtitle": "outcome", "title": "Sleep quality", "type": "outcome", "url": "/outcomes/sleep-quality/" }, { "aliases": [ "Outcome", "outcome", "outcomes", "outcomes subjective sleep quality", "quality", "sleep", "source backed draft", "source-backed draft", "Subjective", "subjective", "Subjective sleep quality" ], "claims": 13, "evidence_rows": 13, "search_boost": 6, "search_terms": [ "Outcome", "outcome", "outcomes", "outcomes subjective sleep quality", "quality", "sleep", "source backed draft", "source-backed draft", "Subjective", "subjective", "Subjective sleep quality" ], "search_text": "Subjective sleep quality Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Subjective sleep quality. The current ledger contributes 13 evidence row s from 5 source s . Identity - Canonical name: subjective-sleep-quality - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 13 - Sources: 5 - Evidence classes: insufficient 4 , preliminary human 9 - Draft sections: human evidence 6 , safety 3 , uncertainty 4 Key Draft Sections - Human evidence: 6 evidence row s . - Safety and tolerability: 3 evidence row s . - Uncertainty and gaps: 4 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Sleep Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 409-413 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 509 CBN studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 20 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 1 1 6 THC studied for Sleep Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 500-502 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 6 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 7 CBN decreases Sleep onset latency; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 8 CBN increases Subjective sleep quality; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: Subjective sleep quality . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 9 CBN increases NREM-2 sleep; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: polysomnography NREM-2 sleep . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 15 CBN associated with Adverse events; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN, or placebo; outcome measure: mild-to-moderate adverse events across arms . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 20 CBN studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabinol CBN; 30 and 300 mg effects on sleep and next-day function...", "sources": 5, "status": "source-backed draft", "subtitle": "outcome", "title": "Subjective sleep quality", "type": "outcome", "url": "/outcomes/subjective-sleep-quality/" }, { "aliases": [ "daytime sleepiness", "Outcome", "outcome", "outcomes", "outcomes subjective sleepiness", "sleepiness", "source backed draft", "source-backed draft", "Subjective", "subjective", "Subjective sleepiness", "subjective sleepiness" ], "claims": 12, "evidence_rows": 12, "search_boost": 6, "search_terms": [ "daytime sleepiness", "Outcome", "outcome", "outcomes", "outcomes subjective sleepiness", "sleepiness", "source backed draft", "source-backed draft", "Subjective", "subjective", "Subjective sleepiness", "subjective sleepiness" ], "search_text": "Subjective sleepiness Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Subjective sleepiness. The current ledger contributes 12 evidence row s from 11 source s . Identity - Canonical name: subjective-sleepiness - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 12 - Sources: 11 - Evidence classes: insufficient 3 , mechanistic or pharmacological 1 , preliminary human 8 - Draft sections: human evidence 4 , safety 6 , uncertainty 2 Key Draft Sections - Human evidence: 4 evidence row s . - Safety and tolerability: 6 evidence row s . - Uncertainty and gaps: 2 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 1 , preliminary human 4 5 5 rows 227-324 CBD studied for Sleep Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 408-409 CBG studied for Appetite and metabolic outcomes Early human research summary: preliminary human 1 1 629 CBN studied for Sleep Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 20-107 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 322 THC studied for Sleep Early human research summary: preliminary human 1 1 500 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 20 CBN studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabinol CBN; 30 and 300 mg effects on sleep and next-day function in insomnia disorder 'CUPID' study : protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. PMID 37612115; DOI 10.1136/bmjopen-2022-071148 107 CBN studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes . Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. PMID 42207928; DOI 10.1097/jxx.0000000000001289 227 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PMID 42204954; DOI 10.1177/10445463261452514 320 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 321 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PMID 26724101; DOI 10.1016/s1474-4422 15 00379-8 322 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabinoid treatment for autism: a proof-of-concept randomized trial. PMID 33536055; DOI 10.1186/s13229-021-00420-2 323 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outco...", "sources": 11, "status": "source-backed draft", "subtitle": "outcome", "title": "Subjective sleepiness", "type": "outcome", "url": "/outcomes/subjective-sleepiness/" }, { "aliases": [ "Outcome", "outcome", "outcomes", "outcomes total sleep time", "sleep", "source backed draft", "source-backed draft", "time", "Total", "total", "Total sleep time" ], "claims": 9, "evidence_rows": 9, "search_boost": 6, "search_terms": [ "Outcome", "outcome", "outcomes", "outcomes total sleep time", "sleep", "source backed draft", "source-backed draft", "time", "Total", "total", "Total sleep time" ], "search_text": "Total sleep time Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Total sleep time. The current ledger contributes 9 evidence row s from 5 source s . Identity - Canonical name: total-sleep-time - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 9 - Sources: 5 - Evidence classes: mechanistic or pharmacological 1 , preclinical 3 , preliminary human 5 - Draft sections: human evidence 5 , mechanistic evidence 1 , preclinical evidence 3 Key Draft Sections - Human evidence: 5 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Sleep Early human research summary: preliminary human 2 2 2 rows 406-409 CBN increases NREM sleep Preclinical research summary: preclinical 1 1 11 CBN increases REM sleep Preclinical research summary: preclinical 1 1 12 CBN studied for Sleep Early human research summary: preliminary human 1 1 107 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats Mechanistic research summary: mechanistic or pharmacological 1 1 13 CBN increases Total sleep time Preclinical research summary: preclinical 1 1 10 THC studied for Sleep Early human research summary: preliminary human 2 2 2 rows 500-503 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 10 CBN increases Total sleep time; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: total sleep time . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 11 CBN increases NREM sleep; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: NREM sleep . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 12 CBN increases REM sleep; evidence class: preclinical population or model: rats; study design: rat polysomnography study; outcome measure: REM sleep . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 13 CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats; evidence class: mechanistic or pharmacological population or model: rats; study design: rat and pharmacological study . A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PMID 39528623; DOI 10.1038/s41386-024-02018-7 107 CBN studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes . Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. PMID 42207928; DOI 10.1097/jxx.0000000000001289 406 CBD studied for Sleep; evidence class: preliminary human study design: Human clinical study; outcome measure: sleep-related outcomes . Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PMID 39167421; DOI 10.5664/jcsm.11324 409 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 500 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 503 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabidiol CBD and \u03949-tetrahydrocannabinol THC for chronic insomnia disorder 'CANSLEEP' tri...", "sources": 5, "status": "source-backed draft", "subtitle": "outcome", "title": "Total sleep time", "type": "outcome", "url": "/outcomes/total-sleep-time/" }, { "aliases": [ "after", "onset", "Outcome", "outcome", "outcomes", "outcomes wake after sleep onset", "sleep", "source backed draft", "source-backed draft", "Wake", "wake", "Wake after sleep onset" ], "claims": 20, "evidence_rows": 20, "search_boost": 6, "search_terms": [ "after", "onset", "Outcome", "outcome", "outcomes", "outcomes wake after sleep onset", "sleep", "source backed draft", "source-backed draft", "Wake", "wake", "Wake after sleep onset" ], "search_text": "Wake after sleep onset Page type: outcome Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This outcome page summarizes cannabinoid-related evidence connected to Wake after sleep onset. The current ledger contributes 20 evidence row s from 6 source s . Identity - Canonical name: wake-after-sleep-onset - Type: outcome - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 20 - Sources: 6 - Evidence classes: insufficient 1 , preliminary human 19 - Draft sections: human evidence 15 , safety 4 , uncertainty 1 Key Draft Sections - Human evidence: 15 evidence row s . - Safety and tolerability: 4 evidence row s . - Uncertainty and gaps: 1 evidence row s . Compounds Studied With This Outcome Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBD studied for Anxiety-related outcomes Early human research summary: preliminary human 1 1 57 CBD studied for Sleep Early human research summary: preliminary human 2 2 2 rows 403-409 CBN associated with Adverse events Early human research summary: preliminary human 1 1 15 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN increases NREM-2 sleep Early human research summary: preliminary human 1 1 9 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 1 1 14 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 1 1 149 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Early human research summary: preliminary human 2 2 2 rows 508-509 CBN studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 20 CBN decreases Sleep onset latency Early human research summary: preliminary human 1 1 7 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN increases Subjective sleep quality Early human research summary: preliminary human 1 1 8 CBN no detected effect on Wake after sleep onset Early human research summary: preliminary human 2 2 2 rows 6-17 THC studied for Sleep Early human research summary: preliminary human 2 2 2 rows 500-503 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 6 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 7 CBN decreases Sleep onset latency; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 8 CBN increases...", "sources": 6, "status": "source-backed draft", "subtitle": "outcome", "title": "Wake after sleep onset", "type": "outcome", "url": "/outcomes/wake-after-sleep-onset/" }, { "aliases": [ "Adenosine", "adenosine", "Adenosine signaling", "Pathway", "pathway", "pathways", "pathways adenosine signaling", "signaling", "source backed draft", "source-backed draft" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "Adenosine", "adenosine", "Adenosine signaling", "Pathway", "pathway", "pathways", "pathways adenosine signaling", "signaling", "source backed draft", "source-backed draft" ], "search_text": "Adenosine signaling Page type: pathway Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This page has 15 source-backed evidence row s from 15 source s . Identity - Canonical name: adenosine-signaling - Type: pathway - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 8 , mechanistic or pharmacological 6 , preclinical 1 - Draft sections: mechanistic evidence 6 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Relationships Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 259-267 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3 , mechanistic or pharmacological 2 , preclinical 1 6 6 rows 253-261 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 258-265 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 253 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. PMID 33522084; DOI 10.1111/ejn.15134 254 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. PMID 23924692; DOI 10.1016/j.neuropharm.2013.07.024 255 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPAR\u03b3 receptors. PMID 39657242; DOI 10.1093/ijnp/pyae064 256 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol: Pharmaceutical formulations and biomedical applications. PMID 42212209; DOI 10.22038/ijbms.2026.89134.19592 257 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. PMID 40432283; DOI 10.1111/bph.70070 258 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms . Cys-loop receptors on cannabinoids: All high? PMID 36439263; DOI 10.3389/fphys.2022.1044575 259 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Allosteric modulation of glycine receptors. PMID 21557733; DOI 10.1111/j.1476-5381.2011.01471.x 260 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. PMID 18755158; DOI 10.1016/j.bcp.2008.07.037 26...", "sources": 15, "status": "source-backed draft", "subtitle": "pathway", "title": "Adenosine signaling", "type": "pathway", "url": "/pathways/adenosine-signaling/" }, { "aliases": [ "Dopamine", "dopamine", "Dopamine glutamate GABA systems", "Dopamine/glutamate/GABA systems", "GABA", "gaba", "glutamate", "Pathway", "pathway", "pathways", "pathways dopamine glutamate gaba systems", "source backed draft", "source-backed draft", "systems" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "Dopamine", "dopamine", "Dopamine glutamate GABA systems", "Dopamine/glutamate/GABA systems", "GABA", "gaba", "glutamate", "Pathway", "pathway", "pathways", "pathways dopamine glutamate gaba systems", "source backed draft", "source-backed draft", "systems" ], "search_text": "Dopamine/glutamate/GABA systems Page type: pathway Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This page has 15 source-backed evidence row s from 15 source s . Identity - Canonical name: dopamine-glutamate-gaba - Type: pathway - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 8 , mechanistic or pharmacological 6 , preclinical 1 - Draft sections: mechanistic evidence 6 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Relationships Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 259-267 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3 , mechanistic or pharmacological 2 , preclinical 1 6 6 rows 253-261 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 258-265 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 253 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. PMID 33522084; DOI 10.1111/ejn.15134 254 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. PMID 23924692; DOI 10.1016/j.neuropharm.2013.07.024 255 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPAR\u03b3 receptors. PMID 39657242; DOI 10.1093/ijnp/pyae064 256 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol: Pharmaceutical formulations and biomedical applications. PMID 42212209; DOI 10.22038/ijbms.2026.89134.19592 257 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. PMID 40432283; DOI 10.1111/bph.70070 258 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms . Cys-loop receptors on cannabinoids: All high? PMID 36439263; DOI 10.3389/fphys.2022.1044575 259 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Allosteric modulation of glycine receptors. PMID 21557733; DOI 10.1111/j.1476-5381.2011.01471.x 260 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. PMID 18755158; DOI 10.1016/j.bc...", "sources": 15, "status": "source-backed draft", "subtitle": "pathway", "title": "Dopamine/glutamate/GABA systems", "type": "pathway", "url": "/pathways/dopamine-glutamate-gaba-systems/" }, { "aliases": [ "cross", "cross talk", "cross-talk", "Opioid", "opioid", "opioid cross talk", "opioid cross-talk", "opioid crosstalk", "opioid receptor", "Opioid receptor cross talk", "opioid receptor cross talk", "Opioid receptor cross-talk", "opioid receptor cross-talk", "opioid receptor crosstalk", "opioid-receptor", "Pathway", "pathway", "pathways", "pathways opioid receptor cross talk", "receptor", "source backed draft", "source-backed draft", "talk" ], "claims": 27, "evidence_rows": 27, "search_boost": 5, "search_terms": [ "cross", "cross talk", "cross-talk", "Opioid", "opioid", "opioid cross talk", "opioid cross-talk", "opioid crosstalk", "opioid receptor", "Opioid receptor cross talk", "opioid receptor cross talk", "Opioid receptor cross-talk", "opioid receptor cross-talk", "opioid receptor crosstalk", "opioid-receptor", "Pathway", "pathway", "pathways", "pathways opioid receptor cross talk", "receptor", "source backed draft", "source-backed draft", "talk" ], "search_text": "Opioid receptor cross-talk Page type: pathway Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This page has 27 source-backed evidence row s from 25 source s . Identity - Canonical name: opioid-receptor-crosstalk - Type: pathway - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 27 - Sources: 25 - Evidence classes: insufficient 17 , mechanistic or pharmacological 9 , preclinical 1 - Draft sections: mechanistic evidence 9 , preclinical evidence 1 , safety 1 , uncertainty 16 Key Draft Sections - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 16 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 9 evidence row s . Evidence Relationships Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 259-267 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1055-1060 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1011-1014 Cannabinoids modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1024 CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 696 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3 , mechanistic or pharmacological 2 , preclinical 1 6 6 rows 253-261 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 69 Endocannabinoids modulates GPR18 Mapped evidence with interpretation limits: insufficient 1 1 958 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 258-265 Endocannabinoids modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1059 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1147 THCV studied for Appetite and metabolic outcomes Mapped evidence with interpretation limits: insufficient 1 1 78 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 739 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 69 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. PMID 31899693; DOI 10.14309/ctg.0000000000000120 78 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . CB\u2081-independent mechanisms of \u0394\u2079-THCV, AM251 and SR141716 rimonabant . PMID 21740450; DOI 10.1111/j.1365-2710.2011.01284.x 253 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. PMID 33522084; DOI 10.1111/ejn.15134 254 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. PMID 23924692; DOI 10.1016/j.neuropharm.2013.07.024 255 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . A novel insight into the antidepressant effect of canna...", "sources": 25, "status": "source-backed draft", "subtitle": "pathway", "title": "Opioid receptor cross-talk", "type": "pathway", "url": "/pathways/opioid-receptor-cross-talk/" }, { "aliases": [ "Cardiovascular", "cardiovascular", "Cardiovascular risk", "risk", "Safety", "safety", "safety cardiovascular risk", "safety topic", "source backed draft", "source-backed draft" ], "claims": 16, "evidence_rows": 16, "search_boost": 6, "search_terms": [ "Cardiovascular", "cardiovascular", "Cardiovascular risk", "risk", "Safety", "safety", "safety cardiovascular risk", "safety topic", "source backed draft", "source-backed draft" ], "search_text": "Cardiovascular risk Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Cardiovascular risk. It contains 16 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: cardiovascular-risk - Type: safety topic - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 16 - Sources: 14 - Evidence classes: insufficient 13 , preclinical 1 , preliminary human 2 - Draft sections: human evidence 2 , safety 7 , uncertainty 7 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 7 evidence row s . - Uncertainty and gaps: 7 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Preclinical research summary: insufficient 2 , preclinical 1 3 3 rows 223-318 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 2 2 2 rows 222-319 THC studied for Cardiovascular risk Developed but mixed human research summary: insufficient 7 , preliminary human 2 9 9 rows 443-451 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 2 2 2 rows 316-317 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 222 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Role of cannabis in cardiovascular disorders. PMID 28840009; DOI 10.21037/jtd.2017.06.104 223 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PMID 36603937; DOI 10.1016/j.hrthm.2022.09.021 315 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? PMID 17005273; DOI 10.1016/j.ijcard.2006.08.001 316 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cardiovascular consequences of marijuana use. PMID 12412838; DOI 10.1002/j.1552-4604.2002.tb06005.x 317 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PMID 39575727; DOI 10.1161/jaha.124.037731 318 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis use and acute coronary syndrome. PMID 30964363; DOI 10.1080/15563650.2019.1601735 319 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Endocannabinoids, blood pressure and the human heart. PMID 18426501; DOI 10.1111/j.1365-2826.2008.01677.x 443 THC studied for Cardiovascular risk; evidence class: insufficient population or model: Human participants or patients mentioned...", "sources": 14, "status": "source-backed draft", "subtitle": "safety topic", "title": "Cardiovascular risk", "type": "safety", "url": "/safety/cardiovascular-risk/" }, { "aliases": [ "and", "Dependence", "dependence", "Dependence and withdrawal", "Safety", "safety", "safety dependence and withdrawal", "safety topic", "source backed draft", "source-backed draft", "withdrawal" ], "claims": 16, "evidence_rows": 16, "search_boost": 6, "search_terms": [ "and", "Dependence", "dependence", "Dependence and withdrawal", "Safety", "safety", "safety dependence and withdrawal", "safety topic", "source backed draft", "source-backed draft", "withdrawal" ], "search_text": "Dependence and withdrawal Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Dependence and withdrawal. It contains 16 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: dependence-withdrawal - Type: safety topic - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 16 - Sources: 11 - Evidence classes: insufficient 16 - Draft sections: safety 7 , uncertainty 9 Key Draft Sections - Safety and tolerability: 7 evidence row s . - Uncertainty and gaps: 9 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 2 2 2 rows 374-376 THC studied for Dependence and withdrawal Mapped evidence with interpretation limits: insufficient 9 9 9 rows 452-460 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 5 5 5 rows 228-375 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 228 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 229 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Clinical management of cannabis withdrawal. PMID 34791767; DOI 10.1111/add.15743 230 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PMID 35510826; DOI 10.1002/14651858.cd013444.pub2 231 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 374 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The Psychiatric Consequences of Cannabinoids. PMID 29678279; DOI 10.1016/j.clinthera.2018.03.013 375 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pharmacotherapies for cannabis dependence. PMID 30687936; DOI 10.1002/14651858.cd008940.pub3 376 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. PMID 32271390; DOI 10.1001/jamanetworkopen.2020.2370 452 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: dependence or withdrawal outcomes . Pharmacother...", "sources": 11, "status": "source-backed draft", "subtitle": "safety topic", "title": "Dependence and withdrawal", "type": "safety", "url": "/safety/dependence-and-withdrawal/" }, { "aliases": [ "Driving", "driving", "Driving impairment", "impairment", "Safety", "safety", "safety driving impairment", "safety topic", "source backed draft", "source-backed draft" ], "claims": 9, "evidence_rows": 9, "search_boost": 6, "search_terms": [ "Driving", "driving", "Driving impairment", "impairment", "Safety", "safety", "safety driving impairment", "safety topic", "source backed draft", "source-backed draft" ], "search_text": "Driving impairment Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Driving impairment. It contains 9 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: driving-impairment - Type: safety topic - Subtype: Not recorded - Description: Heightened-review safety topic; not eligible for autonomous publication. Evidence Snapshot - Evidence rows: 9 - Sources: 8 - Evidence classes: insufficient 9 - Draft sections: safety 2 , uncertainty 7 Key Draft Sections - Safety and tolerability: 2 evidence row s . - Uncertainty and gaps: 7 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 158 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 543 THC associated with driving impairment or safety-relevant performance outcomes Mapped evidence with interpretation limits: insufficient 7 7 7 rows 25-56 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 25 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: driving impairment or performance outcomes . Determining the magnitude and duration of acute \u03949-tetrahydrocannabinol \u03949-THC -induced driving and cognitive impairment: A systematic and meta-analytic review. PMID 33497784; DOI 10.1016/j.neubiorev.2021.01.003 26 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: driving impairment or performance outcomes . Cannabis and driving ability. PMID 33839427; DOI 10.1016/j.copsyc.2021.03.003 27 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Systematic review; outcome measure: driving impairment or performance outcomes . Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. PMID 40172477; DOI 10.1093/ijnp/pyaf021 53 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: driving impairment or performance outcomes . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 54 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Systematic review; outcome measure: driving impairment or performance outcomes . Mechanisms of cannabis impairment: Implications for modeling driving performance. PMID 34634690; DOI 10.1016/j.forsciint.2021.110902 55 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: driving impairment or performance outcomes . Prescribing medicinal cannabis. PMID 33093741; DOI 10.18773/austprescr.2020.052 56 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient outcome measure: driving impairment or performance outcomes . Driving Impairment Cases Involving Etizolam and Flubromazolam. PMID 32399568; DOI 10.1093/jat/bkaa050 158 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Cannabinoids in clinical practice. PMID 11152013; DOI 10.2165/00003495-200060060-00005 543 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrati...", "sources": 8, "status": "source-backed draft", "subtitle": "safety topic", "title": "Driving impairment", "type": "safety", "url": "/safety/driving-impairment/" }, { "aliases": [ "cyp interaction", "Drug", "drug", "drug interaction", "Drug interactions", "interactions", "medication interaction", "Safety", "safety", "safety drug interactions", "safety topic", "source backed draft", "source-backed draft" ], "claims": 35, "evidence_rows": 35, "search_boost": 7, "search_terms": [ "cyp interaction", "Drug", "drug", "drug interaction", "Drug interactions", "interactions", "medication interaction", "Safety", "safety", "safety drug interactions", "safety topic", "source backed draft", "source-backed draft" ], "search_text": "Drug interactions Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Drug interactions. It contains 35 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: drug-interactions - Type: safety topic - Subtype: Not recorded - Description: Heightened-review safety topic; not eligible for autonomous publication. Evidence Snapshot - Evidence rows: 35 - Sources: 22 - Evidence classes: insufficient 34 , mechanistic or pharmacological 1 - Draft sections: mechanistic evidence 1 , safety 13 , uncertainty 21 Key Draft Sections - Safety and tolerability: 13 evidence row s . - Uncertainty and gaps: 21 evidence row s . - Mechanistic evidence: 1 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Mapped evidence with interpretation limits: insufficient 1 1 189 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 330 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mapped evidence with interpretation limits: insufficient 1 1 723 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 660-662 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 639 CBD studied for Anxiety-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 58 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes Mapped evidence with interpretation limits: insufficient 6 6 6 rows 23-52 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Mapped evidence with interpretation limits: insufficient 1 1 372 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Mapped evidence with interpretation limits: insufficient 1 1 176 CBD studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 200 CBD studied for Seizure and neurodevelopmental outcomes Mapped evidence with interpretation limits: insufficient 3 3 3 rows 381-415 CBD studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 408 CBDV studied for Seizure and neurodevelopmental outcomes Mapped evidence with interpretation limits: insufficient 1 1 117 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 167 CBN studied for Sleep Mapped evidence with interpretation limits: insufficient 1 1 21 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 151 THC studied for Nausea and vomiting Mapped evidence with interpretation limits: insufficient 1 1 480 THC studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 471-478 THC studied for Psychiatric risk Mapped evidence with interpretation limits: insufficient 1 1 434 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 329 THC modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 985 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes Mapped evidence with interpretation limits: insufficient 1 1 787 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 762-769 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 742 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 21 CBN studied for Sleep; evidence class: insufficient study design: N...", "sources": 22, "status": "source-backed draft", "subtitle": "safety topic", "title": "Drug interactions", "type": "safety", "url": "/safety/drug-interactions/" }, { "aliases": [ "and", "enzymes", "hepatotoxicity", "Liver", "liver", "liver enzymes", "Liver enzymes and hepatotoxicity", "liver safety", "Safety", "safety", "safety liver enzymes and hepatotoxicity", "safety topic", "source backed draft", "source-backed draft", "transaminases" ], "claims": 17, "evidence_rows": 17, "search_boost": 6, "search_terms": [ "and", "enzymes", "hepatotoxicity", "Liver", "liver", "liver enzymes", "Liver enzymes and hepatotoxicity", "liver safety", "Safety", "safety", "safety liver enzymes and hepatotoxicity", "safety topic", "source backed draft", "source-backed draft", "transaminases" ], "search_text": "Liver enzymes and hepatotoxicity Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Liver enzymes and hepatotoxicity. It contains 17 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: hepatotoxicity - Type: safety topic - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 17 - Sources: 15 - Evidence classes: insufficient 4 , mechanistic or pharmacological 8 , preliminary human 5 - Draft sections: human evidence 3 , mechanistic evidence 6 , safety 4 , uncertainty 4 Key Draft Sections - Human evidence: 3 evidence row s . - Safety and tolerability: 4 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Mechanistic evidence: 6 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Early human research summary: preliminary human 1 1 637 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 5 , preliminary human 3 12 12 rows 224-373 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Early human research summary: mechanistic or pharmacological 1 , preliminary human 1 2 2 rows 163-164 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 511 Endocannabinoids modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1023 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 163 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PMID 42057192; DOI 10.1186/s42238-026-00432-w 164 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PMID 39004335; DOI 10.1016/j.tox.2024.153885 224 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. PMID 25999668; DOI 10.1155/2015/523418 225 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. PMID 37458709; DOI 10.1002/cpt.3004 226 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. PMID 39630203; DOI 10.1007/s00204-024-03904-1 365 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PMID 29768152; DOI 10.1056/nejmoa1714631 366 CBD modul...", "sources": 15, "status": "source-backed draft", "subtitle": "safety topic", "title": "Liver enzymes and hepatotoxicity", "type": "safety", "url": "/safety/liver-enzymes-and-hepatotoxicity/" }, { "aliases": [ "adolescent", "and", "breastfeeding", "developmental", "lactation", "paediatric", "pediatric", "pediatrics", "perinatal", "Pregnancy", "pregnancy", "Pregnancy and pediatrics", "pregnant", "prenatal", "Safety", "safety", "safety pregnancy and pediatrics", "safety topic", "source backed draft", "source-backed draft" ], "claims": 129, "evidence_rows": 129, "search_boost": 11, "search_terms": [ "adolescent", "and", "breastfeeding", "developmental", "lactation", "paediatric", "pediatric", "pediatrics", "perinatal", "Pregnancy", "pregnancy", "Pregnancy and pediatrics", "pregnant", "prenatal", "Safety", "safety", "safety pregnancy and pediatrics", "safety topic", "source backed draft", "source-backed draft" ], "search_text": "Pregnancy and pediatrics Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Pregnancy and pediatrics. It contains 129 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: pregnancy-pediatrics - Type: safety topic - Subtype: Not recorded - Description: Heightened-review population topic; not eligible for autonomous publication. Evidence Snapshot - Evidence rows: 129 - Sources: 106 - Evidence classes: insufficient 91 , mechanistic or pharmacological 10 , preclinical 8 , preliminary human 20 - Draft sections: human evidence 14 , mechanistic evidence 9 , preclinical evidence 8 , safety 27 , uncertainty 71 Key Draft Sections - Human evidence: 14 evidence row s . - Safety and tolerability: 27 evidence row s . - Uncertainty and gaps: 71 evidence row s . - Preclinical evidence: 8 evidence row s . - Mechanistic evidence: 9 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1069 Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes Mapped evidence with interpretation limits: insufficient 1 1 234 Cannabinoids modulates CB2 Mechanistic research summary: mechanistic or pharmacological 1 1 915 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 11 , preliminary human 2 13 13 rows 100-195 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 3 3 3 rows 220-374 CBC studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 71 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 673 CBC studied for Skin and inflammatory dermatology Mapped evidence with interpretation limits: insufficient 1 1 714 CBD studied for Anxiety-related outcomes Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 29-58 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes Mapped evidence with interpretation limits: insufficient 4 4 4 rows 22-50 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Early human research summary: mechanistic or pharmacological 1 , preliminary human 1 2 2 rows 365-370 CBD studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 430 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 7 , preclinical 1 , preliminary human 1 9 9 rows 98-194 CBD studied for receptor, target, or pharmacology mechanisms Preclinical research summary: preclinical 1 1 280 CBD studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 3 3 3 rows 197-200 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 2 , preliminary human 4 5 6 rows 217-324 CBD studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 14 , mechanistic or pharmacological 1 , preliminary human 3 18 18 rows 380-429 CBDA studied for nausea-related or inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 125 CBDV studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 11 , mechanistic or pharmacological 3 , preclinical 5 , preliminary human 2 21 21 rows 40-124 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 70 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 158 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 543-556...", "sources": 106, "status": "source-backed draft", "subtitle": "safety topic", "title": "Pregnancy and pediatrics", "type": "safety", "url": "/safety/pregnancy-and-pediatrics/" }, { "aliases": [ "and", "contamination", "formulation", "Product", "product", "Product contamination and formulation risk", "risk", "Safety", "safety", "safety product contamination and formulation risk", "safety topic", "source backed draft", "source-backed draft" ], "claims": 12, "evidence_rows": 12, "search_boost": 6, "search_terms": [ "and", "contamination", "formulation", "Product", "product", "Product contamination and formulation risk", "risk", "Safety", "safety", "safety product contamination and formulation risk", "safety topic", "source backed draft", "source-backed draft" ], "search_text": "Product contamination and formulation risk Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Product contamination and formulation risk. It contains 12 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: contamination-formulation-risk - Type: safety topic - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 11 , preliminary human 1 - Draft sections: safety 12 Key Draft Sections - Safety and tolerability: 12 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 2 2 2 rows 328-330 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 3 3 3 rows 232-331 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 335 THC studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 5 , preliminary human 1 6 6 rows 325-334 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 232 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. PMID 38562466; DOI 10.3389/fphar.2024.1335441 325 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5 326 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Statewide Variation in Cannabinoid Regulations. PMID 36848540 327 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. PMID 33013414; DOI 10.3389/fphar.2020.571832 328 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. PMID 31471034; DOI 10.1016/j.jes.2019.04.028 329 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cautious Hope for Cannabidiol CBD in Rheumatology Care. PMID 32144889; DOI 10.1002/acr.24176 330 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. PMID 27683558; DOI 10.3389/fphar.2016.00309 331 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol CBD products. PMID 35987236; DOI 10.1016/j.scitotenv.2022.158110 332 THC studied for safety, risk, adve...", "sources": 12, "status": "source-backed draft", "subtitle": "safety topic", "title": "Product contamination and formulation risk", "type": "safety", "url": "/safety/product-contamination-and-formulation-risk/" }, { "aliases": [ "anxiety risk", "mental health", "Psychiatric", "psychiatric", "Psychiatric risk", "psychosis", "risk", "Safety", "safety", "safety psychiatric risk", "safety topic", "source backed draft", "source-backed draft" ], "claims": 17, "evidence_rows": 17, "search_boost": 6, "search_terms": [ "anxiety risk", "mental health", "Psychiatric", "psychiatric", "Psychiatric risk", "psychosis", "risk", "Safety", "safety", "safety psychiatric risk", "safety topic", "source backed draft", "source-backed draft" ], "search_text": "Psychiatric risk Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Psychiatric risk. It contains 17 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: psychiatric-risk - Type: safety topic - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 17 - Sources: 16 - Evidence classes: insufficient 15 , preliminary human 2 - Draft sections: human evidence 1 , safety 6 , uncertainty 10 Key Draft Sections - Human evidence: 1 evidence row s . - Safety and tolerability: 6 evidence row s . - Uncertainty and gaps: 10 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 2 2 2 rows 219-220 CBD studied for Anxiety-related outcomes Early human research summary: preliminary human 1 1 59 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 217 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 152 THC studied for Cardiovascular risk Mapped evidence with interpretation limits: insufficient 1 1 446 THC studied for Psychiatric risk Mapped evidence with interpretation limits: insufficient 9 9 9 rows 434-442 THC studied for safety, risk, adverse-event, or formulation-specific concerns Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 218-221 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 59 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. PMID 39680411; DOI 10.1001/jamanetworkopen.2024.50391 152 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. PMID 39805119; DOI 10.1097/wnf.0000000000000619 217 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 218 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis Use and the Risk for Psychosis and Affective Disorders. PMID 31647377; DOI 10.1080/15504263.2019.1674991 219 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. PMID 42309106; DOI 10.1016/s2215-0366 26 00086-6 220 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis and psychiatric disorders. PMID 20562767 221 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The contribution of addictovigilance data to the F...", "sources": 16, "status": "source-backed draft", "subtitle": "safety topic", "title": "Psychiatric risk", "type": "safety", "url": "/safety/psychiatric-risk/" }, { "aliases": [ "and", "daytime sleepiness", "fatigue", "next day", "next-day", "Safety", "safety", "safety sedation and somnolence", "safety topic", "Sedation", "sedation", "Sedation and somnolence", "sleepiness", "somnolence", "source backed draft", "source-backed draft" ], "claims": 81, "evidence_rows": 81, "search_boost": 9, "search_terms": [ "and", "daytime sleepiness", "fatigue", "next day", "next-day", "Safety", "safety", "safety sedation and somnolence", "safety topic", "Sedation", "sedation", "Sedation and somnolence", "sleepiness", "somnolence", "source backed draft", "source-backed draft" ], "search_text": "Sedation and somnolence Page type: safety Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary This safety page summarizes source-backed cannabinoid evidence about Sedation and somnolence. It contains 81 evidence row s ; wording should stay descriptive and avoid instructions. Identity - Canonical name: sedation-somnolence - Type: safety topic - Subtype: Not recorded - Description: Not recorded Evidence Snapshot - Evidence rows: 81 - Sources: 53 - Evidence classes: insufficient 33 , mechanistic or pharmacological 8 , preclinical 1 , preliminary human 39 - Draft sections: human evidence 30 , mechanistic evidence 3 , preclinical evidence 1 , safety 27 , uncertainty 20 Key Draft Sections - Human evidence: 30 evidence row s . - Safety and tolerability: 27 evidence row s . - Uncertainty and gaps: 20 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 3 evidence row s . Safety Evidence By Compound Or Product Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes Mapped evidence with interpretation limits: insufficient 1 1 234 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 93 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 636 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 700 CBD studied for Anxiety-related outcomes Early human research summary: preliminary human 2 2 2 rows 62-63 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 1 4 4 rows 22-51 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms Early human research summary: insufficient 1 , preliminary human 1 2 2 rows 365-372 CBD studied for Pain-related outcomes Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 394-432 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts Developed but mixed human research summary: insufficient 3 , preliminary human 1 4 4 rows 98-188 CBD studied for safety, adverse-event, impairment, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 3 3 3 rows 196-199 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Developed but mixed human research summary: insufficient 2 , preliminary human 4 5 6 rows 217-324 CBD studied for Seizure and neurodevelopmental outcomes Developed but mixed human research summary: insufficient 3 , mechanistic or pharmacological 1 , preliminary human 6 10 10 rows 380-422 CBD studied for Sleep Developed but mixed human research summary: insufficient 2 , preliminary human 3 5 5 rows 404-414 CBDV studied for Seizure and neurodevelopmental outcomes Preclinical research summary: preclinical 1 1 110 CBG studied for Appetite and metabolic outcomes Early human research summary: preliminary human 1 1 629 CBG studied for safety, adverse-event, impairment, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 161 CBN no detected effect on Daytime fatigue Early human research summary: preliminary human 1 1 18 CBN decreases Nighttime awakenings Early human research summary: preliminary human 1 1 2 CBN decreases Overall sleep disturbance Early human research summary: preliminary human 1 1 14 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 4 9 9 rows 508-516 CBN studied for Sleep Developed but mixed human research summary: insufficient 1 , preliminary human 2 3 3 rows 20-108 CBN no detected effect on Sleep onset latency Early human research summary: preliminary human 1 1 16 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue Early human research summary: preliminary human 1 1 3 CBN associated with sleep-promoting claims in the pre-2021 evidence base Mapped evidence with interpretation limits: insufficient 1 1 1 CBN no detected effect on Wak...", "sources": 53, "status": "source-backed draft", "subtitle": "safety topic", "title": "Sedation and somnolence", "type": "safety", "url": "/safety/sedation-and-somnolence/" }, { "aliases": [ "5", "5 HT1A", "5 ht1a", "5-HT1A", "5ht1a", "biological target serotonin receptor", "biological target / serotonin receptor", "ht1a", "serotonin 5 ht1a", "serotonin 5-ht1a", "serotonin receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets 5 ht1a" ], "claims": 35, "evidence_rows": 35, "search_boost": 8, "search_terms": [ "5", "5 HT1A", "5 ht1a", "5-HT1A", "5ht1a", "biological target serotonin receptor", "biological target / serotonin receptor", "ht1a", "serotonin 5 ht1a", "serotonin 5-ht1a", "serotonin receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets 5 ht1a" ], "search_text": "5-HT1A Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary 5-HT1A is a cannabinoid-relevant target page. The current evidence ledger links it to 35 evidence row s from 30 source s , mostly framed as mechanistic or pharmacological 17 , insufficient 16 , preclinical 2 . Identity - Canonical name: 5-ht1a - Type: biological target - Subtype: serotonin receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 35 - Sources: 30 - Evidence classes: insufficient 16 , mechanistic or pharmacological 17 , preclinical 2 - Draft sections: mechanistic evidence 17 , preclinical evidence 2 , safety 1 , uncertainty 15 Key Draft Sections - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 15 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 17 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates CB1 Mechanistic research summary: mechanistic or pharmacological 1 1 859 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 259-267 CBC studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 71 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3 , mechanistic or pharmacological 2 , preclinical 1 6 6 rows 253-261 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic and preclinical research summary: insufficient 1 , mechanistic or pharmacological 5 , preclinical 1 7 7 rows 125-133 CBG studied for Appetite and metabolic outcomes Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 623-627 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 70 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 567-578 CBG modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1051 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 258-265 THC studied for Psychiatric risk Mapped evidence with interpretation limits: insufficient 1 1 440 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 359 THCA studied for THCA-specific safety, effect, or mechanism claims Mechanistic research summary: mechanistic or pharmacological 1 1 44 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 754 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 44 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological outcome measure: safety, effect, or mechanism claims . Cannabis Therapeutics and the Future of Neurology. PMID 30405366; DOI 10.3389/fnint.2018.00051 70 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 125 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 127 CBDA studied for nausea-related or inflammation-related outcomes; evidence class:...", "sources": 30, "status": "source-backed draft", "subtitle": "biological target / serotonin receptor", "title": "5-HT1A", "type": "target", "url": "/targets/5-ht1a/" }, { "aliases": [ "ABHD12", "abhd12", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets abhd12" ], "claims": 17, "evidence_rows": 17, "search_boost": 7, "search_terms": [ "ABHD12", "abhd12", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets abhd12" ], "search_text": "ABHD12 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary ABHD12 is a cannabinoid-relevant target page. The current evidence ledger links it to 17 evidence row s from 16 source s , mostly framed as insufficient 9 , preclinical 3 , mechanistic or pharmacological 3 , preliminary human 2 . Identity - Canonical name: abhd12 - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 17 - Sources: 16 - Evidence classes: insufficient 9 , mechanistic or pharmacological 3 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 3 , preclinical evidence 3 , uncertainty 9 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 9 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 3 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1079 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 203 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PMID 34179865; DOI 10.1016/j.ibneur.2021.01.004 300 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. PMID 32203086; DOI 10.1038/s41401-020-0385-7 301 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. PMID 40269679; DOI 10.1186/s10194-025-02030-2 302 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? PMID 34217798; DOI 10.1016/j.brainresbull.2021.06.022 303 THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. PMID 20047159 304 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential of Fatty Acid Amide Hydrolase FAAH , Monoacylglycerol Lipase MAGL , and Diacylglycerol Lipase DAGL Enzymes as Targets for Obesity Treatment: A Narrative Review. PMID 3...", "sources": 16, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "ABHD12", "type": "target", "url": "/targets/abhd12/" }, { "aliases": [ "ABHD6", "abhd6", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets abhd6" ], "claims": 18, "evidence_rows": 18, "search_boost": 7, "search_terms": [ "ABHD6", "abhd6", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets abhd6" ], "search_text": "ABHD6 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary ABHD6 is a cannabinoid-relevant target page. The current evidence ledger links it to 18 evidence row s from 17 source s , mostly framed as insufficient 9 , mechanistic or pharmacological 4 , preclinical 3 , preliminary human 2 . Identity - Canonical name: abhd6 - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 18 - Sources: 17 - Evidence classes: insufficient 9 , mechanistic or pharmacological 4 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 4 , preclinical evidence 3 , uncertainty 9 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 9 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 4 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1079-1088 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 203 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PMID 34179865; DOI 10.1016/j.ibneur.2021.01.004 300 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. PMID 32203086; DOI 10.1038/s41401-020-0385-7 301 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. PMID 40269679; DOI 10.1186/s10194-025-02030-2 302 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? PMID 34217798; DOI 10.1016/j.brainresbull.2021.06.022 303 THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. PMID 20047159 304 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential of Fatty Acid Amide Hydrolase FAAH , Monoacylglycerol Lipase MAGL , and Diacylglycerol Lipase DAGL Enzymes as Targets for Obesity Treatme...", "sources": 17, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "ABHD6", "type": "target", "url": "/targets/abhd6/" }, { "aliases": [ "biological target canonical cannabinoid receptor", "biological target / canonical cannabinoid receptor", "cannabinoid receptor 1", "CB1", "cb1", "cb1 receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cb1" ], "claims": 339, "evidence_rows": 339, "search_boost": 17, "search_terms": [ "biological target canonical cannabinoid receptor", "biological target / canonical cannabinoid receptor", "cannabinoid receptor 1", "CB1", "cb1", "cb1 receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cb1" ], "search_text": "CB1 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CB1 is a cannabinoid-relevant target page. The current evidence ledger links it to 339 evidence row s from 255 source s , mostly framed as insufficient 174 , mechanistic or pharmacological 147 , preclinical 16 , preliminary human 2 . Identity - Canonical name: cb1 - Type: biological target - Subtype: canonical cannabinoid receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 339 - Sources: 255 - Evidence classes: insufficient 174 , mechanistic or pharmacological 147 , preclinical 16 , preliminary human 2 - Draft sections: human evidence 1 , mechanistic evidence 143 , preclinical evidence 14 , safety 21 , uncertainty 160 Key Draft Sections - Human evidence: 1 evidence row s . - Safety and tolerability: 21 evidence row s . - Uncertainty and gaps: 160 evidence row s . - Preclinical evidence: 14 evidence row s . - Mechanistic evidence: 143 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic and preclinical research summary: insufficient 6 , mechanistic or pharmacological 5 , preclinical 1 12 12 rows 1078-1091 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 6 , mechanistic or pharmacological 2 8 8 rows 1063-1077 Anandamide modulates CB2 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 890-894 Anandamide modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 979 Cannabinoids studied for Cannabinoids and immune modulation research outcomes Mapped evidence with interpretation limits: insufficient 1 1 276 Cannabinoids modulates CB1 Mechanistic research summary: insufficient 13 , mechanistic or pharmacological 16 28 29 rows 806-860 Cannabinoids modulates CB2 Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 8 13 13 rows 864-916 Cannabinoids modulates GPR18 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 944-945 Cannabinoids modulates GPR55 Mapped evidence with interpretation limits: insufficient 4 4 4 rows 926-934 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 2 6 6 rows 206-263 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 242 Cannabinoids modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1038 Cannabinoids modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1026 CBC studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 35-76 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 721-723 CBC studied for Pain-related outcomes Mechanistic and preclinical research summary: insufficient 2 , mechanistic or pharmacological 4 , preclinical 1 7 7 rows 684-694 CBC studied for receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 284 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 4 7 7 rows 662-679 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 646-648 CBC studied for Skin and inflammatory dermatology Mechanistic and preclinical research summary: mechanistic or pharmacological 1 , preclinical 1 2 2 rows 704-711 CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics Mechanistic research summary: mechanistic or pharmacological 1 1 292 CBD modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 955-962 CBD modulates GPR55 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 3 4 4 rows 935-943 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3...", "sources": 255, "status": "source-backed draft", "subtitle": "biological target / canonical cannabinoid receptor", "title": "CB1", "type": "target", "url": "/targets/cb1/" }, { "aliases": [ "biological target canonical cannabinoid receptor", "biological target / canonical cannabinoid receptor", "cannabinoid receptor 2", "CB2", "cb2", "cb2 receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cb2" ], "claims": 269, "evidence_rows": 269, "search_boost": 17, "search_terms": [ "biological target canonical cannabinoid receptor", "biological target / canonical cannabinoid receptor", "cannabinoid receptor 2", "CB2", "cb2", "cb2 receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cb2" ], "search_text": "CB2 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CB2 is a cannabinoid-relevant target page. The current evidence ledger links it to 269 evidence row s from 196 source s , mostly framed as insufficient 152 , mechanistic or pharmacological 106 , preclinical 10 , preliminary human 1 . Identity - Canonical name: cb2 - Type: biological target - Subtype: canonical cannabinoid receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 269 - Sources: 196 - Evidence classes: insufficient 152 , mechanistic or pharmacological 106 , preclinical 10 , preliminary human 1 - Draft sections: mechanistic evidence 104 , preclinical evidence 8 , safety 16 , uncertainty 141 Key Draft Sections - Safety and tolerability: 16 evidence row s . - Uncertainty and gaps: 141 evidence row s . - Preclinical evidence: 8 evidence row s . - Mechanistic evidence: 104 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic and preclinical research summary: insufficient 5 , mechanistic or pharmacological 3 , preclinical 1 9 9 rows 1078-1091 2-AG modulates CB2 Mechanistic research summary: mechanistic or pharmacological 1 1 920 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 2 6 6 rows 1063-1076 Anandamide modulates CB2 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 890-894 Cannabinoids studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 274-276 Cannabinoids modulates CB1 Mapped evidence with interpretation limits: insufficient 4 4 4 rows 806-839 Cannabinoids modulates CB2 Mechanistic research summary: insufficient 13 , mechanistic or pharmacological 24 37 37 rows 864-925 Cannabinoids modulates GPR18 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 944-945 Cannabinoids modulates GPR55 Mapped evidence with interpretation limits: insufficient 4 4 4 rows 926-934 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 1 5 5 rows 206-212 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 242 Cannabinoids modulates TRPA1 Mapped evidence with interpretation limits: insufficient 1 1 1040 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 1 1 1055 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 1 1 1014 Cannabinoids modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1024-1026 CBC studied for Pain-related outcomes Mechanistic and preclinical research summary: insufficient 2 , mechanistic or pharmacological 1 , preclinical 1 4 4 rows 686-694 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 4 7 7 rows 663-679 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 646-648 CBC studied for Skin and inflammatory dermatology Mechanistic and preclinical research summary: mechanistic or pharmacological 1 , preclinical 1 2 2 rows 704-711 CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics Mechanistic research summary: mechanistic or pharmacological 1 1 292 CBD modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 955-962 CBD modulates GPR55 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 935-940 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 2 , mechanistic or pharmacological 1 , preclinical 1 4 4 rows 253-261 CBD studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 340 CBD modulates TRP channel activity or ionotropic cannabino...", "sources": 196, "status": "source-backed draft", "subtitle": "biological target / canonical cannabinoid receptor", "title": "CB2", "type": "target", "url": "/targets/cb2/" }, { "aliases": [ "2", "biological target metabolic enzyme", "biological target / metabolic enzyme", "cox", "COX 2", "COX-2", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cox 2" ], "claims": 32, "evidence_rows": 32, "search_boost": 8, "search_terms": [ "2", "biological target metabolic enzyme", "biological target / metabolic enzyme", "cox", "COX 2", "COX-2", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cox 2" ], "search_text": "COX-2 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary COX-2 is a cannabinoid-relevant target page. The current evidence ledger links it to 32 evidence row s from 27 source s , mostly framed as insufficient 14 , mechanistic or pharmacological 11 , preclinical 5 , preliminary human 2 . Identity - Canonical name: cox-2 - Type: biological target - Subtype: metabolic enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 32 - Sources: 27 - Evidence classes: insufficient 14 , mechanistic or pharmacological 11 , preclinical 5 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 11 , preclinical evidence 5 , uncertainty 14 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 14 evidence row s . - Preclinical evidence: 5 evidence row s . - Mechanistic evidence: 11 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 71 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 679 CBDA studied for nausea-related or inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 2 2 2 rows 43-125 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 CBG studied for Appetite and metabolic outcomes Mapped evidence with interpretation limits: insufficient 1 1 627 CBG studied for Inflammation-related outcomes Mechanistic and preclinical research summary: mechanistic or pharmacological 2 , preclinical 1 3 3 rows 589-603 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 70 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1116 THC studied for Cannabinoids and immune modulation research outcomes Preclinical research summary: preclinical 1 1 269 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 784-786 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 764 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 1 1 1006 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 43 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. PMID 30627539; DOI 10.1155/2018/1691428 70 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 125 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, ado...", "sources": 27, "status": "source-backed draft", "subtitle": "biological target / metabolic enzyme", "title": "COX-2", "type": "target", "url": "/targets/cox-2/" }, { "aliases": [ "biological target metabolic enzyme", "biological target / metabolic enzyme", "CYP", "cyp", "CYP enzymes", "enzymes", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cyp enzymes" ], "claims": 16, "evidence_rows": 16, "search_boost": 7, "search_terms": [ "biological target metabolic enzyme", "biological target / metabolic enzyme", "CYP", "cyp", "CYP enzymes", "enzymes", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets cyp enzymes" ], "search_text": "CYP enzymes Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary CYP enzymes is a cannabinoid-relevant target page. The current evidence ledger links it to 16 evidence row s from 16 source s , mostly framed as insufficient 8 , preclinical 3 , mechanistic or pharmacological 3 , preliminary human 2 . Identity - Canonical name: cyp-enzymes - Type: biological target - Subtype: metabolic enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 16 - Sources: 16 - Evidence classes: insufficient 8 , mechanistic or pharmacological 3 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 3 , preclinical evidence 3 , uncertainty 8 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 3 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 203 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PMID 34179865; DOI 10.1016/j.ibneur.2021.01.004 300 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. PMID 32203086; DOI 10.1038/s41401-020-0385-7 301 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. PMID 40269679; DOI 10.1186/s10194-025-02030-2 302 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? PMID 34217798; DOI 10.1016/j.brainresbull.2021.06.022 303 THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. PMID 20047159 304 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential of Fatty Acid Amide Hydrolase FAAH , Monoacylglycerol Lipase MAGL , and Diacylglycerol Lipase DAGL Enzymes as Targets for Obesity Treatment: A Narrative Review. PMID 34959715; DOI 10.3390/ph14121316 305 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacologica...", "sources": 16, "status": "source-backed draft", "subtitle": "biological target / metabolic enzyme", "title": "CYP enzymes", "type": "target", "url": "/targets/cyp-enzymes/" }, { "aliases": [ "alpha", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "dagl", "DAGL alpha", "dagl alpha", "dagl \u03b1", "DAGL-alpha", "dagl-alpha", "dagl-\u03b1", "dagla", "dagl\u03b1", "diacylglycerol lipase alpha", "diacylglycerol lipase \u03b1", "diacylglycerol lipase-alpha", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets dagl alpha" ], "claims": 8, "evidence_rows": 8, "search_boost": 7, "search_terms": [ "alpha", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "dagl", "DAGL alpha", "dagl alpha", "dagl \u03b1", "DAGL-alpha", "dagl-alpha", "dagl-\u03b1", "dagla", "dagl\u03b1", "diacylglycerol lipase alpha", "diacylglycerol lipase \u03b1", "diacylglycerol lipase-alpha", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets dagl alpha" ], "search_text": "DAGL-alpha Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary DAGL-alpha is a cannabinoid-relevant target page. The current evidence ledger links it to 8 evidence row s from 6 source s , mostly framed as mechanistic or pharmacological 4 , preliminary human 2 , insufficient 1 , preclinical 1 . Identity - Canonical name: dagl-alpha - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 8 - Sources: 6 - Evidence classes: insufficient 1 , mechanistic or pharmacological 4 , preclinical 1 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 4 , preclinical evidence 1 , uncertainty 1 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 1 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 4 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 711 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 304-306 Endocannabinoids modulates GPR119 Early human research summary: preliminary human 1 1 968 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Early human research summary: preliminary human 1 1 311 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 364 THC modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1050 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 765 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 304 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential of Fatty Acid Amide Hydrolase FAAH , Monoacylglycerol Lipase MAGL , and Diacylglycerol Lipase DAGL Enzymes as Targets for Obesity Treatment: A Narrative Review. PMID 34959715; DOI 10.3390/ph14121316 306 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Subcellular localization of NAPE-PLD and DAGL-\u03b1 in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. PMID 24346263; DOI 10.1007/s00418-013-1174-x 311 THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. PMID 32829065; DOI 10.1016/j.bbalip.2020.158807 364 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. PMID 21175579; DOI 10.1111/j.1476-5381.2010.01166.x 711 CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. PMID 35628241; DOI 10.3390/ijms23105430 765 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study;...", "sources": 6, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "DAGL-alpha", "type": "target", "url": "/targets/dagl-alpha/" }, { "aliases": [ "beta", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "dagl", "DAGL beta", "dagl beta", "DAGL-beta", "dagl-beta", "daglb", "diacylglycerol lipase beta", "diacylglycerol lipase-beta", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets dagl beta" ], "claims": 1, "evidence_rows": 1, "search_boost": 7, "search_terms": [ "beta", "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "dagl", "DAGL beta", "dagl beta", "DAGL-beta", "dagl-beta", "daglb", "diacylglycerol lipase beta", "diacylglycerol lipase-beta", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets dagl beta" ], "search_text": "DAGL-beta Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary DAGL-beta is a cannabinoid-relevant target page. The current evidence ledger links it to 1 evidence row s from 1 source s , mostly framed as mechanistic or pharmacological 1 . Identity - Canonical name: dagl-beta - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 1 - Sources: 1 - Evidence classes: mechanistic or pharmacological 1 - Draft sections: mechanistic evidence 1 Key Draft Sections - Mechanistic evidence: 1 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Endocannabinoids studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 271 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 271 Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Phospholipase C\u03b32 regulates endocannabinoid and eicosanoid networks in innate immune cells. PMID 34607960; DOI 10.1073/pnas.2112971118 Related Pages - Endocannabinoids References - Phospholipase C\u03b32 regulates endocannabinoid and eicosanoid networks in innate immune cells. PMID 34607960; DOI 10.1073/pnas.2112971118", "sources": 1, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "DAGL-beta", "type": "target", "url": "/targets/dagl-beta/" }, { "aliases": [ "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "FAAH", "faah", "fatty acid amide hydrolase", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets faah" ], "claims": 57, "evidence_rows": 57, "search_boost": 9, "search_terms": [ "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "FAAH", "faah", "fatty acid amide hydrolase", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets faah" ], "search_text": "FAAH Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary FAAH is a cannabinoid-relevant target page. The current evidence ledger links it to 57 evidence row s from 50 source s , mostly framed as insufficient 31 , mechanistic or pharmacological 21 , preclinical 3 , preliminary human 2 . Identity - Canonical name: faah - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 57 - Sources: 50 - Evidence classes: insufficient 31 , mechanistic or pharmacological 21 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 20 , preclinical evidence 3 , safety 2 , uncertainty 30 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 2 evidence row s . - Uncertainty and gaps: 30 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 20 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1080-1083 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 2 6 6 rows 1064-1077 Anandamide modulates GPR119 Mapped evidence with interpretation limits: insufficient 1 1 965 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 1 1 1011 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 668 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 711-713 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 CBDV studied for Seizure and neurodevelopmental outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 119 CBG studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 601 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 580 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 527 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1169 Endocannabinoids modulates CB1 Mapped evidence with interpretation limits: insufficient 1 1 814 Endocannabinoids modulates CB2 Mapped evidence with interpretation limits: insufficient 1 1 868 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 Endocannabinoids modulates GPR119 Mapped evidence with interpretation limits: insufficient 1 1 969 Endocannabinoids modulates GPR18 Mapped evidence with interpretation limits: insufficient 1 1 961 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 347 Endocannabinoids modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1041 Endocannabinoids modulates TRPV1 Mechanistic research summary: mechanistic or pharmacological 1 1 982 Endocannabinoids modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1023 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1180 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 1119-1127 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1186-1200 THC studied for Cannabinoids and nausea/vomiting res...", "sources": 50, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "FAAH", "type": "target", "url": "/targets/faah/" }, { "aliases": [ "biological target ligand gated ion channel", "biological target / ligand gated ion channel", "Glycine", "glycine", "Glycine receptors", "receptors", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets glycine receptors" ], "claims": 15, "evidence_rows": 15, "search_boost": 7, "search_terms": [ "biological target ligand gated ion channel", "biological target / ligand gated ion channel", "Glycine", "glycine", "Glycine receptors", "receptors", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets glycine receptors" ], "search_text": "Glycine receptors Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary Glycine receptors is a cannabinoid-relevant target page. The current evidence ledger links it to 15 evidence row s from 15 source s , mostly framed as insufficient 8 , mechanistic or pharmacological 6 , preclinical 1 . Identity - Canonical name: glycine-receptors - Type: biological target - Subtype: ligand gated ion channel - Description: Not recorded Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 8 , mechanistic or pharmacological 6 , preclinical 1 - Draft sections: mechanistic evidence 6 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 2 5 5 rows 259-267 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: insufficient 3 , mechanistic or pharmacological 2 , preclinical 1 6 6 rows 253-261 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 258-265 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 253 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. PMID 33522084; DOI 10.1111/ejn.15134 254 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. PMID 23924692; DOI 10.1016/j.neuropharm.2013.07.024 255 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPAR\u03b3 receptors. PMID 39657242; DOI 10.1093/ijnp/pyae064 256 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol: Pharmaceutical formulations and biomedical applications. PMID 42212209; DOI 10.22038/ijbms.2026.89134.19592 257 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. PMID 40432283; DOI 10.1111/bph.70070 258 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms . Cys-loop receptors on cannabinoids: All high? PMID 36439263; DOI 10.3389/fphys.2022.1044575 259 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Allosteric modulation of glycine receptors. PMID 21557733; DOI 10.1111/j.1476-5381.2011.01471.x 260 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, targe...", "sources": 15, "status": "source-backed draft", "subtitle": "biological target / ligand gated ion channel", "title": "Glycine receptors", "type": "target", "url": "/targets/glycine-receptors/" }, { "aliases": [ "biological target g protein coupled receptor", "biological target / g protein coupled receptor", "GPR119", "gpr119", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets gpr119" ], "claims": 29, "evidence_rows": 29, "search_boost": 8, "search_terms": [ "biological target g protein coupled receptor", "biological target / g protein coupled receptor", "GPR119", "gpr119", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets gpr119" ], "search_text": "GPR119 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary GPR119 is a cannabinoid-relevant target page. The current evidence ledger links it to 29 evidence row s from 21 source s , mostly framed as insufficient 22 , mechanistic or pharmacological 5 , preclinical 1 , preliminary human 1 . Identity - Canonical name: gpr119 - Type: biological target - Subtype: g protein coupled receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 29 - Sources: 21 - Evidence classes: insufficient 22 , mechanistic or pharmacological 5 , preclinical 1 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 5 , preclinical evidence 1 , uncertainty 22 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 22 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 5 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1063 Anandamide modulates GPR119 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 964-965 Cannabinoids modulates CB1 Mapped evidence with interpretation limits: insufficient 1 1 839 Cannabinoids modulates GPR18 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 944-951 Cannabinoids modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 926 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 211-212 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics Mapped evidence with interpretation limits: insufficient 1 1 295 Endocannabinoids modulates GPR119 Developed but mixed human research summary: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 1 6 6 rows 963-970 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 209-210 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1172 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 3 7 7 rows 1092-1104 OEA modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 977 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1186 THC modulates receptor, target, or pharmacology mechanisms Preclinical research summary: preclinical 1 1 213 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 209 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. PMID 31146657; DOI 10.2174/1570159x17666190118143014 210 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. PMID 30670965; DOI 10.3389/fphar.2018.01496 211 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PMID 28826536; DOI 10.1016/bs.apha.2017.04.004 212 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . New Insights in Cannabinoid Receptor Structure...", "sources": 21, "status": "source-backed draft", "subtitle": "biological target / g protein coupled receptor", "title": "GPR119", "type": "target", "url": "/targets/gpr119/" }, { "aliases": [ "biological target orphan g protein coupled receptor", "biological target / orphan g protein coupled receptor", "GPR18", "gpr18", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets gpr18" ], "claims": 28, "evidence_rows": 28, "search_boost": 8, "search_terms": [ "biological target orphan g protein coupled receptor", "biological target / orphan g protein coupled receptor", "GPR18", "gpr18", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets gpr18" ], "search_text": "GPR18 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary GPR18 is a cannabinoid-relevant target page. The current evidence ledger links it to 28 evidence row s from 24 source s , mostly framed as insufficient 14 , mechanistic or pharmacological 13 , preclinical 1 . Identity - Canonical name: gpr18 - Type: biological target - Subtype: orphan g protein coupled receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 28 - Sources: 24 - Evidence classes: insufficient 14 , mechanistic or pharmacological 13 , preclinical 1 - Draft sections: mechanistic evidence 13 , preclinical evidence 1 , uncertainty 14 Key Draft Sections - Uncertainty and gaps: 14 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 13 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates CB1 Mapped evidence with interpretation limits: insufficient 1 1 839 Cannabinoids modulates GPR18 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 944-951 Cannabinoids modulates GPR55 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 926-933 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 211-212 CBD modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 5 5 5 rows 955-962 Endocannabinoids modulates GPR18 Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 2 7 7 rows 947-961 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 209-210 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1134 THC modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 946-957 THC modulates receptor, target, or pharmacology mechanisms Preclinical research summary: preclinical 1 1 213 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 209 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. PMID 31146657; DOI 10.2174/1570159x17666190118143014 210 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. PMID 30670965; DOI 10.3389/fphar.2018.01496 211 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PMID 28826536; DOI 10.1016/bs.apha.2017.04.004 212 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . New Insights in Cannabinoid Receptor Structure and Signaling. PMID 30767756; DOI 10.2174/1874467212666190215112036 213 THC modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . \u03949-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. PMID 30550613; DOI 10.1167/iovs.18-24838 839 Cannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . New Insights in Cannabinoid Receptor Structure and Signaling. PMID 30767756; DOI 10.2174/1874467212666190215112036 926 Cannabinoids modulates G...", "sources": 24, "status": "source-backed draft", "subtitle": "biological target / orphan g protein coupled receptor", "title": "GPR18", "type": "target", "url": "/targets/gpr18/" }, { "aliases": [ "biological target orphan g protein coupled receptor", "biological target / orphan g protein coupled receptor", "g protein coupled receptor 55", "g protein-coupled receptor 55", "GPR55", "gpr55", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets gpr55" ], "claims": 59, "evidence_rows": 59, "search_boost": 9, "search_terms": [ "biological target orphan g protein coupled receptor", "biological target / orphan g protein coupled receptor", "g protein coupled receptor 55", "g protein-coupled receptor 55", "GPR55", "gpr55", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets gpr55" ], "search_text": "GPR55 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary GPR55 is a cannabinoid-relevant target page. The current evidence ledger links it to 59 evidence row s from 47 source s , mostly framed as insufficient 42 , mechanistic or pharmacological 15 , preclinical 2 . Identity - Canonical name: gpr55 - Type: biological target - Subtype: orphan g protein coupled receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 59 - Sources: 47 - Evidence classes: insufficient 42 , mechanistic or pharmacological 15 , preclinical 2 - Draft sections: mechanistic evidence 15 , preclinical evidence 2 , safety 1 , uncertainty 41 Key Draft Sections - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 41 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 15 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1063-1064 Cannabinoids modulates CB1 Mapped evidence with interpretation limits: insufficient 1 1 839 Cannabinoids modulates GPR18 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 944-951 Cannabinoids modulates GPR55 Mapped evidence with interpretation limits: insufficient 5 5 5 rows 926-934 Cannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 211-212 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 663 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 711 CBD modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 955-962 CBD modulates GPR55 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 3 5 5 rows 935-943 CBD modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 255 CBD studied for receptor, target, or pharmacology mechanisms Mechanistic and preclinical research summary: mechanistic or pharmacological 1 , preclinical 1 2 2 rows 279-280 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 568 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 557 CBN modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 517 Endocannabinoids modulates GPR119 Mapped evidence with interpretation limits: insufficient 1 1 966 Endocannabinoids modulates GPR18 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 947-952 Endocannabinoids modulates GPR55 Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 1 5 5 rows 929-941 Endocannabinoids modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 209-210 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1134 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1094-1104 OEA modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 977 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1109-1114 THC modulates GPR18 Mechanistic research summary: mechanistic or pharmacological 1 1 949 THC modulates GPR55 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 927-939 THC modulates receptor, target, or pharmacology mechanisms Preclinical research summary: preclinical 1 1 213 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: in...", "sources": 47, "status": "source-backed draft", "subtitle": "biological target / orphan g protein coupled receptor", "title": "GPR55", "type": "target", "url": "/targets/gpr55/" }, { "aliases": [ "12 lox", "12-lox", "15 lox", "15-lox", "5 lox", "5-lox", "biological target metabolic enzyme", "biological target / metabolic enzyme", "enzymes", "lipoxygenase", "lipoxygenases", "LOX", "lox", "lox enzyme", "LOX enzymes", "lox enzymes", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets lox enzymes" ], "claims": 5, "evidence_rows": 5, "search_boost": 7, "search_terms": [ "12 lox", "12-lox", "15 lox", "15-lox", "5 lox", "5-lox", "biological target metabolic enzyme", "biological target / metabolic enzyme", "enzymes", "lipoxygenase", "lipoxygenases", "LOX", "lox", "lox enzyme", "LOX enzymes", "lox enzymes", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets lox enzymes" ], "search_text": "LOX enzymes Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary LOX enzymes is a cannabinoid-relevant target page. The current evidence ledger links it to 5 evidence row s from 5 source s , mostly framed as insufficient 3 , preclinical 1 , mechanistic or pharmacological 1 . Identity - Canonical name: lox-enzymes - Type: biological target - Subtype: metabolic enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 3 , mechanistic or pharmacological 1 , preclinical 1 - Draft sections: mechanistic evidence 1 , preclinical evidence 1 , uncertainty 3 Key Draft Sections - Uncertainty and gaps: 3 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 1 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1063-1068 CBG studied for Inflammation-related outcomes Preclinical research summary: preclinical 1 1 603 Endocannabinoids modulates TRPV4 Mechanistic research summary: mechanistic or pharmacological 1 1 1027 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 603 CBG studied for Inflammation-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. PMID 39128189; DOI 10.1016/j.biopha.2024.117286 1027 Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. PMID 26294342; DOI 10.1111/bph.13312 1063 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. PMID 36150527; DOI 10.1016/j.plipres.2022.101194 1064 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Metabolism of endocannabinoids. PMID 27516570; DOI 10.5604/17322693.1213898 1068 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoid metabolism by cytochrome P450 monooxygenases. PMID 25461979; DOI 10.1016/j.prostaglandins.2014.11.002 Related Pages - Anandamide - CBG - Endocannabinoids - Inflammation-related outcomes - TRPV4 References - Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. PMID 39128189; DOI 10.1016/j.biopha.2024.117286 - Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. PMID 26294342; DOI 10.1111/bph.13312 - Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. PMID 36150527; DOI 10.1016/j.plipres.2022.101194 - Metabolism of endocannabinoids. PMID 27516570; DOI 10.5604/17322693.1213898 - Endocannabinoid metabolism by cytochrome P450 monooxygenases. PMID 25461979; DOI 10.1016/j.prostaglandins.2014.11.002", "sources": 5, "status": "source-backed draft", "subtitle": "biological target / metabolic enzyme", "title": "LOX enzymes", "type": "target", "url": "/targets/lox-enzymes/" }, { "aliases": [ "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "MAGL", "magl", "MAGL MGLL", "MAGL / MGLL", "MGLL", "mgll", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets magl mgll" ], "claims": 39, "evidence_rows": 39, "search_boost": 8, "search_terms": [ "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "MAGL", "magl", "MAGL MGLL", "MAGL / MGLL", "MGLL", "mgll", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets magl mgll" ], "search_text": "MAGL / MGLL Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary MAGL / MGLL is a cannabinoid-relevant target page. The current evidence ledger links it to 39 evidence row s from 36 source s , mostly framed as mechanistic or pharmacological 17 , insufficient 16 , preclinical 4 , preliminary human 2 . Identity - Canonical name: magl - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 39 - Sources: 36 - Evidence classes: insufficient 16 , mechanistic or pharmacological 17 , preclinical 4 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 17 , preclinical evidence 4 , safety 1 , uncertainty 15 Key Draft Sections - Human evidence: 2 evidence row s . - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 15 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 17 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic and preclinical research summary: insufficient 4 , mechanistic or pharmacological 5 , preclinical 1 10 10 rows 1079-1091 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1064-1076 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 711-713 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 CBDV studied for Seizure and neurodevelopmental outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 119 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 527 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 Endocannabinoids modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1041 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 364 THC modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1050 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 765 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 756 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1165 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 119 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. PMID 31447649; DOI 10.3389/fncel.2019.00367 203 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PMID 34179865; DOI 10.1016/j.ibneur.2021.01.004 300 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mech...", "sources": 36, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "MAGL / MGLL", "type": "target", "url": "/targets/magl-mgll/" }, { "aliases": [ "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "nape", "NAPE PLD", "NAPE-PLD", "pld", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets nape pld" ], "claims": 20, "evidence_rows": 20, "search_boost": 7, "search_terms": [ "biological target endocannabinoid enzyme", "biological target / endocannabinoid enzyme", "nape", "NAPE PLD", "NAPE-PLD", "pld", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets nape pld" ], "search_text": "NAPE-PLD Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary NAPE-PLD is a cannabinoid-relevant target page. The current evidence ledger links it to 20 evidence row s from 19 source s , mostly framed as insufficient 8 , mechanistic or pharmacological 7 , preclinical 3 , preliminary human 2 . Identity - Canonical name: nape-pld - Type: biological target - Subtype: endocannabinoid enzyme - Description: Not recorded Evidence Snapshot - Evidence rows: 20 - Sources: 19 - Evidence classes: insufficient 8 , mechanistic or pharmacological 7 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 7 , preclinical evidence 3 , uncertainty 8 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 7 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 668 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 711 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms Preclinical research summary: preclinical 1 1 203 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 580 CBN studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 527 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 6 , mechanistic or pharmacological 3 , preclinical 2 , preliminary human 1 12 12 rows 300-314 THC modulates endocannabinoid enzyme activity or metabolic mechanisms Developed but mixed human research summary: insufficient 2 , preliminary human 1 3 3 rows 303-311 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 203 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PMID 34179865; DOI 10.1016/j.ibneur.2021.01.004 300 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. PMID 32203086; DOI 10.1038/s41401-020-0385-7 301 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. PMID 40269679; DOI 10.1186/s10194-025-02030-2 302 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? PMID 34217798; DOI 10.1016/j.brainresbull.2021.06.022 303 THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. PMID 20047159 304 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insuffici...", "sources": 19, "status": "source-backed draft", "subtitle": "biological target / endocannabinoid enzyme", "title": "NAPE-PLD", "type": "target", "url": "/targets/nape-pld/" }, { "aliases": [ "alpha", "biological target nuclear receptor", "biological target / nuclear receptor", "peroxisome proliferator activated receptor alpha", "peroxisome proliferator activated receptor \u03b1", "peroxisome proliferator-activated receptor alpha", "peroxisome proliferator-activated receptor \u03b1", "ppar", "PPAR alpha", "ppar alpha", "ppar \u03b1", "PPAR-alpha", "ppar-alpha", "ppar-\u03b1", "ppara", "ppar\u03b1", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets ppar alpha" ], "claims": 42, "evidence_rows": 42, "search_boost": 8, "search_terms": [ "alpha", "biological target nuclear receptor", "biological target / nuclear receptor", "peroxisome proliferator activated receptor alpha", "peroxisome proliferator activated receptor \u03b1", "peroxisome proliferator-activated receptor alpha", "peroxisome proliferator-activated receptor \u03b1", "ppar", "PPAR alpha", "ppar alpha", "ppar \u03b1", "PPAR-alpha", "ppar-alpha", "ppar-\u03b1", "ppara", "ppar\u03b1", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets ppar alpha" ], "search_text": "PPAR-alpha Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary PPAR-alpha is a cannabinoid-relevant target page. The current evidence ledger links it to 42 evidence row s from 34 source s , mostly framed as insufficient 28 , mechanistic or pharmacological 13 , preclinical 1 . Identity - Canonical name: ppar-alpha - Type: biological target - Subtype: nuclear receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 42 - Sources: 34 - Evidence classes: insufficient 28 , mechanistic or pharmacological 13 , preclinical 1 - Draft sections: mechanistic evidence 13 , preclinical evidence 1 , safety 2 , uncertainty 26 Key Draft Sections - Safety and tolerability: 2 evidence row s . - Uncertainty and gaps: 26 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 13 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1063 Anandamide modulates GPR119 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 964-965 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 648 CBC studied for Skin and inflammatory dermatology Mechanistic research summary: mechanistic or pharmacological 1 1 711 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 130 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 558 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 202-295 Endocannabinoids modulates GPR119 Mapped evidence with interpretation limits: insufficient 4 4 4 rows 963-970 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms Preclinical research summary: insufficient 2 , preclinical 1 3 3 rows 1172-1178 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: insufficient 8 , mechanistic or pharmacological 3 11 11 rows 1092-1104 PEA studied for Cannabinoids and immune modulation research outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 270 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 6 11 11 rows 1106-1118 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1186 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics Mapped evidence with interpretation limits: insufficient 2 2 2 rows 293-294 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 130 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Effect of combined doses of \u03949-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. PMID 31897571; DOI 10.1007/s00213-019-05428-4 202 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPAR\u03b1. PMID 31325449; DOI 10.1016/j.bcp.2019.07.017 270 PEA studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Ani...", "sources": 34, "status": "source-backed draft", "subtitle": "biological target / nuclear receptor", "title": "PPAR-alpha", "type": "target", "url": "/targets/ppar-alpha/" }, { "aliases": [ "biological target nuclear receptor", "biological target / nuclear receptor", "gamma", "peroxisome proliferator activated receptor gamma", "peroxisome proliferator activated receptor \u03b3", "peroxisome proliferator-activated receptor gamma", "peroxisome proliferator-activated receptor \u03b3", "ppar", "PPAR gamma", "ppar gamma", "ppar \u03b3", "PPAR-gamma", "ppar-gamma", "ppar-\u03b3", "pparg", "ppar\u03b3", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets ppar gamma" ], "claims": 21, "evidence_rows": 21, "search_boost": 7, "search_terms": [ "biological target nuclear receptor", "biological target / nuclear receptor", "gamma", "peroxisome proliferator activated receptor gamma", "peroxisome proliferator activated receptor \u03b3", "peroxisome proliferator-activated receptor gamma", "peroxisome proliferator-activated receptor \u03b3", "ppar", "PPAR gamma", "ppar gamma", "ppar \u03b3", "PPAR-gamma", "ppar-gamma", "ppar-\u03b3", "pparg", "ppar\u03b3", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets ppar gamma" ], "search_text": "PPAR-gamma Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary PPAR-gamma is a cannabinoid-relevant target page. The current evidence ledger links it to 21 evidence row s from 17 source s , mostly framed as insufficient 16 , mechanistic or pharmacological 5 . Identity - Canonical name: ppar-gamma - Type: biological target - Subtype: nuclear receptor - Description: Not recorded Evidence Snapshot - Evidence rows: 21 - Sources: 17 - Evidence classes: insufficient 16 , mechanistic or pharmacological 5 - Draft sections: mechanistic evidence 5 , safety 3 , uncertainty 13 Key Draft Sections - Safety and tolerability: 3 evidence row s . - Uncertainty and gaps: 13 evidence row s . - Mechanistic evidence: 5 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1089 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 1 1 1063 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 242 CBC studied for Inflammation-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 71 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 676 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 648 CBD modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 935 CBD modulates receptor, target, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 3 3 3 rows 253-256 CBD modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 983 CBDA studied for nausea-related or inflammation-related outcomes Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 125-146 CBG studied for Appetite and metabolic outcomes Mapped evidence with interpretation limits: insufficient 1 1 622 CBG studied for Pain-related outcomes Mapped evidence with interpretation limits: insufficient 1 1 70 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 571 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 558 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1139 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics Mapped evidence with interpretation limits: insufficient 2 2 2 rows 293-294 THCA studied for THCA-specific safety, effect, or mechanism claims Mechanistic research summary: mechanistic or pharmacological 1 1 44 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 44 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological outcome measure: safety, effect, or mechanism claims . Cannabis Therapeutics and the Future of Neurology. PMID 30405366; DOI 10.3389/fnint.2018.00051 70 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 125 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Pediatric...", "sources": 17, "status": "source-backed draft", "subtitle": "biological target / nuclear receptor", "title": "PPAR-gamma", "type": "target", "url": "/targets/ppar-gamma/" }, { "aliases": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpa1", "transient receptor potential ankyrin 1", "trpa 1", "TRPA1", "trpa1" ], "claims": 65, "evidence_rows": 65, "search_boost": 9, "search_terms": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpa1", "transient receptor potential ankyrin 1", "trpa 1", "TRPA1", "trpa1" ], "search_text": "TRPA1 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary TRPA1 is a cannabinoid-relevant target page. The current evidence ledger links it to 65 evidence row s from 37 source s , mostly framed as insufficient 36 , mechanistic or pharmacological 29 . Identity - Canonical name: trpa1 - Type: biological target - Subtype: trp channel - Description: Not recorded Evidence Snapshot - Evidence rows: 65 - Sources: 37 - Evidence classes: insufficient 36 , mechanistic or pharmacological 29 - Draft sections: mechanistic evidence 29 , uncertainty 36 Key Draft Sections - Uncertainty and gaps: 36 evidence row s . - Mechanistic evidence: 29 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPA1 Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 3 6 6 rows 1034-1042 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1054-1060 Cannabinoids modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 997 Cannabinoids modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 1020-1026 CBC studied for Pain-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 699 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 675-680 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPA1 Mechanistic research summary: insufficient 3 , mechanistic or pharmacological 3 6 6 rows 1031-1047 CBD modulates TRPM8 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1048-1058 CBD modulates TRPV3 Mapped evidence with interpretation limits: insufficient 1 1 1005 CBD modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1017 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 570 CBG modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 1051-1062 Endocannabinoids modulates TRPA1 Mechanistic research summary: mechanistic or pharmacological 1 1 1041 Endocannabinoids modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1025 THC modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 927 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 214-364 THC modulates TRPA1 Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 1 5 5 rows 1030-1039 THC modulates TRPM8 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 1049-1053 THC modulates TRPV1 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 971-972 THC modulates TRPV2 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 989-996 THC modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1004-1015 THC modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1016 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 784 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 764-782 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 1 1 1006 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 214 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabinoid Ligands Targeting TRP Channels. PMID 30...", "sources": 37, "status": "source-backed draft", "subtitle": "biological target / trp channel", "title": "TRPA1", "type": "target", "url": "/targets/trpa1/" }, { "aliases": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpm8", "transient receptor potential melastatin 8", "trpm 8", "TRPM8", "trpm8" ], "claims": 61, "evidence_rows": 61, "search_boost": 9, "search_terms": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpm8", "transient receptor potential melastatin 8", "trpm 8", "TRPM8", "trpm8" ], "search_text": "TRPM8 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary TRPM8 is a cannabinoid-relevant target page. The current evidence ledger links it to 61 evidence row s from 28 source s , mostly framed as insufficient 40 , mechanistic or pharmacological 21 . Identity - Canonical name: trpm8 - Type: biological target - Subtype: trp channel - Description: Not recorded Evidence Snapshot - Evidence rows: 61 - Sources: 28 - Evidence classes: insufficient 40 , mechanistic or pharmacological 21 - Draft sections: mechanistic evidence 20 , safety 3 , uncertainty 38 Key Draft Sections - Safety and tolerability: 3 evidence row s . - Uncertainty and gaps: 38 evidence row s . - Mechanistic evidence: 20 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPA1 Mapped evidence with interpretation limits: insufficient 1 1 1034 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1054-1060 Cannabinoids modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 997 Cannabinoids modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1020-1026 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 663 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mapped evidence with interpretation limits: insufficient 1 1 648 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPA1 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1031-1047 CBD modulates TRPM8 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1048-1058 CBD modulates TRPV3 Mapped evidence with interpretation limits: insufficient 1 1 1005 CBD modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1017 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 568-572 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 548-558 CBG modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 1051-1062 CBN modulates receptor, target, metabolic, or pharmacology mechanisms Mapped evidence with interpretation limits: insufficient 1 1 517 Endocannabinoids modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 1059-1061 Endocannabinoids modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1025 THC modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 927 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 214-364 THC modulates TRPA1 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1030-1033 THC modulates TRPM8 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 1049-1056 THC modulates TRPV1 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 971-972 THC modulates TRPV2 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 989-996 THC modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1004-1015 THC modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1016 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 784 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 764-765 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV...", "sources": 28, "status": "source-backed draft", "subtitle": "biological target / trp channel", "title": "TRPM8", "type": "target", "url": "/targets/trpm8/" }, { "aliases": [ "biological target trp channel", "biological target / trp channel", "capsaicin receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv1", "trpv 1", "TRPV1", "trpv1", "vanilloid receptor 1" ], "claims": 144, "evidence_rows": 144, "search_boost": 12, "search_terms": [ "biological target trp channel", "biological target / trp channel", "capsaicin receptor", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv1", "trpv 1", "TRPV1", "trpv1", "vanilloid receptor 1" ], "search_text": "TRPV1 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary TRPV1 is a cannabinoid-relevant target page. The current evidence ledger links it to 144 evidence row s from 96 source s , mostly framed as insufficient 70 , mechanistic or pharmacological 66 , preclinical 8 . Identity - Canonical name: trpv1 - Type: biological target - Subtype: trp channel - Description: Not recorded Evidence Snapshot - Evidence rows: 144 - Sources: 96 - Evidence classes: insufficient 70 , mechanistic or pharmacological 66 , preclinical 8 - Draft sections: mechanistic evidence 65 , preclinical evidence 6 , safety 6 , uncertainty 67 Key Draft Sections - Safety and tolerability: 6 evidence row s . - Uncertainty and gaps: 67 evidence row s . - Preclinical evidence: 6 evidence row s . - Mechanistic evidence: 65 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1063-1064 Anandamide modulates GPR119 Mapped evidence with interpretation limits: insufficient 1 1 964 Anandamide modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 979 Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPA1 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 3 5 5 rows 1034-1042 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1054-1060 Cannabinoids modulates TRPV1 Preclinical research summary: insufficient 2 , preclinical 1 3 3 rows 974-981 Cannabinoids modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 997 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 1 1 1011 Cannabinoids modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 1020-1026 CBC studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 35-76 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 721 CBC studied for Pain-related outcomes Mechanistic and preclinical research summary: mechanistic or pharmacological 5 , preclinical 1 6 6 rows 684-699 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 663-674 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns Preclinical research summary: insufficient 1 , preclinical 1 2 2 rows 646-648 CBC studied for Skin and inflammatory dermatology Mechanistic and preclinical research summary: mechanistic or pharmacological 2 , preclinical 1 3 3 rows 704-713 CBD modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 942 CBD modulates receptor, target, or pharmacology mechanisms Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 254-256 CBD studied for receptor, target, or pharmacology mechanisms Preclinical research summary: preclinical 1 1 280 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPA1 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 1031-1046 CBD modulates TRPM8 Mapped evidence with interpretation limits: insufficient 1 1 1048 CBD modulates TRPV1 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 978-983 CBD modulates TRPV2 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 991-1001 CBD modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 3 4 4 rows 1005-1012 CBD modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1017-1029 CBDV studied for Seizure and neurodevelopmental outcomes Preclinical research summary: preclinical 1 1 116 CBG modulates receptor, target, metabolic, or pharmacology mechanisms M...", "sources": 96, "status": "source-backed draft", "subtitle": "biological target / trp channel", "title": "TRPV1", "type": "target", "url": "/targets/trpv1/" }, { "aliases": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv2", "transient receptor potential vanilloid 2", "trpv 2", "TRPV2", "trpv2" ], "claims": 58, "evidence_rows": 58, "search_boost": 9, "search_terms": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv2", "transient receptor potential vanilloid 2", "trpv 2", "TRPV2", "trpv2" ], "search_text": "TRPV2 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary TRPV2 is a cannabinoid-relevant target page. The current evidence ledger links it to 58 evidence row s from 30 source s , mostly framed as insufficient 29 , mechanistic or pharmacological 29 . Identity - Canonical name: trpv2 - Type: biological target - Subtype: trp channel - Description: Not recorded Evidence Snapshot - Evidence rows: 58 - Sources: 30 - Evidence classes: insufficient 29 , mechanistic or pharmacological 29 - Draft sections: mechanistic evidence 29 , uncertainty 29 Key Draft Sections - Uncertainty and gaps: 29 evidence row s . - Mechanistic evidence: 29 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPA1 Mapped evidence with interpretation limits: insufficient 1 1 1034 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 1 1 1054 Cannabinoids modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 997 Cannabinoids modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1020 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPV1 Mechanistic research summary: mechanistic or pharmacological 1 1 978 CBD modulates TRPV2 Mechanistic research summary: mechanistic or pharmacological 9 9 9 rows 991-1003 CBD modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 3 4 4 rows 1005-1012 CBD modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 1017-1029 CBG modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 570 CBG modulates TRPM8 Mechanistic research summary: mechanistic or pharmacological 1 1 1051 Endocannabinoids modulates TRPV4 Mapped evidence with interpretation limits: insufficient 1 1 1025 THC modulates GPR55 Mapped evidence with interpretation limits: insufficient 1 1 927 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 214-364 THC modulates TRPA1 Mapped evidence with interpretation limits: insufficient 3 3 3 rows 1030-1033 THC modulates TRPM8 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1050-1053 THC modulates TRPV1 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 971-972 THC modulates TRPV2 Mechanistic research summary: insufficient 4 , mechanistic or pharmacological 1 5 5 rows 989-999 THC modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1004-1008 THC modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1016-1019 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 784 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 4 4 4 rows 764-780 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 1 1 1006 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 214 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 215 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PMID 33362478; DOI 10.3389/fncel.2020.615811 216 THCV modulates TRP channel activity or iono...", "sources": 30, "status": "source-backed draft", "subtitle": "biological target / trp channel", "title": "TRPV2", "type": "target", "url": "/targets/trpv2/" }, { "aliases": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv3", "transient receptor potential vanilloid 3", "trpv 3", "TRPV3", "trpv3" ], "claims": 37, "evidence_rows": 37, "search_boost": 8, "search_terms": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv3", "transient receptor potential vanilloid 3", "trpv 3", "TRPV3", "trpv3" ], "search_text": "TRPV3 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary TRPV3 is a cannabinoid-relevant target page. The current evidence ledger links it to 37 evidence row s from 20 source s , mostly framed as mechanistic or pharmacological 20 , insufficient 17 . Identity - Canonical name: trpv3 - Type: biological target - Subtype: trp channel - Description: Not recorded Evidence Snapshot - Evidence rows: 37 - Sources: 20 - Evidence classes: insufficient 17 , mechanistic or pharmacological 20 - Draft sections: mechanistic evidence 20 , uncertainty 17 Key Draft Sections - Uncertainty and gaps: 17 evidence row s . - Mechanistic evidence: 20 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPV3 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1011-1014 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPV1 Mechanistic research summary: mechanistic or pharmacological 1 1 978 CBD modulates TRPV2 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 991-1001 CBD modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 4 5 5 rows 1005-1013 CBD modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1017-1021 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 214-364 THC modulates TRPA1 Mapped evidence with interpretation limits: insufficient 1 1 1030 THC modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 971 THC modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 989 THC modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 1004-1015 THC modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1016-1019 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 784 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 3 3 3 rows 764-780 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 1006-1007 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 214 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 215 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PMID 33362478; DOI 10.3389/fncel.2020.615811 216 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Pure \u03949-tetrahydrocannabivarin and a Cannabis sativa extract with high content in \u03949-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PMID 27498155; DOI 10.1016/j.phrs.2016.07.045 357 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . An Introduction to the Endogenous Cannabinoid System. PMID 26698193; DOI 10.1016/j.biopsych.2015.07.028 358 Cannabinoids modulates TRP channel activity...", "sources": 20, "status": "source-backed draft", "subtitle": "biological target / trp channel", "title": "TRPV3", "type": "target", "url": "/targets/trpv3/" }, { "aliases": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv4", "transient receptor potential vanilloid 4", "trpv 4", "TRPV4", "trpv4" ], "claims": 43, "evidence_rows": 43, "search_boost": 8, "search_terms": [ "biological target trp channel", "biological target / trp channel", "source backed draft", "source-backed draft", "Target", "target", "targets", "targets trpv4", "transient receptor potential vanilloid 4", "trpv 4", "TRPV4", "trpv4" ], "search_text": "TRPV4 Page type: target Draft status: source-backed draft Template: 0.1-public-draft Plain-Language Summary TRPV4 is a cannabinoid-relevant target page. The current evidence ledger links it to 43 evidence row s from 24 source s , mostly framed as insufficient 23 , mechanistic or pharmacological 20 . Identity - Canonical name: trpv4 - Type: biological target - Subtype: trp channel - Description: Not recorded Evidence Snapshot - Evidence rows: 43 - Sources: 24 - Evidence classes: insufficient 23 , mechanistic or pharmacological 20 - Draft sections: mechanistic evidence 19 , safety 1 , uncertainty 23 Key Draft Sections - Safety and tolerability: 1 evidence row s . - Uncertainty and gaps: 23 evidence row s . - Mechanistic evidence: 19 evidence row s . Ligands And Modulators Subject Relationship Object Or Focus Evidence Summary Sources Evidence Rows --- --- --- --- ---: --- Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mapped evidence with interpretation limits: insufficient 1 1 358 Cannabinoids modulates TRPA1 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1034-1035 Cannabinoids modulates TRPM8 Mapped evidence with interpretation limits: insufficient 2 2 2 rows 1054-1055 Cannabinoids modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 997 Cannabinoids modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 2 4 4 rows 1020-1026 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 1 3 3 rows 215-361 CBD modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1005-1012 CBD modulates TRPV4 Mechanistic research summary: insufficient 2 , mechanistic or pharmacological 3 5 5 rows 1017-1029 Endocannabinoids modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 2 3 3 rows 1023-1027 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: insufficient 5 , mechanistic or pharmacological 1 6 6 rows 214-364 THC modulates TRPA1 Mapped evidence with interpretation limits: insufficient 1 1 1030 THC modulates TRPV1 Mapped evidence with interpretation limits: insufficient 1 1 971 THC modulates TRPV2 Mapped evidence with interpretation limits: insufficient 1 1 989 THC modulates TRPV3 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1004-1008 THC modulates TRPV4 Mechanistic research summary: insufficient 1 , mechanistic or pharmacological 1 2 2 rows 1016-1019 THCV studied for Inflammation-related outcomes Mechanistic research summary: mechanistic or pharmacological 1 1 784 THCV modulates receptor, target, metabolic, or pharmacology mechanisms Mechanistic research summary: mechanistic or pharmacological 2 2 2 rows 764-780 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns Mechanistic research summary: mechanistic or pharmacological 1 1 752 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 216 THCV modulates TRPV3 Mechanistic research summary: mechanistic or pharmacological 1 1 1006 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms Mechanistic research summary: mechanistic or pharmacological 1 1 1166 Source-Backed Evidence Table Evidence Row Statement Source ---: --- --- 214 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 215 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PMID 33362478; DOI 10.3389/fncel.2020.615811 216 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; stu...", "sources": 24, "status": "source-backed draft", "subtitle": "biological target / trp channel", "title": "TRPV4", "type": "target", "url": "/targets/trpv4/" }, { "aliases": [ "2", "2 AG", "2 AG research summary", "2-AG", "2-AG research summary", "ag", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics 2 ag research summary", "What evidence defines 2 AG biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 14, "evidence_rows": 14, "search_boost": 4, "search_terms": [ "2", "2 AG", "2 AG research summary", "2-AG", "2-AG research summary", "ag", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics 2 ag research summary", "What evidence defines 2 AG biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "2-AG research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 14 source-backed evidence row s and 14 source s . Main entities represented: 2-AG. Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 8 , mechanistic or pharmacological 5 , preclinical 1 - Draft sections: mechanistic evidence 5 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1078 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The Endocannabinoid System and its Modulation by Phytocannabinoids. PMID 26271952; DOI 10.1007/s13311-015-0374-6 1079 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. PMID 21418147; DOI 10.1111/j.1748-1716.2011.02280.x 1080 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Cannabinergic ligands. PMID 12505686; DOI 10.1016/s0009-3084 02 00143-3 1081 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. PMID 16678907; DOI 10.1016/j.plipres.2006.03.003 1082 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoid overload. PMID 20952498; DOI 10.1124/mol.110.069427 1083 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoid hydrolases. PMID 12432941; DOI 10.1016/s0090-6980 02 00053-9 1084 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. PMID 39612328; DOI 10.1126/sciadv.adq4779 1085 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. PMID 24768821; DOI 10.1016/j.exger.2014.04.008 1086 2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evid...", "sources": 14, "status": "source-backed draft", "subtitle": "What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?", "title": "2-AG", "type": "topic", "url": "/topics/2-ag-evidence-map/" }, { "aliases": [ "Acidic", "acidic", "Acidic cannabinoid precursor research summary", "cannabinoid", "Deep Review", "evidence", "map", "precursor", "source backed draft", "source-backed draft", "topic", "topics", "topics acidic cannabinoid precursor research summary", "What evidence exists for acidic cannabinoid precursors such as CBGA, CBCA, THCVA, CBDVA, and CBNA?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "Acidic", "acidic", "Acidic cannabinoid precursor research summary", "cannabinoid", "Deep Review", "evidence", "map", "precursor", "source backed draft", "source-backed draft", "topic", "topics", "topics acidic cannabinoid precursor research summary", "What evidence exists for acidic cannabinoid precursors such as CBGA, CBCA, THCVA, CBDVA, and CBNA?" ], "search_text": "Acidic cannabinoid precursor research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence exists for acidic cannabinoid precursors such as CBGA, CBCA, THCVA, CBDVA, and CBNA? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: THC, CBD, CBC, CBCA. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 8 , mechanistic or pharmacological 3 , preclinical 1 - Draft sections: mechanistic evidence 3 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 201 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. PMID 36257598; DOI 10.1055/a-1962-8165 277 THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . Antiviral activities of hemp cannabinoids. PMID 37083031; DOI 10.1042/cs20220193 278 THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabigerolic Acid CBGA Inhibits the TRPM7 Ion Channel Through its Kinase Domain. PMID 38162115; DOI 10.1093/function/zqad069 279 CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. PMID 34980287; DOI 10.1186/s42238-021-00113-w 280 CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. PMID 34384142; DOI 10.1111/bph.15661 281 CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Pharmacokinetics of Non-Psychotropic Phytocannabinoids. PMID 40006604; DOI 10.3390/pharmaceutics17020236 282 CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. PMID 32824356; DOI 10.3390/antibiotics9080523 283 CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. PMID 39808700; DOI 10.1021/acssynbio.4c00721 284 CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. PMID 35306000; DOI 10.1016/j.ejphar.2022.174836 285 THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient outcome measure: receptor, target, or pharmacology mechanisms . Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for t...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence exists for acidic cannabinoid precursors such as CBGA, CBCA, THCVA, CBDVA, and CBNA?", "title": "Acidic cannabinoid precursor", "type": "topic", "url": "/topics/acidic-cannabinoid-precursor-evidence-map/" }, { "aliases": [ "Anandamide", "anandamide", "Anandamide research summary", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics anandamide research summary", "What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "Anandamide", "anandamide", "Anandamide research summary", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics anandamide research summary", "What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "Anandamide research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 15 source-backed evidence row s and 15 source s . Main entities represented: Anandamide. Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 11 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 11 Key Draft Sections - Uncertainty and gaps: 11 evidence row s . - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1063 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. PMID 36150527; DOI 10.1016/j.plipres.2022.101194 1064 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Metabolism of endocannabinoids. PMID 27516570; DOI 10.5604/17322693.1213898 1065 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide uptake explained? PMID 22297258; DOI 10.1016/j.tips.2012.01.001 1066 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide receptors. PMID 12052051; DOI 10.1054/plef.2001.0349 1067 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The major endocannabinoid anandamide AEA induces apoptosis of human granulosa cells. PMID 34126378; DOI 10.1016/j.plefa.2021.102311 1068 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoid metabolism by cytochrome P450 monooxygenases. PMID 25461979; DOI 10.1016/j.prostaglandins.2014.11.002 1069 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and pregnancy. PMID 20302856; DOI 10.1016/j.cca.2010.03.012 1070 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Anandamide and its metabolites: what are their roles in the kidney? PMID 27100705; DOI 10.2741/s461 1071 Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or i...", "sources": 15, "status": "source-backed draft", "subtitle": "What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?", "title": "Anandamide", "type": "topic", "url": "/topics/anandamide-evidence-map/" }, { "aliases": [ "and", "Cannabinoid", "cannabinoid", "Cannabinoid product contamination and formulation risk review", "contamination", "Deep Review", "formulation", "product", "review", "risk", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoid product contamination and formulation risk review", "What evidence exists for contamination, labeling, formulation, or product quality risks in cannabinoid products?", "What evidence exists for contamination, labeling, formulation, or product-quality risks in cannabinoid products?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "and", "Cannabinoid", "cannabinoid", "Cannabinoid product contamination and formulation risk review", "contamination", "Deep Review", "formulation", "product", "review", "risk", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoid product contamination and formulation risk review", "What evidence exists for contamination, labeling, formulation, or product quality risks in cannabinoid products?", "What evidence exists for contamination, labeling, formulation, or product-quality risks in cannabinoid products?" ], "search_text": "Cannabinoid product contamination and formulation risk review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence exists for contamination, labeling, formulation, or product-quality risks in cannabinoid products? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: THC, CBD, Cannabinoids, Delta-8 THC. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 11 , preliminary human 1 - Draft sections: safety 12 Key Draft Sections - Safety and tolerability: 12 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 232 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. PMID 38562466; DOI 10.3389/fphar.2024.1335441 325 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5 326 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Statewide Variation in Cannabinoid Regulations. PMID 36848540 327 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. PMID 33013414; DOI 10.3389/fphar.2020.571832 328 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. PMID 31471034; DOI 10.1016/j.jes.2019.04.028 329 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cautious Hope for Cannabidiol CBD in Rheumatology Care. PMID 32144889; DOI 10.1002/acr.24176 330 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. PMID 27683558; DOI 10.3389/fphar.2016.00309 331 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol CBD products. PMID 35987236; DOI 10.1016/j.scitotenv.2022.158110 332 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. PMID 40454463; DOI 10.1089/can.2024.0167 333 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. PMID 40250991; DOI 10.1089/can.2025.0015 334 THC studied for safety, risk, adverse-event, or formulation-spe...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence exists for contamination, labeling, formulation, or product-quality risks in cannabinoid products?", "title": "Cannabinoid product contamination and formulation risk review", "type": "topic", "url": "/topics/cannabinoid-product-contamination-and-formulation-risk-review/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and cardiovascular risk heightened review queue", "Cannabinoids and cardiovascular risk heightened-review queue", "cardiovascular", "Deep Review", "heightened", "heightened review", "heightened-review", "queue", "review", "risk", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and cardiovascular risk heightened review queue", "Which cannabinoid evidence requires heightened review for cardiovascular risk?" ], "claims": 7, "evidence_rows": 7, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and cardiovascular risk heightened review queue", "Cannabinoids and cardiovascular risk heightened-review queue", "cardiovascular", "Deep Review", "heightened", "heightened review", "heightened-review", "queue", "review", "risk", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and cardiovascular risk heightened review queue", "Which cannabinoid evidence requires heightened review for cardiovascular risk?" ], "search_text": "Cannabinoids and cardiovascular risk heightened-review queue Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question Which cannabinoid evidence requires heightened review for cardiovascular risk? Draft Summary This draft topic page is generated from 7 source-backed evidence row s and 7 source s . Main entities represented: Cannabinoids, Endocannabinoids, THC. Evidence Snapshot - Evidence rows: 7 - Sources: 7 - Evidence classes: insufficient 6 , preclinical 1 - Draft sections: safety 7 Key Draft Sections - Safety and tolerability: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 222 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Role of cannabis in cardiovascular disorders. PMID 28840009; DOI 10.21037/jtd.2017.06.104 223 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PMID 36603937; DOI 10.1016/j.hrthm.2022.09.021 315 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? PMID 17005273; DOI 10.1016/j.ijcard.2006.08.001 316 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cardiovascular consequences of marijuana use. PMID 12412838; DOI 10.1002/j.1552-4604.2002.tb06005.x 317 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PMID 39575727; DOI 10.1161/jaha.124.037731 318 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis use and acute coronary syndrome. PMID 30964363; DOI 10.1080/15563650.2019.1601735 319 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Endocannabinoids, blood pressure and the human heart. PMID 18426501; DOI 10.1111/j.1365-2826.2008.01677.x References - Role of cannabis in cardiovascular disorders. PMID 28840009; DOI 10.21037/jtd.2017.06.104 - Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PMID 36603937; DOI 10.1016/j.hrthm.2022.09.021 - Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? PMID 17005273; DOI 10.1016/j.ijcard.2006.08.001 - Cardiovascular consequences of marijuana use. PMID 12412838; DOI 10.1002/j.1552-4604.2002.tb06005.x - Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PMID 39575727; DOI 10.1161/jaha.124.037731 - Cannabis use and acute coronary syndrome. PMID 30964363; DOI 10.1080/15563650.2019.1601735 - Endocannabinoids, blood pressure and the human heart. PMID 18426501; DOI 10.1111/j.1365-2826.2008.01677.x", "sources": 7, "status": "source-backed draft", "subtitle": "Which cannabinoid evidence requires heightened review for cardiovascular risk?", "title": "Cannabinoids and cardiovascular risk heightened-review queue", "type": "topic", "url": "/topics/cannabinoids-and-cardiovascular-risk-heightened-review-queue/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and cognition memory research summary", "Cannabinoids and cognition/memory research summary", "cognition", "Deep Review", "evidence", "map", "memory", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and cognition memory research summary", "What evidence connects cannabinoids with cognition, memory, attention, or learning outcomes?" ], "claims": 5, "evidence_rows": 5, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and cognition memory research summary", "Cannabinoids and cognition/memory research summary", "cognition", "Deep Review", "evidence", "map", "memory", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and cognition memory research summary", "What evidence connects cannabinoids with cognition, memory, attention, or learning outcomes?" ], "search_text": "Cannabinoids and cognition/memory research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with cognition, memory, attention, or learning outcomes? Draft Summary This draft topic page is generated from 5 source-backed evidence row s and 5 source s . Main entities represented: Endocannabinoids, Cannabinoids, CBD. Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 4 , preliminary human 1 - Draft sections: safety 5 Key Draft Sections - Safety and tolerability: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 237 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabinoids and monoaminergic system: implications for learning and memory. PMID 39206116; DOI 10.3389/fnins.2024.1425532 238 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Adverse Effects of Recreational and Medical Cannabis. PMID 33897066; DOI 10.64719/pb.4395 239 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Prenatal cannabinoid exposure and altered neurotransmission. PMID 30771373; DOI 10.1016/j.neuropharm.2019.02.018 240 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. PMID 26858214; DOI 10.1016/j.biopsych.2015.12.002 241 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Endocannabinoid signaling and long-term synaptic plasticity. PMID 19575681; DOI 10.1146/annurev.physiol.010908.163149 References - Cannabinoids and monoaminergic system: implications for learning and memory. PMID 39206116; DOI 10.3389/fnins.2024.1425532 - Adverse Effects of Recreational and Medical Cannabis. PMID 33897066; DOI 10.64719/pb.4395 - Prenatal cannabinoid exposure and altered neurotransmission. PMID 30771373; DOI 10.1016/j.neuropharm.2019.02.018 - Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. PMID 26858214; DOI 10.1016/j.biopsych.2015.12.002 - Endocannabinoid signaling and long-term synaptic plasticity. PMID 19575681; DOI 10.1146/annurev.physiol.010908.163149", "sources": 5, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with cognition, memory, attention, or learning outcomes?", "title": "Cannabinoids and cognition/memory", "type": "topic", "url": "/topics/cannabinoids-and-cognition-memory-evidence-map/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and immune modulation research summary", "Deep Review", "evidence", "immune", "map", "modulation", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and immune modulation research summary", "What evidence connects cannabinoids with immune modulation or immune system outcomes?", "What evidence connects cannabinoids with immune modulation or immune-system outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and immune modulation research summary", "Deep Review", "evidence", "immune", "map", "modulation", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and immune modulation research summary", "What evidence connects cannabinoids with immune modulation or immune system outcomes?", "What evidence connects cannabinoids with immune modulation or immune-system outcomes?" ], "search_text": "Cannabinoids and immune modulation research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with immune modulation or immune-system outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: Endocannabinoids, Cannabinoids, THC, PEA. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 3 , mechanistic or pharmacological 5 , preclinical 1 - Draft sections: mechanistic evidence 5 , preclinical evidence 1 , uncertainty 3 Key Draft Sections - Uncertainty and gaps: 3 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 268 Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations. PMID 40016352; DOI 10.1038/s41593-025-01891-9 269 THC studied for Cannabinoids and immune modulation research outcomes; evidence class: preclinical population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring. PMID 36746342; DOI 10.1016/j.bbi.2023.02.002 270 PEA studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PMID 35176443; DOI 10.1016/j.bbi.2022.02.008 271 Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Phospholipase C\u03b32 regulates endocannabinoid and eicosanoid networks in innate immune cells. PMID 34607960; DOI 10.1073/pnas.2112971118 272 Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Impact of Chronic Moderate Exercise on Immune Cells and Cytokine Levels in Rats: Focus on the Endocannabinergic Pathway. PMID 37962860; DOI 10.1089/jir.2023.0120 273 THC studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes . Pharmacokinetics and pharmacodynamics of cannabinoids. PMID 12648025; DOI 10.2165/00003088-200342040-00003 274 Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes . Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. PMID 39334169; DOI 10.1186/s12974-024-03221-5 275 Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes . CB2 receptor in the CNS: From immune and neuronal modulation to behavior. PMID 37164044; DOI 10.1016/j.neubiorev.2023.105226 276 Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design:...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with immune modulation or immune-system outcomes?", "title": "Cannabinoids and immune modulation", "type": "topic", "url": "/topics/cannabinoids-and-immune-modulation-evidence-map/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and liver enzyme hepatotoxicity safety review", "Cannabinoids and liver enzyme/hepatotoxicity safety review", "Deep Review", "enzyme", "hepatotoxicity", "liver", "review", "safety", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and liver enzyme hepatotoxicity safety review", "What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and liver enzyme hepatotoxicity safety review", "Cannabinoids and liver enzyme/hepatotoxicity safety review", "Deep Review", "enzyme", "hepatotoxicity", "liver", "review", "safety", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and liver enzyme hepatotoxicity safety review", "What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring?" ], "search_text": "Cannabinoids and liver enzyme/hepatotoxicity safety review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: CBD. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 4 , mechanistic or pharmacological 5 , preliminary human 3 - Draft sections: human evidence 3 , mechanistic evidence 5 , uncertainty 4 Key Draft Sections - Human evidence: 3 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Mechanistic evidence: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 224 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. PMID 25999668; DOI 10.1155/2015/523418 225 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. PMID 37458709; DOI 10.1002/cpt.3004 226 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. PMID 39630203; DOI 10.1007/s00204-024-03904-1 365 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PMID 29768152; DOI 10.1056/nejmoa1714631 366 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. PMID 40622698; DOI 10.1001/jamainternmed.2025.2366 367 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. PMID 33022751; DOI 10.1002/cpt.2071 368 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. PMID 34918948; DOI 10.1089/can.2021.0114 369 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip. PMID 40750820; DOI 10.1038/s41598-025-12846-2 370 CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring?", "title": "Cannabinoids and liver enzyme/hepatotoxicity safety review", "type": "topic", "url": "/topics/cannabinoids-and-liver-enzyme-hepatotoxicity-safety-review/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and nausea vomiting research summary", "Cannabinoids and nausea/vomiting research summary", "Deep Review", "evidence", "map", "nausea", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and nausea vomiting research summary", "vomiting", "What evidence connects cannabinoids with nausea, vomiting, emesis, or antiemetic outcomes?" ], "claims": 7, "evidence_rows": 7, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and nausea vomiting research summary", "Cannabinoids and nausea/vomiting research summary", "Deep Review", "evidence", "map", "nausea", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and nausea vomiting research summary", "vomiting", "What evidence connects cannabinoids with nausea, vomiting, emesis, or antiemetic outcomes?" ], "search_text": "Cannabinoids and nausea/vomiting research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with nausea, vomiting, emesis, or antiemetic outcomes? Draft Summary This draft topic page is generated from 7 source-backed evidence row s and 7 source s . Main entities represented: THC, Cannabinoids. Evidence Snapshot - Evidence rows: 7 - Sources: 7 - Evidence classes: insufficient 6 , preliminary human 1 - Draft sections: human evidence 1 , uncertainty 6 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 233 THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PMID 39151115; DOI 10.1200/jco.23.01836 234 Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review. PMID 36791365; DOI 10.14309/ajg.0000000000002216 235 Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. PMID 38478773; DOI 10.1200/jco.23.02596 236 Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews. PMID 29168289; DOI 10.1002/ptr.5975 377 THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Regulation of nausea and vomiting by cannabinoids. PMID 21175589; DOI 10.1111/j.1476-5381.2010.01176.x 378 THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting. PMID 30720344; DOI 10.2217/fon-2018-0530 379 THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes . Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. PMID 27507945; DOI 10.3389/fphar.2016.00221 References - Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PMID 39151115; DOI 10.1200/jco.23.01836 - Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review. PMID 36791365; DOI 10.14309/ajg.0000000000002216 - Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. PMID 38478773; DOI 10.1200/jco.23.02596 - Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews. PMID 29168289; DOI 10.1002/ptr.5975 - Regulation of nausea and vomiting by cannabinoids. PMID 21175589; DOI 10.1111/j.1476-5381.2010.01176.x - Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting. PMID 30720344; DOI 10.2217/fon-2018-0530 - Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. PMID 27507945; DOI 10.3389/fphar.2016.002...", "sources": 7, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with nausea, vomiting, emesis, or antiemetic outcomes?", "title": "Cannabinoids and nausea/vomiting", "type": "topic", "url": "/topics/cannabinoids-and-nausea-vomiting-evidence-map/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and pregnancy pediatrics heightened-review queue", "Cannabinoids and pregnancy/pediatrics heightened review queue", "Cannabinoids and pregnancy/pediatrics heightened-review queue", "Deep Review", "heightened", "heightened review", "heightened-review", "pediatrics", "pregnancy", "queue", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and pregnancy pediatrics heightened review queue", "Which cannabinoid evidence requires heightened review for pregnancy, pediatric, or developmental contexts?" ], "claims": 30, "evidence_rows": 30, "search_boost": 5, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and pregnancy pediatrics heightened-review queue", "Cannabinoids and pregnancy/pediatrics heightened review queue", "Cannabinoids and pregnancy/pediatrics heightened-review queue", "Deep Review", "heightened", "heightened review", "heightened-review", "pediatrics", "pregnancy", "queue", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and pregnancy pediatrics heightened review queue", "Which cannabinoid evidence requires heightened review for pregnancy, pediatric, or developmental contexts?" ], "search_text": "Cannabinoids and pregnancy/pediatrics heightened-review queue Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question Which cannabinoid evidence requires heightened review for pregnancy, pediatric, or developmental contexts? Draft Summary This draft topic page is generated from 30 source-backed evidence row s and 30 source s . Main entities represented: Cannabinoids, CBD, THC. Evidence Snapshot - Evidence rows: 30 - Sources: 30 - Evidence classes: insufficient 24 , mechanistic or pharmacological 1 , preclinical 1 , preliminary human 4 - Draft sections: human evidence 4 , mechanistic evidence 1 , preclinical evidence 1 , uncertainty 24 Key Draft Sections - Human evidence: 4 evidence row s . - Uncertainty and gaps: 24 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 98 CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 99 THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation. PMID 40164212; DOI 10.1542/neo.26-4-006 100 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. PMID 35903331; DOI 10.3389/fphar.2022.919630 101 THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review. PMID 40589083; DOI 10.1089/can.2025.0027 102 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review. PMID 34035677; DOI 10.5863/1551-6776-26.4.339 103 THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: mechanistic or pharmacological population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model. PMID 39903192; DOI 10.1152/ajplung.00360.2024 104 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts . Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis. PMID 36730710; DOI 10.1089/can.2022.0262 105 Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental conte...", "sources": 30, "status": "source-backed draft", "subtitle": "Which cannabinoid evidence requires heightened review for pregnancy, pediatric, or developmental contexts?", "title": "Cannabinoids and pregnancy/pediatrics heightened-review queue", "type": "topic", "url": "/topics/cannabinoids-and-pregnancy-pediatrics-heightened-review-queue/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and psychiatric risk heightened review queue", "Cannabinoids and psychiatric risk heightened-review queue", "Deep Review", "heightened", "heightened review", "heightened-review", "psychiatric", "queue", "review", "risk", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and psychiatric risk heightened review queue", "Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?" ], "claims": 5, "evidence_rows": 5, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and psychiatric risk heightened review queue", "Cannabinoids and psychiatric risk heightened-review queue", "Deep Review", "heightened", "heightened review", "heightened-review", "psychiatric", "queue", "review", "risk", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and psychiatric risk heightened review queue", "Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?" ], "search_text": "Cannabinoids and psychiatric risk heightened-review queue Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality? Draft Summary This draft topic page is generated from 5 source-backed evidence row s and 5 source s . Main entities represented: THC, Cannabinoids, CBD. Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 4 , preliminary human 1 - Draft sections: safety 5 Key Draft Sections - Safety and tolerability: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 217 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 218 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis Use and the Risk for Psychosis and Affective Disorders. PMID 31647377; DOI 10.1080/15504263.2019.1674991 219 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. PMID 42309106; DOI 10.1016/s2215-0366 26 00086-6 220 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis and psychiatric disorders. PMID 20562767 221 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The contribution of addictovigilance data to the French medical cannabis experimentation. PMID 39547825; DOI 10.1016/j.therap.2024.10.060 References - Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 - Cannabis Use and the Risk for Psychosis and Affective Disorders. PMID 31647377; DOI 10.1080/15504263.2019.1674991 - Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. PMID 42309106; DOI 10.1016/s2215-0366 26 00086-6 - Cannabis and psychiatric disorders. PMID 20562767 - The contribution of addictovigilance data to the French medical cannabis experimentation. PMID 39547825; DOI 10.1016/j.therap.2024.10.060", "sources": 5, "status": "source-backed draft", "subtitle": "Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?", "title": "Cannabinoids and psychiatric risk heightened-review queue", "type": "topic", "url": "/topics/cannabinoids-and-psychiatric-risk-heightened-review-queue/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and sedation somnolence safety review", "Cannabinoids and sedation/somnolence safety review", "Deep Review", "review", "safety", "sedation", "somnolence", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and sedation somnolence safety review", "What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next day impairment?", "What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next-day impairment?" ], "claims": 6, "evidence_rows": 6, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and sedation somnolence safety review", "Cannabinoids and sedation/somnolence safety review", "Deep Review", "review", "safety", "sedation", "somnolence", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and sedation somnolence safety review", "What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next day impairment?", "What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next-day impairment?" ], "search_text": "Cannabinoids and sedation/somnolence safety review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next-day impairment? Draft Summary This draft topic page is generated from 6 source-backed evidence row s and 6 source s . Main entities represented: CBD, THC. Evidence Snapshot - Evidence rows: 6 - Sources: 6 - Evidence classes: insufficient 1 , mechanistic or pharmacological 1 , preliminary human 4 - Draft sections: safety 6 Key Draft Sections - Safety and tolerability: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 227 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PMID 42204954; DOI 10.1177/10445463261452514 320 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 321 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PMID 26724101; DOI 10.1016/s1474-4422 15 00379-8 322 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabinoid treatment for autism: a proof-of-concept randomized trial. PMID 33536055; DOI 10.1186/s13229-021-00420-2 323 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PMID 29768152; DOI 10.1056/nejmoa1714631 324 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. PMID 28538134; DOI 10.1056/nejmoa1611618 References - A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PMID 42204954; DOI 10.1177/10445463261452514 - Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID 37648266; DOI 10.1136/bmj-2022-072348 - Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PMID 26724101; DOI 10.1016/s1474-4422 15 00379-8 - Cannabinoid treatment for autism: a proof-of-concept randomized trial. PMID 33536055; DOI 10.1186/s13229-021-00420-2 - Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PMID 29768152; DOI 10.1056/nejmoa1714631 - Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. PMID 28538134; DOI 10.1056/nejmoa1611618", "sources": 6, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next-day impairment?", "title": "Cannabinoids and sedation/somnolence safety review", "type": "topic", "url": "/topics/cannabinoids-and-sedation-somnolence-safety-review/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and skin dermatology research summary", "Cannabinoids and skin/dermatology research summary", "Deep Review", "dermatology", "evidence", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and skin dermatology research summary", "What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes?" ], "claims": 13, "evidence_rows": 13, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids and skin dermatology research summary", "Cannabinoids and skin/dermatology research summary", "Deep Review", "dermatology", "evidence", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids and skin dermatology research summary", "What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes?" ], "search_text": "Cannabinoids and skin/dermatology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes? Draft Summary This draft topic page is generated from 13 source-backed evidence row s and 13 source s . Main entities represented: Endocannabinoids, Cannabinoids, CBD. Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 11 , mechanistic or pharmacological 1 , preliminary human 1 - Draft sections: safety 13 Key Draft Sections - Safety and tolerability: 13 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 242 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. PMID 42076122; DOI 10.3390/pharmaceutics18040469 336 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The potential role of cannabinoids in dermatology. PMID 31599175; DOI 10.1080/09546634.2019.1675854 337 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis and the skin. PMID 34785006; DOI 10.1016/j.clindermatol.2021.05.006 338 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabinoids in dermatology: a scoping review. PMID 30142706 339 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabinoids and Their Receptors in Skin Diseases. PMID 38003712; DOI 10.3390/ijms242216523 340 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. PMID 41008526; DOI 10.3390/biom15091219 341 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. PMID 33851375; DOI 10.1055/a-1420-5780 342 CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. PMID 38904694; DOI 10.1007/s00403-024-03131-9 343 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. PMID 33909195; DOI 10.1007/s11033-021-06366-1 344 Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formul...", "sources": 13, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes?", "title": "Cannabinoids and skin/dermatology", "type": "topic", "url": "/topics/cannabinoids-and-skin-dermatology-evidence-map/" }, { "aliases": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids dependence and withdrawal review", "Deep Review", "dependence", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids dependence and withdrawal review", "What evidence connects cannabinoids with dependence, withdrawal, craving, or cannabis use disorder outcomes?", "withdrawal" ], "claims": 7, "evidence_rows": 7, "search_boost": 4, "search_terms": [ "and", "Cannabinoids", "cannabinoids", "Cannabinoids dependence and withdrawal review", "Deep Review", "dependence", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cannabinoids dependence and withdrawal review", "What evidence connects cannabinoids with dependence, withdrawal, craving, or cannabis use disorder outcomes?", "withdrawal" ], "search_text": "Cannabinoids dependence and withdrawal review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with dependence, withdrawal, craving, or cannabis use disorder outcomes? Draft Summary This draft topic page is generated from 7 source-backed evidence row s and 7 source s . Main entities represented: THC, Cannabinoids. Evidence Snapshot - Evidence rows: 7 - Sources: 7 - Evidence classes: insufficient 7 - Draft sections: safety 7 Key Draft Sections - Safety and tolerability: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 228 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 229 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Clinical management of cannabis withdrawal. PMID 34791767; DOI 10.1111/add.15743 230 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PMID 35510826; DOI 10.1002/14651858.cd013444.pub2 231 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 374 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . The Psychiatric Consequences of Cannabinoids. PMID 29678279; DOI 10.1016/j.clinthera.2018.03.013 375 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Pharmacotherapies for cannabis dependence. PMID 30687936; DOI 10.1002/14651858.cd008940.pub3 376 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. PMID 32271390; DOI 10.1001/jamanetworkopen.2020.2370 References - Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 - Clinical management of cannabis withdrawal. PMID 34791767; DOI 10.1111/add.15743 - Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PMID 35510826; DOI 10.1002/14651858.cd013444.pub2 - The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 - The Psychiatric Consequences of Cannabinoids. PMID 29678279; DOI 10.1016/j.clinthera.2018.03.013 - Pharmacotherapies for cannabis dependence. PMID 30687936; DOI 10.1002/14651858.cd008940.pub3 - Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. PMID 32271390; DOI 10.1001/jamanetworkopen.2020.2370", "sources": 7, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with dependence, withdrawal, craving, or cannabis use disorder outcomes?", "title": "Cannabinoids dependence and withdrawal review", "type": "topic", "url": "/topics/cannabinoids-dependence-and-withdrawal-review/" }, { "aliases": [ "and", "CB1", "cb1", "CB1 and CB2 receptor pharmacology research summary", "CB2", "cb2", "Deep Review", "evidence", "map", "pharmacology", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb1 and cb2 receptor pharmacology research summary", "What evidence defines cannabinoid activity at CB1 and CB2 receptors?" ], "claims": 5, "evidence_rows": 5, "search_boost": 4, "search_terms": [ "and", "CB1", "cb1", "CB1 and CB2 receptor pharmacology research summary", "CB2", "cb2", "Deep Review", "evidence", "map", "pharmacology", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb1 and cb2 receptor pharmacology research summary", "What evidence defines cannabinoid activity at CB1 and CB2 receptors?" ], "search_text": "CB1 and CB2 receptor pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines cannabinoid activity at CB1 and CB2 receptors? Draft Summary This draft topic page is generated from 5 source-backed evidence row s and 5 source s . Main entities represented: Cannabinoids, THC. Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 4 , mechanistic or pharmacological 1 - Draft sections: mechanistic evidence 1 , uncertainty 4 Key Draft Sections - Uncertainty and gaps: 4 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 204 THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PMID 17828291; DOI 10.1038/sj.bjp.0707442 205 THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. PMID 25220897; DOI 10.1016/j.drugalcdep.2014.08.005 206 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabinoid receptor 2 CB2 modulators: A patent review 2016-2024 . PMID 39288632; DOI 10.1016/j.bioorg.2024.107775 207 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . Oxa-adamantyl cannabinoids. PMID 33636308; DOI 10.1016/j.bmcl.2021.127882 208 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PMID 18537620; DOI 10.2174/092986708784567716 References - The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PMID 17828291; DOI 10.1038/sj.bjp.0707442 - Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. PMID 25220897; DOI 10.1016/j.drugalcdep.2014.08.005 - Cannabinoid receptor 2 CB2 modulators: A patent review 2016-2024 . PMID 39288632; DOI 10.1016/j.bioorg.2024.107775 - Oxa-adamantyl cannabinoids. PMID 33636308; DOI 10.1016/j.bmcl.2021.127882 - Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PMID 18537620; DOI 10.2174/092986708784567716", "sources": 5, "status": "source-backed draft", "subtitle": "What evidence defines cannabinoid activity at CB1 and CB2 receptors?", "title": "CB1 and CB2 receptor pharmacology", "type": "topic", "url": "/topics/cb1-and-cb2-receptor-pharmacology-evidence-map/" }, { "aliases": [ "CB1", "cb1", "CB1 receptor neurobehavioral metabolic research summary", "CB1 receptor neurobehavioral/metabolic research summary", "Deep Review", "evidence", "map", "metabolic", "neurobehavioral", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb1 receptor neurobehavioral metabolic research summary", "What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition related mechanisms?", "What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition-related mechanisms?" ], "claims": 24, "evidence_rows": 24, "search_boost": 4, "search_terms": [ "CB1", "cb1", "CB1 receptor neurobehavioral metabolic research summary", "CB1 receptor neurobehavioral/metabolic research summary", "Deep Review", "evidence", "map", "metabolic", "neurobehavioral", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb1 receptor neurobehavioral metabolic research summary", "What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition related mechanisms?", "What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition-related mechanisms?" ], "search_text": "CB1 receptor neurobehavioral/metabolic research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition-related mechanisms? Draft Summary This draft topic page is generated from 24 source-backed evidence row s and 24 source s . Main entities represented: Cannabinoids, Endocannabinoids, THC. Evidence Snapshot - Evidence rows: 24 - Sources: 24 - Evidence classes: insufficient 14 , mechanistic or pharmacological 10 - Draft sections: mechanistic evidence 10 , uncertainty 14 Key Draft Sections - Uncertainty and gaps: 14 evidence row s . - Mechanistic evidence: 10 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 839 Cannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . New Insights in Cannabinoid Receptor Structure and Signaling. PMID 30767756; DOI 10.2174/1874467212666190215112036 840 Cannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. PMID 28527758; DOI 10.1016/j.neuropharm.2017.05.018 841 Cannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? PMID 20590557; DOI 10.1111/j.1476-5381.2010.00777.x 842 Endocannabinoids modulates CB1; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review. PMID 34050525; DOI 10.1007/s43440-021-00270-y 843 THC modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Endocannabinoid System: A Multi-Facet Therapeutic Target. PMID 27086601; DOI 10.2174/1574884711666160418105339 844 Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. PMID 17895407; DOI 10.1124/mol.107.039263 845 Cannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. PMID 31771126; DOI 10.3390/ijms20235874 846 Endocannabinoids modulates CB1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . The pharmacology of cannabinoid receptors and their ligands: an overview. PMID 16570099; DOI 10.1038/sj.ijo.0803272 847 Endocannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Latest advances in cannabinoid receptor agonists. PMID 19939187; DOI 10.1517/13543770903436505 848 THC modulates CB1; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms . Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. PMID 19285266; DOI 10.1016/j.beem.2008.09.003 849 Endocannabinoids modul...", "sources": 24, "status": "source-backed draft", "subtitle": "What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition-related mechanisms?", "title": "CB1 receptor neurobehavioral/metabolic", "type": "topic", "url": "/topics/cb1-receptor-neurobehavioral-metabolic-evidence-map/" }, { "aliases": [ "CB1", "cb1", "CB1 receptor pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb1 receptor pharmacology research summary", "What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1?" ], "claims": 33, "evidence_rows": 33, "search_boost": 5, "search_terms": [ "CB1", "cb1", "CB1 receptor pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb1 receptor pharmacology research summary", "What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1?" ], "search_text": "CB1 receptor pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1? Draft Summary This draft topic page is generated from 33 source-backed evidence row s and 33 source s . Main entities represented: Cannabinoids, THC, Endocannabinoids, HHC. Evidence Snapshot - Evidence rows: 33 - Sources: 33 - Evidence classes: insufficient 16 , mechanistic or pharmacological 17 - Draft sections: mechanistic evidence 17 , uncertainty 16 Key Draft Sections - Uncertainty and gaps: 16 evidence row s . - Mechanistic evidence: 17 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 806 Cannabinoids modulates CB1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Oxa-adamantyl cannabinoids. PMID 33636308; DOI 10.1016/j.bmcl.2021.127882 807 Cannabinoids modulates CB1; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PMID 18537620; DOI 10.2174/092986708784567716 808 THC modulates CB1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Pharmacological actions of cannabinoids. PMID 16596770; DOI 10.1007/3-540-26573-2 1 809 HHC modulates CB1; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Crystal structures of agonist-bound human cannabinoid receptor CB1. PMID 40866700; DOI 10.1038/s41586-025-09454-5 810 THC modulates CB1; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. PMID 35489334; DOI 10.1016/j.cell.2022.04.005 811 Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism. PMID 38101408; DOI 10.1016/j.cell.2023.11.017 812 Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . A cryptic pocket in CB1 drives peripheral and functional selectivity. PMID 40044849; DOI 10.1038/s41586-025-08618-7 813 Cannabinoids modulates CB1; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. PMID 28527758; DOI 10.1016/j.neuropharm.2017.05.018 814 Endocannabinoids modulates CB1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Cannabinergic ligands. PMID 12505686; DOI 10.1016/s0009-3084 02 00143-3 815 Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Assay of CB1 Receptor Binding. PMID 27245890; DOI 10.1007/978-1-4939-3539-0 5 816 THC modulates CB1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms . Structure-based identification of...", "sources": 33, "status": "source-backed draft", "subtitle": "What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1?", "title": "CB1 receptor pharmacology", "type": "topic", "url": "/topics/cb1-receptor-pharmacology-evidence-map/" }, { "aliases": [ "CB2", "cb2", "CB2 receptor immune inflammation research summary", "CB2 receptor immune/inflammation research summary", "Deep Review", "evidence", "immune", "inflammation", "map", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb2 receptor immune inflammation research summary", "What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain related mechanisms?", "What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain-related mechanisms?" ], "claims": 31, "evidence_rows": 31, "search_boost": 5, "search_terms": [ "CB2", "cb2", "CB2 receptor immune inflammation research summary", "CB2 receptor immune/inflammation research summary", "Deep Review", "evidence", "immune", "inflammation", "map", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb2 receptor immune inflammation research summary", "What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain related mechanisms?", "What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain-related mechanisms?" ], "search_text": "CB2 receptor immune/inflammation research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain-related mechanisms? Draft Summary This draft topic page is generated from 31 source-backed evidence row s and 31 source s . Main entities represented: Cannabinoids, Endocannabinoids, THC, 2-AG. Evidence Snapshot - Evidence rows: 31 - Sources: 31 - Evidence classes: insufficient 8 , mechanistic or pharmacological 23 - Draft sections: mechanistic evidence 23 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Mechanistic evidence: 23 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 895 Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. PMID 39334169; DOI 10.1186/s12974-024-03221-5 896 Cannabinoids modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. PMID 19152719; DOI 10.1017/s1462399409000957 897 Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. PMID 38662453; DOI 10.1172/jci175205 898 Cannabinoids modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . CB\u2082: therapeutic target-in-waiting. PMID 22197668; DOI 10.1016/j.pnpbp.2011.12.001 899 Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation. PMID 39173999; DOI 10.1016/j.lfs.2024.123002 900 Endocannabinoids modulates CB2; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. PMID 39264450; DOI 10.1007/s00213-024-06683-w 901 Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation. PMID 36475439; DOI 10.1098/rspb.2022.1941 902 Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice. PMID 37061199; DOI 10.1016/j.bbr.2023.114439 903 Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms . The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. PMID 18615177; DOI 10.2174/157015907780866884 904 Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome...", "sources": 31, "status": "source-backed draft", "subtitle": "What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain-related mechanisms?", "title": "CB2 receptor immune/inflammation", "type": "topic", "url": "/topics/cb2-receptor-immune-inflammation-evidence-map/" }, { "aliases": [ "CB2", "cb2", "CB2 receptor pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb2 receptor pharmacology research summary", "What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, selectivity, or structural pharmacology at CB2?" ], "claims": 32, "evidence_rows": 32, "search_boost": 5, "search_terms": [ "CB2", "cb2", "CB2 receptor pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "receptor", "source backed draft", "source-backed draft", "topic", "topics", "topics cb2 receptor pharmacology research summary", "What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, selectivity, or structural pharmacology at CB2?" ], "search_text": "CB2 receptor pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, selectivity, or structural pharmacology at CB2? Draft Summary This draft topic page is generated from 32 source-backed evidence row s and 32 source s . Main entities represented: Cannabinoids, THC, Endocannabinoids, Anandamide. Evidence Snapshot - Evidence rows: 32 - Sources: 32 - Evidence classes: insufficient 17 , mechanistic or pharmacological 15 - Draft sections: mechanistic evidence 15 , uncertainty 17 Key Draft Sections - Uncertainty and gaps: 17 evidence row s . - Mechanistic evidence: 15 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 863 THC modulates CB2; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PMID 17828291; DOI 10.1038/sj.bjp.0707442 864 Cannabinoids modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Cannabinoid receptor 2 CB2 modulators: A patent review 2016-2024 . PMID 39288632; DOI 10.1016/j.bioorg.2024.107775 865 Cannabinoids modulates CB2; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. PMID 18537620; DOI 10.2174/092986708784567716 866 THC modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . An Introduction to the Endogenous Cannabinoid System. PMID 26698193; DOI 10.1016/j.biopsych.2015.07.028 867 THC modulates CB2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Cannabichromene is a cannabinoid CB2 receptor agonist. PMID 31368508; DOI 10.1111/bph.14815 868 Endocannabinoids modulates CB2; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Cannabinergic ligands. PMID 12505686; DOI 10.1016/s0009-3084 02 00143-3 869 Cannabinoids modulates CB2; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Pharmacology of cannabinoid receptor ligands. PMID 10469884 870 THC modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. PMID 33811300; DOI 10.1007/s12272-021-01326-6 871 THC modulates CB2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay. PMID 40271066; DOI 10.3389/fphar.2025.1469986 872 Endocannabinoids modulates CB2; evidence class: insufficient study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms . Functional Selectivity at Cannabinoid Receptors. PMID 28826535; DOI 10.1016/bs.apha.2017.03.005 873 Cannabinoids modulates CB2; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacol...", "sources": 32, "status": "source-backed draft", "subtitle": "What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, selectivity, or structural pharmacology at CB2?", "title": "CB2 receptor pharmacology", "type": "topic", "url": "/topics/cb2-receptor-pharmacology-evidence-map/" }, { "aliases": [ "and", "CBC", "cbc", "CBC and inflammation related outcomes research summary", "CBC and inflammation-related outcomes research summary", "Deep Review", "evidence", "inflammation", "inflammation related", "inflammation-related", "map", "outcomes", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and inflammation related outcomes research summary", "What evidence connects CBC with inflammation related or pain related outcomes?", "What evidence connects CBC with inflammation-related or pain-related outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "CBC", "cbc", "CBC and inflammation related outcomes research summary", "CBC and inflammation-related outcomes research summary", "Deep Review", "evidence", "inflammation", "inflammation related", "inflammation-related", "map", "outcomes", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and inflammation related outcomes research summary", "What evidence connects CBC with inflammation related or pain related outcomes?", "What evidence connects CBC with inflammation-related or pain-related outcomes?" ], "search_text": "CBC and inflammation-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBC with inflammation-related or pain-related outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: CBC. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 2 , mechanistic or pharmacological 4 , preclinical 2 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 4 , preclinical evidence 2 , uncertainty 2 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 2 evidence row s . - Preclinical evidence: 2 evidence row s . - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 34 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 35 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 36 CBC studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. PMID 37332213; DOI 10.1097/sap.0000000000003547 71 CBC studied for Inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 72 CBC studied for Inflammation-related outcomes; evidence class: preliminary human outcome measure: inflammation-related or pain-related outcomes . Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. PMID 41213439; DOI 10.1016/j.jep.2025.120856 73 CBC studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PMID 39921943; DOI 10.1016/j.jpet.2025.103389 74 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or pain-related outcomes . Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 75 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. PMID 41256665; DOI 10.1101/2025.10.02.680148 76 CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes . Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. PMID 42139799; DOI 10.1016/j.jpet.2026.104901 References - Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x - Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 4168...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects CBC with inflammation-related or pain-related outcomes?", "title": "CBC and inflammation-related outcomes", "type": "topic", "url": "/topics/cbc-and-inflammation-related-outcomes-evidence-map/" }, { "aliases": [ "and", "CBC", "cbc", "CBC and neurobehavioral neurogenesis outcomes review", "CBC and neurobehavioral/neurogenesis outcomes review", "Deep Review", "neurobehavioral", "neurogenesis", "outcomes", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and neurobehavioral neurogenesis outcomes review", "What evidence connects CBC with neurobehavioral, mood, neural stem cell, or neurogenesis outcomes?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "and", "CBC", "cbc", "CBC and neurobehavioral neurogenesis outcomes review", "CBC and neurobehavioral/neurogenesis outcomes review", "Deep Review", "neurobehavioral", "neurogenesis", "outcomes", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and neurobehavioral neurogenesis outcomes review", "What evidence connects CBC with neurobehavioral, mood, neural stem cell, or neurogenesis outcomes?" ], "search_text": "CBC and neurobehavioral/neurogenesis outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBC with neurobehavioral, mood, neural stem cell, or neurogenesis outcomes? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: CBC. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 5 , mechanistic or pharmacological 6 , preclinical 1 - Draft sections: mechanistic evidence 6 , preclinical evidence 1 , uncertainty 5 Key Draft Sections - Uncertainty and gaps: 5 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 721 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 722 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. PMID 39808700; DOI 10.1021/acssynbio.4c00721 723 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. PMID 35306000; DOI 10.1016/j.ejphar.2022.174836 724 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PMID 37414155; DOI 10.1016/j.arr.2023.101998 725 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. PMID 41934896; DOI 10.1016/j.biopha.2026.119298 726 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Cannabigerol and cannabichromene in Cannabis sativa L. PMID 36654096; DOI 10.2478/acph-2021-0021 727 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. PMID 39769302; DOI 10.3390/ijms252413539 728 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes . Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis. PMID 36983897; DOI 10.3390/life13030742 729 CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehav...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence connects CBC with neurobehavioral, mood, neural stem cell, or neurogenesis outcomes?", "title": "CBC and neurobehavioral/neurogenesis outcomes review", "type": "topic", "url": "/topics/cbc-and-neurobehavioral-neurogenesis-outcomes-review/" }, { "aliases": [ "and", "CBC", "cbc", "CBC and pain related outcomes research summary", "CBC and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and pain related outcomes research summary", "What evidence connects CBC with pain related outcomes?", "What evidence connects CBC with pain-related outcomes?" ], "claims": 17, "evidence_rows": 17, "search_boost": 4, "search_terms": [ "and", "CBC", "cbc", "CBC and pain related outcomes research summary", "CBC and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and pain related outcomes research summary", "What evidence connects CBC with pain related outcomes?", "What evidence connects CBC with pain-related outcomes?" ], "search_text": "CBC and pain-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBC with pain-related outcomes? Draft Summary This draft topic page is generated from 17 source-backed evidence row s and 17 source s . Main entities represented: CBC. Evidence Snapshot - Evidence rows: 17 - Sources: 17 - Evidence classes: insufficient 3 , mechanistic or pharmacological 9 , preclinical 4 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 9 , preclinical evidence 4 , uncertainty 3 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 3 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 683 CBC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 684 CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 685 CBC studied for Pain-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. PMID 37332213; DOI 10.1097/sap.0000000000003547 686 CBC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 687 CBC studied for Pain-related outcomes; evidence class: preliminary human outcome measure: pain-related outcomes . Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. PMID 41213439; DOI 10.1016/j.jep.2025.120856 688 CBC studied for Pain-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PMID 39921943; DOI 10.1016/j.jpet.2025.103389 689 CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. PMID 41256665; DOI 10.1101/2025.10.02.680148 690 CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. PMID 42139799; DOI 10.1016/j.jpet.2026.104901 691 CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PMID 33230154; DOI 10.1038/s41598-020-77175-y 692 CBC studied for Pain-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . The antinociceptive activity and mechanism of action of cannabigerol. PMID 36916438; DOI 10.1016/j.biopha.2022.114163 693 CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological outcome measure: pain-related outcomes . Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PMID 19679411;...", "sources": 17, "status": "source-backed draft", "subtitle": "What evidence connects CBC with pain-related outcomes?", "title": "CBC and pain-related outcomes", "type": "topic", "url": "/topics/cbc-and-pain-related-outcomes-evidence-map/" }, { "aliases": [ "and", "CBC", "cbc", "CBC and safety tolerability research summary", "CBC and safety/tolerability research summary", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "tolerability", "topic", "topics", "topics cbc and safety tolerability research summary", "What evidence connects CBC with safety, tolerability, adverse event, impairment, or formulation specific outcomes?", "What evidence connects CBC with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?" ], "claims": 21, "evidence_rows": 21, "search_boost": 4, "search_terms": [ "and", "CBC", "cbc", "CBC and safety tolerability research summary", "CBC and safety/tolerability research summary", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "tolerability", "topic", "topics", "topics cbc and safety tolerability research summary", "What evidence connects CBC with safety, tolerability, adverse event, impairment, or formulation specific outcomes?", "What evidence connects CBC with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?" ], "search_text": "CBC and safety/tolerability research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBC with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes? Draft Summary This draft topic page is generated from 21 source-backed evidence row s and 21 source s . Main entities represented: CBC. Evidence Snapshot - Evidence rows: 21 - Sources: 21 - Evidence classes: insufficient 12 , mechanistic or pharmacological 4 , preclinical 3 , preliminary human 2 - Draft sections: safety 21 Key Draft Sections - Safety and tolerability: 21 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 636 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PMID 42163693; DOI 10.2174/0109298673390667251201115054 637 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PMID 42057192; DOI 10.1186/s42238-026-00432-w 638 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . The Potential of Cannabichromene CBC as a Therapeutic Agent. PMID 38777605; DOI 10.1124/jpet.124.002166 639 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PMID 40872492; DOI 10.3390/ph18081101 640 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PMID 37630401; DOI 10.3390/molecules28166149 641 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PMID 37162192; DOI 10.1080/27697061.2023.2203221 642 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient study design: Systematic review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PMID 38229238; DOI 10.1002/dta.3628 643 CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives...", "sources": 21, "status": "source-backed draft", "subtitle": "What evidence connects CBC with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?", "title": "CBC and safety/tolerability", "type": "topic", "url": "/topics/cbc-and-safety-tolerability-evidence-map/" }, { "aliases": [ "and", "CBC", "cbc", "CBC and skin dermatology research summary", "CBC and skin/dermatology research summary", "Deep Review", "dermatology", "evidence", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and skin dermatology research summary", "What evidence connects CBC with skin, dermatology, antimicrobial, or topical inflammatory outcomes?" ], "claims": 21, "evidence_rows": 21, "search_boost": 4, "search_terms": [ "and", "CBC", "cbc", "CBC and skin dermatology research summary", "CBC and skin/dermatology research summary", "Deep Review", "dermatology", "evidence", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cbc and skin dermatology research summary", "What evidence connects CBC with skin, dermatology, antimicrobial, or topical inflammatory outcomes?" ], "search_text": "CBC and skin/dermatology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBC with skin, dermatology, antimicrobial, or topical inflammatory outcomes? Draft Summary This draft topic page is generated from 21 source-backed evidence row s and 21 source s . Main entities represented: CBC. Evidence Snapshot - Evidence rows: 21 - Sources: 21 - Evidence classes: insufficient 11 , mechanistic or pharmacological 6 , preclinical 3 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 6 , preclinical evidence 3 , uncertainty 11 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 11 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 700 CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PMID 42163693; DOI 10.2174/0109298673390667251201115054 701 CBC studied for Skin and inflammatory dermatology; evidence class: insufficient study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . The Potential of Cannabichromene CBC as a Therapeutic Agent. PMID 38777605; DOI 10.1124/jpet.124.002166 702 CBC studied for Skin and inflammatory dermatology; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PMID 37630401; DOI 10.3390/molecules28166149 703 CBC studied for Skin and inflammatory dermatology; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PMID 40580638; DOI 10.1016/j.ejmech.2025.117888 704 CBC studied for Skin and inflammatory dermatology; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . The antinociceptive activity and mechanism of action of cannabigerol. PMID 36916438; DOI 10.1016/j.biopha.2022.114163 705 CBC studied for Skin and inflammatory dermatology; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 706 CBC studied for Skin and inflammatory dermatology; evidence class: insufficient outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. PMID 38889235; DOI 10.1021/acs.jnatprod.4c00212 707 CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. PMID 27094344; DOI 10.1111/exd.13042 708 CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes . Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. PMID 39769302; DOI 10.3390/ijms252413539 709 CBC studied for Skin and inflammatory dermatology; evidence class...", "sources": 21, "status": "source-backed draft", "subtitle": "What evidence connects CBC with skin, dermatology, antimicrobial, or topical inflammatory outcomes?", "title": "CBC and skin/dermatology", "type": "topic", "url": "/topics/cbc-and-skin-dermatology-evidence-map/" }, { "aliases": [ "and", "CBC", "cbc", "CBC and target pharmacology research summary", "CBC and target/pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics cbc and target pharmacology research summary", "What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms?" ], "claims": 26, "evidence_rows": 26, "search_boost": 5, "search_terms": [ "and", "CBC", "cbc", "CBC and target pharmacology research summary", "CBC and target/pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics cbc and target pharmacology research summary", "What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms?" ], "search_text": "CBC and target/pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms? Draft Summary This draft topic page is generated from 26 source-backed evidence row s and 26 source s . Main entities represented: CBC. Evidence Snapshot - Evidence rows: 26 - Sources: 26 - Evidence classes: insufficient 16 , mechanistic or pharmacological 10 - Draft sections: mechanistic evidence 10 , uncertainty 16 Key Draft Sections - Uncertainty and gaps: 16 evidence row s . - Mechanistic evidence: 10 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 657 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 658 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 659 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . The Potential of Cannabichromene CBC as a Therapeutic Agent. PMID 38777605; DOI 10.1124/jpet.124.002166 660 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PMID 40872492; DOI 10.3390/ph18081101 661 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Pharmacokinetics of Non-Psychotropic Phytocannabinoids. PMID 40006604; DOI 10.3390/pharmaceutics17020236 662 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. PMID 35306000; DOI 10.1016/j.ejphar.2022.174836 663 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PMID 40967679; DOI 10.1016/bs.pbr.2025.07.006 664 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Molecular Pharmacology of Phytocannabinoids. PMID 28120231; DOI 10.1007/978-3-319-45541-9 3 665 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms . Cannabinoids, inflammation, and fibrosis. PMID 27435265; DOI 10.1096/fj.201600646r 666 CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class:...", "sources": 26, "status": "source-backed draft", "subtitle": "What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms?", "title": "CBC and target/pharmacology", "type": "topic", "url": "/topics/cbc-and-target-pharmacology-evidence-map/" }, { "aliases": [ "and", "anxiety", "anxiety related", "anxiety-related", "CBD", "cbd", "CBD and anxiety related outcomes review", "CBD and anxiety-related outcomes review", "Deep Review", "outcomes", "related", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and anxiety related outcomes review", "What evidence connects CBD with anxiety related outcomes across human, animal, or mechanistic research?", "What evidence connects CBD with anxiety-related outcomes across human, animal, or mechanistic research?" ], "claims": 10, "evidence_rows": 10, "search_boost": 4, "search_terms": [ "and", "anxiety", "anxiety related", "anxiety-related", "CBD", "cbd", "CBD and anxiety related outcomes review", "CBD and anxiety-related outcomes review", "Deep Review", "outcomes", "related", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and anxiety related outcomes review", "What evidence connects CBD with anxiety related outcomes across human, animal, or mechanistic research?", "What evidence connects CBD with anxiety-related outcomes across human, animal, or mechanistic research?" ], "search_text": "CBD and anxiety-related outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBD with anxiety-related outcomes across human, animal, or mechanistic research? Draft Summary This draft topic page is generated from 10 source-backed evidence row s and 10 source s . Main entities represented: CBD. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 3 , preliminary human 7 - Draft sections: human evidence 7 , uncertainty 3 Key Draft Sections - Human evidence: 7 evidence row s . - Uncertainty and gaps: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 28 CBD studied for Anxiety-related outcomes; evidence class: preliminary human study design: Human clinical study; outcome measure: anxiety-related outcomes . Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution 150 mg/mL versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PMID 38797087; DOI 10.1016/j.ajp.2024.104073 29 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. PMID 35617670; DOI 10.47626/2237-6089-2021-0396 30 CBD studied for Anxiety-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes . Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. PMID 33424664; DOI 10.3389/fpsyt.2020.595584 57 CBD studied for Anxiety-related outcomes; evidence class: preliminary human study design: Human clinical study; outcome measure: anxiety-related outcomes . Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PMID 38174873; DOI 10.5664/jcsm.10998 58 CBD studied for Anxiety-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes . Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 59 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. PMID 39680411; DOI 10.1001/jamanetworkopen.2024.50391 60 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. PMID 39505200; DOI 10.1016/j.joen.2024.10.010 61 CBD studied for Anxiety-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: anxiety-related outcomes . Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PMID 35982439; DOI 10.1186/s12916-022-02459-1 62 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PMID 39151115; DOI 10.1200/jco.23.01836 63 CBD studied for Anxiety-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes . Cannabidiol for Treatment-Resistant Anxiety Disorders in...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence connects CBD with anxiety-related outcomes across human, animal, or mechanistic research?", "title": "CBD and anxiety-related outcomes review", "type": "topic", "url": "/topics/cbd-and-anxiety-related-outcomes-review/" }, { "aliases": [ "and", "CBD", "cbd", "CBD and drug interaction safety review", "CBD and drug-interaction safety review", "Deep Review", "drug", "drug interaction", "drug-interaction", "interaction", "review", "safety", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and drug interaction safety review", "What evidence connects CBD exposure with drug interaction mechanisms or safety relevant outcomes?", "What evidence connects CBD exposure with drug-interaction mechanisms or safety-relevant outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "CBD", "cbd", "CBD and drug interaction safety review", "CBD and drug-interaction safety review", "Deep Review", "drug", "drug interaction", "drug-interaction", "interaction", "review", "safety", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and drug interaction safety review", "What evidence connects CBD exposure with drug interaction mechanisms or safety relevant outcomes?", "What evidence connects CBD exposure with drug-interaction mechanisms or safety-relevant outcomes?" ], "search_text": "CBD and drug-interaction safety review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBD exposure with drug-interaction mechanisms or safety-relevant outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: CBD. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 8 , mechanistic or pharmacological 1 - Draft sections: safety 9 Key Draft Sections - Safety and tolerability: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 22 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: drug-interaction or safety-relevant outcomes . Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PMID 36206805; DOI 10.1016/j.expneurol.2022.114238 23 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes . Cannabidiol's impact on drug-metabolization. PMID 37541924; DOI 10.1016/j.ejim.2023.07.029 24 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: drug-interaction or safety-relevant outcomes . A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. PMID 35156171; DOI 10.1007/s40263-022-00898-1 47 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: drug-interaction or safety-relevant outcomes . A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PMID 30374683; DOI 10.1007/s40263-018-0578-5 48 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: drug-interaction or safety-relevant outcomes . Memantine for autism spectrum disorder. PMID 36006807; DOI 10.1002/14651858.cd013845.pub2 49 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes . Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PMID 39007525; DOI 10.1002/epi4.12956 50 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes . Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. PMID 39854828; DOI 10.1016/j.yebeh.2024.110261 51 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes . Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol CBD Use. PMID 31288397; DOI 10.3390/jcm8070989 52 CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert rev...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects CBD exposure with drug-interaction mechanisms or safety-relevant outcomes?", "title": "CBD and drug-interaction safety review", "type": "topic", "url": "/topics/cbd-and-drug-interaction-safety-review/" }, { "aliases": [ "and", "CBD", "cbd", "CBD and pain related outcomes research summary", "CBD and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and pain related outcomes research summary", "What evidence connects CBD with pain related outcomes?", "What evidence connects CBD with pain-related outcomes?" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "and", "CBD", "cbd", "CBD and pain related outcomes research summary", "CBD and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and pain related outcomes research summary", "What evidence connects CBD with pain related outcomes?", "What evidence connects CBD with pain-related outcomes?" ], "search_text": "CBD and pain-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBD with pain-related outcomes? Draft Summary This draft topic page is generated from 15 source-backed evidence row s and 15 source s . Main entities represented: CBD. Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 7 , mechanistic or pharmacological 1 , preliminary human 7 - Draft sections: human evidence 7 , mechanistic evidence 1 , uncertainty 7 Key Draft Sections - Human evidence: 7 evidence row s . - Uncertainty and gaps: 7 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 392 CBD studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes . Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PMID 35510826; DOI 10.1002/14651858.cd013444.pub2 393 CBD studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pain-related outcomes . Cannabis-based medicines for chronic neuropathic pain in adults. PMID 29513392; DOI 10.1002/14651858.cd012182.pub2 394 CBD studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes . Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. PMID 41429020; DOI 10.7326/annals-25-03152 395 CBD studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes . Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. PMID 37630995; DOI 10.3390/ph16081079 396 CBD studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes . High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. PMID 42256679; DOI 10.1016/j.eclinm.2026.103986 397 CBD studied for Pain-related outcomes; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: pain-related outcomes . Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. PMID 33561282; DOI 10.1093/pm/pnab050 398 CBD studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes . The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. PMID 31793418; DOI 10.2174/1389201020666191202111534 399 CBD studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabinoids: Medical implications. PMID 26912385; DOI 10.3109/07853890.2016.1145794 400 CBD studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. PMID 39445260; DOI 10.7759/cureus.70021 401 CBD studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes . Oral capsules of tetra-hydro-cannabinol THC , cannabidiol CBD and their combination in peripheral neuropathic pain treatment. PMID 36571471; DOI 10.1002/ejp.2072 402 CBD studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; ou...", "sources": 15, "status": "source-backed draft", "subtitle": "What evidence connects CBD with pain-related outcomes?", "title": "CBD and pain-related outcomes", "type": "topic", "url": "/topics/cbd-and-pain-related-outcomes-evidence-map/" }, { "aliases": [ "and", "CBD", "cbd", "CBD and seizure related outcomes review", "CBD and seizure-related outcomes review", "Deep Review", "outcomes", "related", "review", "seizure", "seizure related", "seizure-related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and seizure related outcomes review", "What evidence connects CBD with seizure related outcomes or epilepsy related clinical endpoints?", "What evidence connects CBD with seizure-related outcomes or epilepsy-related clinical endpoints?" ], "claims": 27, "evidence_rows": 27, "search_boost": 5, "search_terms": [ "and", "CBD", "cbd", "CBD and seizure related outcomes review", "CBD and seizure-related outcomes review", "Deep Review", "outcomes", "related", "review", "seizure", "seizure related", "seizure-related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and seizure related outcomes review", "What evidence connects CBD with seizure related outcomes or epilepsy related clinical endpoints?", "What evidence connects CBD with seizure-related outcomes or epilepsy-related clinical endpoints?" ], "search_text": "CBD and seizure-related outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBD with seizure-related outcomes or epilepsy-related clinical endpoints? Draft Summary This draft topic page is generated from 27 source-backed evidence row s and 27 source s . Main entities represented: CBD. Evidence Snapshot - Evidence rows: 27 - Sources: 27 - Evidence classes: insufficient 18 , mechanistic or pharmacological 2 , preliminary human 7 - Draft sections: human evidence 7 , mechanistic evidence 2 , uncertainty 18 Key Draft Sections - Human evidence: 7 evidence row s . - Uncertainty and gaps: 18 evidence row s . - Mechanistic evidence: 2 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 380 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes . Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PMID 36206805; DOI 10.1016/j.expneurol.2022.114238 381 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes . Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PMID 39007525; DOI 10.1002/epi4.12956 382 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes . Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. PMID 33346789; DOI 10.1001/jamaneurol.2020.4607 383 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: seizure-related outcomes . Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. PMID 33754312; DOI 10.1007/s40263-021-00807-y 384 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes . Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. PMID 33332006; DOI 10.1007/978-3-030-57369-0 7 385 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes . Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PMID 36417631; DOI 10.1590/1806-9282.2022d689 386 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes . Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. PMID 36194365; DOI 10.1007/s40263-022-00955-9 387 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: seizure-related outcomes . Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex. PMID 37769547; DOI 10.1016/j.seizure.2023.09.015 388 CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: seizure-related outcomes . Retrospective Multicenter Chart Review Study of Adjunctiv...", "sources": 27, "status": "source-backed draft", "subtitle": "What evidence connects CBD with seizure-related outcomes or epilepsy-related clinical endpoints?", "title": "CBD and seizure-related outcomes review", "type": "topic", "url": "/topics/cbd-and-seizure-related-outcomes-review/" }, { "aliases": [ "and", "CBD", "cbd", "CBD and sleep related outcomes review", "CBD and sleep-related outcomes review", "Deep Review", "outcomes", "related", "review", "sleep", "sleep related", "sleep-related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and sleep related outcomes review", "What evidence connects CBD with sleep related outcomes?", "What evidence connects CBD with sleep-related outcomes?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "and", "CBD", "cbd", "CBD and sleep related outcomes review", "CBD and sleep-related outcomes review", "Deep Review", "outcomes", "related", "review", "sleep", "sleep related", "sleep-related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbd and sleep related outcomes review", "What evidence connects CBD with sleep related outcomes?", "What evidence connects CBD with sleep-related outcomes?" ], "search_text": "CBD and sleep-related outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBD with sleep-related outcomes? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: CBD. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 5 , preliminary human 7 - Draft sections: human evidence 7 , uncertainty 5 Key Draft Sections - Human evidence: 7 evidence row s . - Uncertainty and gaps: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 403 CBD studied for Sleep; evidence class: preliminary human study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PMID 38174873; DOI 10.5664/jcsm.10998 404 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PMID 39980821; DOI 10.1002/hsr2.70481 405 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PMID 36539991; DOI 10.1111/jsr.13793 406 CBD studied for Sleep; evidence class: preliminary human study design: Human clinical study; outcome measure: sleep-related outcomes . Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PMID 39167421; DOI 10.5664/jcsm.11324 407 CBD studied for Sleep; evidence class: preliminary human study design: Human clinical study; outcome measure: sleep-related outcomes . The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial. PMID 39153080; DOI 10.1007/s00213-024-06674-x 408 CBD studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes . The Effects of Cannabinoids on Sleep. PMID 35459406; DOI 10.1177/21501319221081277 409 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 410 CBD studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: sleep-related outcomes . Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. PMID 40929927; DOI 10.1016/j.smrv.2025.102156 411 CBD studied for Sleep; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: sleep-related outcomes . The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. PMID 41856154; DOI 10.1016/s2215-0366 26 00015-5 412 CBD studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes . Should Oncologists Recommend Cannabis? PMID 31161270; DOI 10.1007/s11864-019-0659-9 413 CBD studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes . Cannabis dosing and administration for sleep: a systematic review. PMID 36107800; DOI 10.1093/sleep/zsac218 414 CBD studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; stu...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence connects CBD with sleep-related outcomes?", "title": "CBD and sleep-related outcomes review", "type": "topic", "url": "/topics/cbd-and-sleep-related-outcomes-review/" }, { "aliases": [ "and", "CBDA", "cbda", "CBDA and nausea inflammation research summary", "CBDA and nausea/inflammation research summary", "Deep Review", "evidence", "inflammation", "map", "nausea", "source backed draft", "source-backed draft", "topic", "topics", "topics cbda and nausea inflammation research summary", "What evidence connects CBDA with nausea related or inflammation related outcomes?", "What evidence connects CBDA with nausea-related or inflammation-related outcomes?" ], "claims": 25, "evidence_rows": 25, "search_boost": 5, "search_terms": [ "and", "CBDA", "cbda", "CBDA and nausea inflammation research summary", "CBDA and nausea/inflammation research summary", "Deep Review", "evidence", "inflammation", "map", "nausea", "source backed draft", "source-backed draft", "topic", "topics", "topics cbda and nausea inflammation research summary", "What evidence connects CBDA with nausea related or inflammation related outcomes?", "What evidence connects CBDA with nausea-related or inflammation-related outcomes?" ], "search_text": "CBDA and nausea/inflammation research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBDA with nausea-related or inflammation-related outcomes? Draft Summary This draft topic page is generated from 25 source-backed evidence row s and 25 source s . Main entities represented: CBDA. Evidence Snapshot - Evidence rows: 25 - Sources: 25 - Evidence classes: insufficient 12 , mechanistic or pharmacological 9 , preclinical 4 - Draft sections: mechanistic evidence 9 , preclinical evidence 4 , uncertainty 12 Key Draft Sections - Uncertainty and gaps: 12 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 43 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. PMID 30627539; DOI 10.1155/2018/1691428 125 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 126 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes . Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. PMID 34115951; DOI 10.1089/can.2021.0041 127 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. PMID 29057454; DOI 10.1111/bph.14073 128 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Evaluation of Sex Differences in the Potential of \u03949-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats. PMID 35984924; DOI 10.1089/can.2022.0158 129 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Evaluation of repeated or acute treatment with cannabidiol CBD , cannabidiolic acid CBDA or CBDA methyl ester HU-580 on nausea and/or vomiting in rats and shrews. PMID 32488349; DOI 10.1007/s00213-020-05559-z 130 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Effect of combined doses of \u03949-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. PMID 31897571; DOI 10.1007/s00213-019-05428-4 131 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes . Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. PMID 23121618; DOI 10.1111/bph.12043 132 CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinica...", "sources": 25, "status": "source-backed draft", "subtitle": "What evidence connects CBDA with nausea-related or inflammation-related outcomes?", "title": "CBDA and nausea/inflammation", "type": "topic", "url": "/topics/cbda-and-nausea-inflammation-evidence-map/" }, { "aliases": [ "and", "CBDV", "cbdv", "CBDV and seizure neurodevelopmental outcomes review", "CBDV and seizure/neurodevelopmental outcomes review", "Deep Review", "neurodevelopmental", "outcomes", "review", "seizure", "source backed draft", "source-backed draft", "topic", "topics", "topics cbdv and seizure neurodevelopmental outcomes review", "What evidence connects CBDV with seizure related or neurodevelopmental outcomes?", "What evidence connects CBDV with seizure-related or neurodevelopmental outcomes?" ], "claims": 21, "evidence_rows": 21, "search_boost": 4, "search_terms": [ "and", "CBDV", "cbdv", "CBDV and seizure neurodevelopmental outcomes review", "CBDV and seizure/neurodevelopmental outcomes review", "Deep Review", "neurodevelopmental", "outcomes", "review", "seizure", "source backed draft", "source-backed draft", "topic", "topics", "topics cbdv and seizure neurodevelopmental outcomes review", "What evidence connects CBDV with seizure related or neurodevelopmental outcomes?", "What evidence connects CBDV with seizure-related or neurodevelopmental outcomes?" ], "search_text": "CBDV and seizure/neurodevelopmental outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBDV with seizure-related or neurodevelopmental outcomes? Draft Summary This draft topic page is generated from 21 source-backed evidence row s and 21 source s . Main entities represented: CBDV. Evidence Snapshot - Evidence rows: 21 - Sources: 21 - Evidence classes: insufficient 11 , mechanistic or pharmacological 3 , preclinical 5 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 3 , preclinical evidence 5 , uncertainty 11 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 11 evidence row s . - Preclinical evidence: 5 evidence row s . - Mechanistic evidence: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 40 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. PMID 33895189; DOI 10.1016/j.pharmthera.2021.107878 41 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabis sativa: Much more beyond \u03949-tetrahydrocannabinol. PMID 32335286; DOI 10.1016/j.phrs.2020.104822 42 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. PMID 32825313; DOI 10.3390/brainsci10090572 84 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. PMID 42339654; DOI 10.1177/10445463261462382 85 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? PMID 33613289; DOI 10.3389/fphar.2020.635763 109 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Investigational cannabinoids in seizure disorders, what have we learned thus far? PMID 29842819; DOI 10.1080/13543784.2018.1482275 110 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes . Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. PMID 35364618; DOI 10.1111/epi.17247 111 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes . Phytocannabinoids and epilepsy. PMID 25475762; DOI 10.1111/jcpt.12235 112 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical outcome measure: seizure-related or neurodevelopmental outcomes . Cannabidivarin CBDV suppresses pentylenetetrazole PTZ -induced increases in epilepsy-related gene expression. PMID 24282673; DOI 10.7717/peerj.214 113 CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; outcome measure: seizure-rel...", "sources": 21, "status": "source-backed draft", "subtitle": "What evidence connects CBDV with seizure-related or neurodevelopmental outcomes?", "title": "CBDV and seizure/neurodevelopmental outcomes review", "type": "topic", "url": "/topics/cbdv-and-seizure-neurodevelopmental-outcomes-review/" }, { "aliases": [ "and", "appetite", "CBG", "cbg", "CBG and appetite metabolic outcomes review", "CBG and appetite/metabolic outcomes review", "Deep Review", "metabolic", "outcomes", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and appetite metabolic outcomes review", "What evidence connects CBG with appetite related, weight, glucose, or metabolic outcomes?", "What evidence connects CBG with appetite-related, weight, glucose, or metabolic outcomes?" ], "claims": 16, "evidence_rows": 16, "search_boost": 4, "search_terms": [ "and", "appetite", "CBG", "cbg", "CBG and appetite metabolic outcomes review", "CBG and appetite/metabolic outcomes review", "Deep Review", "metabolic", "outcomes", "review", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and appetite metabolic outcomes review", "What evidence connects CBG with appetite related, weight, glucose, or metabolic outcomes?", "What evidence connects CBG with appetite-related, weight, glucose, or metabolic outcomes?" ], "search_text": "CBG and appetite/metabolic outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBG with appetite-related, weight, glucose, or metabolic outcomes? Draft Summary This draft topic page is generated from 16 source-backed evidence row s and 16 source s . Main entities represented: CBG. Evidence Snapshot - Evidence rows: 16 - Sources: 16 - Evidence classes: insufficient 5 , mechanistic or pharmacological 5 , preclinical 4 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 5 , preclinical evidence 4 , uncertainty 5 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 5 evidence row s . - Preclinical evidence: 4 evidence row s . - Mechanistic evidence: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 620 CBG studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 621 CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PMID 33230154; DOI 10.1038/s41598-020-77175-y 622 CBG studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. PMID 42105814; DOI 10.1016/j.bcp.2026.118032 623 CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . Cannabigerol modulates \u03b12-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. PMID 37305529; DOI 10.3389/fphar.2023.1183019 624 CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? PMID 41056638; DOI 10.1016/j.biopha.2025.118623 625 CBG studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . Cannabigerol and cannabichromene in Cannabis sativa L. PMID 36654096; DOI 10.2478/acph-2021-0021 626 CBG studied for Appetite and metabolic outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. PMID 27503475; DOI 10.1007/s00213-016-4397-4 627 CBG studied for Appetite and metabolic outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. PMID 36397993; DOI 10.1155/2022/3336516 628 CBG studied for Appetite and metabolic outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes . A cannabigerol-rich Cannabis sativa extract, devoid of INCREMENT 9-tetrahydrocannabinol, elicits hyperphagia in rats. PMID 28125508; DOI 10.1097/fbp.0000000000000285 629 CBG studied for Appetite and metabolic outcomes; evidence cla...", "sources": 16, "status": "source-backed draft", "subtitle": "What evidence connects CBG with appetite-related, weight, glucose, or metabolic outcomes?", "title": "CBG and appetite/metabolic outcomes review", "type": "topic", "url": "/topics/cbg-and-appetite-metabolic-outcomes-review/" }, { "aliases": [ "and", "CBG", "cbg", "CBG and inflammation immune outcomes research summary", "CBG and inflammation/immune outcomes research summary", "Deep Review", "evidence", "immune", "inflammation", "map", "outcomes", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and inflammation immune outcomes research summary", "What evidence connects CBG with inflammation related or immune outcomes?", "What evidence connects CBG with inflammation-related or immune outcomes?" ], "claims": 22, "evidence_rows": 22, "search_boost": 4, "search_terms": [ "and", "CBG", "cbg", "CBG and inflammation immune outcomes research summary", "CBG and inflammation/immune outcomes research summary", "Deep Review", "evidence", "immune", "inflammation", "map", "outcomes", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and inflammation immune outcomes research summary", "What evidence connects CBG with inflammation related or immune outcomes?", "What evidence connects CBG with inflammation-related or immune outcomes?" ], "search_text": "CBG and inflammation/immune outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBG with inflammation-related or immune outcomes? Draft Summary This draft topic page is generated from 22 source-backed evidence row s and 22 source s . Main entities represented: CBG. Evidence Snapshot - Evidence rows: 22 - Sources: 22 - Evidence classes: insufficient 7 , mechanistic or pharmacological 8 , preclinical 7 - Draft sections: mechanistic evidence 8 , preclinical evidence 7 , uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . - Preclinical evidence: 7 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 584 CBG studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes . Cannabigerol CBG : A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PMID 39598860; DOI 10.3390/molecules29225471 585 CBG studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 586 CBG studied for Inflammation-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Orally administered Cannabigerol CBG in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. PMID 39322049; DOI 10.1016/j.pbb.2024.173883 587 CBG studied for Inflammation-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: inflammation-related or immune outcomes . The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PMID 33998900; DOI 10.1089/can.2020.0105 588 CBG studied for Inflammation-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. PMID 39921943; DOI 10.1016/j.jpet.2025.103389 589 CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. PMID 23415610; DOI 10.1016/j.bcp.2013.01.017 590 CBG studied for Inflammation-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. PMID 39699828; DOI 10.1007/s12640-024-00724-0 591 CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. PMID 36615835; DOI 10.3390/nu15010178 592 CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes . Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation. PMID 40818359; DOI 10.1016/j.biopha.2025.118463 593 CBG studied for Inflammation-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Na...", "sources": 22, "status": "source-backed draft", "subtitle": "What evidence connects CBG with inflammation-related or immune outcomes?", "title": "CBG and inflammation/immune outcomes", "type": "topic", "url": "/topics/cbg-and-inflammation-immune-outcomes-evidence-map/" }, { "aliases": [ "and", "CBG", "cbg", "CBG and pain related outcomes research summary", "CBG and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and pain related outcomes research summary", "What evidence connects CBG with pain related outcomes?", "What evidence connects CBG with pain-related outcomes?" ], "claims": 11, "evidence_rows": 11, "search_boost": 4, "search_terms": [ "and", "CBG", "cbg", "CBG and pain related outcomes research summary", "CBG and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and pain related outcomes research summary", "What evidence connects CBG with pain related outcomes?", "What evidence connects CBG with pain-related outcomes?" ], "search_text": "CBG and pain-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBG with pain-related outcomes? Draft Summary This draft topic page is generated from 11 source-backed evidence row s and 11 source s . Main entities represented: CBG. Evidence Snapshot - Evidence rows: 11 - Sources: 11 - Evidence classes: insufficient 7 , mechanistic or pharmacological 1 , preclinical 3 - Draft sections: mechanistic evidence 1 , preclinical evidence 3 , uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 31 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabigerol CBG : A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PMID 39598860; DOI 10.3390/molecules29225471 32 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 33 CBG studied for Pain-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Orally administered Cannabigerol CBG in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. PMID 39322049; DOI 10.1016/j.pbb.2024.173883 64 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes . The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PMID 33998900; DOI 10.1089/can.2020.0105 65 CBG studied for Pain-related outcomes; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. PMID 35994012; DOI 10.1089/can.2021.0244 66 CBG studied for Pain-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. PMID 34577072; DOI 10.3390/molecules26185601 67 CBG studied for Pain-related outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: pain-related outcomes . Applications of Cannabinoids in Neuropathic Pain: An Updated Review. PMID 37824417; DOI 10.1615/critrevtherdrugcarriersyst.2022038592 68 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry. PMID 35910331; DOI 10.1093/function/zqac033 69 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. PMID 31899693; DOI 10.14309/ctg.0000000000000120 70 CBG studied for Pain-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Therapeutic potential of acidic cannabinoids: an update. PMID 41545891; DOI 10.1186/s42238-026-00387-y 540 CBG studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PMID 33230154; DOI 10.1038/s41598-020-77175-y...", "sources": 11, "status": "source-backed draft", "subtitle": "What evidence connects CBG with pain-related outcomes?", "title": "CBG and pain-related outcomes", "type": "topic", "url": "/topics/cbg-and-pain-related-outcomes-evidence-map/" }, { "aliases": [ "and", "CBG", "cbg", "CBG and safety tolerability research summary", "CBG and safety/tolerability research summary", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "tolerability", "topic", "topics", "topics cbg and safety tolerability research summary", "What evidence connects CBG with safety, tolerability, adverse event, impairment, or formulation specific outcomes?", "What evidence connects CBG with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?" ], "claims": 22, "evidence_rows": 22, "search_boost": 4, "search_terms": [ "and", "CBG", "cbg", "CBG and safety tolerability research summary", "CBG and safety/tolerability research summary", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "tolerability", "topic", "topics", "topics cbg and safety tolerability research summary", "What evidence connects CBG with safety, tolerability, adverse event, impairment, or formulation specific outcomes?", "What evidence connects CBG with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?" ], "search_text": "CBG and safety/tolerability research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBG with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes? Draft Summary This draft topic page is generated from 22 source-backed evidence row s and 22 source s . Main entities represented: CBG. Evidence Snapshot - Evidence rows: 22 - Sources: 22 - Evidence classes: insufficient 11 , mechanistic or pharmacological 8 , preclinical 1 , preliminary human 2 - Draft sections: safety 22 Key Draft Sections - Safety and tolerability: 22 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 541 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Cannabigerol CBG : A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PMID 39598860; DOI 10.3390/molecules29225471 542 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Exploring Cannabidiol CBD and Cannabigerol CBG Safety Profile and Skincare Potential. PMID 39596290; DOI 10.3390/ijms252212224 543 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Cannabinoids in clinical practice. PMID 11152013; DOI 10.2165/00003495-200060060-00005 544 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol CBD - and cannabigerol CBG -based beverage powder to support recovery from delayed onset muscle soreness DOMS . PMID 37947792; DOI 10.1080/15502783.2023.2280113 545 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PMID 40206058; DOI 10.3389/fphar.2025.1561385 546 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Safety study of cannabidiol products in healthy dogs. PMID 38496308; DOI 10.3389/fvets.2024.1349590 547 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. PMID 36796712; DOI 10.1016/j.tox.2023.153460 548 CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns . Identification of C...", "sources": 22, "status": "source-backed draft", "subtitle": "What evidence connects CBG with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?", "title": "CBG and safety/tolerability", "type": "topic", "url": "/topics/cbg-and-safety-tolerability-evidence-map/" }, { "aliases": [ "and", "CBG", "cbg", "CBG and skin dermatology research summary", "CBG and skin/dermatology research summary", "Deep Review", "dermatology", "evidence", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and skin dermatology research summary", "What evidence connects CBG with skin, dermatology, or topical inflammatory outcomes?" ], "claims": 14, "evidence_rows": 14, "search_boost": 4, "search_terms": [ "and", "CBG", "cbg", "CBG and skin dermatology research summary", "CBG and skin/dermatology research summary", "Deep Review", "dermatology", "evidence", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cbg and skin dermatology research summary", "What evidence connects CBG with skin, dermatology, or topical inflammatory outcomes?" ], "search_text": "CBG and skin/dermatology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBG with skin, dermatology, or topical inflammatory outcomes? Draft Summary This draft topic page is generated from 14 source-backed evidence row s and 14 source s . Main entities represented: CBG. Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 3 , mechanistic or pharmacological 9 , preclinical 1 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 9 , preclinical evidence 1 , uncertainty 3 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 3 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 606 CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes . Exploring Cannabidiol CBD and Cannabigerol CBG Safety Profile and Skincare Potential. PMID 39596290; DOI 10.3390/ijms252212224 607 CBG studied for Skin and inflammatory dermatology; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes . The antinociceptive activity and mechanism of action of cannabigerol. PMID 36916438; DOI 10.1016/j.biopha.2022.114163 608 CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes . Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. PMID 40725084; DOI 10.3390/ijms26146840 609 CBG studied for Skin and inflammatory dermatology; evidence class: insufficient outcome measure: skin, dermatology, or topical inflammatory outcomes . Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. PMID 36768709; DOI 10.3390/ijms24032389 610 CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: skin, dermatology, or topical inflammatory outcomes . In Vitro and Clinical Evaluation of Cannabigerol CBG Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. PMID 35056807; DOI 10.3390/molecules27020491 611 CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes . Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NF\u03baB Signaling Pathway. PMID 39851511; DOI 10.3390/cells14020083 612 CBG studied for Skin and inflammatory dermatology; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, or topical inflammatory outcomes . Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. PMID 40124934; DOI 10.2147/ccid.s472746 613 CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes . Mannich-type modifications of - -cannabidiol and - -cannabigerol leading to new, bioactive derivatives. PMID 37949940; DOI 10.1038/s41598-023-45565-7 614 CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes . Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests. PMID 39647320; DOI 10.1016/j.biopha.2024.117736 615 CBG studied for Skin and in...", "sources": 14, "status": "source-backed draft", "subtitle": "What evidence connects CBG with skin, dermatology, or topical inflammatory outcomes?", "title": "CBG and skin/dermatology", "type": "topic", "url": "/topics/cbg-and-skin-dermatology-evidence-map/" }, { "aliases": [ "and", "CBG", "cbg", "CBG and target pharmacology research summary", "CBG and target/pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics cbg and target pharmacology research summary", "What evidence connects CBG with receptor, target, metabolic, or pharmacology mechanisms?" ], "claims": 21, "evidence_rows": 21, "search_boost": 4, "search_terms": [ "and", "CBG", "cbg", "CBG and target pharmacology research summary", "CBG and target/pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics cbg and target pharmacology research summary", "What evidence connects CBG with receptor, target, metabolic, or pharmacology mechanisms?" ], "search_text": "CBG and target/pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBG with receptor, target, metabolic, or pharmacology mechanisms? Draft Summary This draft topic page is generated from 21 source-backed evidence row s and 21 source s . Main entities represented: CBG. Evidence Snapshot - Evidence rows: 21 - Sources: 21 - Evidence classes: insufficient 13 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 13 Key Draft Sections - Uncertainty and gaps: 13 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 563 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Cannabigerol CBG : A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PMID 39598860; DOI 10.3390/molecules29225471 564 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. PMID 21749363; DOI 10.1111/j.1476-5381.2011.01238.x 565 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. PMID 33998900; DOI 10.1089/can.2020.0105 566 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 567 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . The Pharmacological Case for Cannabigerol. PMID 33168643; DOI 10.1124/jpet.120.000340 568 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PMID 40967679; DOI 10.1016/bs.pbr.2025.07.006 569 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Molecular Pharmacology of Phytocannabinoids. PMID 28120231; DOI 10.1007/978-3-319-45541-9 3 570 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. PMID 25269802; DOI 10.1093/carcin/bgu205 571 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. PMID 42105814; DOI 10.1016/j.bcp.2026.118032 572 CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacolog...", "sources": 21, "status": "source-backed draft", "subtitle": "What evidence connects CBG with receptor, target, metabolic, or pharmacology mechanisms?", "title": "CBG and target/pharmacology", "type": "topic", "url": "/topics/cbg-and-target-pharmacology-evidence-map/" }, { "aliases": [ "and", "CBN", "cbn", "CBN and pain related outcomes research summary", "CBN and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbn and pain related outcomes research summary", "What evidence connects CBN with pain related outcomes?", "What evidence connects CBN with pain-related outcomes?" ], "claims": 6, "evidence_rows": 6, "search_boost": 4, "search_terms": [ "and", "CBN", "cbn", "CBN and pain related outcomes research summary", "CBN and pain-related outcomes research summary", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "topic", "topics", "topics cbn and pain related outcomes research summary", "What evidence connects CBN with pain related outcomes?", "What evidence connects CBN with pain-related outcomes?" ], "search_text": "CBN and pain-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBN with pain-related outcomes? Draft Summary This draft topic page is generated from 6 source-backed evidence row s and 6 source s . Main entities represented: CBN. Evidence Snapshot - Evidence rows: 6 - Sources: 6 - Evidence classes: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 1 , uncertainty 4 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 534 CBN studied for Pain-related outcomes; evidence class: mechanistic or pharmacological outcome measure: pain-related outcomes . Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PMID 19679411; DOI 10.1016/j.drugalcdep.2009.06.009 535 CBN studied for Pain-related outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes . Cannabinoid receptor 2 Cb2r mediates cannabinol CBN induced developmental defects in zebrafish. PMID 36424484; DOI 10.1038/s41598-022-23495-0 536 CBN studied for Pain-related outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabinoids, inflammation, and fibrosis. PMID 27435265; DOI 10.1096/fj.201600646r 537 CBN studied for Pain-related outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: pain-related outcomes . Marijuana--2000 . PMID 11367861 538 CBN studied for Pain-related outcomes; evidence class: preliminary human outcome measure: pain-related outcomes . Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. PMID 39835903; DOI 10.1073/pnas.2416886122 539 CBN studied for Pain-related outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabis: Chemistry, extraction and therapeutic applications. PMID 34838836; DOI 10.1016/j.chemosphere.2021.133012 References - Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PMID 19679411; DOI 10.1016/j.drugalcdep.2009.06.009 - Cannabinoid receptor 2 Cb2r mediates cannabinol CBN induced developmental defects in zebrafish. PMID 36424484; DOI 10.1038/s41598-022-23495-0 - Cannabinoids, inflammation, and fibrosis. PMID 27435265; DOI 10.1096/fj.201600646r - Marijuana--2000 . PMID 11367861 - Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. PMID 39835903; DOI 10.1073/pnas.2416886122 - Cannabis: Chemistry, extraction and therapeutic applications. PMID 34838836; DOI 10.1016/j.chemosphere.2021.133012", "sources": 6, "status": "source-backed draft", "subtitle": "What evidence connects CBN with pain-related outcomes?", "title": "CBN and pain-related outcomes", "type": "topic", "url": "/topics/cbn-and-pain-related-outcomes-evidence-map/" }, { "aliases": [ "and", "CBN", "cbn", "CBN and safety tolerability research summary", "CBN and safety/tolerability research summary", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "tolerability", "topic", "topics", "topics cbn and safety tolerability research summary", "What evidence connects CBN with safety, tolerability, sedation, adverse event, or impairment outcomes?", "What evidence connects CBN with safety, tolerability, sedation, adverse-event, or impairment outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "CBN", "cbn", "CBN and safety tolerability research summary", "CBN and safety/tolerability research summary", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "tolerability", "topic", "topics", "topics cbn and safety tolerability research summary", "What evidence connects CBN with safety, tolerability, sedation, adverse event, or impairment outcomes?", "What evidence connects CBN with safety, tolerability, sedation, adverse-event, or impairment outcomes?" ], "search_text": "CBN and safety/tolerability research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBN with safety, tolerability, sedation, adverse-event, or impairment outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: CBN. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 4 , mechanistic or pharmacological 1 , preliminary human 4 - Draft sections: safety 9 Key Draft Sections - Safety and tolerability: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 508 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 509 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 510 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PMID 39980821; DOI 10.1002/hsr2.70481 511 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PMID 39004335; DOI 10.1016/j.tox.2024.153885 512 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PMID 37162192; DOI 10.1080/27697061.2023.2203221 513 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. PMID 38924151; DOI 10.1002/jat.4646 514 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns . Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences . PMID 27428345 515 CBN studied for safety, tolerability, sedation, adverse-event, impairment, or...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects CBN with safety, tolerability, sedation, adverse-event, or impairment outcomes?", "title": "CBN and safety/tolerability", "type": "topic", "url": "/topics/cbn-and-safety-tolerability-evidence-map/" }, { "aliases": [ "and", "CBN", "cbn", "CBN and skin inflammation research summary", "CBN and skin/inflammation research summary", "Deep Review", "evidence", "inflammation", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cbn and skin inflammation research summary", "What evidence connects CBN with skin, dermatology, inflammatory, or immune modulation outcomes?", "What evidence connects CBN with skin, dermatology, inflammatory, or immune-modulation outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "CBN", "cbn", "CBN and skin inflammation research summary", "CBN and skin/inflammation research summary", "Deep Review", "evidence", "inflammation", "map", "skin", "source backed draft", "source-backed draft", "topic", "topics", "topics cbn and skin inflammation research summary", "What evidence connects CBN with skin, dermatology, inflammatory, or immune modulation outcomes?", "What evidence connects CBN with skin, dermatology, inflammatory, or immune-modulation outcomes?" ], "search_text": "CBN and skin/inflammation research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBN with skin, dermatology, inflammatory, or immune-modulation outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: CBN. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 2 , mechanistic or pharmacological 7 - Draft sections: mechanistic evidence 7 , uncertainty 2 Key Draft Sections - Uncertainty and gaps: 2 evidence row s . - Mechanistic evidence: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 525 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. PMID 41680865; DOI 10.1186/s42238-025-00384-7 526 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 527 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. PMID 39275884; DOI 10.1002/biof.2122 528 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. PMID 36228902; DOI 10.1016/j.fct.2022.113458 529 CBN studied for Skin and inflammatory dermatology; evidence class: insufficient study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. PMID 38673788; DOI 10.3390/ijms25084204 530 CBN studied for Skin and inflammatory dermatology; evidence class: insufficient study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Cannabinoids, inflammation, and fibrosis. PMID 27435265; DOI 10.1096/fj.201600646r 531 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices. PMID 41478536; DOI 10.1016/j.jep.2025.121134 532 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis. PMID 40580876; DOI 10.1016/j.biopha.2025.118288 533 CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes . Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons. PMID 40568800; DOI 10.1021/acs.jmedchem.5c00938 References - Anti-inflammatory and analgesic potential of mi...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects CBN with skin, dermatology, inflammatory, or immune-modulation outcomes?", "title": "CBN and skin/inflammation", "type": "topic", "url": "/topics/cbn-and-skin-inflammation-evidence-map/" }, { "aliases": [ "and", "CBN", "cbn", "CBN and sleep pilot", "Deep Review", "pilot", "sleep", "source backed draft", "source-backed draft", "topic", "topics", "topics cbn and sleep pilot", "What evidence connects CBN with sleep related outcomes?", "What evidence connects CBN with sleep-related outcomes?" ], "claims": 23, "evidence_rows": 23, "search_boost": 4, "search_terms": [ "and", "CBN", "cbn", "CBN and sleep pilot", "Deep Review", "pilot", "sleep", "source backed draft", "source-backed draft", "topic", "topics", "topics cbn and sleep pilot", "What evidence connects CBN with sleep related outcomes?", "What evidence connects CBN with sleep-related outcomes?" ], "search_text": "CBN and sleep pilot Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBN with sleep-related outcomes? Draft Summary This draft topic page is generated from 23 source-backed evidence row s and 10 source s . Main entities represented: CBN. Evidence Snapshot - Evidence rows: 23 - Sources: 10 - Evidence classes: insufficient 4 , mechanistic or pharmacological 1 , preclinical 3 , preliminary human 15 - Draft sections: human evidence 13 , mechanistic evidence 1 , preclinical evidence 3 , safety 2 , uncertainty 4 Key Draft Sections - Human evidence: 13 evidence row s . - Safety and tolerability: 2 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1 CBN associated with sleep-promoting claims in the pre-2021 evidence base; evidence class: insufficient study design: narrative review . Cannabinol and Sleep: Separating Fact from Fiction PMID 34468204; DOI 10.1089/can.2021.0006 2 CBN decreases Nighttime awakenings; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 3 CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue . A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PMID 37796540; DOI 10.1037/pha0000682 4 CBN decreases Overall sleep disturbance; evidence class: preliminary human population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose: 25 mg, 50 mg, or 100 mg oral CBN formulation; outcome measure: PROMIS Sleep Disturbance 8A . A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PMID 39204082; DOI 10.3390/ph17080977 5 CBN no detected effect on Side effect frequency; evidence class: preliminary human population or model: Participants in randomized sleep-quality trial; study design: decentralized randomized double-blind placebo-controlled trial; dose: 25 mg, 50 mg, or 100 mg oral CBN formulation; outcome measure: Side effect frequency . A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PMID 39204082; DOI 10.3390/ph17080977 6 CBN no detected effect on Wake after sleep onset; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: single oral dose of 30 mg or 300 mg CBN; outcome measure: polysomnography wake after sleep onset . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 7 CBN decreases Sleep onset latency; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: sleep onset latency . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 8 CBN increases Subjective sleep quality; evidence class: preliminary human population or model: 20 adults with physician-diagnosed insomnia disorder; study design: randomized double-blind placebo-controlled crossover trial; dose: 300 mg CBN; outcome measure: Subjective sleep quality . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence connects CBN with sleep-related outcomes?", "title": "CBN and sleep pilot", "type": "topic", "url": "/topics/cbn-and-sleep-pilot/" }, { "aliases": [ "and", "CBN", "cbn", "CBN and target pharmacology research summary", "CBN and target/pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics cbn and target pharmacology research summary", "What evidence connects CBN with receptor, target, metabolic, or pharmacology mechanisms?" ], "claims": 8, "evidence_rows": 8, "search_boost": 4, "search_terms": [ "and", "CBN", "cbn", "CBN and target pharmacology research summary", "CBN and target/pharmacology research summary", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics cbn and target pharmacology research summary", "What evidence connects CBN with receptor, target, metabolic, or pharmacology mechanisms?" ], "search_text": "CBN and target/pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects CBN with receptor, target, metabolic, or pharmacology mechanisms? Draft Summary This draft topic page is generated from 8 source-backed evidence row s and 8 source s . Main entities represented: CBN. Evidence Snapshot - Evidence rows: 8 - Sources: 8 - Evidence classes: insufficient 5 , mechanistic or pharmacological 3 - Draft sections: mechanistic evidence 3 , uncertainty 5 Key Draft Sections - Uncertainty and gaps: 5 evidence row s . - Mechanistic evidence: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 517 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PMID 40967679; DOI 10.1016/bs.pbr.2025.07.006 518 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Cannabinoid receptor 2 Cb2r mediates cannabinol CBN induced developmental defects in zebrafish. PMID 36424484; DOI 10.1038/s41598-022-23495-0 519 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Pharmacological actions of cannabinoids. PMID 16596770; DOI 10.1007/3-540-26573-2 1 520 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Molecular Pharmacology of Phytocannabinoids. PMID 28120231; DOI 10.1007/978-3-319-45541-9 3 521 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. PMID 10036999; DOI 10.3109/10428199809059244 522 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Affinity-Based Protein Profiling Reveals IDH2 as a Mitochondrial Target of Cannabinol in Receptor-Independent Neuroprotection. PMID 40388656; DOI 10.1002/chem.202501143 523 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. PMID 38673788; DOI 10.3390/ijms25084204 524 CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. PMID 36091813; DOI 10.3389/fphar.2022.956030 References - Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. PMID 40967679; DOI 10.1016/bs.pbr.2025.07.006 - Cannabinoid receptor 2 Cb2r mediates cannabinol CBN induced developmental defects in zebrafish. PMID 36424484; DOI 10.1038/s41598-022-23495-0 - Pharmacological actions of cannabinoids. PMID 16596770; DOI 10.1007/3-540-26573-2 1 - Molecular Pharmacology of Phytocannabinoids. PMID 28120231; DOI 10.1007/978-3-319-45541-9 3 - The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. PMID 10036999; DOI 10.3109/104281998...", "sources": 8, "status": "source-backed draft", "subtitle": "What evidence connects CBN with receptor, target, metabolic, or pharmacology mechanisms?", "title": "CBN and target/pharmacology", "type": "topic", "url": "/topics/cbn-and-target-pharmacology-evidence-map/" }, { "aliases": [ "and", "cannabinoids", "Commercial", "commercial", "Commercial and semi synthetic cannabinoids safety review", "Commercial and semi-synthetic cannabinoids safety review", "Deep Review", "review", "safety", "semi", "semi synthetic", "semi-synthetic", "source backed draft", "source-backed draft", "synthetic", "topic", "topics", "topics commercial and semi synthetic cannabinoids safety review", "What safety evidence exists for Delta 8 THC, Delta 10 THC, HHC, and related commercial cannabinoid formulations?", "What safety evidence exists for Delta-8 THC, Delta-10 THC, HHC, and related commercial cannabinoid formulations?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "and", "cannabinoids", "Commercial", "commercial", "Commercial and semi synthetic cannabinoids safety review", "Commercial and semi-synthetic cannabinoids safety review", "Deep Review", "review", "safety", "semi", "semi synthetic", "semi-synthetic", "source backed draft", "source-backed draft", "synthetic", "topic", "topics", "topics commercial and semi synthetic cannabinoids safety review", "What safety evidence exists for Delta 8 THC, Delta 10 THC, HHC, and related commercial cannabinoid formulations?", "What safety evidence exists for Delta-8 THC, Delta-10 THC, HHC, and related commercial cannabinoid formulations?" ], "search_text": "Commercial and semi-synthetic cannabinoids safety review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What safety evidence exists for Delta-8 THC, Delta-10 THC, HHC, and related commercial cannabinoid formulations? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: HHC, Delta-8 THC, THC, Cannabinoids. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 6 , mechanistic or pharmacological 1 , preclinical 2 , preliminary human 3 - Draft sections: safety 12 Key Draft Sections - Safety and tolerability: 12 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 243 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. PMID 42106886; DOI 10.1186/s42238-026-00435-7 244 Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Not all drugs are the same . PMID 23974649; DOI 10.1007/s00063-013-0219-1 245 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. PMID 41324909; DOI 10.1080/10826084.2025.2592227 348 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System FAERS Database. PMID 36742440; DOI 10.2147/dhps.s391857 349 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. PMID 38686923; DOI 10.1080/15563650.2024.2340115 350 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. PMID 38127427; DOI 10.2196/49469 351 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Derivation of a health-based guidance value for \u03948-tetrahydrocannabinol \u03948-THC and its occurrence in food. PMID 41262681; DOI 10.2903/j.efsa.2025.9735 352 Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. PMID 36342930; DOI 10.1089/can.2022.0079 353 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns . Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. PMID 40643195; DOI 10.1093/ijnp/pyaf041 354 HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human study design: Cas...", "sources": 12, "status": "source-backed draft", "subtitle": "What safety evidence exists for Delta-8 THC, Delta-10 THC, HHC, and related commercial cannabinoid formulations?", "title": "Commercial and semi-synthetic cannabinoids safety review", "type": "topic", "url": "/topics/commercial-and-semi-synthetic-cannabinoids-safety-review/" }, { "aliases": [ "Deep Review", "DHEA", "dhea", "DHEA synaptamide research summary", "DHEA/synaptamide research summary", "evidence", "map", "source backed draft", "source-backed draft", "synaptamide", "topic", "topics", "topics dhea synaptamide research summary", "What evidence defines DHEA synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms?", "What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 5, "evidence_rows": 5, "search_boost": 4, "search_terms": [ "Deep Review", "DHEA", "dhea", "DHEA synaptamide research summary", "DHEA/synaptamide research summary", "evidence", "map", "source backed draft", "source-backed draft", "synaptamide", "topic", "topics", "topics dhea synaptamide research summary", "What evidence defines DHEA synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms?", "What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "DHEA/synaptamide research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 5 source-backed evidence row s and 5 source s . Main entities represented: DHEA / synaptamide. Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 2 , mechanistic or pharmacological 3 - Draft sections: mechanistic evidence 3 , uncertainty 2 Key Draft Sections - Uncertainty and gaps: 2 evidence row s . - Mechanistic evidence: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1167 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. PMID 22959887; DOI 10.1016/j.plefa.2012.08.002 1168 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. PMID 27809877; DOI 10.1186/s12974-016-0751-z 1169 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. PMID 23570577; DOI 10.1111/jnc.12255 1170 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . Orphan GPR110 ADGRF1 targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. PMID 27759003; DOI 10.1038/ncomms13123 1171 DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms . A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. PMID 21810478; DOI 10.1016/j.prostaglandins.2011.07.002 References - Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. PMID 22959887; DOI 10.1016/j.plefa.2012.08.002 - N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. PMID 27809877; DOI 10.1186/s12974-016-0751-z - N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. PMID 23570577; DOI 10.1111/jnc.12255 - Orphan GPR110 ADGRF1 targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. PMID 27759003; DOI 10.1038/ncomms13123 - A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. PMID 21810478; DOI 10.1016/j.prostaglandins.2011.07.002", "sources": 5, "status": "source-backed draft", "subtitle": "What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms?", "title": "DHEA/synaptamide", "type": "topic", "url": "/topics/dhea-synaptamide-evidence-map/" }, { "aliases": [ "Deep Review", "Endocannabinoid", "endocannabinoid", "Endocannabinoid enzyme research summary", "enzyme", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics endocannabinoid enzyme research summary", "What evidence connects FAAH, MAGL, DAGL, NAPE PLD, ABHD6, ABHD12, COX 2, LOX, and CYP enzymes with cannabinoid biology?", "What evidence connects FAAH, MAGL, DAGL, NAPE-PLD, ABHD6, ABHD12, COX-2, LOX, and CYP enzymes with cannabinoid biology?" ], "claims": 16, "evidence_rows": 16, "search_boost": 4, "search_terms": [ "Deep Review", "Endocannabinoid", "endocannabinoid", "Endocannabinoid enzyme research summary", "enzyme", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics endocannabinoid enzyme research summary", "What evidence connects FAAH, MAGL, DAGL, NAPE PLD, ABHD6, ABHD12, COX 2, LOX, and CYP enzymes with cannabinoid biology?", "What evidence connects FAAH, MAGL, DAGL, NAPE-PLD, ABHD6, ABHD12, COX-2, LOX, and CYP enzymes with cannabinoid biology?" ], "search_text": "Endocannabinoid enzyme research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects FAAH, MAGL, DAGL, NAPE-PLD, ABHD6, ABHD12, COX-2, LOX, and CYP enzymes with cannabinoid biology? Draft Summary This draft topic page is generated from 16 source-backed evidence row s and 16 source s . Main entities represented: Endocannabinoids, THC, CBDV. Evidence Snapshot - Evidence rows: 16 - Sources: 16 - Evidence classes: insufficient 8 , mechanistic or pharmacological 3 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 3 , preclinical evidence 3 , uncertainty 8 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 203 CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. PMID 34179865; DOI 10.1016/j.ibneur.2021.01.004 300 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. PMID 32203086; DOI 10.1038/s41401-020-0385-7 301 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. PMID 40269679; DOI 10.1186/s10194-025-02030-2 302 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? PMID 34217798; DOI 10.1016/j.brainresbull.2021.06.022 303 THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. PMID 20047159 304 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Potential of Fatty Acid Amide Hydrolase FAAH , Monoacylglycerol Lipase MAGL , and Diacylglycerol Lipase DAGL Enzymes as Targets for Obesity Treatment: A Narrative Review. PMID 34959715; DOI 10.3390/ph14121316 305 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. PMID 41092478; DOI 10.1093/ejendo/lvaf212 306 Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms . Subcellular localization of NAPE-PLD and DAGL-\u03b1 in the ventromedial nucleus of the hypoth...", "sources": 16, "status": "source-backed draft", "subtitle": "What evidence connects FAAH, MAGL, DAGL, NAPE-PLD, ABHD6, ABHD12, COX-2, LOX, and CYP enzymes with cannabinoid biology?", "title": "Endocannabinoid enzyme", "type": "topic", "url": "/topics/endocannabinoid-enzyme-evidence-map/" }, { "aliases": [ "and", "Deep Review", "endocannabinoid", "endocannabinoid like", "endocannabinoid-like", "Endocannabinoids", "endocannabinoids", "Endocannabinoids and endocannabinoid like lipids research summary", "Endocannabinoids and endocannabinoid-like lipids research summary", "evidence", "like", "lipids", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics endocannabinoids and endocannabinoid like lipids research summary", "What evidence defines endogenous cannabinoids and endocannabinoid like lipids relevant to the encyclopedia?", "What evidence defines endogenous cannabinoids and endocannabinoid-like lipids relevant to the encyclopedia?" ], "claims": 13, "evidence_rows": 13, "search_boost": 4, "search_terms": [ "and", "Deep Review", "endocannabinoid", "endocannabinoid like", "endocannabinoid-like", "Endocannabinoids", "endocannabinoids", "Endocannabinoids and endocannabinoid like lipids research summary", "Endocannabinoids and endocannabinoid-like lipids research summary", "evidence", "like", "lipids", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics endocannabinoids and endocannabinoid like lipids research summary", "What evidence defines endogenous cannabinoids and endocannabinoid like lipids relevant to the encyclopedia?", "What evidence defines endogenous cannabinoids and endocannabinoid-like lipids relevant to the encyclopedia?" ], "search_text": "Endocannabinoids and endocannabinoid-like lipids research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines endogenous cannabinoids and endocannabinoid-like lipids relevant to the encyclopedia? Draft Summary This draft topic page is generated from 13 source-backed evidence row s and 13 source s . Main entities represented: Endocannabinoids, THC, CBD. Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 10 , mechanistic or pharmacological 2 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 2 , uncertainty 10 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 10 evidence row s . - Mechanistic evidence: 2 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 202 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPAR\u03b1. PMID 31325449; DOI 10.1016/j.bcp.2019.07.017 288 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . An Introduction to the Endogenous Cannabinoid System. PMID 26698193; DOI 10.1016/j.biopsych.2015.07.028 289 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . The Endocannabinoid System and its Modulation by Phytocannabinoids. PMID 26271952; DOI 10.1007/s13311-015-0374-6 290 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Endocannabinoid Turnover. PMID 28826539; DOI 10.1016/bs.apha.2017.03.006 291 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Endocannabinoids. PMID 9831287; DOI 10.1016/s0014-2999 98 00649-9 292 CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. PMID 17965195; DOI 10.1124/mol.107.041863 293 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. PMID 19833407; DOI 10.1016/j.imbio.2009.09.007 294 THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. PMID 17704824; DOI 10.1038/sj.bjp.0707423 295 Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics . Classical...", "sources": 13, "status": "source-backed draft", "subtitle": "What evidence defines endogenous cannabinoids and endocannabinoid-like lipids relevant to the encyclopedia?", "title": "Endocannabinoids and endocannabinoid-like lipids", "type": "topic", "url": "/topics/endocannabinoids-and-endocannabinoid-like-lipids-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "GPR119", "gpr119", "GPR119 cannabinoid target research summary", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics gpr119 cannabinoid target research summary", "What evidence connects cannabinoids, endocannabinoids, or endocannabinoid like lipids with GPR119 activity, binding, signaling, or physiology?", "What evidence connects cannabinoids, endocannabinoids, or endocannabinoid-like lipids with GPR119 activity, binding, signaling, or physiology?" ], "claims": 8, "evidence_rows": 8, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "GPR119", "gpr119", "GPR119 cannabinoid target research summary", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics gpr119 cannabinoid target research summary", "What evidence connects cannabinoids, endocannabinoids, or endocannabinoid like lipids with GPR119 activity, binding, signaling, or physiology?", "What evidence connects cannabinoids, endocannabinoids, or endocannabinoid-like lipids with GPR119 activity, binding, signaling, or physiology?" ], "search_text": "GPR119 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids, endocannabinoids, or endocannabinoid-like lipids with GPR119 activity, binding, signaling, or physiology? Draft Summary This draft topic page is generated from 8 source-backed evidence row s and 8 source s . Main entities represented: Endocannabinoids, Anandamide. Evidence Snapshot - Evidence rows: 8 - Sources: 8 - Evidence classes: insufficient 6 , mechanistic or pharmacological 1 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 1 , uncertainty 6 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 6 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 963 Endocannabinoids modulates GPR119; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Endocannabinoids and nutrition. PMID 18426507; DOI 10.1111/j.1365-2826.2008.01687.x 964 Anandamide modulates GPR119; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . N-acylethanolamines, anandamide and food intake. PMID 19413995; DOI 10.1016/j.bcp.2009.04.024 965 Anandamide modulates GPR119; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PMID 20353771; DOI 10.1016/j.expneurol.2010.03.022 966 Endocannabinoids modulates GPR119; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PMID 19285259; DOI 10.1016/j.beem.2008.10.003 967 Endocannabinoids modulates GPR119; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Regulation of GPR119 receptor activity with endocannabinoid-like lipids. PMID 23074242; DOI 10.1152/ajpendo.00269.2012 968 Endocannabinoids modulates GPR119; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. PMID 30787385; DOI 10.1038/s41598-019-38865-4 969 Endocannabinoids modulates GPR119; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Fatty acid amide hydrolase FAAH and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies. PMID 42144898; DOI 10.1111/bph.70511 970 Endocannabinoids modulates GPR119; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology . Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. PMID 30537148; DOI 10.1002/jcp.27913 References - Endocannabinoids and nutrition. PMID 18426507; DOI 10.1111/j.1365-2826.2008.01687.x - N-acylethanolamines, anandamide and food intake. PMID 19413995; DOI 10.1016/j.bcp.2009.04.024 - Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PMID 20353771; DOI 10.1016/j.expneurol.2010.03.022 - Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PMID 19285259; DOI 10.1016/j.beem.2008.10.003 - Regulation of GPR119 receptor activity with endocannabinoid-like lipids. PMID 23074242; DOI 10.1152/ajpendo.00269.2012 - Members of the endocannabinoid system are distin...", "sources": 8, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids, endocannabinoids, or endocannabinoid-like lipids with GPR119 activity, binding, signaling, or physiology?", "title": "GPR119 cannabinoid target", "type": "topic", "url": "/topics/gpr119-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "GPR18", "gpr18", "GPR18 cannabinoid target research summary", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics gpr18 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with GPR18 activity, binding, signaling, or physiology?" ], "claims": 19, "evidence_rows": 19, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "GPR18", "gpr18", "GPR18 cannabinoid target research summary", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics gpr18 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with GPR18 activity, binding, signaling, or physiology?" ], "search_text": "GPR18 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with GPR18 activity, binding, signaling, or physiology? Draft Summary This draft topic page is generated from 19 source-backed evidence row s and 19 source s . Main entities represented: Endocannabinoids, CBD, THC, Cannabinoids. Evidence Snapshot - Evidence rows: 19 - Sources: 19 - Evidence classes: insufficient 7 , mechanistic or pharmacological 12 - Draft sections: mechanistic evidence 12 , uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . - Mechanistic evidence: 12 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 944 Cannabinoids modulates GPR18; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PMID 28826536; DOI 10.1016/bs.apha.2017.04.004 945 Cannabinoids modulates GPR18; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Cannabinoid receptor ligand bias: implications in the central nervous system. PMID 27835801; DOI 10.1016/j.coph.2016.10.005 946 THC modulates GPR18; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18. PMID 32365486; DOI 10.3390/biom10050686 947 Endocannabinoids modulates GPR18; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Cannabinoids in Gynecological Diseases. PMID 34676329; DOI 10.1159/000499164 948 Endocannabinoids modulates GPR18; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders. PMID 42114685; DOI 10.1016/j.bcp.2026.118038 949 THC modulates GPR18; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. PMID 29902723; DOI 10.1016/j.ejmech.2018.05.050 950 THC modulates GPR18; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. PMID 24762058; DOI 10.1111/bph.12746 951 Cannabinoids modulates GPR18; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . Structural insights into the activation of G protein-coupled receptor 119 by the agonist GSK1292263 and ligands selectivity among novel cannabinoid receptors. PMID 40562148; DOI 10.1016/j.ijbiomac.2025.145476 952 Endocannabinoids modulates GPR18; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. PMID 29098189; DOI 10.1089/can.2017.0036 953 Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology . GPR18 undergoe...", "sources": 19, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with GPR18 activity, binding, signaling, or physiology?", "title": "GPR18 cannabinoid target", "type": "topic", "url": "/topics/gpr18-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "GPR55", "gpr55", "GPR55 cannabinoid target research summary", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics gpr55 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with GPR55 activity, binding, signaling, or physiology?" ], "claims": 18, "evidence_rows": 18, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "GPR55", "gpr55", "GPR55 cannabinoid target research summary", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics gpr55 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with GPR55 activity, binding, signaling, or physiology?" ], "search_text": "GPR55 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with GPR55 activity, binding, signaling, or physiology? Draft Summary This draft topic page is generated from 18 source-backed evidence row s and 18 source s . Main entities represented: Cannabinoids, Endocannabinoids, CBD, THC. Evidence Snapshot - Evidence rows: 18 - Sources: 18 - Evidence classes: insufficient 14 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 14 Key Draft Sections - Uncertainty and gaps: 14 evidence row s . - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 926 Cannabinoids modulates GPR55; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PMID 28826536; DOI 10.1016/bs.apha.2017.04.004 927 THC modulates GPR55; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . Cannabinoids in the landscape of cancer. PMID 34259916; DOI 10.1007/s00432-021-03710-7 928 Cannabinoids modulates GPR55; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . The enigmatic pharmacology of GPR55. PMID 19233486; DOI 10.1016/j.tips.2008.12.004 929 Endocannabinoids modulates GPR55; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity. PMID 35862111; DOI 10.1002/jcp.30837 930 Endocannabinoids modulates GPR55; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . Is GPR55 an anandamide receptor? PMID 19647110; DOI 10.1016/s0083-6729 09 81005-4 931 Endocannabinoids modulates GPR55; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. PMID 18757503; DOI 10.1096/fj.08-108670 932 Cannabinoids modulates GPR55; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . GPR55 - a putative \"type 3\" cannabinoid receptor in inflammation. PMID 26669245; DOI 10.1515/jbcpp-2015-0080 933 Cannabinoids modulates GPR55; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . Cannabinoid receptor ligand bias: implications in the central nervous system. PMID 27835801; DOI 10.1016/j.coph.2016.10.005 934 Cannabinoids modulates GPR55; evidence class: insufficient study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? PMID 20370712; DOI 10.2174/156802610791164229 935 CBD modulates GPR55; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . A narrative review of molecular mechanism and therapeutic effect of cannabidiol CBD . PMID 35083862; DOI 10.1111/bcpt.13710 936 CBD modulates GPR55; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology . The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. PMID 17704827; DOI...", "sources": 18, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with GPR55 activity, binding, signaling, or physiology?", "title": "GPR55 cannabinoid target", "type": "topic", "url": "/topics/gpr55-cannabinoid-target-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "LEA", "lea", "LEA research summary", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics lea research summary", "What evidence defines LEA biology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines LEA biology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 14, "evidence_rows": 14, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "LEA", "lea", "LEA research summary", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics lea research summary", "What evidence defines LEA biology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines LEA biology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "LEA research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines LEA biology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 14 source-backed evidence row s and 14 source s . Main entities represented: LEA. Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 4 , mechanistic or pharmacological 5 , preclinical 3 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 5 , preclinical evidence 3 , uncertainty 4 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Preclinical evidence: 3 evidence row s . - Mechanistic evidence: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1172 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Classical endocannabinoid-like compounds and their regulation by nutrients. PMID 24677570; DOI 10.1002/biof.1158 1173 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males. PMID 29778785; DOI 10.1016/j.prostaglandins.2018.05.009 1174 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. PMID 24681513; DOI 10.1016/j.phrs.2014.03.006 1175 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder. PMID 37298321; DOI 10.3390/ijms24119371 1176 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide. PMID 36733808; DOI 10.3389/fendo.2022.1056116 1177 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. PMID 35203453; DOI 10.3390/biomedicines10020243 1178 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. PMID 18316044; DOI 10.1016/j.bbalip.2008.01.006 1179 LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms . Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine. PMID 21573043; DOI 10.2147/opth.s18309 1180 LEA studied for LEA biology, metabolism, ph...", "sources": 14, "status": "source-backed draft", "subtitle": "What evidence defines LEA biology, metabolism, physiology, or safety-relevant mechanisms?", "title": "LEA", "type": "topic", "url": "/topics/lea-evidence-map/" }, { "aliases": [ "cannabinoids", "Deep Review", "map", "Minor", "minor", "Minor cannabinoids safety surveillance map", "safety", "source backed draft", "source-backed draft", "surveillance", "topic", "topics", "topics minor cannabinoids safety surveillance map", "Which safety, adverse event, or impairment evidence exists for less studied cannabinoids and commercial formulations?", "Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations?" ], "claims": 36, "evidence_rows": 36, "search_boost": 5, "search_terms": [ "cannabinoids", "Deep Review", "map", "Minor", "minor", "Minor cannabinoids safety surveillance map", "safety", "source backed draft", "source-backed draft", "surveillance", "topic", "topics", "topics minor cannabinoids safety surveillance map", "Which safety, adverse event, or impairment evidence exists for less studied cannabinoids and commercial formulations?", "Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations?" ], "search_text": "Minor cannabinoids safety surveillance map Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations? Draft Summary This draft topic page is generated from 36 source-backed evidence row s and 36 source s . Main entities represented: CBG, Delta-8 THC, Cannabinoids, CBD. Evidence Snapshot - Evidence rows: 36 - Sources: 36 - Evidence classes: insufficient 21 , mechanistic or pharmacological 4 , preclinical 3 , preliminary human 8 - Draft sections: safety 36 Key Draft Sections - Safety and tolerability: 36 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 93 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Pharmacologic treatment of fibromyalgia: an update. PMID 41142233; DOI 10.3389/fphar.2025.1651181 94 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . The safety of studies with intravenous \u0394\u2079-tetrahydrocannabinol in humans, with case histories. PMID 21845389; DOI 10.1007/s00213-011-2417-y 95 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Cannabis-based medicines for chronic neuropathic pain in adults. PMID 41548880; DOI 10.1002/14651858.cd012182.pub3 96 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. PMID 40708053; DOI 10.1186/s40337-025-01328-5 97 Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Adverse events associated with medical cannabis reported within a centralized call center. PMID 42158949; DOI 10.3389/fphar.2026.1792520 149 CBN studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PMID 41698831; DOI 10.1111/jsr.70284 150 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Self-reported adverse events associated with \u22068-Tetrahydrocannabinol Delta-8-THC Use. PMID 37217977; DOI 10.1186/s42238-023-00191-y 151 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns . Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. PMID 38868665; DOI 10.3389/fphar.2024.1282831 152 Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, ad...", "sources": 36, "status": "source-backed draft", "subtitle": "Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations?", "title": "Minor cannabinoids safety surveillance map", "type": "topic", "url": "/topics/minor-cannabinoids-safety-surveillance-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "NADA", "nada", "NADA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics nada research summary", "What evidence defines NADA biology, receptor or TRP channel pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 13, "evidence_rows": 13, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "NADA", "nada", "NADA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics nada research summary", "What evidence defines NADA biology, receptor or TRP channel pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "NADA research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 13 source-backed evidence row s and 13 source s . Main entities represented: NADA. Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 1 , mechanistic or pharmacological 12 - Draft sections: mechanistic evidence 12 , uncertainty 1 Key Draft Sections - Uncertainty and gaps: 1 evidence row s . - Mechanistic evidence: 12 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1131 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. PMID 29082315; DOI 10.1089/can.2017.0015 1132 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . TRPV1 and CB 1 receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. PMID 15245490; DOI 10.1111/j.1460-9568.2004.03481.x 1133 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . Arvanil, anandamide and N-arachidonoyl-dopamine NADA inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. PMID 17459108; DOI 10.1111/j.1460-9568.2007.05521.x 1134 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . The endocannabinoid/endovanilloid N-arachidonoyl dopamine NADA and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. PMID 24644287; DOI 10.1074/jbc.m113.536953 1135 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endovanilloids are potential activators of the trigeminovascular nocisensor complex. PMID 27189587; DOI 10.1186/s10194-016-0644-7 1136 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms . Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. PMID 20354008; DOI 10.1093/bja/aeq067 1137 NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: NADA biology, re...", "sources": 13, "status": "source-backed draft", "subtitle": "What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms?", "title": "NADA", "type": "topic", "url": "/topics/nada-evidence-map/" }, { "aliases": [ "Deep Review", "ether", "evidence", "map", "Noladin", "noladin", "Noladin ether research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics noladin ether research summary", "What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "Deep Review", "ether", "evidence", "map", "Noladin", "noladin", "Noladin ether research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics noladin ether research summary", "What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "Noladin ether research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: Noladin ether. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 2 , mechanistic or pharmacological 9 , preclinical 1 - Draft sections: mechanistic evidence 9 , preclinical evidence 1 , uncertainty 2 Key Draft Sections - Uncertainty and gaps: 2 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1144 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and Their Pharmacological Actions. PMID 26408156; DOI 10.1007/978-3-319-20825-1 1 1145 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. PMID 11259648; DOI 10.1073/pnas.061029898 1146 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The cannabinoid receptors. PMID 12432948; DOI 10.1016/s0090-6980 02 00060-6 1147 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. PMID 17698254; DOI 10.1016/j.neuint.2007.06.033 1148 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Noladin ether acts on trabecular meshwork cannabinoid CB1 receptors to enhance aqueous humor outflow facility. PMID 16639008; DOI 10.1167/iovs.05-0729 1149 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Ether-linked analogue of 2-arachidonoylglycerol noladin ether was not detected in the brains of various mammalian species. PMID 12787057; DOI 10.1046/j.1471-4159.2003.01804.x 1150 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. PMID 15901805; DOI 10.1124/jpet.105.085282 1151 Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; ev...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?", "title": "Noladin ether", "type": "topic", "url": "/topics/noladin-ether-evidence-map/" }, { "aliases": [ "cannabinoid", "canonical", "Deep Review", "evidence", "map", "non", "Non canonical", "Non canonical cannabinoid target research summary", "Non-canonical", "Non-canonical cannabinoid target research summary", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics non canonical cannabinoid target research summary", "What evidence connects cannabinoids with PPARs, 5 HT1A, glycine receptors, adenosine signaling, opioid cross talk, or dopamine/glutamate/GABA systems?", "What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine glutamate GABA systems?", "What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine/glutamate/GABA systems?" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "cannabinoid", "canonical", "Deep Review", "evidence", "map", "non", "Non canonical", "Non canonical cannabinoid target research summary", "Non-canonical", "Non-canonical cannabinoid target research summary", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics non canonical cannabinoid target research summary", "What evidence connects cannabinoids with PPARs, 5 HT1A, glycine receptors, adenosine signaling, opioid cross talk, or dopamine/glutamate/GABA systems?", "What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine glutamate GABA systems?", "What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine/glutamate/GABA systems?" ], "search_text": "Non-canonical cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine/glutamate/GABA systems? Draft Summary This draft topic page is generated from 15 source-backed evidence row s and 15 source s . Main entities represented: CBD, Cannabinoids, Endocannabinoids. Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 8 , mechanistic or pharmacological 6 , preclinical 1 - Draft sections: mechanistic evidence 6 , preclinical evidence 1 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 253 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments. PMID 33522084; DOI 10.1111/ejn.15134 254 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. PMID 23924692; DOI 10.1016/j.neuropharm.2013.07.024 255 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPAR\u03b3 receptors. PMID 39657242; DOI 10.1093/ijnp/pyae064 256 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol: Pharmaceutical formulations and biomedical applications. PMID 42212209; DOI 10.22038/ijbms.2026.89134.19592 257 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets. PMID 40432283; DOI 10.1111/bph.70070 258 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms . Cys-loop receptors on cannabinoids: All high? PMID 36439263; DOI 10.3389/fphys.2022.1044575 259 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Allosteric modulation of glycine receptors. PMID 21557733; DOI 10.1111/j.1476-5381.2011.01471.x 260 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms . Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. PMID 18755158; DOI 10.1016/j.bcp.2008.07.037 261 CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . Cannabinoids suppress inflammatory and neuropathic pain by targeting \u03b13 glycine receptors. PMID 22585736; DOI 10.1084/jem.20120242 262 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or mo...", "sources": 15, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine/glutamate/GABA systems?", "title": "Non-canonical cannabinoid target", "type": "topic", "url": "/topics/non-canonical-cannabinoid-target-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "OEA", "oea", "OEA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics oea research summary", "What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety relevant mechanisms?", "What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety-relevant mechanisms?" ], "claims": 14, "evidence_rows": 14, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "OEA", "oea", "OEA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics oea research summary", "What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety relevant mechanisms?", "What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety-relevant mechanisms?" ], "search_text": "OEA research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 14 source-backed evidence row s and 14 source s . Main entities represented: OEA. Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 10 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 10 Key Draft Sections - Uncertainty and gaps: 10 evidence row s . - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1092 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and nutrition. PMID 18426507; DOI 10.1111/j.1365-2826.2008.01687.x 1093 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . N-acylethanolamines, anandamide and food intake. PMID 19413995; DOI 10.1016/j.bcp.2009.04.024 1094 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PMID 19285259; DOI 10.1016/j.beem.2008.10.003 1095 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. PMID 30537148; DOI 10.1002/jcp.27913 1096 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . A fatty gut feeling. PMID 23567058; DOI 10.1016/j.tem.2013.03.001 1097 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Analgesic properties of oleoylethanolamide OEA in visceral and inflammatory pain. PMID 17449181; DOI 10.1016/j.pain.2007.03.008 1098 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . Regulation of food intake by oleoylethanolamide. PMID 15770421; DOI 10.1007/s00018-004-4494-0 1099 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms . The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? PMID 40274041; DOI 10.1016/j.physbeh.2025.114929 1100 OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcom...", "sources": 14, "status": "source-backed draft", "subtitle": "What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety-relevant mechanisms?", "title": "OEA", "type": "topic", "url": "/topics/oea-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "Oleamide", "oleamide", "Oleamide research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics oleamide research summary", "What evidence defines oleamide biology, sleep related physiology, receptor pharmacology, metabolism, or safety relevant mechanisms?", "What evidence defines oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms?" ], "claims": 13, "evidence_rows": 13, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "Oleamide", "oleamide", "Oleamide research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics oleamide research summary", "What evidence defines oleamide biology, sleep related physiology, receptor pharmacology, metabolism, or safety relevant mechanisms?", "What evidence defines oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms?" ], "search_text": "Oleamide research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 13 source-backed evidence row s and 13 source s . Main entities represented: Oleamide. Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 9 , mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 , uncertainty 9 Key Draft Sections - Uncertainty and gaps: 9 evidence row s . - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1119 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Endocannabinoid hydrolases. PMID 12432941; DOI 10.1016/s0090-6980 02 00053-9 1120 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. PMID 11945157; DOI 10.2174/1381612023395655 1121 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Oleamide: a member of the endocannabinoid family? PMID 14691053; DOI 10.1038/sj.bjp.0705608 1122 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? PMID 17445087; DOI 10.1111/j.1527-3466.2007.00004.x 1123 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? PMID 10469890 1124 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . The role of the CB1 receptor in the regulation of sleep. PMID 18514375; DOI 10.1016/j.pnpbp.2008.04.008 1125 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms . The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. PMID 9344854; DOI 10.1006/bbrc.1997.7431 1126 Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabol...", "sources": 13, "status": "source-backed draft", "subtitle": "What evidence defines oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms?", "title": "Oleamide", "type": "topic", "url": "/topics/oleamide-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "Orphan", "orphan", "Orphan receptor cannabinoid targets research summary", "receptor", "source backed draft", "source-backed draft", "targets", "topic", "topics", "topics orphan receptor cannabinoid targets research summary", "What evidence connects cannabinoids or endocannabinoids with GPR55, GPR18, and GPR119?" ], "claims": 5, "evidence_rows": 5, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "Orphan", "orphan", "Orphan receptor cannabinoid targets research summary", "receptor", "source backed draft", "source-backed draft", "targets", "topic", "topics", "topics orphan receptor cannabinoid targets research summary", "What evidence connects cannabinoids or endocannabinoids with GPR55, GPR18, and GPR119?" ], "search_text": "Orphan receptor cannabinoid targets research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with GPR55, GPR18, and GPR119? Draft Summary This draft topic page is generated from 5 source-backed evidence row s and 5 source s . Main entities represented: Endocannabinoids, Cannabinoids, THC. Evidence Snapshot - Evidence rows: 5 - Sources: 5 - Evidence classes: insufficient 4 , preclinical 1 - Draft sections: preclinical evidence 1 , uncertainty 4 Key Draft Sections - Uncertainty and gaps: 4 evidence row s . - Preclinical evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 209 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. PMID 31146657; DOI 10.2174/1570159x17666190118143014 210 Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. PMID 30670965; DOI 10.3389/fphar.2018.01496 211 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PMID 28826536; DOI 10.1016/bs.apha.2017.04.004 212 Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms . New Insights in Cannabinoid Receptor Structure and Signaling. PMID 30767756; DOI 10.2174/1874467212666190215112036 213 THC modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms . \u03949-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. PMID 30550613; DOI 10.1167/iovs.18-24838 References - Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. PMID 31146657; DOI 10.2174/1570159x17666190118143014 - Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. PMID 30670965; DOI 10.3389/fphar.2018.01496 - Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. PMID 28826536; DOI 10.1016/bs.apha.2017.04.004 - New Insights in Cannabinoid Receptor Structure and Signaling. PMID 30767756; DOI 10.2174/1874467212666190215112036 - \u03949-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. PMID 30550613; DOI 10.1167/iovs.18-24838", "sources": 5, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with GPR55, GPR18, and GPR119?", "title": "Orphan receptor cannabinoid targets", "type": "topic", "url": "/topics/orphan-receptor-cannabinoid-targets-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "PEA", "pea", "PEA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics pea research summary", "What evidence defines PEA biology, receptor pharmacology, inflammation, pain related mechanisms, metabolism, or safety relevant mechanisms?", "What evidence defines PEA biology, receptor pharmacology, inflammation, pain-related mechanisms, metabolism, or safety-relevant mechanisms?" ], "claims": 13, "evidence_rows": 13, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "PEA", "pea", "PEA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics pea research summary", "What evidence defines PEA biology, receptor pharmacology, inflammation, pain related mechanisms, metabolism, or safety relevant mechanisms?", "What evidence defines PEA biology, receptor pharmacology, inflammation, pain-related mechanisms, metabolism, or safety-relevant mechanisms?" ], "search_text": "PEA research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines PEA biology, receptor pharmacology, inflammation, pain-related mechanisms, metabolism, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 13 source-backed evidence row s and 13 source s . Main entities represented: PEA. Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 7 , mechanistic or pharmacological 6 - Draft sections: mechanistic evidence 6 , uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1106 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PMID 35176443; DOI 10.1016/j.bbi.2022.02.008 1107 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Mechanisms and clinical applications of palmitoylethanolamide PEA in the treatment of neuropathic pain. PMID 39714723; DOI 10.1007/s10787-024-01623-8 1108 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . The search for the palmitoylethanolamide receptor. PMID 15963531; DOI 10.1016/j.lfs.2005.05.012 1109 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. PMID 40563990; DOI 10.3390/biomedicines13061271 1110 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Probiotics and palmitoylethanolamide PEA for osteoarthritic pain: individual effects in a multiple baseline design study. PMID 41709243; DOI 10.1186/s12906-025-05187-0 1111 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. PMID 28215162; DOI 10.2174/0929867324666170216113756 1112 PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms . Cannabimimetic fatty acid derivatives in cancer and inflammation. PMID 10785541; DOI 10.1016/s0090-6980 00 00054-x 1113...", "sources": 13, "status": "source-backed draft", "subtitle": "What evidence defines PEA biology, receptor pharmacology, inflammation, pain-related mechanisms, metabolism, or safety-relevant mechanisms?", "title": "PEA", "type": "topic", "url": "/topics/pea-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "phytocannabinoids", "Rare", "rare", "Rare phytocannabinoids research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics rare phytocannabinoids research summary", "What evidence exists for rare phytocannabinoids such as CBL, CBLA, CBT, CBCV, CBGV, and related acidic precursors?" ], "claims": 7, "evidence_rows": 7, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "phytocannabinoids", "Rare", "rare", "Rare phytocannabinoids research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics rare phytocannabinoids research summary", "What evidence exists for rare phytocannabinoids such as CBL, CBLA, CBT, CBCV, CBGV, and related acidic precursors?" ], "search_text": "Rare phytocannabinoids research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence exists for rare phytocannabinoids such as CBL, CBLA, CBT, CBCV, CBGV, and related acidic precursors? Draft Summary This draft topic page is generated from 7 source-backed evidence row s and 7 source s . Main entities represented: THC, CBD, HHC, CBG. Evidence Snapshot - Evidence rows: 7 - Sources: 7 - Evidence classes: insufficient 7 - Draft sections: uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 246 CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 247 HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 248 CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids research topics . Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 249 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics . Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PMID 35648593; DOI 10.1021/acs.jnatprod.2c00155 250 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. PMID 36770831; DOI 10.3390/molecules28031164 251 CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient outcome measure: Rare phytocannabinoids research topics . Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. PMID 34078070; DOI 10.1021/acs.joc.1c00451 252 THC studied for Rare phytocannabinoids research topics; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics . A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5 References - Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. PMID 34617621; DOI 10.1002/mrc.5224 - Isolation and Characterization of Impurities in Commercially Marketed \u03948-THC Products. PMID 36827690; DOI 10.1021/acs.jnatprod.2c01008 - Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PMID 38885660; DOI 10.1055/a-2320-8822 - Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. PMID 35648593; DOI 10.1021/acs.jnatprod.2c00155 - Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. PMID 36770831; DOI 10.3390/molecules28031164 - Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. PMID 34078070; DOI 10.1021/acs.joc.1c00451 - A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PMID 38940871; DOI 10.1007/s00216-024-05396-5", "sources": 7, "status": "source-backed draft", "subtitle": "What evidence exists for rare phytocannabinoids such as CBL, CBLA, CBT, CBCV, CBGV, and related acidic precursors?", "title": "Rare phytocannabinoids", "type": "topic", "url": "/topics/rare-phytocannabinoids-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "SEA", "sea", "SEA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics sea research summary", "What evidence defines SEA biology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines SEA biology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 16, "evidence_rows": 16, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "SEA", "sea", "SEA research summary", "source backed draft", "source-backed draft", "topic", "topics", "topics sea research summary", "What evidence defines SEA biology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines SEA biology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "SEA research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines SEA biology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 16 source-backed evidence row s and 16 source s . Main entities represented: SEA. Evidence Snapshot - Evidence rows: 16 - Sources: 16 - Evidence classes: insufficient 4 , mechanistic or pharmacological 5 , preclinical 6 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 5 , preclinical evidence 6 , uncertainty 4 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Preclinical evidence: 6 evidence row s . - Mechanistic evidence: 5 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1186 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PMID 20353771; DOI 10.1016/j.expneurol.2010.03.022 1187 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. PMID 31881191; DOI 10.1016/j.bcp.2019.113783 1188 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Roles of fatty acid ethanolamides FAE in traumatic and ischemic brain injury. PMID 24874648; DOI 10.1016/j.phrs.2014.05.009 1189 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. PMID 12010121; DOI 10.1042/bj20020438 1190 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PMID 22125609; DOI 10.1371/journal.pone.0027257 1191 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. PMID 23707281; DOI 10.1016/j.pain.2013.05.002 1192 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . Serum levels of endocannabinoids and related lipids in painful vs painless diabetic neuropathy: results from the Pain in Neuropathy Study. PMID 37578507; DOI 10.1097/j.pain.0000000000003015 1193 SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms . High levels of endogenous lipid mediators N-acylethanolamines in women with chronic widespread pain during acute tissue trauma. PMID 27531672; DOI 10.1177/1744806916662886 1194 SEA studied for SEA biology, metabolism, physiology, or safet...", "sources": 16, "status": "source-backed draft", "subtitle": "What evidence defines SEA biology, metabolism, physiology, or safety-relevant mechanisms?", "title": "SEA", "type": "topic", "url": "/topics/sea-evidence-map/" }, { "aliases": [ "and", "appetite", "Deep Review", "metabolic", "outcomes", "review", "source backed draft", "source-backed draft", "THC", "thc", "THC and appetite metabolic outcomes review", "THC and appetite/metabolic outcomes review", "topic", "topics", "topics thc and appetite metabolic outcomes review", "What evidence connects THC or dronabinol with appetite, anorexia, weight, or metabolic outcomes?" ], "claims": 10, "evidence_rows": 10, "search_boost": 4, "search_terms": [ "and", "appetite", "Deep Review", "metabolic", "outcomes", "review", "source backed draft", "source-backed draft", "THC", "thc", "THC and appetite metabolic outcomes review", "THC and appetite/metabolic outcomes review", "topic", "topics", "topics thc and appetite metabolic outcomes review", "What evidence connects THC or dronabinol with appetite, anorexia, weight, or metabolic outcomes?" ], "search_text": "THC and appetite/metabolic outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC or dronabinol with appetite, anorexia, weight, or metabolic outcomes? Draft Summary This draft topic page is generated from 10 source-backed evidence row s and 10 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 8 , preliminary human 2 - Draft sections: human evidence 2 , uncertainty 8 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 488 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes . Dronabinol delta9-tetrahydrocannabinol in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia . PMID 23570087 489 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes . Cancer cachexia and cannabinoids. PMID 10575285; DOI 10.1159/000057152 490 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes . Orexigenic and anabolic agents. PMID 12608509; DOI 10.1016/s0749-0690 02 00036-8 491 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes . Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. PMID 29670357; DOI 10.2147/tcrm.s126849 492 THC studied for Appetite and metabolic outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite or metabolic outcomes . Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. PMID 16849753; DOI 10.1200/jco.2005.05.1847 493 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: appetite or metabolic outcomes . Systematic review and meta-analysis of cannabinoids in palliative medicine. PMID 29400010; DOI 10.1002/jcsm.12273 494 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes . Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. PMID 26929669; DOI 10.2147/hiv.s81420 495 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: appetite or metabolic outcomes . Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. PMID 15050664; DOI 10.1016/j.jpainsymman.2003.09.007 496 THC studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes . The cancer cachexia syndrome. PMID 9208884 497 THC studied for Appetite and metabolic outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: appetite or metabolic outcomes . The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. PMID 31595793; DOI 10.1177/1534735419881498 References - Dronabinol delta9-tetrahydrocannabin...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence connects THC or dronabinol with appetite, anorexia, weight, or metabolic outcomes?", "title": "THC and appetite/metabolic outcomes review", "type": "topic", "url": "/topics/thc-and-appetite-metabolic-outcomes-review/" }, { "aliases": [ "and", "cardiovascular", "cardiovascular risk", "cardiovascular-risk", "Deep Review", "heightened", "heightened review", "heightened-review", "queue", "review", "risk", "source backed draft", "source-backed draft", "THC", "thc", "THC and cardiovascular risk heightened review queue", "THC and cardiovascular-risk heightened-review queue", "topic", "topics", "topics thc and cardiovascular risk heightened review queue", "What evidence connects THC exposure with cardiovascular outcomes or cardiovascular risk markers?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "cardiovascular", "cardiovascular risk", "cardiovascular-risk", "Deep Review", "heightened", "heightened review", "heightened-review", "queue", "review", "risk", "source backed draft", "source-backed draft", "THC", "thc", "THC and cardiovascular risk heightened review queue", "THC and cardiovascular-risk heightened-review queue", "topic", "topics", "topics thc and cardiovascular risk heightened review queue", "What evidence connects THC exposure with cardiovascular outcomes or cardiovascular risk markers?" ], "search_text": "THC and cardiovascular-risk heightened-review queue Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC exposure with cardiovascular outcomes or cardiovascular risk markers? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 7 , preliminary human 2 - Draft sections: human evidence 2 , uncertainty 7 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 443 THC studied for Cardiovascular risk; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cardiovascular risk outcomes . Cardiovascular consequences of marijuana use. PMID 12412838; DOI 10.1002/j.1552-4604.2002.tb06005.x 444 THC studied for Cardiovascular risk; evidence class: insufficient outcome measure: cardiovascular risk outcomes . Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PMID 39575727; DOI 10.1161/jaha.124.037731 445 THC studied for Cardiovascular risk; evidence class: insufficient study design: Narrative or expert review; outcome measure: cardiovascular risk outcomes . Cardiovascular system effects of marijuana. PMID 12412837; DOI 10.1002/j.1552-4604.2002.tb06004.x 446 THC studied for Cardiovascular risk; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cardiovascular risk outcomes . Cannabinoids and the heart-a psychiatrist's perspective. PMID 39331072; DOI 10.1007/s00059-024-05273-y 447 THC studied for Cardiovascular risk; evidence class: insufficient outcome measure: cardiovascular risk outcomes . The acute cardiovascular response to dynamic exercise and recovery following cannabis use. PMID 41115058; DOI 10.1152/ajpheart.00608.2025 448 THC studied for Cardiovascular risk; evidence class: insufficient study design: Narrative or expert review; outcome measure: cardiovascular risk outcomes . At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. PMID 22503477; DOI 10.1016/j.tips.2012.03.002 449 THC studied for Cardiovascular risk; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: cardiovascular risk outcomes . A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of \u0394\u2078-Tetrahydrocannabinol. PMID 29385080; DOI 10.3390/ph11010013 450 THC studied for Cardiovascular risk; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: cardiovascular risk outcomes . The effects of combinations of intranasal cocaine, smoked marijuana, and task performance on heart rate and blood pressure. PMID 2162543; DOI 10.1016/0091-3057 90 90409-b 451 THC studied for Cardiovascular risk; evidence class: preliminary human outcome measure: cardiovascular risk outcomes . Cumulative Effects of Cannabis Oils on Body Temperature, Electrocardiography, Heart Rate Variability, Blood Pressure, and Respiratory Function in Telemetered Dogs. PMID 42131827; DOI 10.4103/ijvsm.ijvsm 3 25 References - Cardiovascular consequences of marijuana use. PMID 12412838; DOI 10.1002/j.1552-4604.2002.tb06005.x - Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PMID 39575727; DOI 10.1161/jaha.124.037731 - Cardiovascular system effects of marijuana. PMID 12412837; DOI 10.1002/j.1552-4604.2002.tb06004.x - Cannabinoids and the heart-a psychiatrist's perspective. PMID 39331072; DOI 10.1007/s00059-024-05273-y - The acute cardiovascular response to dynamic exercise and recovery following cannabis use. PMID 41115058; DOI 10.1152/ajpheart.00608.2025 - At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. PMID 22503477; DOI 10.1016/j.tips.2012.03.002 - A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of \u0394\u2078-Tetrahydrocannabinol. PMID 29385080; DOI 10.3390/ph11010013 - The effects of combinations of intranasal cocaine, smoked marijuana, and task performance on heart rate and blood pressure....", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects THC exposure with cardiovascular outcomes or cardiovascular risk markers?", "title": "THC and cardiovascular-risk heightened-review queue", "type": "topic", "url": "/topics/thc-and-cardiovascular-risk-heightened-review-queue/" }, { "aliases": [ "and", "cognition", "Deep Review", "memory", "outcomes", "review", "source backed draft", "source-backed draft", "THC", "thc", "THC and cognition memory outcomes review", "THC and cognition/memory outcomes review", "topic", "topics", "topics thc and cognition memory outcomes review", "What evidence connects THC exposure with cognition, memory, attention, learning, or acute impairment outcomes?" ], "claims": 10, "evidence_rows": 10, "search_boost": 4, "search_terms": [ "and", "cognition", "Deep Review", "memory", "outcomes", "review", "source backed draft", "source-backed draft", "THC", "thc", "THC and cognition memory outcomes review", "THC and cognition/memory outcomes review", "topic", "topics", "topics thc and cognition memory outcomes review", "What evidence connects THC exposure with cognition, memory, attention, learning, or acute impairment outcomes?" ], "search_text": "THC and cognition/memory outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC exposure with cognition, memory, attention, learning, or acute impairment outcomes? Draft Summary This draft topic page is generated from 10 source-backed evidence row s and 10 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 6 , mechanistic or pharmacological 1 , preliminary human 3 - Draft sections: human evidence 3 , mechanistic evidence 1 , uncertainty 6 Key Draft Sections - Human evidence: 3 evidence row s . - Uncertainty and gaps: 6 evidence row s . - Mechanistic evidence: 1 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 461 THC studied for Cognition and memory; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes . Cannabinoids: Medical implications. PMID 26912385; DOI 10.3109/07853890.2016.1145794 462 THC studied for Cognition and memory; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: cognition or memory outcomes . \u03949-Tetrahydrocannabinol THC impairs visual working memory performance: a randomized crossover trial. PMID 32386395; DOI 10.1038/s41386-020-0690-3 463 THC studied for Cognition and memory; evidence class: insufficient study design: Human clinical study; outcome measure: cognition or memory outcomes . Developing a phone-based measure of impairment after acute oral \u22069-tetrahydrocannabinol. PMID 31407943; DOI 10.1177/0269881119862533 464 THC studied for Cognition and memory; evidence class: insufficient outcome measure: cognition or memory outcomes . Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study. PMID 33526107; DOI 10.1186/s42238-020-00034-0 465 THC studied for Cognition and memory; evidence class: mechanistic or pharmacological outcome measure: cognition or memory outcomes . Acute administration of THC impairs spatial but not associative memory function in zebrafish. PMID 24639045; DOI 10.1007/s00213-014-3522-5 466 THC studied for Cognition and memory; evidence class: insufficient study design: Systematic review; outcome measure: cognition or memory outcomes . Effects of different methods of cannabis use on cognition and blood THC: A systematic review. PMID 40368229; DOI 10.1016/j.pnpbp.2025.111399 467 THC studied for Cognition and memory; evidence class: insufficient study design: Narrative or expert review; outcome measure: cognition or memory outcomes . Cannabis: Similarities and differences with tobacco . PMID 32381378; DOI 10.1016/j.rmr.2020.04.002 468 THC studied for Cognition and memory; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: cognition or memory outcomes . The Individual and Interactive Effects of Alpha-Pinene and Delta-9-Tetrahydrocannabinol in Healthy Adults. PMID 40734690; DOI 10.1159/000547014 469 THC studied for Cognition and memory; evidence class: preliminary human study design: Human clinical study; outcome measure: cognition or memory outcomes . Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol THC in infrequent cannabis users. PMID 12373420; DOI 10.1007/s00213-002-1169-0 470 THC studied for Cognition and memory; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes . The acute effects of cannabis on human executive function. PMID 30199388; DOI 10.1097/fbp.0000000000000426 References - Cannabinoids: Medical implications. PMID 26912385; DOI 10.3109/07853890.2016.1145794 - \u03949-Tetrahydrocannabinol THC impairs visual working memory performance: a randomized crossover trial. PMID 32386395; DOI 10.1038/s41386-020-0690-3 - Developing a phone-based measure of impairment after acute oral \u22069-tetrahydrocannabinol. PMID 31407943; DOI 10.1177/0269881119862533 - Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study. PMID 33526107; DOI 10.1186/s42238-020-00034-0 - Acute administration of THC impairs spatial but not associative memory function in zebrafish. PMI...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence connects THC exposure with cognition, memory, attention, learning, or acute impairment outcomes?", "title": "THC and cognition/memory outcomes review", "type": "topic", "url": "/topics/thc-and-cognition-memory-outcomes-review/" }, { "aliases": [ "and", "Deep Review", "dependence", "review", "source backed draft", "source-backed draft", "THC", "thc", "THC and dependence withdrawal review", "THC and dependence/withdrawal review", "topic", "topics", "topics thc and dependence withdrawal review", "What evidence connects THC exposure with dependence, withdrawal, craving, or cannabis use disorder outcomes?", "withdrawal" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "Deep Review", "dependence", "review", "source backed draft", "source-backed draft", "THC", "thc", "THC and dependence withdrawal review", "THC and dependence/withdrawal review", "topic", "topics", "topics thc and dependence withdrawal review", "What evidence connects THC exposure with dependence, withdrawal, craving, or cannabis use disorder outcomes?", "withdrawal" ], "search_text": "THC and dependence/withdrawal review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC exposure with dependence, withdrawal, craving, or cannabis use disorder outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 9 - Draft sections: uncertainty 9 Key Draft Sections - Uncertainty and gaps: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 452 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: dependence or withdrawal outcomes . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 453 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: dependence or withdrawal outcomes . Clinical management of cannabis withdrawal. PMID 34791767; DOI 10.1111/add.15743 454 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: dependence or withdrawal outcomes . Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PMID 35510826; DOI 10.1002/14651858.cd013444.pub2 455 THC studied for Dependence and withdrawal; evidence class: insufficient study design: Systematic review; outcome measure: dependence or withdrawal outcomes . The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 456 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: dependence or withdrawal outcomes . Pharmacotherapies for cannabis dependence. PMID 30687936; DOI 10.1002/14651858.cd008940.pub3 457 THC studied for Dependence and withdrawal; evidence class: insufficient study design: Narrative or expert review; outcome measure: dependence or withdrawal outcomes . Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. PMID 19367504; DOI 10.1080/09540260902782752 458 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: dependence or withdrawal outcomes . Cannabis use and cannabis use disorders . PMID 39134752; DOI 10.1007/s00115-024-01722-5 459 THC studied for Dependence and withdrawal; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: dependence or withdrawal outcomes . Pharmacotherapies for cannabis dependence. PMID 25515775; DOI 10.1002/14651858.cd008940.pub2 460 THC studied for Dependence and withdrawal; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: dependence or withdrawal outcomes . Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. PMID 36434879; DOI 10.1016/j.drugalcdep.2022.109702 References - Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 - Clinical management of cannabis withdrawal. PMID 34791767; DOI 10.1111/add.15743 - Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PMID 35510826; DOI 10.1002/14651858.cd013444.pub2 - The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 - Pharmacotherapies for cannabis dependence. PMID 30687936; DOI 10.1002/14651858.cd008940.pub3 - Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. PMID 19367504; DOI 10.1080/09540260902782752 - Cannabis use and cannabis use disorders . PMID 39134752; DOI 10.1007/s00115-024-01722-5 - Pharmacotherapies for cannabis dependence. PMID 25515775; DOI 10.1002/14651858.cd008940.pub2 - A...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects THC exposure with dependence, withdrawal, craving, or cannabis use disorder outcomes?", "title": "THC and dependence/withdrawal review", "type": "topic", "url": "/topics/thc-and-dependence-withdrawal-review/" }, { "aliases": [ "and", "Deep Review", "driving", "driving impairment", "driving-impairment", "impairment", "review", "safety", "source backed draft", "source-backed draft", "THC", "thc", "THC and driving impairment safety review", "THC and driving-impairment safety review", "topic", "topics", "topics thc and driving impairment safety review", "What evidence connects THC exposure with driving impairment or other safety relevant performance outcomes?", "What evidence connects THC exposure with driving impairment or other safety-relevant performance outcomes?" ], "claims": 7, "evidence_rows": 7, "search_boost": 4, "search_terms": [ "and", "Deep Review", "driving", "driving impairment", "driving-impairment", "impairment", "review", "safety", "source backed draft", "source-backed draft", "THC", "thc", "THC and driving impairment safety review", "THC and driving-impairment safety review", "topic", "topics", "topics thc and driving impairment safety review", "What evidence connects THC exposure with driving impairment or other safety relevant performance outcomes?", "What evidence connects THC exposure with driving impairment or other safety-relevant performance outcomes?" ], "search_text": "THC and driving-impairment safety review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC exposure with driving impairment or other safety-relevant performance outcomes? Draft Summary This draft topic page is generated from 7 source-backed evidence row s and 7 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 7 - Sources: 7 - Evidence classes: insufficient 7 - Draft sections: uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 25 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Meta-analysis or systematic evidence synthesis; outcome measure: driving impairment or performance outcomes . Determining the magnitude and duration of acute \u03949-tetrahydrocannabinol \u03949-THC -induced driving and cognitive impairment: A systematic and meta-analytic review. PMID 33497784; DOI 10.1016/j.neubiorev.2021.01.003 26 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: driving impairment or performance outcomes . Cannabis and driving ability. PMID 33839427; DOI 10.1016/j.copsyc.2021.03.003 27 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Systematic review; outcome measure: driving impairment or performance outcomes . Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. PMID 40172477; DOI 10.1093/ijnp/pyaf021 53 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: driving impairment or performance outcomes . Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 54 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient study design: Systematic review; outcome measure: driving impairment or performance outcomes . Mechanisms of cannabis impairment: Implications for modeling driving performance. PMID 34634690; DOI 10.1016/j.forsciint.2021.110902 55 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: driving impairment or performance outcomes . Prescribing medicinal cannabis. PMID 33093741; DOI 10.18773/austprescr.2020.052 56 THC associated with driving impairment or safety-relevant performance outcomes; evidence class: insufficient outcome measure: driving impairment or performance outcomes . Driving Impairment Cases Involving Etizolam and Flubromazolam. PMID 32399568; DOI 10.1093/jat/bkaa050 References - Determining the magnitude and duration of acute \u03949-tetrahydrocannabinol \u03949-THC -induced driving and cognitive impairment: A systematic and meta-analytic review. PMID 33497784; DOI 10.1016/j.neubiorev.2021.01.003 - Cannabis and driving ability. PMID 33839427; DOI 10.1016/j.copsyc.2021.03.003 - Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. PMID 40172477; DOI 10.1093/ijnp/pyaf021 - Pharmacotherapies for cannabis use disorder. PMID 41025421; DOI 10.1002/14651858.cd008940.pub4 - Mechanisms of cannabis impairment: Implications for modeling driving performance. PMID 34634690; DOI 10.1016/j.forsciint.2021.110902 - Prescribing medicinal cannabis. PMID 33093741; DOI 10.18773/austprescr.2020.052 - Driving Impairment Cases Involving Etizolam and Flubromazolam. PMID 32399568; DOI 10.1093/jat/bkaa050", "sources": 7, "status": "source-backed draft", "subtitle": "What evidence connects THC exposure with driving impairment or other safety-relevant performance outcomes?", "title": "THC and driving-impairment safety review", "type": "topic", "url": "/topics/thc-and-driving-impairment-safety-review/" }, { "aliases": [ "and", "Deep Review", "evidence", "map", "nausea", "outcomes", "source backed draft", "source-backed draft", "THC", "thc", "THC and nausea vomiting outcomes research summary", "THC and nausea/vomiting outcomes research summary", "topic", "topics", "topics thc and nausea vomiting outcomes research summary", "vomiting", "What evidence connects THC or dronabinol with nausea, vomiting, emesis, or antiemetic outcomes?" ], "claims": 8, "evidence_rows": 8, "search_boost": 4, "search_terms": [ "and", "Deep Review", "evidence", "map", "nausea", "outcomes", "source backed draft", "source-backed draft", "THC", "thc", "THC and nausea vomiting outcomes research summary", "THC and nausea/vomiting outcomes research summary", "topic", "topics", "topics thc and nausea vomiting outcomes research summary", "vomiting", "What evidence connects THC or dronabinol with nausea, vomiting, emesis, or antiemetic outcomes?" ], "search_text": "THC and nausea/vomiting outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC or dronabinol with nausea, vomiting, emesis, or antiemetic outcomes? Draft Summary This draft topic page is generated from 8 source-backed evidence row s and 8 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 8 - Sources: 8 - Evidence classes: insufficient 7 , preliminary human 1 - Draft sections: human evidence 1 , uncertainty 7 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 7 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 480 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes . Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 481 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: nausea, vomiting, or antiemetic outcomes . Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PMID 35982439; DOI 10.1186/s12916-022-02459-1 482 THC studied for Nausea and vomiting; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: nausea, vomiting, or antiemetic outcomes . Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PMID 39151115; DOI 10.1200/jco.23.01836 483 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes . Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. PMID 39299947; DOI 10.1007/s00406-024-01880-2 484 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes . Cannabinoids: Therapeutic Use in Clinical Practice. PMID 35328765; DOI 10.3390/ijms23063344 485 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes . Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. PMID 27274310; DOI 10.2147/cmar.s81425 486 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes . The Risk of QTc Prolongation with Antiemetics in the Palliative Care Setting: A Narrative Review. PMID 33974499; DOI 10.1080/15360288.2021.1900491 487 THC studied for Nausea and vomiting; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes . Chemotherapy-induced nausea and vomiting. PMID 18391612; DOI 10.1097/ppo.0b013e31816a0f07 References - Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 - Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PMID 35982439; DOI 10.1186/s12916-022-02459-1 - Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PMID 39151115; DOI 10.1200/jco.23.01836 - Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. PMID 39299947; DOI 10.1007/s00406-024-01880-2 - Cannabinoids: Therapeutic Use in Clinical Practice. PMID 35328765; DOI 10.3390/ijms23063344 - Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. PMID 27274310; DOI 10.2147/cmar.s81425 - Th...", "sources": 8, "status": "source-backed draft", "subtitle": "What evidence connects THC or dronabinol with nausea, vomiting, emesis, or antiemetic outcomes?", "title": "THC and nausea/vomiting outcomes", "type": "topic", "url": "/topics/thc-and-nausea-vomiting-outcomes-evidence-map/" }, { "aliases": [ "and", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "THC", "thc", "THC and pain related outcomes research summary", "THC and pain-related outcomes research summary", "topic", "topics", "topics thc and pain related outcomes research summary", "What evidence connects THC with pain related outcomes?", "What evidence connects THC with pain-related outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "THC", "thc", "THC and pain related outcomes research summary", "THC and pain-related outcomes research summary", "topic", "topics", "topics thc and pain related outcomes research summary", "What evidence connects THC with pain related outcomes?", "What evidence connects THC with pain-related outcomes?" ], "search_text": "THC and pain-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC with pain-related outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 8 , preliminary human 1 - Draft sections: human evidence 1 , uncertainty 8 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 471 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 472 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pain-related outcomes . Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PMID 35982439; DOI 10.1186/s12916-022-02459-1 473 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes . Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. PMID 41429020; DOI 10.7326/annals-25-03152 474 THC studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes . Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. PMID 33118602; DOI 10.1093/pm/pnaa303 475 THC studied for Pain-related outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: pain-related outcomes . Pharmacology of Medical Cannabis. PMID 31332738; DOI 10.1007/978-3-030-21737-2 8 476 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pain-related outcomes . Cannabis-based medicines and medical cannabis for adults with cancer pain. PMID 37283486; DOI 10.1002/14651858.cd014915.pub2 477 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes . Cannabis-Based Products for Chronic Pain : A Systematic Review. PMID 35667066; DOI 10.7326/m21-4520 478 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Practical considerations in medical cannabis administration and dosing. PMID 29307505; DOI 10.1016/j.ejim.2018.01.004 479 THC studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. PMID 34802112; DOI 10.1007/s40263-021-00879-w References - Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 - Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. PMID 35982439; DOI 10.1186/s12916-022-02459-1 - Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. PMID 41429020; DOI 10.7326/annals-25-03152 - Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. PMID 33118602; DOI 10.1093/pm/pnaa303 - Pharmacology of Medical Cannabis. PMID 31332738; DOI 10.1007/978-3-030-21737-2 8 - Cannabis-based medicines and medical cannabis for adults with cancer pain. PMID 37283486; DOI 10.1002/14651858.cd014915.pub2 - Cannabis-Based Products for Chronic Pain : A Sys...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects THC with pain-related outcomes?", "title": "THC and pain-related outcomes", "type": "topic", "url": "/topics/thc-and-pain-related-outcomes-evidence-map/" }, { "aliases": [ "and", "Deep Review", "heightened", "heightened review", "heightened-review", "psychiatric", "psychiatric risk", "psychiatric-risk", "queue", "review", "risk", "source backed draft", "source-backed draft", "THC", "thc", "THC and psychiatric risk heightened review queue", "THC and psychiatric-risk heightened-review queue", "topic", "topics", "topics thc and psychiatric risk heightened review queue", "What evidence connects THC exposure with psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "Deep Review", "heightened", "heightened review", "heightened-review", "psychiatric", "psychiatric risk", "psychiatric-risk", "queue", "review", "risk", "source backed draft", "source-backed draft", "THC", "thc", "THC and psychiatric risk heightened review queue", "THC and psychiatric-risk heightened-review queue", "topic", "topics", "topics thc and psychiatric risk heightened review queue", "What evidence connects THC exposure with psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?" ], "search_text": "THC and psychiatric-risk heightened-review queue Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC exposure with psychiatric risk, psychosis, anxiety worsening, depression, or suicidality? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 9 - Draft sections: uncertainty 9 Key Draft Sections - Uncertainty and gaps: 9 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 434 THC studied for Psychiatric risk; evidence class: insufficient population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes . Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 435 THC studied for Psychiatric risk; evidence class: insufficient study design: Systematic review; outcome measure: psychiatric risk outcomes . Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. PMID 39541799; DOI 10.1016/j.euroneuro.2024.10.006 436 THC studied for Psychiatric risk; evidence class: insufficient study design: Narrative or expert review; outcome measure: psychiatric risk outcomes . Cannabis Use and the Risk for Psychosis and Affective Disorders. PMID 31647377; DOI 10.1080/15504263.2019.1674991 437 THC studied for Psychiatric risk; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes . Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. PMID 39299947; DOI 10.1007/s00406-024-01880-2 438 THC studied for Psychiatric risk; evidence class: insufficient population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes . Cannabis and Mental Health: A Review. PMID 41801216; DOI 10.1001/jamainternmed.2025.8215 439 THC studied for Psychiatric risk; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: psychiatric risk outcomes . Association of cannabis potency with mental ill health and addiction: a systematic review. PMID 35901795; DOI 10.1016/s2215-0366 22 00161-4 440 THC studied for Psychiatric risk; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes . Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. PMID 33228239; DOI 10.3390/biom10111575 441 THC studied for Psychiatric risk; evidence class: insufficient study design: Systematic review; outcome measure: psychiatric risk outcomes . High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. PMID 40854216; DOI 10.7326/annals-24-03819 442 THC studied for Psychiatric risk; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: psychiatric risk outcomes . Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. PMID 31672337; DOI 10.1016/s2215-0366 19 30401-8 References - Therapeutic Use of Cannabis and Cannabinoids: A Review. PMID 41296368; DOI 10.1001/jama.2025.19433 - Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. PMID 39541799; DOI 10.1016/j.euroneuro.2024.10.006 - Cannabis Use and the Risk for Psychosis and Affective Disorders. PMID 31647377; DOI 10.1080/15504263.2019.1674991 - Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. PMID 39299947; DOI 10.1007/s00406-024-01880-2 - Cannabis and Mental Health: A Review. PMID 41801216; DOI 10.1001/jamainternmed.2025.8215 - Association of cannabis potency with mental ill health and addiction: a systematic review. PMID 35901795; DOI 10.1016/s2215-0366 22 00161-4 - Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. PMID 33228239; DOI 10.3390/bio...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects THC exposure with psychiatric risk, psychosis, anxiety worsening, depression, or suicidality?", "title": "THC and psychiatric-risk heightened-review queue", "type": "topic", "url": "/topics/thc-and-psychiatric-risk-heightened-review-queue/" }, { "aliases": [ "and", "Deep Review", "outcomes", "related", "review", "sleep", "sleep related", "sleep-related", "source backed draft", "source-backed draft", "THC", "thc", "THC and sleep related outcomes review", "THC and sleep-related outcomes review", "topic", "topics", "topics thc and sleep related outcomes review", "What evidence connects THC with sleep related outcomes?", "What evidence connects THC with sleep-related outcomes?" ], "claims": 10, "evidence_rows": 10, "search_boost": 4, "search_terms": [ "and", "Deep Review", "outcomes", "related", "review", "sleep", "sleep related", "sleep-related", "source backed draft", "source-backed draft", "THC", "thc", "THC and sleep related outcomes review", "THC and sleep-related outcomes review", "topic", "topics", "topics thc and sleep related outcomes review", "What evidence connects THC with sleep related outcomes?", "What evidence connects THC with sleep-related outcomes?" ], "search_text": "THC and sleep-related outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THC with sleep-related outcomes? Draft Summary This draft topic page is generated from 10 source-backed evidence row s and 10 source s . Main entities represented: THC. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 6 , preliminary human 4 - Draft sections: human evidence 4 , uncertainty 6 Key Draft Sections - Human evidence: 4 evidence row s . - Uncertainty and gaps: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 498 THC studied for Sleep; evidence class: insufficient study design: Systematic review; outcome measure: sleep-related outcomes . The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 499 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PMID 36539991; DOI 10.1111/jsr.13793 500 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 501 THC studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes . Should Oncologists Recommend Cannabis? PMID 31161270; DOI 10.1007/s11864-019-0659-9 502 THC studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes . Cannabis dosing and administration for sleep: a systematic review. PMID 36107800; DOI 10.1093/sleep/zsac218 503 THC studied for Sleep; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabidiol CBD and \u03949-tetrahydrocannabinol THC for chronic insomnia disorder 'CANSLEEP' trial : protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. PMID 32430450; DOI 10.1136/bmjopen-2019-034421 504 THC studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: sleep-related outcomes . Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis. PMID 33244728; DOI 10.1007/s40263-020-00773-x 505 THC studied for Sleep; evidence class: preliminary human population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes . Cannabis: are there any benefits? PMID 33215831; DOI 10.1111/imj.15052 506 THC studied for Sleep; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes . Use of Cannabidiol in the Management of Insomnia: A Systematic Review. PMID 36149724; DOI 10.1089/can.2022.0122 507 THC studied for Sleep; evidence class: insufficient study design: Systematic review; outcome measure: sleep-related outcomes . Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. PMID 32603954; DOI 10.1016/j.smrv.2020.101339 References - The differential effects of medicinal cannabis on mental health: A systematic review. PMID 40186931; DOI 10.1016/j.cpr.2025.102581 - Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PMID 36539991; DOI 10.1111/jsr.13793 - Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PMID 40631525; DOI 10.1111/jsr.70124 - Should Oncologists Recommend Cannabis? PMID 31161270; DOI 10.1007/s11864-019-0659-9 - Cannabis dosing and administration for sleep: a systematic rev...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence connects THC with sleep-related outcomes?", "title": "THC and sleep-related outcomes review", "type": "topic", "url": "/topics/thc-and-sleep-related-outcomes-review/" }, { "aliases": [ "and", "claims", "Deep Review", "effect", "review", "safety", "source backed draft", "source-backed draft", "THCA", "thca", "THCA and safety effect claims review", "THCA and safety/effect claims review", "topic", "topics", "topics thca and safety effect claims review", "What evidence exists for THCA specific safety, effect, or mechanism claims?", "What evidence exists for THCA-specific safety, effect, or mechanism claims?" ], "claims": 10, "evidence_rows": 10, "search_boost": 4, "search_terms": [ "and", "claims", "Deep Review", "effect", "review", "safety", "source backed draft", "source-backed draft", "THCA", "thca", "THCA and safety effect claims review", "THCA and safety/effect claims review", "topic", "topics", "topics thca and safety effect claims review", "What evidence exists for THCA specific safety, effect, or mechanism claims?", "What evidence exists for THCA-specific safety, effect, or mechanism claims?" ], "search_text": "THCA and safety/effect claims review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence exists for THCA-specific safety, effect, or mechanism claims? Draft Summary This draft topic page is generated from 10 source-backed evidence row s and 10 source s . Main entities represented: THCA. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 5 , mechanistic or pharmacological 2 , preclinical 1 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 2 , preclinical evidence 1 , uncertainty 5 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 5 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 2 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 44 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological outcome measure: safety, effect, or mechanism claims . Cannabis Therapeutics and the Future of Neurology. PMID 30405366; DOI 10.3389/fnint.2018.00051 45 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, effect, or mechanism claims . Investigational cannabinoids in seizure disorders, what have we learned thus far? PMID 29842819; DOI 10.1080/13543784.2018.1482275 46 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: safety, effect, or mechanism claims . Cannabinoid Content in Cannabis Flowers and Homemade Cannabis-Based Products Used for Therapeutic Purposes in Argentina. PMID 33998894; DOI 10.1089/can.2020.0117 86 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preliminary human study design: Human clinical study; outcome measure: safety, effect, or mechanism claims . Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows. PMID 37641272; DOI 10.3168/jds.2023-23222 87 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient outcome measure: safety, effect, or mechanism claims . Semiquantitative Screening of THC Analogues by Silica Gel TLC with an Ag I Retention Zone and Chromogenic Smartphone Detection. PMID 36178203; DOI 10.1021/acs.analchem.2c01627 88 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological study design: Human clinical study; outcome measure: safety, effect, or mechanism claims . Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle. PMID 41358942; DOI 10.1093/jas/skaf418 89 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preclinical population or model: Human participants or patients mentioned; outcome measure: safety, effect, or mechanism claims . Determination of Cannabinoids in Meat Products and Animal Feeds in Singapore Using Liquid Chromatography-Tandem Mass Spectrometry. PMID 39200508; DOI 10.3390/foods13162581 90 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient population or model: Human participants or patients mentioned; outcome measure: safety, effect, or mechanism claims . Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation-Eemission Matrix Fluorescence Coupled with Parallel Factor Analysis. PMID 37810707; DOI 10.1021/acsomega.3c04913 91 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient outcome measure: safety, effect, or mechanism claims . Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, \u03948-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PMID 38862388; DOI 10.1021/acs.analchem.3c05879 92 THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: insufficient outcome measure: safety, effect, or mechanism claims . Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. PMID 28117322; DOI 10.3390/scipharm84030567 References - Cannabis Therapeutics and the Future...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence exists for THCA-specific safety, effect, or mechanism claims?", "title": "THCA and safety/effect claims review", "type": "topic", "url": "/topics/thca-and-safety-effect-claims-review/" }, { "aliases": [ "and", "appetite", "Deep Review", "metabolic", "outcomes", "review", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and appetite metabolic outcomes review", "THCV and appetite/metabolic outcomes review", "topic", "topics", "topics thcv and appetite metabolic outcomes review", "What evidence connects THCV with appetite related or metabolic outcomes?", "What evidence connects THCV with appetite-related or metabolic outcomes?" ], "claims": 13, "evidence_rows": 13, "search_boost": 4, "search_terms": [ "and", "appetite", "Deep Review", "metabolic", "outcomes", "review", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and appetite metabolic outcomes review", "THCV and appetite/metabolic outcomes review", "topic", "topics", "topics thcv and appetite metabolic outcomes review", "What evidence connects THCV with appetite related or metabolic outcomes?", "What evidence connects THCV with appetite-related or metabolic outcomes?" ], "search_text": "THCV and appetite/metabolic outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THCV with appetite-related or metabolic outcomes? Draft Summary This draft topic page is generated from 13 source-backed evidence row s and 13 source s . Main entities represented: THCV. Evidence Snapshot - Evidence rows: 13 - Sources: 13 - Evidence classes: insufficient 3 , mechanistic or pharmacological 8 , preliminary human 2 - Draft sections: human evidence 2 , mechanistic evidence 8 , uncertainty 3 Key Draft Sections - Human evidence: 2 evidence row s . - Uncertainty and gaps: 3 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 37 THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . \u03949-Tetrahydrocannabivarin THCV : a commentary on potential therapeutic benefit for the management of obesity and diabetes. PMID 33526143; DOI 10.1186/s42238-020-0016-7 38 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . The role of tetrahydrocannabivarin THCV in metabolic disorders: A promising cannabinoid for diabetes and weight management. PMID 40270953; DOI 10.3934/neuroscience.2025003 39 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 77 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PMID 27573936; DOI 10.2337/dc16-0650 78 THCV studied for Appetite and metabolic outcomes; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes . CB\u2081-independent mechanisms of \u0394\u2079-THCV, AM251 and SR141716 rimonabant . PMID 21740450; DOI 10.1111/j.1365-2710.2011.01284.x 79 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes . SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r G894C Zebrafish Model of Obesity. PMID 42196303; DOI 10.3390/ijms27104321 80 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes . In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PMID 33230154; DOI 10.1038/s41598-020-77175-y 81 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes . Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin THCV -Infused Mucoadhesive Strips. PMID 39968488; DOI 10.26828/cannabis/2024/000206 82 THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes . The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 \u03b2-Cells Under High-Glucose and High-Lipid Conditions. PMID 40363798; DOI 10.3390/molecules30091991 83 THCV studied for Appetite...", "sources": 13, "status": "source-backed draft", "subtitle": "What evidence connects THCV with appetite-related or metabolic outcomes?", "title": "THCV and appetite/metabolic outcomes review", "type": "topic", "url": "/topics/thcv-and-appetite-metabolic-outcomes-review/" }, { "aliases": [ "and", "Deep Review", "evidence", "immune", "inflammation", "map", "outcomes", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and inflammation immune outcomes research summary", "THCV and inflammation/immune outcomes research summary", "topic", "topics", "topics thcv and inflammation immune outcomes research summary", "What evidence connects THCV with inflammation related or immune outcomes?", "What evidence connects THCV with inflammation-related or immune outcomes?" ], "claims": 4, "evidence_rows": 4, "search_boost": 4, "search_terms": [ "and", "Deep Review", "evidence", "immune", "inflammation", "map", "outcomes", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and inflammation immune outcomes research summary", "THCV and inflammation/immune outcomes research summary", "topic", "topics", "topics thcv and inflammation immune outcomes research summary", "What evidence connects THCV with inflammation related or immune outcomes?", "What evidence connects THCV with inflammation-related or immune outcomes?" ], "search_text": "THCV and inflammation/immune outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THCV with inflammation-related or immune outcomes? Draft Summary This draft topic page is generated from 4 source-backed evidence row s and 4 source s . Main entities represented: THCV. Evidence Snapshot - Evidence rows: 4 - Sources: 4 - Evidence classes: mechanistic or pharmacological 4 - Draft sections: mechanistic evidence 4 Key Draft Sections - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 783 THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes . Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 784 THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes . Pure \u03949-tetrahydrocannabivarin and a Cannabis sativa extract with high content in \u03949-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PMID 27498155; DOI 10.1016/j.phrs.2016.07.045 785 THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes . Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. PMID 33446817; DOI 10.1038/s41598-021-81049-2 786 THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes . Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. PMID 36559009; DOI 10.3390/ph15121559 References - Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 - Pure \u03949-tetrahydrocannabivarin and a Cannabis sativa extract with high content in \u03949-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PMID 27498155; DOI 10.1016/j.phrs.2016.07.045 - Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. PMID 33446817; DOI 10.1038/s41598-021-81049-2 - Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. PMID 36559009; DOI 10.3390/ph15121559", "sources": 4, "status": "source-backed draft", "subtitle": "What evidence connects THCV with inflammation-related or immune outcomes?", "title": "THCV and inflammation/immune outcomes", "type": "topic", "url": "/topics/thcv-and-inflammation-immune-outcomes-evidence-map/" }, { "aliases": [ "and", "cognition", "Deep Review", "neurobehavioral", "outcomes", "review", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and neurobehavioral cognition outcomes review", "THCV and neurobehavioral/cognition outcomes review", "topic", "topics", "topics thcv and neurobehavioral cognition outcomes review", "What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC interaction outcomes?", "What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes?" ], "claims": 9, "evidence_rows": 9, "search_boost": 4, "search_terms": [ "and", "cognition", "Deep Review", "neurobehavioral", "outcomes", "review", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and neurobehavioral cognition outcomes review", "THCV and neurobehavioral/cognition outcomes review", "topic", "topics", "topics thcv and neurobehavioral cognition outcomes review", "What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC interaction outcomes?", "What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes?" ], "search_text": "THCV and neurobehavioral/cognition outcomes review Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes? Draft Summary This draft topic page is generated from 9 source-backed evidence row s and 9 source s . Main entities represented: THCV. Evidence Snapshot - Evidence rows: 9 - Sources: 9 - Evidence classes: insufficient 4 , mechanistic or pharmacological 4 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 4 , uncertainty 4 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 4 evidence row s . - Mechanistic evidence: 4 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 787 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PMID 40872492; DOI 10.3390/ph18081101 788 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . \u03948 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. PMID 31454413; DOI 10.1111/bph.14844 789 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. PMID 25542687; DOI 10.1093/ijnp/pyu094 790 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy. PMID 28109780; DOI 10.1016/j.yebeh.2016.11.020 791 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PMID 26577065; DOI 10.1177/0269881115615104 792 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . Medical use of cannabis. Cannabidiol: a new light for schizophrenia? PMID 23109356; DOI 10.1002/dta.1425 793 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. PMID 26362774; DOI 10.1093/ijnp/pyv092 794 THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes . Molecular pathway and structural mechanism...", "sources": 9, "status": "source-backed draft", "subtitle": "What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes?", "title": "THCV and neurobehavioral/cognition outcomes review", "type": "topic", "url": "/topics/thcv-and-neurobehavioral-cognition-outcomes-review/" }, { "aliases": [ "and", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and pain related outcomes research summary", "THCV and pain-related outcomes research summary", "topic", "topics", "topics thcv and pain related outcomes research summary", "What evidence connects THCV with pain related outcomes?", "What evidence connects THCV with pain-related outcomes?" ], "claims": 10, "evidence_rows": 10, "search_boost": 4, "search_terms": [ "and", "Deep Review", "evidence", "map", "outcomes", "pain", "pain related", "pain-related", "related", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and pain related outcomes research summary", "THCV and pain-related outcomes research summary", "topic", "topics", "topics thcv and pain related outcomes research summary", "What evidence connects THCV with pain related outcomes?", "What evidence connects THCV with pain-related outcomes?" ], "search_text": "THCV and pain-related outcomes research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THCV with pain-related outcomes? Draft Summary This draft topic page is generated from 10 source-backed evidence row s and 10 source s . Main entities represented: THCV. Evidence Snapshot - Evidence rows: 10 - Sources: 10 - Evidence classes: insufficient 2 , mechanistic or pharmacological 6 , preclinical 1 , preliminary human 1 - Draft sections: human evidence 1 , mechanistic evidence 6 , preclinical evidence 1 , uncertainty 2 Key Draft Sections - Human evidence: 1 evidence row s . - Uncertainty and gaps: 2 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 6 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 796 THCV studied for Pain-related outcomes; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 797 THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes . Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. PMID 37764262; DOI 10.3390/molecules28186487 798 THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. PMID 33230154; DOI 10.1038/s41598-020-77175-y 799 THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological outcome measure: pain-related outcomes . Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. PMID 19679411; DOI 10.1016/j.drugalcdep.2009.06.009 800 THCV studied for Pain-related outcomes; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. PMID 42151379; DOI 10.1038/s41598-026-51275-7 801 THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes . The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. PMID 20590571; DOI 10.1111/j.1476-5381.2010.00756.x 802 THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes . The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. PMID 17245367; DOI 10.1038/sj.bjp.0707124 803 THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological outcome measure: pain-related outcomes . Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans. PMID 41135090; DOI 10.1139/cjpp-2025-0243 804 THCV studied for Pain-related outcomes; evidence class: preliminary human population or model: Human participants or patients mentioned; outcome measure: pain-related outcomes . Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry. PMID 30350275; DOI 10.1007/978-1-4939-8823-5 2 805 THCV studied for Pain-related outcomes; evidence class: insufficient study design: Narrative or expert review; outcome measure: pain-related outcomes . The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. PMID 22155112; DOI 10.1016/j.ajpath.2011.11.003 References - It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 - Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human...", "sources": 10, "status": "source-backed draft", "subtitle": "What evidence connects THCV with pain-related outcomes?", "title": "THCV and pain-related outcomes", "type": "topic", "url": "/topics/thcv-and-pain-related-outcomes-evidence-map/" }, { "aliases": [ "and", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and safety tolerability research summary", "THCV and safety/tolerability research summary", "tolerability", "topic", "topics", "topics thcv and safety tolerability research summary", "What evidence connects THCV with safety, tolerability, adverse event, impairment, or formulation specific outcomes?", "What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?" ], "claims": 24, "evidence_rows": 24, "search_boost": 4, "search_terms": [ "and", "Deep Review", "evidence", "map", "safety", "source backed draft", "source-backed draft", "THCV", "thcv", "THCV and safety tolerability research summary", "THCV and safety/tolerability research summary", "tolerability", "topic", "topics", "topics thcv and safety tolerability research summary", "What evidence connects THCV with safety, tolerability, adverse event, impairment, or formulation specific outcomes?", "What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?" ], "search_text": "THCV and safety/tolerability research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes? Draft Summary This draft topic page is generated from 24 source-backed evidence row s and 24 source s . Main entities represented: THCV. Evidence Snapshot - Evidence rows: 24 - Sources: 24 - Evidence classes: insufficient 15 , mechanistic or pharmacological 6 , preclinical 2 , preliminary human 1 - Draft sections: safety 24 Key Draft Sections - Safety and tolerability: 24 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 736 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . The role of tetrahydrocannabivarin THCV in metabolic disorders: A promising cannabinoid for diabetes and weight management. PMID 40270953; DOI 10.3934/neuroscience.2025003 737 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . Investigational cannabinoids in seizure disorders, what have we learned thus far? PMID 29842819; DOI 10.1080/13543784.2018.1482275 738 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PMID 27573936; DOI 10.2337/dc16-0650 739 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . CB\u2081-independent mechanisms of \u0394\u2079-THCV, AM251 and SR141716 rimonabant . PMID 21740450; DOI 10.1111/j.1365-2710.2011.01284.x 740 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r G894C Zebrafish Model of Obesity. PMID 42196303; DOI 10.3390/ijms27104321 741 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, \u03948-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PMID 38862388; DOI 10.1021/acs.analchem.3c05879 742 THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns . Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PMID 40872492; DOI 10.3390/ph...", "sources": 24, "status": "source-backed draft", "subtitle": "What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?", "title": "THCV and safety/tolerability", "type": "topic", "url": "/topics/thcv-and-safety-tolerability-evidence-map/" }, { "aliases": [ "and", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "THCV", "thcv", "THCV and target pharmacology research summary", "THCV and target/pharmacology research summary", "topic", "topics", "topics thcv and target pharmacology research summary", "What evidence connects THCV with receptor, target, metabolic, or pharmacology mechanisms?" ], "claims": 23, "evidence_rows": 23, "search_boost": 4, "search_terms": [ "and", "Deep Review", "evidence", "map", "pharmacology", "source backed draft", "source-backed draft", "target", "THCV", "thcv", "THCV and target pharmacology research summary", "THCV and target/pharmacology research summary", "topic", "topics", "topics thcv and target pharmacology research summary", "What evidence connects THCV with receptor, target, metabolic, or pharmacology mechanisms?" ], "search_text": "THCV and target/pharmacology research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects THCV with receptor, target, metabolic, or pharmacology mechanisms? Draft Summary This draft topic page is generated from 23 source-backed evidence row s and 23 source s . Main entities represented: THCV. Evidence Snapshot - Evidence rows: 23 - Sources: 23 - Evidence classes: insufficient 6 , mechanistic or pharmacological 17 - Draft sections: mechanistic evidence 17 , uncertainty 6 Key Draft Sections - Uncertainty and gaps: 6 evidence row s . - Mechanistic evidence: 17 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 760 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. PMID 32899626; DOI 10.3390/molecules25184036 761 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r G894C Zebrafish Model of Obesity. PMID 42196303; DOI 10.3390/ijms27104321 762 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PMID 40872492; DOI 10.3390/ph18081101 763 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. PMID 17828291; DOI 10.1038/sj.bjp.0707442 764 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Pure \u03949-tetrahydrocannabivarin and a Cannabis sativa extract with high content in \u03949-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PMID 27498155; DOI 10.1016/j.phrs.2016.07.045 765 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. PMID 21175579; DOI 10.1111/j.1476-5381.2010.01166.x 766 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Molecular Pharmacology of Phytocannabinoids. PMID 28120231; DOI 10.1007/978-3-319-45541-9 3 767 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Are cannabidiol and \u0394 9 -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. PMID 25257544; DOI 10.1111/bph.12944 768 THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms . Evidence th...", "sources": 23, "status": "source-backed draft", "subtitle": "What evidence connects THCV with receptor, target, metabolic, or pharmacology mechanisms?", "title": "THCV and target/pharmacology", "type": "topic", "url": "/topics/thcv-and-target-pharmacology-evidence-map/" }, { "aliases": [ "cannabinoid", "channel", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trp channel cannabinoid target research summary", "TRP", "trp", "TRP channel cannabinoid target research summary", "What evidence connects cannabinoids with TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8?" ], "claims": 11, "evidence_rows": 11, "search_boost": 4, "search_terms": [ "cannabinoid", "channel", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trp channel cannabinoid target research summary", "TRP", "trp", "TRP channel cannabinoid target research summary", "What evidence connects cannabinoids with TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8?" ], "search_text": "TRP channel cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids with TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8? Draft Summary This draft topic page is generated from 11 source-backed evidence row s and 11 source s . Main entities represented: THC, CBD, THCV, Cannabinoids. Evidence Snapshot - Evidence rows: 11 - Sources: 11 - Evidence classes: insufficient 8 , mechanistic or pharmacological 3 - Draft sections: mechanistic evidence 3 , uncertainty 8 Key Draft Sections - Uncertainty and gaps: 8 evidence row s . - Mechanistic evidence: 3 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 214 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 215 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PMID 33362478; DOI 10.3389/fncel.2020.615811 216 THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Pure \u03949-tetrahydrocannabivarin and a Cannabis sativa extract with high content in \u03949-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PMID 27498155; DOI 10.1016/j.phrs.2016.07.045 357 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . An Introduction to the Endogenous Cannabinoid System. PMID 26698193; DOI 10.1016/j.biopsych.2015.07.028 358 Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation. PMID 33155670; DOI 10.1111/bph.15310 359 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . The Pharmacological Case for Cannabigerol. PMID 33168643; DOI 10.1124/jpet.120.000340 360 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. PMID 33629929; DOI 10.1080/15548627.2021.1885203 361 CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Pharmacological effects of cannabidiol by transient receptor potential channels. PMID 35483477; DOI 10.1016/j.lfs.2022.120582 362 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Cannabinoids in the landscape of cancer. PMID 34259916; DOI 10.1007/s00432-021-03710-7 363 THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms . Plant-derived cannabinoids modulate the activity of transien...", "sources": 11, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids with TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8?", "title": "TRP channel cannabinoid target", "type": "topic", "url": "/topics/trp-channel-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpa1 cannabinoid target research summary", "TRPA1", "trpa1", "TRPA1 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPA1 channel activity, binding, or signaling?" ], "claims": 18, "evidence_rows": 18, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpa1 cannabinoid target research summary", "TRPA1", "trpa1", "TRPA1 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPA1 channel activity, binding, or signaling?" ], "search_text": "TRPA1 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with TRPA1 channel activity, binding, or signaling? Draft Summary This draft topic page is generated from 18 source-backed evidence row s and 18 source s . Main entities represented: CBD, Cannabinoids, THC, Endocannabinoids. Evidence Snapshot - Evidence rows: 18 - Sources: 18 - Evidence classes: insufficient 10 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 10 Key Draft Sections - Uncertainty and gaps: 10 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1030 THC modulates TRPA1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 1031 CBD modulates TRPA1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Pharmacological effects of cannabidiol by transient receptor potential channels. PMID 35483477; DOI 10.1016/j.lfs.2022.120582 1032 THC modulates TRPA1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabinoids in the landscape of cancer. PMID 34259916; DOI 10.1007/s00432-021-03710-7 1033 THC modulates TRPA1; evidence class: insufficient outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. PMID 29240420; DOI 10.1021/acs.jnatprod.7b00946 1034 Cannabinoids modulates TRPA1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PMID 19070372; DOI 10.1016/j.tips.2008.10.008 1035 Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Modification of TRPV4 activity by acetaminophen. PMID 32051870; DOI 10.1016/j.heliyon.2020.e03301 1036 Cannabinoids modulates TRPA1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . TRPA1. PMID 24756722; DOI 10.1007/978-3-642-54215-2 23 1037 THC modulates TRPA1; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Identification of the TRPA1 cannabinoid-binding site. PMID 39368566; DOI 10.1016/j.phrs.2024.107444 1038 Cannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Affinin, Isolated from Heliopsis longipes, Induces an Antihypertensive Effect That Involves CB1 Cannabinoid Receptors and TRPA1 and TRPV1 Channel Activation. PMID 38219731; DOI 10.1055/a-2244-8855 1039 THC modulates TRPA1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . Molecular Targets of the Phytocannabinoids: A Complex Picture. PMID 28120232; DOI 10.1007/978-3-319-45541-9 4 1040 Cannabinoids modulates TRPA1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology . G-protein coupled receptors regulating cough. PMID 21727026; DOI 10.1016/j.coph.2011.06.005 1041 Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: A...", "sources": 18, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with TRPA1 channel activity, binding, or signaling?", "title": "TRPA1 cannabinoid target", "type": "topic", "url": "/topics/trpa1-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpm8 cannabinoid target research summary", "TRPM8", "trpm8", "TRPM8 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPM8 channel activity, binding, or signaling?" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpm8 cannabinoid target research summary", "TRPM8", "trpm8", "TRPM8 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPM8 channel activity, binding, or signaling?" ], "search_text": "TRPM8 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with TRPM8 channel activity, binding, or signaling? Draft Summary This draft topic page is generated from 15 source-backed evidence row s and 15 source s . Main entities represented: THC, CBD, CBG, Cannabinoids. Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 7 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 7 Key Draft Sections - Uncertainty and gaps: 7 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1048 CBD modulates TRPM8; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Pharmacological effects of cannabidiol by transient receptor potential channels. PMID 35483477; DOI 10.1016/j.lfs.2022.120582 1049 THC modulates TRPM8; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. PMID 18354058; DOI 10.1124/jpet.107.134809 1050 THC modulates TRPM8; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. PMID 21175579; DOI 10.1111/j.1476-5381.2010.01166.x 1051 CBG modulates TRPM8; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. PMID 25269802; DOI 10.1093/carcin/bgu205 1052 CBG modulates TRPM8; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. PMID 40540228; DOI 10.1021/acs.jmedchem.4c03220 1053 THC modulates TRPM8; evidence class: insufficient outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. PMID 29240420; DOI 10.1021/acs.jnatprod.7b00946 1054 Cannabinoids modulates TRPM8; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PMID 19070372; DOI 10.1016/j.tips.2008.10.008 1055 Cannabinoids modulates TRPM8; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. PMID 29470146; DOI 10.1152/ajpgi.00013.2018 1056 THC modulates TRPM8; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Molecular Targets of the Phytocannabinoids: A Complex Picture. PMID 28120232; DOI 10.1007/978-3-319-45541-9 4 1057 CBD modulates TRPM8; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. PMID 35605018; DOI 10.1089/can.2021.0154 1058 CBD modulates TRPM8; evidence class: mechanistic or pharmacological outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology . Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannab...", "sources": 15, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with TRPM8 channel activity, binding, or signaling?", "title": "TRPM8 cannabinoid target", "type": "topic", "url": "/topics/trpm8-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv1 cannabinoid target research summary", "TRPV1", "trpv1", "TRPV1 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV1 channel activity, desensitization, binding, or signaling?" ], "claims": 18, "evidence_rows": 18, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv1 cannabinoid target research summary", "TRPV1", "trpv1", "TRPV1 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV1 channel activity, desensitization, binding, or signaling?" ], "search_text": "TRPV1 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with TRPV1 channel activity, desensitization, binding, or signaling? Draft Summary This draft topic page is generated from 18 source-backed evidence row s and 18 source s . Main entities represented: THC, Cannabinoids, Endocannabinoids, CBD. Evidence Snapshot - Evidence rows: 18 - Sources: 18 - Evidence classes: insufficient 15 , mechanistic or pharmacological 2 , preclinical 1 - Draft sections: mechanistic evidence 2 , preclinical evidence 1 , uncertainty 15 Key Draft Sections - Uncertainty and gaps: 15 evidence row s . - Preclinical evidence: 1 evidence row s . - Mechanistic evidence: 2 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 971 THC modulates TRPV1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 972 THC modulates TRPV1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabinoids in the landscape of cancer. PMID 34259916; DOI 10.1007/s00432-021-03710-7 973 THC modulates TRPV1; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Pharmacological actions of cannabinoids. PMID 16596770; DOI 10.1007/3-540-26573-2 1 974 Cannabinoids modulates TRPV1; evidence class: preclinical population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels. PMID 40465624; DOI 10.1073/pnas.2413811122 975 Cannabinoids modulates TRPV1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabinoid signalling. PMID 16109430; DOI 10.1016/j.lfs.2005.05.055 976 THC modulates TRPV1; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabinoids and anxiety. PMID 21309120; DOI 10.1007/7854 2009 16 977 OEA modulates TRPV1; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Novel cannabinoid receptors. PMID 17906678; DOI 10.1038/sj.bjp.0707481 978 CBD modulates TRPV1; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PMID 37199723; DOI 10.7554/elife.86166 979 Anandamide modulates TRPV1; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. PMID 26411767; DOI 10.2174/1570159x13666150216222543 980 Endocannabinoids modulates TRPV1; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Endocannabinoid signaling in microglia. PMID 36222019; DOI 10.1002/glia.24281 981 Cannabinoids modulates TRPV1; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology . Modulation of TRPV1 channel function by natural products in the treatment of pain. PMID 32738201; DOI 10.1016/j.cbi.2020.109178 982 Endocannabinoids modulates TRPV1; evidence class...", "sources": 18, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with TRPV1 channel activity, desensitization, binding, or signaling?", "title": "TRPV1 cannabinoid target", "type": "topic", "url": "/topics/trpv1-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv2 cannabinoid target research summary", "TRPV2", "trpv2", "TRPV2 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV2 channel activity, binding, or signaling?" ], "claims": 15, "evidence_rows": 15, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv2 cannabinoid target research summary", "TRPV2", "trpv2", "TRPV2 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV2 channel activity, binding, or signaling?" ], "search_text": "TRPV2 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with TRPV2 channel activity, binding, or signaling? Draft Summary This draft topic page is generated from 15 source-backed evidence row s and 15 source s . Main entities represented: CBD, THC, Cannabinoids. Evidence Snapshot - Evidence rows: 15 - Sources: 15 - Evidence classes: insufficient 5 , mechanistic or pharmacological 10 - Draft sections: mechanistic evidence 10 , uncertainty 5 Key Draft Sections - Uncertainty and gaps: 5 evidence row s . - Mechanistic evidence: 10 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 989 THC modulates TRPV2; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 990 THC modulates TRPV2; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Cannabinoids in the landscape of cancer. PMID 34259916; DOI 10.1007/s00432-021-03710-7 991 CBD modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PMID 37199723; DOI 10.7554/elife.86166 992 CBD modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Tyrosine phosphorylation and palmitoylation of TRPV2 ion channel tune microglial beta-amyloid peptide phagocytosis. PMID 39227967; DOI 10.1186/s12974-024-03204-6 993 CBD modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Cannabinoid non-cannabidiol site modulation of TRPV2 structure and function. PMID 36470868; DOI 10.1038/s41467-022-35163-y 994 CBD modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Molecular mechanism of TRPV2 channel modulation by cannabidiol. PMID 31566564; DOI 10.7554/elife.48792 995 THC modulates TRPV2; evidence class: insufficient outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Cannabidiol interactions with voltage-gated sodium channels. PMID 33089780; DOI 10.7554/elife.58593 996 THC modulates TRPV2; evidence class: insufficient outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids. PMID 29240420; DOI 10.1021/acs.jnatprod.7b00946 997 Cannabinoids modulates TRPV2; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PMID 19070372; DOI 10.1016/j.tips.2008.10.008 998 CBD modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . TRPV2, a novel player in the human ovary and human granulosa cells. PMID 37610352; DOI 10.1093/molehr/gaad029 999 THC modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology . The Protective Effect of CBD in a Model of In Vitro Ischemia May Be Mediated by Agonism on TRPV2 Channel and Microglia Activation. PMID 36292998; DOI 10.3390/ijms232012144 1000 CBD modulates TRPV2; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; out...", "sources": 15, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with TRPV2 channel activity, binding, or signaling?", "title": "TRPV2 cannabinoid target", "type": "topic", "url": "/topics/trpv2-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv3 cannabinoid target research summary", "TRPV3", "trpv3", "TRPV3 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV3 channel activity, binding, or signaling?" ], "claims": 12, "evidence_rows": 12, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv3 cannabinoid target research summary", "TRPV3", "trpv3", "TRPV3 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV3 channel activity, binding, or signaling?" ], "search_text": "TRPV3 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with TRPV3 channel activity, binding, or signaling? Draft Summary This draft topic page is generated from 12 source-backed evidence row s and 12 source s . Main entities represented: CBD, THC, THCV, Cannabinoids. Evidence Snapshot - Evidence rows: 12 - Sources: 12 - Evidence classes: insufficient 4 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 4 Key Draft Sections - Uncertainty and gaps: 4 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1004 THC modulates TRPV3; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 1005 CBD modulates TRPV3; evidence class: insufficient outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PMID 33362478; DOI 10.3389/fncel.2020.615811 1006 THCV modulates TRPV3; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Pure \u03949-tetrahydrocannabivarin and a Cannabis sativa extract with high content in \u03949-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PMID 27498155; DOI 10.1016/j.phrs.2016.07.045 1007 THCV modulates TRPV3; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site. PMID 38691614; DOI 10.1126/sciadv.adn2453 1008 THC modulates TRPV3; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. PMID 21726418; DOI 10.1111/j.1748-1716.2011.02338.x 1009 CBD modulates TRPV3; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PMID 37199723; DOI 10.7554/elife.86166 1010 CBD modulates TRPV3; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Cannabidiol sensitizes TRPV2 channels to activation by 2-APB. PMID 36747846; DOI 10.1101/2023.01.27.525817 1011 Cannabinoids modulates TRPV3; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Pharmacogenetics of new analgesics. PMID 20942817; DOI 10.1111/j.1476-5381.2010.01074.x 1012 CBD modulates TRPV3; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Human podocytes express functional thermosensitive TRPV channels. PMID 28945920; DOI 10.1111/bph.14052 1013 CBD modulates TRPV3; evidence class: mechanistic or pharmacological outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology . Exploring Cannabidiol-TRPV3 Mediated Biological Activities-Findings From Molecular Docking, Simulation and Proteins Network Interactions. PMID 40025806; DOI 10.1002/cbdv.202403494 1014 Cannabi...", "sources": 12, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with TRPV3 channel activity, binding, or signaling?", "title": "TRPV3 cannabinoid target", "type": "topic", "url": "/topics/trpv3-cannabinoid-target-evidence-map/" }, { "aliases": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv4 cannabinoid target research summary", "TRPV4", "trpv4", "TRPV4 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV4 channel activity, binding, or signaling?" ], "claims": 14, "evidence_rows": 14, "search_boost": 4, "search_terms": [ "cannabinoid", "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "target", "topic", "topics", "topics trpv4 cannabinoid target research summary", "TRPV4", "trpv4", "TRPV4 cannabinoid target research summary", "What evidence connects cannabinoids or endocannabinoids with TRPV4 channel activity, binding, or signaling?" ], "search_text": "TRPV4 cannabinoid target research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence connects cannabinoids or endocannabinoids with TRPV4 channel activity, binding, or signaling? Draft Summary This draft topic page is generated from 14 source-backed evidence row s and 14 source s . Main entities represented: CBD, Cannabinoids, Endocannabinoids, THC. Evidence Snapshot - Evidence rows: 14 - Sources: 14 - Evidence classes: insufficient 6 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 6 Key Draft Sections - Uncertainty and gaps: 6 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1016 THC modulates TRPV4; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Cannabinoid Ligands Targeting TRP Channels. PMID 30697147; DOI 10.3389/fnmol.2018.00487 1017 CBD modulates TRPV4; evidence class: insufficient outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors. PMID 33362478; DOI 10.3389/fncel.2020.615811 1018 CBD modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. PMID 33629929; DOI 10.1080/15548627.2021.1885203 1019 THC modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. PMID 21726418; DOI 10.1111/j.1748-1716.2011.02338.x 1020 Cannabinoids modulates TRPV4; evidence class: insufficient study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. PMID 19070372; DOI 10.1016/j.tips.2008.10.008 1021 CBD modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Human podocytes express functional thermosensitive TRPV channels. PMID 28945920; DOI 10.1111/bph.14052 1022 Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Modification of TRPV4 activity by acetaminophen. PMID 32051870; DOI 10.1016/j.heliyon.2020.e03301 1023 Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Human clinical study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. PMID 38750093; DOI 10.1038/s41598-024-61791-z 1024 Cannabinoids modulates TRPV4; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. PMID 29470146; DOI 10.1152/ajpgi.00013.2018 1025 Endocannabinoids modulates TRPV4; evidence class: insufficient population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Potential Future Pharmacological Treatment of Bladder Dysfunction. PMID 26990140; DOI 10.1111/bcpt.12577 1026 Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology . Periphera...", "sources": 14, "status": "source-backed draft", "subtitle": "What evidence connects cannabinoids or endocannabinoids with TRPV4 channel activity, binding, or signaling?", "title": "TRPV4 cannabinoid target", "type": "topic", "url": "/topics/trpv4-cannabinoid-target-evidence-map/" }, { "aliases": [ "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics virodhamine research summary", "Virodhamine", "virodhamine", "Virodhamine research summary", "What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "claims": 11, "evidence_rows": 11, "search_boost": 4, "search_terms": [ "Deep Review", "evidence", "map", "source backed draft", "source-backed draft", "topic", "topics", "topics virodhamine research summary", "Virodhamine", "virodhamine", "Virodhamine research summary", "What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety relevant mechanisms?", "What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?" ], "search_text": "Virodhamine research summary Page type: topic Draft status: source-backed draft Template: 0.1-public-draft Research Question What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? Draft Summary This draft topic page is generated from 11 source-backed evidence row s and 11 source s . Main entities represented: Virodhamine. Evidence Snapshot - Evidence rows: 11 - Sources: 11 - Evidence classes: insufficient 3 , mechanistic or pharmacological 8 - Draft sections: mechanistic evidence 8 , uncertainty 3 Key Draft Sections - Uncertainty and gaps: 3 evidence row s . - Mechanistic evidence: 8 evidence row s . Evidence Table Evidence Row Statement Source ---: --- --- 1156 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Endocannabinoids and Their Pharmacological Actions. PMID 26408156; DOI 10.1007/978-3-319-20825-1 1 1157 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . GPR55: a new member of the cannabinoid receptor clan? PMID 17876300; DOI 10.1038/sj.bjp.0707464 1158 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The role of the CB1 receptor in the regulation of sleep. PMID 18514375; DOI 10.1016/j.pnpbp.2008.04.008 1159 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. PMID 18806815; DOI 10.1038/bjp.2008.371 1160 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. PMID 12023533; DOI 10.1124/jpet.301.3.1020 1161 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. PMID 22454039; DOI 10.1007/s11481-012-9351-6 1162 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms . Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. PMID 32696508; DOI 10.1002/jcp.29949 1163 Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological population or model: Animal model mentioned; s...", "sources": 11, "status": "source-backed draft", "subtitle": "What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?", "title": "Virodhamine", "type": "topic", "url": "/topics/virodhamine-evidence-map/" } ]